

Table of Contents

1. Issuer's activities	
1.1 Issuer's history	1
1.2 Description of the main activities of issuer and its subsidiaries	4
1.3 Information related to operating segments	6
1.4 Production/Marketing/Markets	10
1.5 Main customers	17
1.6 Relevant effects of state regulation	18
1.7 Relevant revenues in the country of the issuer's headquarters and abroad	39
1.8 Relevant effects of foreign regulation	40
1.9 Environmental, social and corporate governance (ESG) information	41
1.10 Information on government-controlled companies	44
1.11 Acquisition or disposal of relevant asset	45
1.12 Corporate operations/Capital increase or reduction	46
1.13 Shareholders' agreements	47
1.14 Significant changes in the business conduction	48
1.15 Relevant agreements entered into by the issuer and its subsidiaries	49
1.16 Other relevant information	50
2. Officers' comments	
2.1 Financial and equity conditions	51
2.2 Operating and financial results	58
2.3 Changes in the Accounting Practices/Modified opinions and emphases	60
2.4 Relevant effects on the Financial Statements	61
2.5 Non-accounting measurements	62
2.6 Events subsequent to the Financial Statements	64
2.7 Distribution of results	65
2.8 Relevant items not evidenced in the Financial Statements	66
2.9 Comments on items not evidenced	67
2.10 Business plans	68
2.11 Other factors that significantly influenced operating performance	70
3. Projections	
3.1 Disclosed projections and premises	71
3.2 Follow-up of projections	72

Table of Contents

4. Risk factors	
4.1 Description of risk factors	73
4.2 Indication of the five (5) main risk factors	82
4.3 Description of main market risks	85
4.4 Relevant non-confidential proceedings	88
4.5 Total amount provisioned for relevant non-confidential proceedings	93
4.6 Relevant confidential proceedings	94
4.7 Other relevant contingencies	95
5. Risk management policy and internal controls	
5.1 Description of the risk management and market risk management	96
5.2 Description of internal controls	100
5.3 Integrity program	103
5.4 Significant changes	107
5.5 Other relevant information	108
6. Control and economic group	
6.1 Shareholding	109
6.3 Capital distribution	121
6.4 Interest in companies	122
6.5 Organizational chart of shareholders and economic group	123
6.6 Other relevant information	124
7. Shareholders' meeting and management	
7.1 Main characteristics of the management bodies and audit committee	125
7.1 D Description of the main characteristics of the management bodies and audit committee	129
7.2 Information related to the board of directors	130
7.3 Members and professional experience of the management and audit committee	134
7.4 Committees composition	148
7.5 Family relationships	152
7.6 Subordination, service provision or control relationships	160
7.7 Managers' agreements/insurance	161
7.8 Other relevant information	162
8. Compensation of managers	
8.1 Compensation policy or practice	165

Table of Contents

8.2 Total compensation per body	169
8.3 Variable compensation	172
8.4 Share-based compensation plans	173
8.5 Share-based compensation (Stock options)	179
8.6 Granting of stock options	180
8.7 Outstanding options	181
8.8 Options exercised and shares delivered	182
8.9 Potential dilution for granting of shares	183
8.10 Granting of shares	184
8.11 Shares delivered	187
8.12 Share/option pricing	188
8.13 Interests held, per body	189
8.14 Welfare plans	190
8.15 Minimum, average and maximum compensation	191
8.16 Compensation/indemnity mechanisms	192
8.17 Percentage of related parties in the compensation	193
8.18 Compensation - Other functions	194
8.19 Recognized compensation of the controlling shareholder/subsidiary	195
8.20 Other relevant information	196
9. Auditors	
9.1 / 9.2 Identification and compensation	197
9.3 Independence and conflict of interests of auditors	198
9.4 Other relevant information	199
10. Human resources	
10.1A Human Resources Description	200
10.1 Human Resources Description	201
10.2 Relevant changes	205
10.3 Employee compensation policies and practices	206
10.4 Relationships between issuer and unions	208
10.5 Other relevant information	216
11. Transactions with related parties	
11.1 Rules, policies and practices	217

Table of Contents

11.2 Transactions with related parties	219
11.2 Items 'n.' and o.'	227
11.3 Other relevant information	229
12. Common stock and Securities	
12.1 Information on common stock	230
12.2 Foreign issuers - Rights and rules	231
12.3 Other securities issued in Brazil	232
12.4 Number of security holders	242
12.5 Trading markets in Brazil	243
12.6 Trading in foreign markets	245
12.7 Securities issued abroad	246
12.8 Allocation of public offering funds	247
12.9 Other relevant information	248
13. Parties responsible for the form	
13.0 Identification	273
13.1 Statement by the chief executive officer	274
13.2 Statement by the investor relations officer	275
13.3 Statement by the chief executive officer/investor relations officer	275

1.1 Issuer History

1.1.1. Briefly describe the history of the issuer

RD – Raia Drogasil S.A is leader in sales revenue and number of pharmacies in the Brazilian pharmaceutical retail. It was created in 2011 from the consolidation between Droga Raia, founded in 1905, and Drogasil, founded in 1935, and combines more than 200 years of history. The chain is present in all Brazilian states and the federal district and, along with the expansion process of pharmacies, the digitalization of the customers' journey has contributed to the growth of RD.

Positioning itself as a company of integrated health solutions and focused on promoting people's health and well-being, RD has the ambition to become the group that contributes the most towards a healthier society in Brazil by 2030. Therefore, we are building a complete integral health ecosystem, which provides customers with different solutions, both in pharmacies and on digital channels, to stay healthy and have a better quality of life.

In this line, feeding the business with technological solutions and processes that collaborate with the ambition to contribute to an increasingly healthy society, RD Ventures appears in 2020, RD's retail and health innovation center focused on building partnerships with startups to develop innovative solutions for people's health and well-being.

About RD's trajectory:

Raia 1905: Pharmacist João Batista Raia inaugurates, in Araraquara (SP), the first Farmácia Raia unit;

Drogasil 1935: two owners of pharmacy groups in the state of São Paulo, Drogaria Bráulio and Drogaria Brasil, consolidate their companies. The new company begins to operate under the name Drogasil Ltda.;

Raia 1937: with the expansion to other cities, Raia becomes a chain with units in Araraquara, Araçatuba, and Piracicaba (SP);

Drogasil 1937: it starts to act as a chain, through the incorporation of five other traditional pharmacies of the time: Drogaria Sul América, Amarante, Ypiranga, Orion, and Morse;

Raia 1966: about 10 years after the founder's death, Arturo Pipponzi consolidates control of the company;

Drogasil 1967: creation of the data processing department, to assist in processes and follow up on new developments;

Drogasil 1972: it becomes a joint-stock company, resulting in Drogasil S.A. Comércio e Indústria, and, on July 20, 1977, it obtains registration with the Brazilian Securities Commission (CVM);

Raia 1987: launch of the loyalty card (Raia Card) with the creation of a database, without involving the extension of credit;

Raia 2005: the company completes 100 years, with 137 branches in four states (São Paulo, Rio de Janeiro, Minas Gerais, and Paraná);

Drogasil 2007: Drogasil makes an offering of shares and is admitted to the Stock Exchange's Novo Mercado, which segment includes companies with the highest level of corporate governance on the Brazilian Stock Exchange;

Raia 2008: with the inflow of Private Equity funds (Pragma and Gávea), Raia strengthens its corporate governance and investment capacity;

Raia 2010: it makes its initial public offering (IPO) and is admitted to the Novo Mercado;

1.1 Issuer History

Drogasil 2010: the company completes 75 years, with 300 units and presence in five Brazilian states;

Raia Drogasil 2011: Drogasil and Raia announce the consolidation of their operations, resulting in the creation of Raia Drogasil, the largest pharmacy chain in Brazil in terms of number of units and sales revenue;

Raia Drogasil 2012: creation of a corporate identity and relocation of all employees from the parent company to the headquarters in the city of São Paulo, in the Butantã district. Incorporation of Raia S.A. and creation of a single company ready to follow the integration and synergy process;

Raia Drogasil 2014: completion of upgrade of the proprietary retail platform and full unification of the corporate systems on February 28 (integration of the entire logistics network, provision of various advanced and proprietary functionalities for pricing, promotions, inventory management, CRM, in addition to other topics, which became shared between all units and brands);

Raia Drogasil 2015: entry into the specialties segment, through the acquisition of control of 4Bio, one of the largest specialty medicine retailers in Brazil;

Raia Drogasil 2016: launch of Univers (own PBM) with a new platform that allows millions of members to buy at any Raia or Drogasil branch;

RD 2017: five years after the beginning of the integration process, the Company announces the change of its corporate brand to RD – Gente, Saúde e Bem-estar [People, health, and Well-Being];

RD 2018: structuring of the North II strategic plan, with two main focuses – closely caring for the health and well-being of people at all times in life, improving the experience, and maximizing value for the customer.

RD 2019: Incorporation of Drogaria Onofre Ltda. by RD, one of the most recognized companies in the Brazilian pharmaceutical retail, a national reference in e-commerce;


RD 2020: announcement of the new strategy, which contemplates the New Pharmacy, the Marketplace, and the Health Platform. Different competences began to be explored to bring customers closer to the pharmacy, a space of care and health for consumers. In October, the Company set up RD Ventures, RD's Corporate Venture Capital platform, with the objective of investing in startups, bringing businesses that complement the company's strategy and add specific skills;

RD 2021: launch of Vitat, a physical and digital network that connects people, services, and products to enhance care and transform the health of customers on a daily basis, including the care and guidance of pharmacists in dedicated spaces in pharmacies;

RD 2022: we evolved in the integration and governance of acquisitions in the RD ecosystem and now have two more companies – eLoopz and SafePill.

1.1 Issuer History

With the expansion of the chain, the logos changed color and layout over the years:



1.2 Description of the main activities of issuer and its subsidiaries

1.2. Make a summary description of the main activities performed by the issuer and its subsidiaries

Raia Drogasil S.A. (“Company”) is a publicly-held corporation with its headquarters in the capital city of the state of São Paulo and registered with B3 S.A. - Brasil, Bolsa, Balcão, in the Novo Mercado segment. The main activity of Raia Drogasil S.A. is the retail trade of medicines, perfume, personal hygiene, and beauty products, cosmetics, and dermocosmetics.

Leader in the Brazilian pharmacy market in gross revenue (BRL 31.0 billion) and number of units (2,697 units), according to the 2022 Abrafarma ranking, RD was born in 2011 as one of the ten largest retail groups in Brazil, from the consolidation of Raia S.A. and Drogasil S.A. The company adopts a differentiated business model, with two leading brands (Raia and Drogasil) that operate independently, with their complementary qualities and specific unit formats.

With an average domestic market share of 15.1% in the 4th quarter of 2022 and strong growth potential, RD operates in 26 states and the Federal District. It has a decentralized logistics structure and, at the end of the year, it operated through 11 distribution centers, located in nine states – SP (Guarulhos, Embu das Artes, and Ribeirão Preto), MG (Contagem), PR (São José dos Pinhais), GO (Aparecida de Goiânia), RJ (Duque de Caxias), PE (Jaboatão dos Guararapes), BA (Salvador), CE (Fortaleza), and RS (Gravataí) – totaling more than 156.0 thousand m² of storage capacity and ensure agility in the supply of pharmacies. In the 1st quarter of 2023, the DC in Cuiabá (MT) was inaugurated, expanding the total storage capacity to more than 173.0 thousand m², with 12 distribution centers.

In 2015, RD acquired the controlling interest of 4Bio Medicamentos S.A.. Founded in 2004, its activities are focused on the sale of special high-tech medicines and related products without compounding of formulas (used to treat serious health conditions or those that threaten life, prescribed by clinical specialists), the provision of medication dispensing services, provision of patient support infrastructure, in addition to activities such as consultancy in business management, information technology, supply and management of human resources, market and public opinion research, and also direct marketing.

In 2019, RD acquired Drogaria Onofre, with a total of 50 units, 47 in the state of São Paulo, two in Rio de Janeiro and one in Minas Gerais. Onofre was one of the most recognized companies in the Brazilian pharmaceutical retail and one of the national references in e-commerce. The incorporation of Drogaria Onofre aimed at optimizing the corporate and business structure of Raia Drogasil, by taking advantage of synergies and reducing costs through the joint management of the Companies.

In 2020, RD created RD Ventures, a Corporate Venture Capital platform with the aim of investing in startups, to bring businesses that would contribute to the growth strategy and accelerate the Company's digitalization journey in healthcare, such as the investment in Manipulaê (digital compounding pharmacy platform), Amplimed (medical records and management platform for clinics and offices that connects more than 20,000 health professionals), Labi Exames (healthtech focused on laboratory exams, tests, check-ups and vaccines, with physical units and home operation), Cuco Health (digital platform focused on adherence to treatment), Healthbit (specialist in big data for health promotion and cost reduction in companies) and SafePill (organizes medication by dose and time, delivering it to customers on a monthly basis).

In 2021, RD launched Vitat, a physical and digital network that connects people, services, and products to enhance care and transform the health of customers on a daily basis. The objective is to integrate services and products into a health ecosystem, comprising the care and guidance of pharmacists in dedicated spaces in pharmacies, with the performance of rapid tests, monitoring of clinical parameters, and application of injections, for example. The existence of exclusive spaces in pharmacies, added to the production of personalized content, marketplace of services and products focused on health and well-being, drives the journey of consumers, preventing diseases and encouraging healthy habits.

In 2022, RD acquired eLoopz, a startup which develops media solutions for retailers, mostly via screens installed in physical units and software for intelligent management of these assets. The acquisition allows RD to develop new publicity and advertising solutions to have an impact on the

1.2 Description of the main activities of issuer and its subsidiaries

customers, intensifying activities in out of home digital media in pharmacies, strengthening the advertising strategy of advertisers in physical and digital channels via RD Ads (RD's advertising arm).

Our RD Way of Being and Doing

Purpose

Together for a healthier society.

Core Values

Take care of people

Driven execute

Build the future

RD Aspiration

To be a reference in the creation of opportunities for employees, in the generation of value for shareholders in the long term, in the relationship of trust with society and, by 2030, to become the group that contributes the most towards a healthier society in Brazil.

Sustainability

In recent years we have grown a lot, we have multiplied the opportunities generated, we have explored new frontiers, and we have helped millions of Brazilians to face their health challenges. But we feel that we can do much more. Therefore, in 2020, an action plan was drawn up with a long-term vision, but with pragmatic goals. There are 35 commitments divided into eight thematic fields, aligned with the UN Sustainable Development Goals (SDGs). We call this plan "Walking Together", after all we know that it will be a gradual construction and we need the joint dedication of our teams, our suppliers, and the customers themselves to go even further.

We have many steps to take, but we have already started a virtuous cycle, contemplating the future of the business, which promotes integral health, and the future of sustainability, which regenerates society and the environment.

About the pillars and objectives of this sustainable journey:

Healthier People (Employees, Customers, Community):

- a) Take care of the health of employees;
- b) Promote healthy habits among RD customers;
- c) Promote integral health in communities.

Healthier Business (Diversity, Education, Shared Value):

- a) Include and empower employees by promoting diversity;
- b) Expand opportunities for personal development of employees;
- c) Promote empowerment and diversity among suppliers.

Healthier Planet (Footprint, Energy, Waste):

- a) Leveraging the circular economy in the RD value chain;
- b) Contribute to global carbon neutrality.

1.3 Information related to operating segments

1.3. For each field of business reported on the latest financial statements for complete fiscal years, or on consolidated financial statements (if any), provide the following information:

a. Products and services traded

The main activity of Raia Drogasil S.A., with its headquarters in the capital city of the state of São Paulo, is the retail sale of pharmaceutical and cosmetic products, including Branded Medicines, Generic Medicines, OTC Medicines, Non-Medicines (Personal Hygiene Products, Cosmetics and Dermocosmetics), and Services.

The Group develops its business activities considering a single operating segment that is used as a basis for the entity's management and for decision-making, although there is a managerial control of the revenue obtained with each line of products and services in the portfolio. Throughout 2022, the Company contributed to the health and well-being of more than 47 million Brazilians, in about 329 million services.

We add to our activities a wide variety of services that help to increase the flow of customers in our units. Thus, in addition to the sale of pharmaceutical and cosmetic products, we also offer in units:

- (i) Special spaces dedicated to beauty care;
- (ii) Agreements with companies for the purchase of products by their employees and payment through payroll deductions, in addition to exclusive discounts;
- (iii) Agreement with the Ministry of Health for the sale of medicines at subsidized prices (through the "Popular Pharmacy" program);
- (iv) Agreements with the main PBMs (Pharmacy Benefit Management) existing in Brazil;
- (v) Customer loyalty programs. On a technical level, we offer pharmaceutical advice in all units in our chain.
- (vi) The Stix Fidelidade program is a coalition of nationwide retailers, references in their segments, offering benefits to customers, including the exchange of points for awards.

In addition to the products displayed in units, we offer customers a series of health services, whether paid or not:

- (i) Pressure measurement: measuring blood pressure, with the purpose of identifying whether these levels are within normal parameters or have any alteration, being used as a basis for the diagnosis of diseases such as high blood pressure;
- (ii) Blood Glucose Test: the capillary blood glucose test is a quick measurement of glucose, it can be found in pharmacies in our chain and gives the result right away. Patients who undergo it have already gone through diabetes screening or risk assessment of developing diabetes with altered results, and need better blood glucose control with pharmacological and non-pharmacological treatment;
- (iii) Bioelectrical impedance analysis: it is a test designed to assess body composition, estimating lean mass, body fat, among other data that provide more accurate information about the patient's body condition;
- (iv) Application of injections: drugs administered by injection may be intramuscular, subcutaneous, among other types. We have a list of drugs that we apply in our chain, we do not apply any type of substance, as some can cause adverse reactions at the time of application and require special care;
- (v) Rapid testing: Glycated Hemoglobin, Beta HCG, Hepatitis B and C, Influenza A and B, among others;
- (vi) Rapid Covid-19 tests: such as Nasal Antigen and Serology; and
- (vii) Vaccines: Tetravalent flu, Meningitis, Triple (Measles, Mumps, and Rubella), Yellow Fever, among others.


1.3 Information related to operating segments

We sell our products directly to final customers. We offer customers a diversified portfolio, consisting of more than 18,000 items purchased from our suppliers.

b. Revenue from the segment and its share in net revenue

We consider in our business activities only one operating segment. Our revenue comes exclusively from the sale in our units of Branded Medicines, Generic Medicines, OTC Products, Non-Medicines (Personal Hygiene Products, Cosmetics, and Dermocosmetics), and Services.

In order to better manage the operational performance of the business, the Company monitors gross revenue instead of net revenue. The following graph depicts, in a managerial manner, the composition of the gross revenue of the controlling shareholder (RD Pharmacies) in the years 2022, 2021, and 2020:



Branded Medicines

We classify in this category all drugs subject to medical prescription, identified by means of a trademark. They are subdivided into (i) Reference Medicines, which are innovative products whose efficacy, safety, and quality have been scientifically proven, upon registration with the National Health Surveillance Agency, or Anvisa, after years of research; and (ii) Similar Medicines, which contain the same active ingredient or ingredients and the same concentration, pharmaceutical form, administration route, dosage, and therapeutic indication of the respective Reference Medicine. Similar Medicines are also identified by means of a trademark and, like Generic Medicines, can only be produced and marketed after expiration or waiver of the patent protection of the respective Reference Medicine. Brand name over-the-counter medicines are classified by us as OTC Products.

Among the products we sell, Branded Medicines represent a significant portion of our gross sales revenue, accounting for 41.9% in 2022, 41.6% in 2021, and 42.0% in 2020. Throughout the year, our main suppliers of Branded Medicines were Novo Nordisk, Aché, Libbs, EMS, and Eurofarma.

Generic Medicines

We classify under this heading drugs subject or not to medical prescription that contain the same active principle or principles and have the same concentration, pharmaceutical form, administration route, dosage and therapeutic, preventive, or diagnostic indication of the respective Reference or OTC Medicine. Generic Medicines are designated by the name of the active ingredient, and may be prescribed

1.3 Information related to operating segments

alternatively to Reference Medicines or substituted at the time of pharmaceutical dispensing. Said replacement at the point of sale is legally permitted. They can only be produced and marketed after the expiration or waiver of their patent protection or other exclusive rights of the Reference or OTC Medicine, after their efficacy, safety, and quality have been proven through Bioequivalence and Bioavailability tests, in which their composition and its absorption by the body are compared to those of the respective Reference or OTC Medicine. Generic Medicines do not have a brand, only the name of the substance associated on the label and packaging with the name of the laboratory that sells it.

Generic Medicines accounted for 11.6% of gross sales revenue in 2022 and 2021. In 2020, they accounted for 11.4%. Our main suppliers of Generic Medicines are EMS, Medley, Eurofarma, Sandoz, and Aché.

The introduction of Generic Medicines in Brazil, in 2000, offered us an important opportunity for the growth of our sales volume and revenue, since it significantly expanded the consumer market for medicines in Brazil, mainly in the low-income population. We believe that Generic Medicines will represent a larger portion of our sales in the long term, in line with the trend of the Brazilian and world pharmaceutical market, as well as providing an increase in the net margins obtained.

OTC Medicines (Over-the-counter medicines)

Over-the-Counter (OTC) Medicines can be both branded and generic, in addition to health and well-being products that are sold over the counter, i.e., without medical prescription. They are generally intended for the treatment of acute conditions that are easy to self-diagnose, such as pain, flu, cough, fever and cold medicines, antacids, vitamins, herbal products, eye products, health equipment, first aid and nutritional products, dietetic and convenience products.

OTC Medicines accounted for 22.4% of our gross sales revenue in 2022, 22.5% in 2021, and 21.3% in 2020. During the year, our main suppliers of OTC Medicines were Hypera, Sanofi, Reckitt, and Haleon, in addition to private label products.

Non-Medicines (Perfumery)

These are hygiene and beauty articles, among which the following stand out: shampoos, conditioners, treatment creams and hair dyes, diapers and children's products, soaps, deodorants, oral hygiene products, sunscreens, men's products, cosmetics, makeup and skin care products, among others.

Non-Medicines accounted for 23.9% of our gross sales revenue in 2022, 24.1% in 2021, and 25.1% in 2020. Throughout the year, our main Non-Medicine suppliers were Procter & Gamble, L'Oreal, Unilever, Kimberly-Clark, and private label products.

Services

These are services provided to our paid or unpaid customers, among which the following stand out: pressure measurement; blood sugar tests; bioelectrical impedance analysis; application of injections; rapid tests such as glycated hemoglobin, hepatitis B and C, influenza A and B, Covid-19; and vaccines (tetraivalent flu, meningitis, among others).

1.3 Information related to operating segments

Services accounted for 0.2% of gross sales revenue in 2022, 0.3% in 2021, and 0.2% in 2020.

c. profit or loss resulting from the segment and its share of the issuer's net income

We do not calculate profitability separately for each type of product we sell or for each operating segment, since all sales revenues and expenses are considered as a single segment.

1.4 Production/Marketing/Markets

1.4. Regarding the products and services that correspond to the operating segments disclosed on item 1.3, describe:

a. Characteristics of the production process

We have no production process. Private label products (Needs, Vegan, Nutri Good, Natz, Caretech, bwell, Raia, and Drogasil) sold in our units are produced by more than 80 suppliers, which undergo a rigorous selection process, aligned with the Company's values, bringing specialization and quality for all our product lines. We also have rigorous quality controls, as well as compliance and adherence to the RD's code of conduct, in addition to supplier registration, regulatory, tax, judicial, and labor analysis, including ESG (Environmental, Social and Governance) criteria.

b. Characteristics of the distribution process

Supply Management

Our supply chain management aims to provide the products we sell in our units at the lowest cost, with the best balance between working capital invested, availability of products in stores, and logistical expenses incurred. This model is based on the automation of the main processes, integrating the supply chain from the generation of purchase orders to the delivery of goods to the unit.

Our supply management is centralized. All purchase and merchandise handling decisions, both in our Distribution Centers and in units, are suggested by the inventory management system, which uses statistical calculation methods and incorporates the particularities of our industry, in addition to the know-how accumulated throughout our history.

The Supply Management area monitors our level of product shortages on a daily basis, both in units and in the Distribution Center, to prevent and cure any shortages. Additionally, we compare our level of product shortages with that of our main competitors from time to time, through comparative surveys of the level of product shortages.

Each unit tracks its inventory movement in real time. Sales are transmitted electronically to our central office. During the night, our system processes the replenishment of orders to be placed in our Distribution Center for each unit.

Even working with thousands of different products across the chain, we seek to operate with very low levels of product shortages in our units. To this end, our supply management system recalculates our inventories from time to time, based on the demand for each product in each of our units.

Procurement

In addition to negotiating low purchase prices, our procurement policy aims to articulate commercial actions in partnership with suppliers that allow us to boost our sales volume, negotiate discounts, and earn commercial revenue, also obtaining competitive payment terms. The frequency of procurement corresponds to an interval of seven or fifteen days, depending on the volume of purchases from each supplier.

In seasonality periods, the demand forecast is adjusted in relation to the sales history and market growth projection. In these periods, we generally obtain better commercial conditions from our suppliers, when the discount granted may increase and the payment term exceeds 55 days. Marketing actions aimed at increasing the sales of our products are also accompanied by a detailed purchase plan, establishing the constant forecast parameters in our system.

1.4 Production/Marketing/Markets

All purchase orders are centralized in our purchasing department, located in our central office in São Paulo, which is responsible for negotiating with suppliers all products we sell.

Logistics

Warehousing and distribution activities are a key element of our business, directly affecting our success and competitiveness. We currently operate with twelve distribution centers, located in Embu das Artes (SP), Guarulhos (SP), São José dos Pinhais (PR), Contagem (MG), Aparecida de Goiânia (GO), Cuiabá (MT), Duque de Caxias (RJ), Ribeirão Preto (SP), Jaboatão dos Guararapes (PE), Fortaleza (CE), Salvador (BA), and Gravataí (RS).

The logistics decentralization strategy is justified by the growth of our operation, the increase in the number of units in other states, and the decentralization of the tax structure in Brazil, which allows the units of the federation to determine independent tax rules for state taxes, which may both favor companies that have Distribution Centers in the state, and burden the transfer of goods to other states.

Our distribution center (DC) located in Guarulhos (SP) has an area of 28.0 thousand m² and is the largest in the chain, followed by Embu das Artes (SP) with an area of 22.7 thousand m². The other distribution centers are distributed across the country as follows:

The Ribeirão Preto DC has an area of 18.5 thousand m²;

the Cuiabá DC has an area of 17.0 thousand m²;

the Aparecida de Goiânia DC has 15.0 thousand m²;

the São José dos Pinhais DC has 12.9 thousand m²;

the Duque de Caxias DC has 12.1 thousand m²;

the Contagem DC has 8,500 m²;

the Fortaleza DC has 10,500 m²;

the Jaboatão dos Guararapes DC has 10.3 thousand m²;

the Gravataí DC has 9.2 thousand m²; and

the Salvador DC has 8,500 m²; totaling more than 173.0 thousand m² of area.

The Distribution Centers are located in areas leased by the Company, so that own funds are not tied up in the purchase of land. For all deliveries made to our Distribution Centers, the goods receipt process ensures that (i) the goods delivered match the order placed; (ii) the goods are in accordance with the invoice; and (iii) the products are in full sale conditions. Our information systems track all inventory movements in real time.

We consider the balancing of processes, lines, and workstations, the use of the main production concepts, in order to seek, more and more, synchronicity among activities. Below, Picture 1 shows one of our semi-automatic sorting lines. Picture 2, in turn, shows the automatic handling of boxes in one of our Distribution Centers.

1.4 Production/Marketing/Markets



Picture 1

Picture 2


The Distribution Centers are organized into sorting sectors. We have semi-automatic and manual processing lines. All plastic boxes, in which the products are placed to be sent to the units, are transported on conveyor belts (from the sorting sector to the shipping dock). At the end of each sorting line, the boxes are transported by conveyor belt to the checking lines. Each unit is scanned to detect and correct any sorting errors. Once the scanning is completed, the boxes are placed back on the conveyor belt, sealed, and sent to dispatch. At this stage, each box is directed to the respective shipping dock, according to the delivery route, and the boxes are counted, checked against the shipping note, and placed on the trucks for delivery to the unit.

Sales Channels

Our sales channels are units, sales by phone, apps (IOS and Android) and websites (www.drogaraia.com.br and www.drogasil.com.br).

Our units are our main sales channel and serve as the basis for the existence of other channels. On December 31, 2022, we had 2,697 units, distributed across 26 States and the Federal District. In addition to these locations, we have 5 4Bio units, located in the states of São Paulo, Rio de Janeiro, Paraná, Tocantins, and Pernambuco. Below is the geographical distribution of the Company's 2,697 units:

1.4 Production/Marketing/Markets



The locations chosen for our units are places of great movement of people, for stores locations at Classes C and D, or vehicles, for locations aimed at Classes A and B, depending on the target public to be reached. The location is determined by several factors, such as the consumer market, the estimate of operating costs, and the evaluation of the competition to be faced, for example.

Once the location of a new unit has been identified, a team specialized in the search for commercial points works to identify the micro-location, for which several factors are considered, such as proximity to competitors, direction of pedestrian and vehicle flow, sunlight incidence, and visibility of the unit to be implemented.

When installing the location, our engineering and architecture area develops a tailor-made layout, aiming to maximize the spaces and provide an internal circulation that makes the shopping environment pleasant and inviting. Even after the unit opens, it is monitored so that its operation can be adapted to the market in which it operates. Such monitoring considers the mix of products used (inventory assortment), the price policy to be applied due to the competition faced, and the appropriate opening hours for that location. During this adaptation period, we evaluate the growth in revenue. Locations that do not fit the growth parameters, subject to the adaptation period, will have their activities closed.

Our pharmacies are essential in the digitalization of customer relations. In addition to representing the main channel for customer acquisition, the majority of orders placed through digital channels are delivered or picked up from pharmacies.

c. Characteristics of the market of operation

With double-digit growth recorded in recent years in our gross revenue, the Brazilian pharmaceutical retail is a market with strong potential for expansion. The ageing of the population and the migration of hygiene and beauty products channels, for example, are some of the factors that have contributed to the good results presented by the health and beauty segments.

Our main expenses refer mainly to personnel expenses, property rentals, credit and debit card administration fees, expenses with transportation, maintenance of assets, utility bills, use and consumption materials, in addition to condominium fees. Our sales and administrative expenses represent 17.6% and 3.5%, respectively, of our gross revenue for 2022 and 18.0% and 3.1%, respectively of our gross revenue for 2021.

1.4 Production/Marketing/Markets

Pharmaceutical Market

Pharmaceutical retail is a booming segment in Brazil. In 2022, according to IQVIA data, the Brazilian pharmaceutical market recorded total revenues of BRL 171 billion, which represents an increase of approximately 18% compared to 2021 (BRL 145 billion).


This results from the combination of a series of factors, the main of which is the ageing of the population, due to the increase in people's life expectancy. The Brazilian pharmaceutical retail is a fragmented market and offers a unique consolidation opportunity. Even in the face of the various concentration movements that began after the creation of RD, the five currently largest pharmaceutical chains have a market share of approximately 30.7%.

Perfume Market

According to data published by ABIHPEC (Brazilian Association of the Personal Hygiene, Perfume, and Cosmetics Industry), Brazil is the fourth largest consumer market for personal hygiene, perfumery, and cosmetics (HPPC) products in the world, only behind the United States, China, and Japan.

With an attractive shopping experience, pharmacies are increasingly differentiating themselves from other retail channels as one of the most popular options for consumers, strengthening the channel migration process. The purchase of these items ceases to be ancillary and becomes consolidated as a destination category.

i. RD's share in each of the markets.



ii. Market competition conditions

We operate in a highly competitive market. Our main competitors are pharmacy chains and independent pharmacies, but we also compete with other types of companies, such as perfume stores, supermarkets, and direct sales companies. Our competitors vary for each market we serve.

The table below shows our main competitors in the ranking released by Abrafarma (Brazilian Association of Pharmacy and Drugstore Chains), based on annual sales revenue and the number of units at the end of 2022.

1.4 Production/Marketing/Markets

Pharmacy Chain Ranking		Gross Revenue (BRL billion)	Growth Gross Rev. vs. 2021	Number of Pharmacies
1	RAIA DROGASIL S.A.	30.9	20.9%	2,697
2	DROGARIAS DPSP S.A.	13.5	15.4%	1,443
3	EMPREENDIMENTOS PAGUE MENOS S.A.*	9.8	21.8%	1,646

Source: Press Release of listed Companies (RD and Pague Menos) and São Paulo Official State Press (DPSP).

* Includes the acquisition of the Extrafarma chain.

d. Any seasonal effects

As with other companies in the industry, we have observed a higher sales volume of certain product categories during the winter or summer period, which tend to offset each other, generating a certain balance in sales volume throughout the year.

During the winter season, we saw an increase in our sales of OTC Products and Medicines for the prevention and treatment of flu, fever, colds and other respiratory illnesses, aggravated by the weather conditions of the season. In the summer, we noticed an increase in sales of Perfume Products, such as sunscreens, moisturizers and lotions, for example.

In the first quarter of the year, our sales are lower due to school holidays (in January and February) and Carnival (in February or March). These periods cause many families to leave the big cities in search of tourist destinations. Our sales also decrease because the month of February only has 28 or 29 days. As a large part of our expenses are fixed, such as the payment of our employees' salaries and rent at commercial points, this lower gross revenue from sales and services is reflected in results lower than the average for the other quarters of the year, both in absolute values and in terms of percentage of our gross revenue from sales and services.

It is worth mentioning that the second quarter of the year is almost always a quarter with a significant increase in gross margin. Every year, at the end of March, the Government approves the adjustment for inflation in the Factory Price and in the Maximum Consumer Price, which is immediately applied by us and by the vast majority of our competitors. As a result, in early April, we sell at adjusted prices products we purchased at the old price, which increases our margins. As our inventory of products purchased at old prices is used up and replaced at the adjusted prices, our margins are reduced and return to normal levels.

In the third quarter of each year, there is an annual salary adjustment for all our employees in the state of São Paulo, where our administrative team, distribution center, and most of our units are located, which causes a significant increase in expenses of personnel compared to the second quarter of the year.

On the other hand, the last quarter is usually the quarter with the highest sales in the year, due to the month of December, in which the weeks before Christmas result in greater circulation of people and greater consumption by families. Additionally, the week between Christmas and New Year is characterized by a strong wave of product purchases in anticipation and preparation for the holidays. We believe that receiving the thirteenth month pay in November and December contributes to increasing disposable income and consumption growth for Brazilian families.

Finally, there are seasonal effects with respect to our investment in working capital. The second and fourth quarters of the year are generally favorable periods, in which our investment in working capital is lower. We start the second quarter purchasing large volumes of seasonal winter products (e.g. anti-flu) with long terms, so that at the end of the quarter, we consumed part of the surplus inventory of these products without having yet paid for these purchases, which resulted in favorable working capital conditions.

The same process takes place with greater intensity in the fourth quarter of the year, at the beginning of which we purchase large volumes with long terms for seasonal summer products (e.g. sunscreens) and end the quarter with a very favorable working capital position, as a result of having consumed part of this

1.4 Production/Marketing/Markets

inventory without having yet paid for purchases, which only occurs in the first quarter of the following year. The stronger the winter and summer cycles, which generally depends on the weather in the period, the more pronounced will be the seasonal effects of working capital. The Company does not present seasonal effects in the general lines of its results, only an alternation between the products sold according to the season of the year.

e. Main inputs and raw materials

i. Description of the relationships with suppliers, including whether they are subject to governmental control or regulation, indicating the agencies and the respective applicable legislation

We purchase our products from approximately 450 suppliers, and our largest supplier accounted for 9.4% of our total purchases in 2022. We maintain a solid and long-term relationship with the most important suppliers in Brazil. In general, we place our orders with suppliers based on our customers' purchasing history, our short-term sales forecasts, and desired inventory levels. Below, we list the relevance of suppliers within the company's purchases:

Supplier	%
First	~ 9%
Second to Tenth	~ 30%
Other Suppliers	~ 60%

ii. Occasional dependence on few suppliers

Among the mix of products sold in our pharmacies, the Company may acquire them from more than one supplier.

iii. Occasional price volatility

The prices of medicines purchased by the Company are not subject to significant volatility, given the annual adjustment promoted by the Federal Government, which takes place on March 31 (determined by Law No. 10,742 of October 06, 2003). Other products, such as Hygiene and Beauty items, are not subject to the annual adjustment and, therefore, the Company can choose whether or not to pass on occasional price volatility to its consumers.

We believe we have competitive prices compared to those charged by other chains, due to, among other reasons, the maintenance of a low-cost operating structure. In addition, we seek to ensure the competitiveness of our prices by carrying out joint promotional actions with suppliers, through which we grant discounts to our customers for certain groups of products. Our pricing policy and the discounts offered in our units depend on the region in which they are located, as well as on local competition. We also have an open channel for discussion with our managers, who actively participate in choosing the best pricing policy for the locations where they operate.

1.5 Main customers

1.5. State whether any client accounts for more than 10% of the issuer's total net revenue, informing

a. Total revenue from the customer

We inform that we do not have customers representing more than 10% of the sales revenue. We have a very dispersed base of individual customers.

b. Operational segments affected by the revenue from the customer

According to the answer above, we do not have customers representing more than 10% of the sales revenue.

1.6 Relevant effects of state regulation

1.6. Describe the relevant effects from government regulation on the issuer's activities, with emphasis on:

a. Need for governmental authorizations for the exercise of activities and history of relationship with the government to obtain such authorizations

Regulation of the Pharmaceutical Industry in Brazil

The pharmaceutical industry is a highly regulated industry in Brazil, similar to what happens in other regulatory environments, such as the European Union and the United States.

In Brazil, regulation of the industry is divided among the Federal Government, States, and Municipalities. The Federal Government sets out laws and regulations of general application, which are reinforced and complemented by the actions of States and Municipalities.

At the federal level, the health and pharmaceutical industries are regulated and supervised by the Ministry of Health, through the National Health Surveillance Agency (ANVISA), created through Federal Law No. 9,782 of January 26, 1999.

Necessary Authorizations for the Business

(i) Product

Medicines sold in Brazil are products subject to mandatory registration with ANVISA, given their sanitary characteristics for the conservation of public and individual health, being a pharmaceutical product with a prophylactic, curative, palliative purpose or even for diagnostic purposes, being subject to a series of specific regulatory conditions and specific requirements, as provided and regulated by Law No. 6,360 of September 23, 1976, and subsequent amendments.

Certain types of non-medicines, such as cosmetics and related products, may also be subject to mandatory registration, under the terms of said Law No. 6,360 of September 23, 1976, depending on their specific characteristics.

Pharmacies do not bear the costs of registering products, being only responsible for verifying that the products sold comply with the mandatory registrations.

(ii) Activity

Pursuant to the provisions of Law No. 5,991 of December 17, 1973, and subsequent amendments, the retail trade of medicines, pharmaceutical supplies, and related products in their original packaging is an economic activity that can only be practiced by pharmacies that are legally authorized and licensed pursuant to the law.

In addition to federal authorization, pharmacies must have a license from the respective local health authority (such as, for example, in the State of São Paulo, the Health Code, created by Law No. 10,083 of September 23, 1998; and in the Municipality of São Paulo, in addition to the aforementioned State Health Code, the Municipal Health Code, created by Law No. 13,725 of January 09, 2004).

In 2014, Law No. 13,021 of August 08, 2014 was enacted, which provides for the exercise and supervision of pharmaceutical activities, which reiterates the role of pharmacies as units for the provision of pharmaceutical services for health care.

In addition, Resolution - RDC No. 197 of December 26, 2017 of the National Health Surveillance Agency ANVISA, allowed the inclusion of the provision of another service in pharmacies, which is the human vaccination service.

The operation of pharmacies without the aforementioned registrations or without the presence, full time, of a pharmaceutical responsible for the technical operation (which is a legal requirement for their operation), as well as any other violation of the laws and rules related to the federal, state or municipal health surveillance standards, subjects the violating pharmacies to penalties such as warning, payment of fines, suspension of activities and cancellation of the permission or registration with the health surveillance authorities.

1.6 Relevant effects of state regulation

We believe that the demanding and growing regulation will lead to an increase in the industry's formalization, with advantages for pharmacy chains that already base their activity on strict compliance with the standards that regulate the industry.

(iii) Regulation of the Commercial Promotion of Medicines and Non-Medicines

According to the Federal Constitution, commercial advertising of medicines and therapies that may be harmful to health is subject to legal restrictions and must contain, whenever necessary, a warning about the harm resulting from their use. Additionally, Federal Law No. 6,360/76, which provides for health surveillance, determines that advertising, in any form of dissemination and means of communication, of over-the-counter medications, dietetic products, cosmetics and hygiene products may only be displayed after authorization by the Ministry of Health, being subject to the action of health surveillance.

b. Main aspects related to compliance with legal and regulatory obligations related to environmental and social issues by the issuer.

Our activities are subject to Brazilian environmental legislation at the federal, state, and municipal levels. Compliance with this legislation is supervised by government bodies and agencies, which may impose administrative sanctions against the Company for any non-compliance with this legislation.

Particularly for the activities we carry out, the generation of health service waste deserves greater attention, such as: needles and syringes that are normally used in the application of injections in our units. With regard to such waste, federal legislation (RDC Resolution No. 222 of March 28, 2018 of ANVISA and Resolution No. 358 of April 29, 2005 of the National Council for the Environment - CONAMA) established general rules on the matter, imposing on establishments providing health services the obligation to prepare a Health Services Waste Management Plan - PGRSS. We have a PGRSS duly prepared for each unit.

In our activities, we use distribution centers to receive, store, sort, and ship the pharmaceutical products we sell. The environmental impact in our distribution centers is deemed low and each municipality will require or not the prior environmental licensing by the competent body.

In general, most medications subject to disposal, due to expired validity date or damage to the packaging, are returned to their respective manufacturers. When we need to take responsibility for the disposal of certain medications, we ask companies duly licensed by environmental agencies and authorized by the Health Surveillance, as well as monitor the destruction of these medications, including certification from the Brazilian Federal Revenue Office. In the case of prescription drugs, we receive prior authorization from the Municipal Health Surveillance Department of the city of São Paulo, for example, before proceeding with their destruction.

Contracting third parties to carry out any intervention in our operations, such as the final disposal of waste, does not exempt us from liability for any environmental damage caused by the contractor, since under the civil law, environmental damage implies joint and strict direct and indirect liability. This means that the obligation to repair the damage caused may affect everyone involved, regardless of the agents' proven fault.

In all our units, we rely on outsourced waste collection and final disposal companies in accordance with the applicable law. To ensure that processes are carried out in compliance with the law, suppliers undergo an approval process with the submission of supporting documentation, respond to a sustainability self-assessment questionnaire from time to time, and are subject to audits to check the information provided.

In addition, for more than 10 years, we have maintained the Conscious Waste Disposal Program in our pharmacies, in accordance with Decree 10,388 of 2020. Customers have the possibility to discard expired or unused medicines and their leaflets and packaging, contributing to preservation of the environment. In 2022, the program advanced and reached all RD pharmacies, i.e., all units have collectors for disposal of such waste.

In order for the medicines to receive the correct destination, first they are discarded by the population in the collectors available in pharmacies and packed in bags suitable for this purpose. They are then taken to our Waste Center in the DCs. Later, on a scheduled date, they are collected by a company approved by the pharmaceutical industry and taken for incineration or co-processing. It is worth mentioning that, at

1.6 Relevant effects of state regulation

the time of collection and during the journey to the final destination, the waste is accompanied by all the required documentation, including the Waste Transport Manifest (MTR).

In addition, we are in good standing with government authorities regarding the use of the distribution centers. We have ISO 14001 certification in our distribution centers.

c. Dependence on relevant patents, trademarks, licenses, permits, franchises, or royalty agreements for the development of activities

In Brazil, ownership of a trademark is acquired only through registration validly issued by the National Institute of Industrial Property - INPI, and the owner is ensured the exclusive use thereof throughout the national territory.

We are the owners of trademarks RAIA DROGASIL, DROGASIL, DROGASIL DELIVERY, DELIVERY 0800-158200, DROGASIL ESSENCE, DROGASIL VIVER FELIZ, FARMASIL, S.O.S DROGASIL, DROGA RAIA, RAIA, RAIA DELIVERY, RAIA EM CASA, RAIA HIPERFARMÁCIA, DROGARAIA, DROGARAIA SAÚDE E BELEZA 24 HORAS, PHARMACIA RAIA, SER PLUS, SER SAUDÁVEL, KID CARD, SENIOR CARD, INTEGREA, DEEX DROGASIL ENCOMENDA EXPRESSA, RAIA TOTAL BENEFÍCIO FARMA, ZAMBELETTI, NEEDS, PLUII, PLUII AMORA ROSA, PLUII BRILHA BAUNILHA, PLUII LIMA LIMÃO, PLUII VERDE ERVA, PLUII VIBRE GENGIBRE, B-WELL, VERDE-ERVA, VIBRE-GENGIBRE, LIMA-LIMÃO, BRILHA-BAUNILHA, AMORA-ROSA, UNIVERS, B-WELL A/Z MULTIVITAMÍNICO, B-WELL CÁLCIO + D, B-WELL GUARANÁ, B-WELL MULTI SILVER, BWELL A/Z MULTIVITAMÍNICO +ÔMEGA, BWELL HOMEM, BWELL MULHER, B-WELL ÓLEO DE PRIMULA, B-WELL ÓLEO DE LINHAÇA, B-WELL ÓLEO DE CÁRTAMO, B-WELL ÓLEO DE CHIA, B-WELL VITAMINA D, B-WELL ÔMEGA 3, PLUII BLU MARINO, PLUII LISS CASSIS, PLUII VERDE VERBENA, RAIA SERVIÇOS FARMACÊUTICOS, FARMASIL SERVIÇOS FARMACÊUTICOS, DROGASIL SERVIÇOS FARMACÊUTICOS, #TODOCUIDADOCONTA, 4BIO, 4BIO VIVER PLATAFORMA DE CUIDADOS, BLACKFARMA % DROGARIA ONOFRE, CARETECH, CUIDAR +, DESAFIO ONOFRE, DROGA RAIA MEDICAMENTOS ESPECIAIS, DROGARIA ONOFRE, DROGARIA ONOFRE BLACKFARMA, DROGASIL & VOCÊ, DROGASIL MEDICAMENTOS ESPECIAIS, DROGASIL MENTORELAX, DROGASIL NUTRI BALANCE, DROGASIL NUTRI KIDS, DROGASIL NUTRI PETIT, DROGASIL NUTRI PETIT PRO, FARMABRASIL, FARMACÊUTICO 40 HORAS, FARMACÊUTICO VIRTUAL DROGASIL, FARMASIL MEDICAMENTOS ESPECIAIS, FASTLINE, FONE FARMÁCIA QUALIDADE DROGASIL, FOUR BIO, GRUPO RD GENTE, SAÚDE E BEM-ESTAR, LEPOP, LOVS, MUFA, MUFA MUSEU DO UNIVERSO DA FARMÁCIA, NEEDS COMPOSTO DE MEL E EXTRATO DE PRÓPOLIS SABOR GENGIBRE E HORTELÃ, NEEDS COMPOSTO DE MEL E EXTRATO DE PRÓPOLIS SABOR GENGIBRE, HORTELÃ E ROMÃ, NEEDS COMPOSTO DE MEL E EXTRATO DE PRÓPOLIS SABOR HORTELÃ, NEEDS EXTRATO AQUOSO DE PRÓPOLIS, NEEDS MEL FLORADA SILVESTRE, NEEDS MEL ORGÂNICO, NUTREAT, NUTRIGOOD, NUTRIGOOD;, ONCLI, ONHEALTH SOLUTIONS, ONOFRE, ONOFRE CLINIC, PORTAL VIVER, PRAVOCÊ DROGA RAIA, PROD-VIT, PROGRAMA MUITO MAIS RAIA, R&D RAIA DROGASIL, RAIA DROGASIL PHARMA, RAIA MENTORELAX, RAIA NUTRI BALANCE, RAIA NUTRI KIDS, RAIA NUTRI PETIT, RAIA NUTRI PETIT PRO, RD, RD RAIA DROGASIL, SUA DROGA RAIA, TRISS, VEGAN BY NEEDS, VOCÊ BEM COM VOCÊ, VITAT, VITAT MOVIMENTO, VITAT CUIDADOS, VITAT SONO, VITAT EQUILÍBRIO, DS DIETA& SAÚDE, WORKOUT, WORKOUT CORPORATE, B2U PROPAGANDA, PONTO LIGHT, CUIDÁI, TECNONUTRI, CHÁ TECNONUTRI, REVISTA MAIS DS, VITATI, AMAVITA, registered under the INPI, in different classes of services and products related to our activities.

We have, in progress at the INPI, trademark applications relating to trademarks 4BIO A VIDA EM PRIMEIRO LUGAR, 4BIO MEDICAMENTOS ESPECIAIS, AMAVITA, AVIGORA, DROGA RAIA CONFIANÇA E RESPEITO DESDE 1905, DROGA RAIA O CUIDADO COMEÇA COM VOCÊ, DROGASIL CONFIE EM QUEM ENTENDE, DROGASIL VOCÊ CONFIA EM QUEM ENTENDE, FORVIV, LEPOP, LOVS, LUMI, MENTORUB, MENTORUB DROGA RAIA, MENTORUB DROGASIL, NEEDS, NEEDS BABY ULTRASAFE, NEEDS BALA DE GENGIBRE, NUTREAT, ONOFRE, PLUII, PORTAL VIVER, PROD-VIT, PULSO DESIGN SYSTEM, RD, RD FARMA, RD GENTE, SAÚDE E BEM ESTAR. RAIA DROGASIL S.A., RD MED, RD PHARMA, RD RAIA DROGASIL, TRISS, VEGAN BY NEEDS, ZEN CHÁ BY

1.6 Relevant effects of state regulation

TECNONUTRI, TECNONUTRI, CHÁ TECNONUTRI, VITAT, WORKOUT, in addition to several figurative trademarks and three-dimensional trademarks, which are just logos.

In addition to the trademarks, we have two Industrial Designs with the INPI, namely: DI 302012001043-8 valid until March 09, 2037 for "Configuration applied in bottles" and DI 302012001042-0 valid until March 09, 2037 for "Configuration applied in soap".

Abroad, we have registered trademarks RAIA DROGASIL and DROGASIL in Argentina, Uruguay, Paraguay, and Bolivia.

PROCEEDINGS	TRADEMARK	PRESENTATION	EXTENSION	STATUS
912052791	PLUII	Tridimensional		APPLICATION
912828820	NUTREAT	Word mark		APPLICATION
917853733	MENTORUB DROGA RAIA	Word and Device mark		APPLICATION
917854586	ProD-vit	Word mark		APPLICATION
917953355	PORTAL VIVER	Word mark		APPLICATION
917953576	PORTAL VIVER	Word mark		APPLICATION
918572614	TRISS	Word and Device mark		APPLICATION
918572878	TRISS	Word and Device mark		APPLICATION
918977584	NEEDS	Word mark		APPLICATION
918977614	NEEDS	Word mark		APPLICATION
919447295	LOVS	Word mark		APPLICATION
919447325	LOVS	Word mark		APPLICATION
919460097	RD	Word and Device mark		APPLICATION
919460224	RD	Word and Device mark		APPLICATION
919460267	RD	Word and Device mark		APPLICATION
919460313	RD	Word and Device mark		APPLICATION
919460399	RD RAIA DROGASIL	Word mark		APPLICATION
919460437	RD RAIA DROGASIL	Word mark		APPLICATION
919460526	RD RAIA DROGASIL	Word mark		APPLICATION
919623506	RD Farma	Word mark		APPLICATION
919787711	RD Pharma	Word mark		APPLICATION
919835511	RD Med	Word mark		APPLICATION
920804357	PULSO DESIGN SYSTEM	Word mark		APPLICATION
921348606	NEEDS BALA DE GENGIBRE	Word and Device mark		APPLICATION
921416059	RD GENTE, SAÚDE E BEM ESTAR. RAIA DROGASIL S.A.	Word and Device mark		APPLICATION
923638288	melhor versão	Word and Device mark		APPLICATION
924718005	NEEDS	Word and Device mark		APPLICATION
925065196	VEGAN BY NEEDS	Word mark		APPLICATION
925065404	VEGAN BY NEEDS	Word mark		APPLICATION
925068560	4BIO	Word and Device mark		APPLICATION
925170780	natu_me	Word mark		APPLICATION
925170836	natu_me	Word mark		APPLICATION
925170887	natu_me	Word mark		APPLICATION
925170941	natu_me	Word mark		APPLICATION

1.6 Relevant effects of state regulation

925171476	natu_me	Word mark		APPLICATION
925171492	Natz	Word mark		APPLICATION
925171522	Natz	Word mark		APPLICATION
925171573	Natz	Word mark		APPLICATION
925171646	Natz	Word mark		APPLICATION
925171697	Natz	Word mark		APPLICATION
925424994	HEALTHBACK	Word mark		APPLICATION
925425079	HEALTHBACK	Word mark		APPLICATION
925425168	HEALTHBACK	Word mark		APPLICATION
003156001	DROGASIL	Word and Device mark	04/05/2032	REGISTRATION
003174646	FARMASIL	Word mark	04/08/2032	REGISTRATION
003155994	FARMASIL	Word and Device mark	05/24/2022	REGISTRATION
005018684	FARMASIL	Word and Device mark	05/24/2022	REGISTRATION
003288978	DROGASIL	Word and Device mark	07/28/2026	REGISTRATION
001979965	DROGASIL	Word and Device mark	07/12/2027	REGISTRATION
003156010	DROGASIL	Word and Device mark	04/05/2032	REGISTRATION
003099091	DROGASIL	Word and Device mark	04/06/2025	REGISTRATION
003662462	DROGASIL	Word mark	11/30/2027	REGISTRATION
004511077	DROGASIL	Word and Device mark	08/17/2022	REGISTRATION
006246222	DROGASIL	Word mark	03/10/2026	REGISTRATION
006246230	DROGASIL	Word and Device mark	03/10/2026	REGISTRATION
003574296	DROGASIL	Word and Device mark	07/16/2027	REGISTRATION
003695360	FARMASIL	Word mark	03/14/2028	REGISTRATION
005013720	FARMASIL	Word mark	03/14/2028	REGISTRATION
710164033	DROGASIL	Word mark	02/09/2032	REGISTRATION
811099253	DROGASIL	Word mark	11/06/2024	REGISTRATION
811099229	DROGASIL	Word mark	12/26/2024	REGISTRATION
811099210	DROGASIL	Word mark	02/05/2025	REGISTRATION
811099237	DROGASIL	Word mark	03/04/2026	REGISTRATION
813251010	DROGASIL	Word and Device mark	10/11/2028	REGISTRATION
813251044	DROGASIL	Word and Device mark	10/11/2028	REGISTRATION
813251060	DROGASIL	Word and Device mark	10/11/2028	REGISTRATION
813251001	DROGASIL	Word and Device mark	08/22/2029	REGISTRATION
813251028	DROGASIL	Word and Device mark	08/28/2030	REGISTRATION
813251052	DROGASIL	Word and Device mark	09/11/2030	REGISTRATION
816681058	DROGA RAIA	Word and Device mark	12/07/2023	REGISTRATION
813251036	DROGASIL	Word and Device mark	02/28/2025	REGISTRATION
817753923	DROGA RAIA	Word and Device mark	12/05/2025	REGISTRATION
818239840	DROGASIL	Word and Device mark	04/01/2027	REGISTRATION
818239832	DROGASIL	Word and Device mark	04/08/2027	REGISTRATION
818239859	DROGASIL	Word and Device mark	04/08/2027	REGISTRATION
818239824	DROGASIL	Word and Device mark	06/10/2027	REGISTRATION
818239867	DROGASIL	Word and Device mark	06/10/2027	REGISTRATION
818574402	RAIA	Word mark	10/28/2027	REGISTRATION
818574410	RAIA	Word mark	09/22/2028	REGISTRATION

1.6 Relevant effects of state regulation

818574429	RAIA	Word mark	10/13/2029	REGISTRATION
820170402	DROGASIL	Word and Device mark	12/07/2029	REGISTRATION
819356999	KID CARD	Word and Device mark	11/18/2023	REGISTRATION
820431230	SER PLUS	Word mark	06/07/2025	REGISTRATION
820431290	SER SAUDEL	Word mark	06/07/2025	REGISTRATION
820534153	ZAMBELETTI	Word mark	06/14/2025	REGISTRATION
820458481	DROGA RAIA	Word and Device mark	07/05/2025	REGISTRATION
819033324	KID CARD	Word mark	07/26/2025	REGISTRATION
819033359	SENIOR CARD	Word mark	07/26/2025	REGISTRATION
820458473	DROGA RAIA	Word and Device mark	07/26/2025	REGISTRATION
820458538	DROGA RAIA	Word and Device mark	08/09/2025	REGISTRATION
822230690	DROGASIL DELIVERY	Word and Device mark	06/20/2026	REGISTRATION
822230712	DROGASIL DELIVERY	Word and Device mark	06/20/2026	REGISTRATION
822230739	DELIVERY 0800-158200	Word and Device mark	06/20/2026	REGISTRATION
819280844	S.O.S.DROGASIL	Word mark	07/04/2026	REGISTRATION
822230704	DROGASIL DELIVERY	Word and Device mark	08/15/2026	REGISTRATION
822230720	DELIVERY 0800-158200	Word and Device mark	08/15/2026	REGISTRATION
822230682	DROGASIL DELIVERY	Word and Device mark	08/29/2026	REGISTRATION
822658224	RAIA DELIVERY	Word mark	03/06/2027	REGISTRATION
824522010	DROGASIL	Word and Device mark	04/24/2027	REGISTRATION
824522028	DROGASIL DELIVERY	Word and Device mark	04/24/2027	REGISTRATION
824522036	DROGASIL DELIVERY	Word and Device mark	04/24/2027	REGISTRATION
824522052	FARMASIL	Word and Device mark	04/24/2027	REGISTRATION
824522060	FARMASIL	Word mark	04/24/2027	REGISTRATION
824707176	DROGASIL	Word and Device mark	04/24/2027	REGISTRATION
824707184	DROGASIL	Word and Device mark	04/24/2027	REGISTRATION
822658151	RAIA DELIVERY	Word mark	05/29/2027	REGISTRATION
822658178	RAIA DELIVERY	Word mark	05/29/2027	REGISTRATION
823757730	RAIA HIPERFARMÁCIA	Word mark	05/29/2027	REGISTRATION
824666941	RAIA	Word mark	08/07/2027	REGISTRATION
826020984	PHARMACIA RAIA	Word mark	08/14/2027	REGISTRATION
822953790		Figurative mark	08/28/2027	REGISTRATION
822416204	DROGARIA ONOFRE	Word and Device mark	10/23/2027	REGISTRATION
827433603	DROGASIL ESSENCE	Word and Device mark	12/11/2027	REGISTRATION
827433611	DROGASIL ESSENCE	Word and Device mark	12/11/2027	REGISTRATION
827433620	DROGASIL ESSENCE	Word and Device mark	12/11/2027	REGISTRATION
822658160	RAIA EM CASA	Word and Device mark	01/29/2028	REGISTRATION
822658186	RAIA EM CASA	Word and Device mark	01/29/2028	REGISTRATION
822658208	RAIA EM CASA	Word and Device mark	01/29/2028	REGISTRATION
822658194	RAIA DELIVERY	Word mark	05/13/2028	REGISTRATION
824522044	DELIVERY 0800-158200	Word and Device mark	06/24/2028	REGISTRATION
823757692	RAIA HIPERFARMÁCIA	Word mark	08/12/2028	REGISTRATION
822953684	RAIA DELIVERY	Word mark	08/19/2028	REGISTRATION
822953692	DROGARIA SAÚDE E BELEZA 24 HORAS	Word mark	08/19/2028	REGISTRATION

1.6 Relevant effects of state regulation

822953706	DROGARAIA	Word mark	08/19/2028	REGISTRATION
822953722	RAIA EM CASA	Word and Device mark	08/19/2028	REGISTRATION
822953730	DROGA RAIA	Word and Device mark	08/19/2028	REGISTRATION
822953773	ZAMBELETTI	Word mark	08/19/2028	REGISTRATION
822953781	DROGA RAIA	Word and Device mark	08/19/2028	REGISTRATION
900522356	ONOFRE	Word and Device mark	12/15/2029	REGISTRATION
829419705	4 BIO	Word and Device mark	12/29/2029	REGISTRATION
829419713	FOUR BIO	Word mark	12/29/2029	REGISTRATION
829011692	DROGASIL	Word and Device mark	01/19/2030	REGISTRATION
829011706	DROGASIL	Word and Device mark	01/19/2030	REGISTRATION
829011722	DROGASIL	Word and Device mark	01/19/2030	REGISTRATION
901250350	INTEGREA	Word mark	02/01/2031	REGISTRATION
829011714	DROGASIL	Word and Device mark	05/24/2031	REGISTRATION
901555967	RAIA	Word and Device mark	12/27/2031	REGISTRATION
901556041	RAIA	Word and Device mark	12/27/2031	REGISTRATION
901556149	DROGA RAIA	Word and Device mark	12/27/2031	REGISTRATION
901556254	DROGA RAIA	Word and Device mark	12/27/2031	REGISTRATION
901556270	RAIA	Word and Device mark	12/27/2031	REGISTRATION
901556378	RAIA	Word and Device mark	12/27/2031	REGISTRATION
901556440	RAIA	Word and Device mark	12/27/2031	REGISTRATION
901555991	DROGA RAIA	Word and Device mark	03/06/2032	REGISTRATION
901926051	DROGASIL VIVER FELIZ	Word and Device mark	07/31/2022	REGISTRATION
901926086	DEEX DROGASIL ENCOMENDA EXPRESSA	Word and Device mark	07/31/2022	REGISTRATION
824707613	RAIA	Word mark	08/07/2022	REGISTRATION
901984264	DROGA RAIA	Word and Device mark	08/07/2022	REGISTRATION
904956776	FIGURATIVE MARK	Figurative mark	07/07/2025	REGISTRATION
904956792	FIGURATIVE MARK	Figurative mark	07/07/2025	REGISTRATION
904957020	FARMASIL	Word and Device mark	07/07/2025	REGISTRATION
904957152	FARMASIL	Word and Device mark	07/07/2025	REGISTRATION
904957179	FARMASIL	Word and Device mark	07/07/2025	REGISTRATION
904957241	FARMASIL	Word and Device mark	07/07/2025	REGISTRATION
904957322	FARMASIL	Word and Device mark	07/07/2025	REGISTRATION
904957438	FARMASIL	Word and Device mark	07/07/2025	REGISTRATION
904803007	RAIA DROGASIL	Word and Device mark	07/14/2025	REGISTRATION
904803023	RAIA DROGASIL	Word and Device mark	07/14/2025	REGISTRATION
904803279	RAIA DROGASIL	Word and Device mark	07/14/2025	REGISTRATION
904803392	RAIA DROGASIL	Word and Device mark	07/14/2025	REGISTRATION
904803538	FIGURATIVE MARK	Figurative mark	07/14/2025	REGISTRATION
904803597	FIGURATIVE MARK	Figurative mark	07/14/2025	REGISTRATION
904803643	FIGURATIVE MARK	Figurative mark	07/14/2025	REGISTRATION
904803678	FIGURATIVE MARK	Figurative mark	07/14/2025	REGISTRATION
904803767	FIGURATIVE MARK	Figurative mark	07/14/2025	REGISTRATION
904803104	RAIA DROGASIL	Word and Device mark	09/01/2025	REGISTRATION
906140935	UNIVERS	Word mark	02/10/2026	REGISTRATION

1.6 Relevant effects of state regulation

906141079	UNIVERS	Word mark	02/10/2026	REGISTRATION
906141150	UNIVERS	Word mark	02/10/2026	REGISTRATION
904956610	RAIA DROGASIL	Word and Device mark	07/05/2026	REGISTRATION
904956695	RAIA DROGASIL	Word and Device mark	07/05/2026	REGISTRATION
831051582	PROGRAMA MUITO MAIS RAIA	Word and Device mark	09/27/2026	REGISTRATION
831089130	B-WELL	Word and Device mark	09/27/2026	REGISTRATION
903176858	NEEDS	Word and Device mark	09/27/2026	REGISTRATION
903177064	NEEDS	Word and Device mark	09/27/2026	REGISTRATION
903232600	PLUII	Word mark	09/27/2026	REGISTRATION
903488345		Figurative mark	09/27/2026	REGISTRATION
903488477		Figurative mark	09/27/2026	REGISTRATION
903906511	PLUII	Word and Device mark	09/27/2026	REGISTRATION
903932628	RAIA DROGASIL	Word mark	09/27/2026	REGISTRATION
904114520	AMORA-ROSA	Word mark	09/27/2026	REGISTRATION
904114538	LIMA-LIMÃO	Word mark	09/27/2026	REGISTRATION
904114562	VIBRE-GENGIBRE	Word mark	09/27/2026	REGISTRATION
904114570	BRILHA-BAUNILHA	Word mark	09/27/2026	REGISTRATION
904114589	VERDE-ERVA	Word mark	09/27/2026	REGISTRATION
904114635	PLUII AMORA ROSA	Word and Device mark	09/27/2026	REGISTRATION
904114651	PLUII VIBRE GENGIBRE	Word and Device mark	09/27/2026	REGISTRATION
904114686	PLUII BRILHA BAUNILHA	Word and Device mark	09/27/2026	REGISTRATION
904114708	PLUII LIMA LIMÃO	Word and Device mark	09/27/2026	REGISTRATION
904114740	PLUII VERDE ERVA	Word and Device mark	09/27/2026	REGISTRATION
904114767	PLUII	Word and Device mark	09/27/2026	REGISTRATION
908818424	B-WELL A/Z MULTIVITAMÍNICO	Word mark	07/25/2027	REGISTRATION
908818432	B-WELL CÁLCIO + D	Word mark	07/25/2027	REGISTRATION
908818467	B-WELL GUARANÁ	Word mark	07/25/2027	REGISTRATION
908818475	B-WELL MULTI SILVER	Word mark	07/25/2027	REGISTRATION
908819528	BWELL AZ MULTIVITAMINICO + OMEGA	Word mark	07/25/2027	REGISTRATION
908819536	BWELL HOMEM	Word mark	07/25/2027	REGISTRATION
908819579	BWELL MULHER	Word mark	07/25/2027	REGISTRATION
908819595	B-WELL ÓLEO DE PRIMULA	Word mark	07/25/2027	REGISTRATION
908819633	B-WELL ÓLEO DE LINHAÇA	Word mark	07/25/2027	REGISTRATION
908819650	B-WELL ÓLEO DE CARTAMO	Word mark	07/25/2027	REGISTRATION
908819676	B-WELL VITAMINA D	Word mark	07/25/2027	REGISTRATION
908819692	B-WELL ÓLEO DE CHIA	Word mark	07/25/2027	REGISTRATION
908819714	B-WELL OMEGA 3	Word mark	07/25/2027	REGISTRATION
908819803	PLUII LISS CASSIS	Word mark	07/25/2027	REGISTRATION
900522488	ONOFRE	Word and Device mark	08/15/2027	REGISTRATION
908821239	PLUII VERDE VERBENA	Word mark	08/15/2027	REGISTRATION
829507426	FONE FARMÁCIA QUALIDADE DROGASIL	Word and Device mark	11/28/2027	REGISTRATION
829507434	FONE FARMÁCIA QUALIDADE DROGASIL	Word and Device mark	11/28/2027	REGISTRATION

1.6 Relevant effects of state regulation

910031070	FARMASIL SERVIÇOS FARMACÊUT ICOS	Word mark	12/26/2027	REGISTRATION
910031096	DROGASIL SERVIÇOS FARMACÊUTI COS	Word mark	12/26/2027	REGISTRATION
904957462	FARMASIL	Word and Device mark	01/09/2028	REGISTRATION
910031037	RAIA SERVIÇOS FARMACÊUTICOS	Word mark	01/09/2028	REGISTRATION
906140960	UNIVERS	Word mark	03/13/2028	REGISTRATION
906141010	UNIVERS	Word mark	03/13/2028	REGISTRATION
911206027	DROGARIA ONOFRE	Word and Device mark	05/02/2028	REGISTRATION
911206116	ONOFRE	Word mark	05/02/2028	REGISTRATION
911206132	ONOFRE	Word mark	05/02/2028	REGISTRATION
910918937	DROGASIL MEDICAMENTOS ESPECIAIS	Word mark	05/15/2028	REGISTRATION
910919194	FARMASIL MEDICAMENTOS ESPECIAIS	Word mark	05/15/2028	REGISTRATION
910919313	DROGA RAIA MEDICAMENTOS ESPECIAIS	Word mark	05/15/2028	REGISTRATION
910919542	RAIA MEDICAMENTOS ESPECIAIS	Word mark	05/15/2028	REGISTRATION
910919747	FARMASIL MEDICAMENTOS ESPECIAIS	Word mark	05/15/2028	REGISTRATION
911125574	RD RAIA DROGASIL	Word mark	06/05/2028	REGISTRATION
911125612	R&D RAIA DROGASIL	Word mark	06/05/2028	REGISTRATION
911399356	CARETECH	Word mark	06/26/2028	REGISTRATION
911399615	CARETECH	Word and Device mark	06/26/2028	REGISTRATION
911399704	CARETECH	Word and Device mark	06/26/2028	REGISTRATION
911399836	CARETECH	Word mark	06/26/2028	REGISTRATION
911400010	CARETECH	Word mark	06/26/2028	REGISTRATION
911400036	CARETECH	Word and Device mark	06/26/2028	REGISTRATION
911737529	DROGARIA ONOFRE	Word and Device mark	06/26/2028	REGISTRATION
911737472	DROGARIA ONOFRE	Word and Device mark	07/03/2028	REGISTRATION
911838449	DROGARIA ONOFRE	Word and Device mark	07/03/2028	REGISTRATION
911838546	ONOFRE	Word and Device mark	07/03/2028	REGISTRATION
911545999	Pra 9VOCÊ Droga Raia	Word and Device mark	07/10/2028	REGISTRATION
912005106	ONOFRE	Word mark	07/31/2028	REGISTRATION
911740538	Drogasil & Você.	Word mark	08/07/2028	REGISTRATION
911740635	Sua Droga Raia.	Word mark	08/07/2028	REGISTRATION
911794581	GRUPO RD GENTE, SAÚDE E BEM- ESTAR.	Word and Device mark	08/21/2028	REGISTRATION
911794611	GRUPO RD GENTE, SAÚDE E BEM- ESTAR.	Word and Device mark	08/21/2028	REGISTRATION
912957263	DESAFIO ONOFRE	Word mark	11/06/2028	REGISTRATION

1.6 Relevant effects of state regulation

912957352	DESAFIO ONOFRE	Word and Device mark	11/06/2028	REGISTRATION
912957840	VOCÊ BEM COM VOCÊ	Word and Device mark	11/06/2028	REGISTRATION
912828609	NUTRIGOOD	Word mark	11/13/2028	REGISTRATION
912828692	NUTRIGOOD	Word mark	12/11/2028	REGISTRATION
912828757	NUTRIGOOD	Word mark	12/11/2028	REGISTRATION
912932686	NUTRIGOOD	Word and Device mark	12/11/2028	REGISTRATION
912932627	NUTRIGOOD	Word and Device mark	12/18/2028	REGISTRATION
913248991	NEEDS	Word and Device mark	01/02/2029	REGISTRATION
913249076	NEEDS	Word and Device mark	01/02/2029	REGISTRATION
913251364	NEEDS	Word and Device mark	01/02/2029	REGISTRATION
913251437	NEEDS	Word and Device mark	01/02/2029	REGISTRATION
913251500	NEEDS	Word and Device mark	01/02/2029	REGISTRATION
913251569	NEEDS	Word and Device mark	01/02/2029	REGISTRATION
913341096	CUIDAR +	Word and Device mark	01/08/2029	REGISTRATION
913654531		Figurative mark	01/08/2029	REGISTRATION
913654779	FASTLINE	Word and Device mark	01/08/2029	REGISTRATION
913688126	BLACKFARMA % DROGARIA ONOFRE	Word and Device mark	01/08/2029	REGISTRATION
913688215	BLACKFARMA % DROGARIA ONOFRE	Word mark	01/08/2029	REGISTRATION
913688274	DROGARIA ONOFRE BLACKFARMA	Word and Device mark	01/08/2029	REGISTRATION
913688363	DROGARIA ONOFRE BLACKFARMA	Word and Device mark	01/08/2029	REGISTRATION
913688401	DROGARIA ONOFRE BLACKFARMA	Word mark	01/08/2029	REGISTRATION
913569313	NUTRIGOOD	Word mark	01/29/2029	REGISTRATION
913569330	NUTRIGOOD	Word and Device mark	01/29/2029	REGISTRATION
912933011	NUTRIGOOD	Word and Device mark	02/19/2029	REGISTRATION
913875848	MUFA - Museu do Universo da Farmácia	Word mark	02/26/2029	REGISTRATION
913875945	MUFA MUSEU DO UNIVERSO DA FARMÁCIA	Word and Device mark	02/26/2029	REGISTRATION
913875996	MUFA	Word and Device mark	02/26/2029	REGISTRATION
914089064	ONOFRE CLINIC	Word and Device mark	02/26/2029	REGISTRATION
914089200	ONOFRE CLINIC	Word and Device mark	03/06/2029	REGISTRATION
914678205	ONCLI	Word and Device mark	04/16/2029	REGISTRATION
914744879	ONCLI	Word and Device mark	04/16/2029	REGISTRATION
914474766	LEPOP	Word and Device mark	05/07/2029	REGISTRATION
914474774	LEPOP	Word and Device mark	05/07/2029	REGISTRATION
914474790	LEPOP	Word and Device mark	05/07/2029	REGISTRATION
914474812	LEPOP	Word and Device mark	05/07/2029	REGISTRATION
914474839	LEPOP	Word and Device mark	05/07/2029	REGISTRATION
914474855	LEPOP	Word and Device mark	05/07/2029	REGISTRATION
914960849	ONHEALTH SOLUTIONS	Word and Device mark	05/14/2029	REGISTRATION
914584456	FARMACÊUTICO 40 HORAS	Word and Device mark	05/21/2029	REGISTRATION
914618776	DROGASIL	Word and Device mark	05/21/2029	REGISTRATION
914618911	DROGASIL	Word and Device mark	05/21/2029	REGISTRATION
914618938	DROGA RAIÁ	Word and Device mark	05/21/2029	REGISTRATION
914618970	DROGASIL	Word and Device mark	05/21/2029	REGISTRATION

1.6 Relevant effects of state regulation

914619004	DROGA RAI A	Word and Device mark	05/21/2029	REGISTRATION
914619039	DROGASIL	Word and Device mark	05/21/2029	REGISTRATION
914619080	DROGASIL	Word and Device mark	05/21/2029	REGISTRATION
914650386	CARETECH	Word and Device mark	05/21/2029	REGISTRATION
914815679	FARMABRASIL	Word mark	06/04/2029	REGISTRATION
914870980	ONCLI	Word and Device mark	07/02/2029	REGISTRATION
914871064	ONCLI	Word and Device mark	07/02/2029	REGISTRATION
915060310	NEEDS COMPOSTO DE MEL E EXTRATO DE PRÓPOLIS SABOR GENGIBRE E HORTELÃ	Word and Device mark	07/02/2029	REGISTRATION
915060604	NEEDS COMPOSTO DE MEL E EXTRATO DE PRÓPOLIS SABOR HORTELÃ	Word and Device mark	07/02/2029	REGISTRATION
915060647	NEEDS EXTRATO AQUOSO DE PRÓPOLIS	Word and Device mark	07/02/2029	REGISTRATION
915060892	NEEDS MEL ORGÂNICO	Word and Device mark	07/02/2029	REGISTRATION
915061040	NEEDS COMPOSTO DE MEL E EXTRATO DE PRÓPOLIS SABOR GENGIBRE, HORTELÃ E ROMÃ	Word and Device mark	07/02/2029	REGISTRATION
915060787	NEEDS MEL FLORADA SILVESTRE	Word and Device mark	08/27/2029	REGISTRATION
910918996	DROGASIL MEDICAMENTOS ESPECIAIS	Word mark	10/22/2029	REGISTRATION
910919976	DROGA RAI A MEDICAMENTOS ESPECIAIS	Word mark	10/22/2029	REGISTRATION
910920087	RAIA MEDICAMENTOS ESPECIAIS	Word mark	10/22/2029	REGISTRATION
829267905	RAIA TOTAL BENEFÍCIO FARMA	Word and Device mark	11/05/2029	REGISTRATION
916738817	ONCLI	Word and Device mark	11/12/2029	REGISTRATION
916913538	VEGAN BY NEEDS	Word mark	12/10/2029	REGISTRATION
916913597	VEGAN BY NEEDS	Word mark	12/10/2029	REGISTRATION
916913708	VEGAN BY NEEDS	Word mark	12/10/2029	REGISTRATION
916914135	VEGAN BY NEEDS	Word mark	12/10/2029	REGISTRATION
916914178	VEGAN BY NEEDS	Word mark	12/10/2029	REGISTRATION
917230531	FARMACÊUTICO VIRTUAL DROGASIL	Word and Device mark	02/11/2030	REGISTRATION
917282825	NEEDS	Word and Device mark	02/11/2030	REGISTRATION
917282930	NEEDS	Word and Device mark	02/11/2030	REGISTRATION
917283007	NEEDS	Word and Device mark	02/11/2030	REGISTRATION
917283147	NEEDS	Word and Device mark	02/11/2030	REGISTRATION
917283228	NEEDS	Word and Device mark	02/11/2030	REGISTRATION
917283309	NEEDS	Word and Device mark	02/11/2030	REGISTRATION
917145119	FOUR BIO	Word mark	02/27/2030	REGISTRATION
917145224	4BIO	Word mark	02/27/2030	REGISTRATION
917145240	4BIO	Word and Device mark	02/27/2030	REGISTRATION

1.6 Relevant effects of state regulation

917145054	4BIO	Word mark	04/14/2030	REGISTRATION
917145178	4BIO	Word and Device mark	04/14/2030	REGISTRATION
917854713	ProD-vit	Word mark	04/22/2030	REGISTRATION
917854748	ProD-vit	Word mark	04/22/2030	REGISTRATION
917855027	ProD-vit	Word mark	04/22/2030	REGISTRATION
917953444	PORTAL VIVER	Word mark	05/05/2030	REGISTRATION
917953550	PORTAL VIVER	Word mark	05/05/2030	REGISTRATION
917953681	4BIO VIVER PLATAFORMA DE CUIDADOS	Word and Device mark	05/05/2030	REGISTRATION
917953762	4BIO VIVER PLATAFORMA DE CUIDADOS	Word and Device mark	05/05/2030	REGISTRATION
917953886	4BIO VIVER PLATAFORMA DE CUIDADOS	Word and Device mark	05/05/2030	REGISTRATION
917953975	4BIO VIVER PLATAFORMA DE CUIDADOS	Word and Device mark	05/05/2030	REGISTRATION
908819757	PLUII BLU MARINO	Word mark	05/19/2030	REGISTRATION
904957063	FARMASIL	Word and Device mark	09/29/2030	REGISTRATION
912828641	NUTREAT	Word mark	09/29/2030	REGISTRATION
918884209	VEGAN BY NEEDS	Word and Device mark	10/20/2030	REGISTRATION
918884411	VEGAN BY NEEDS	Word and Device mark	10/20/2030	REGISTRATION
918884985	VEGAN BY NEEDS	Word and Device mark	10/20/2030	REGISTRATION
918885043	VEGAN BY NEEDS	Word and Device mark	10/20/2030	REGISTRATION
918885116	VEGAN BY NEEDS	Word and Device mark	10/20/2030	REGISTRATION
918977460	NEEDS	Word mark	10/27/2030	REGISTRATION
918977479	NEEDS	Word mark	10/27/2030	REGISTRATION
918977495	NEEDS	Word mark	10/27/2030	REGISTRATION
918977525	NEEDS	Word mark	10/27/2030	REGISTRATION
918977541	NEEDS	Word mark	10/27/2030	REGISTRATION
918977568	NEEDS	Word mark	10/27/2030	REGISTRATION
918977673	NEEDS	Word and Device mark	10/27/2030	REGISTRATION
918977711	NEEDS	Word mark	10/27/2030	REGISTRATION
918977746	DROGASIL	Word mark	10/27/2030	REGISTRATION
918977843	RAIA	Word mark	10/27/2030	REGISTRATION
918977860	DROGASIL	Word mark	10/27/2030	REGISTRATION
919063926	DROGASIL NUTRI KIDS	Word mark	11/10/2030	REGISTRATION
919064051	RAIA NUTRI KIDS	Word mark	11/10/2030	REGISTRATION
919106978	DROGASIL NUTRI PETIT PRO	Word mark	11/17/2030	REGISTRATION
919107010	RAIA NUTRI PETIT PRO	Word mark	11/17/2030	REGISTRATION
919111351	RAIA MENTORELAX	Word mark	11/17/2030	REGISTRATION
919111602	DROGASIL MENTORELAX	Word mark	11/17/2030	REGISTRATION
919091792	RAIA NUTRI BALANCE	Word mark	11/24/2030	REGISTRATION
919091849	DROGASIL NUTRI BALANCE	Word mark	11/24/2030	REGISTRATION
919301002	RAIA NUTRI PETIT	Word mark	12/29/2030	REGISTRATION
919301096	DROGASIL NUTRI PETIT	Word mark	12/29/2030	REGISTRATION
918572436	TRISS	Word and Device mark	01/05/2031	REGISTRATION
918572495	TRISS	Word and Device mark	01/05/2031	REGISTRATION
918572592	TRISS	Word and Device mark	01/05/2031	REGISTRATION

1.6 Relevant effects of state regulation

918572711	TRISS	Word and Device mark	01/05/2031	REGISTRATION
918572819	TRISS	Word and Device mark	01/05/2031	REGISTRATION
918573165	TRISS	Word and Device mark	01/05/2031	REGISTRATION
918573254	TRISS	Word and Device mark	01/05/2031	REGISTRATION
918573319	TRISS	Word and Device mark	01/05/2031	REGISTRATION
918573378	TRISS	Word and Device mark	01/05/2031	REGISTRATION
919447341	LOVS	Word mark	01/12/2031	REGISTRATION
919447350	LOVS	Word mark	01/12/2031	REGISTRATION
919447376	LOVS	Word mark	01/12/2031	REGISTRATION
919447406	LOVS	Word mark	01/12/2031	REGISTRATION
919456235	CARETECH	Word mark	01/19/2031	REGISTRATION
919460330	RD	Word and Device mark	01/19/2031	REGISTRATION
919460445	RD RAIA DROGASIL	Word mark	01/19/2031	REGISTRATION
919460542	RD RAIA DROGASIL	Word mark	01/19/2031	REGISTRATION
919623549	NUTRIGOOD:	Word and Device mark	02/09/2031	REGISTRATION
919623603	NUTRIGOOD:	Word and Device mark	02/09/2031	REGISTRATION
919623689	NUTRIGOOD:	Word and Device mark	02/09/2031	REGISTRATION
919623883	NUTRIGOOD:	Word and Device mark	02/09/2031	REGISTRATION
919661106	#TODOCUIDADOCONTA	Word mark	02/17/2031	REGISTRATION
919661114	#TODOCUIDADOCONTA	Word mark	02/17/2031	REGISTRATION
919661130	#TODOCUIDADOCONTA	Word mark	02/17/2031	REGISTRATION
919835554	Raia Drogasil Pharma	Word mark	03/16/2031	REGISTRATION
919447210	LOVS	Word mark	04/06/2031	REGISTRATION
920003850	NEEDS BABY ULTRASAFE	Word mark	04/20/2031	REGISTRATION
920003931	4BIO MEDICAMENTOS ESPECIAIS	Word mark	04/20/2031	REGISTRATION
914474723	LEPOP	Word and Device mark	07/13/2031	REGISTRATION
914618890	DROGA RAIA O CUIDADO COMEÇA COM VOCÊ	Word and Device mark	08/24/2031	REGISTRATION
920804063	PULSO DESIGN SYSTEM	Word mark	08/24/2031	REGISTRATION
912828790	NUTREAT	Word mark	09/08/2031	REGISTRATION
920959083	ONOFRE	Word mark	09/08/2031	REGISTRATION
920959210	ONOFRE	Word mark	09/08/2031	REGISTRATION
914618822	DROGASIL	Word and Device mark	09/28/2031	REGISTRATION
917283481	NEEDS	Word and Device mark	12/28/2031	REGISTRATION
921774087	UNIVERS	Word and Device mark	12/28/2031	REGISTRATION
921774168	UNIVERS	Word and Device mark	12/28/2031	REGISTRATION
921774214	UNIVERS	Word and Device mark	12/28/2031	REGISTRATION
921774273	UNIVERS	Word and Device mark	12/28/2031	REGISTRATION
921774338	UNIVERS	Word and Device mark	12/28/2031	REGISTRATION
921774389	DROGASIL E VOCÊ	Word and Device mark	12/28/2031	REGISTRATION
917789334	Mentorub	Word mark	01/25/2032	REGISTRATION
917853881	MENTORUB DROGA RAIA	Word and Device mark	01/25/2032	REGISTRATION
917853954	MENTORUB DROGASIL	Word and Device mark	01/25/2032	REGISTRATION
917854004	MENTORUB DROGASIL	Word and Device mark	01/25/2032	REGISTRATION
922358176	RD MARKETPLACE DROGA RAIA DROGASIL	Word and Device mark	03/03/2032	REGISTRATION

1.6 Relevant effects of state regulation

922358249	RD MARKETPLACE DROGA RAI A DROGASIL	Word and Device mark	03/03/2032	REGISTRATION
922358320	RD MARKETPLACE DROGA RAI A DROGASIL	Word and Device mark	03/03/2032	REGISTRATION
922358397	RD MARKETPLACE DROGA RAI A DROGASIL	Word and Device mark	03/03/2032	REGISTRATION
922358508	RD MARKETPLACE DROGA RAI A DROGASIL	Word and Device mark	03/03/2032	REGISTRATION
922358702	RD MARKETPLACE DROGA RAI A DROGASIL	Word and Device mark	03/03/2032	REGISTRATION
826428959	B2U PROPAGANDA	Word and Device mark	08/28/2027	REGISTRATION
901337447	PONTO LIGHT	Word mark	02/22/2031	REGISTRATION
903460912	TECNONUTRI	Word and Device mark	10/03/2027	REGISTRATION
904718638	DIETA E SAÚDE	Word mark	05/19/2025	REGISTRATION
906665680	REVISTA MAIS DS	Word and Device mark	06/28/2026	REGISTRATION
906665787	REVISTA MAIS DS	Word and Device mark	06/28/2026	REGISTRATION
916160866	TECNONUTRI	Word and Device mark	07/30/2029	REGISTRATION
917238648	TECNONUTRI	Word and Device mark	01/19/2031	REGISTRATION
917238672	TECNONUTRI	Word and Device mark		APPLICATION
917238680	TECNONUTRI	Word and Device mark	10/26/2031	REGISTRATION
917238737	TECNONUTRI	Word and Device mark	11/26/2029	REGISTRATION
917238761	TECNONUTRI	Word and Device mark	11/26/2029	REGISTRATION
917972937	ZEN CHÁ BY TECNONUTRI	Word and Device mark	08/15/2019	APPLICATION
918215773	CUIDAÍ	Word mark	04/22/2030	REGISTRATION
918215790	CUIDAÍ	Word mark	04/22/2030	REGISTRATION
918215803	CUIDAÍ	Word mark	04/22/2030	REGISTRATION
919193897	CUIDAÍ	Word mark	10/20/2030	REGISTRATION
919193951	CUIDAÍ	Word mark	10/20/2030	REGISTRATION
919193978	CUIDAÍ	Word mark	10/20/2030	REGISTRATION
919945562	CUIDAÍ	Word and Device mark	04/13/2031	REGISTRATION
919945724	CUIDAÍ	Word and Device mark	04/13/2031	REGISTRATION
919479448	WORKOUT	Word mark	11/24/2030	REGISTRATION
919479502	WORKOUT	Word mark	11/24/2030	REGISTRATION
921426666	VITAT	Word mark	10/26/2031	REGISTRATION
921426739	VITAT	Word mark	10/26/2031	REGISTRATION
921426950	VITAT	Word mark	10/26/2031	REGISTRATION
921427077	VITAT	Word mark	10/26/2031	REGISTRATION
921427140	VITAT	Word mark	10/26/2031	REGISTRATION
921427298	VITAT	Word mark	10/26/2031	REGISTRATION
921541163	AMAVITA	Word mark	12/07/2031	REGISTRATION
921541279	AMAVITA	Word mark	12/07/2031	REGISTRATION
921541562	AMAVITA	Word mark	12/07/2031	REGISTRATION
921541716	AMAVITA	Word mark	12/07/2031	REGISTRATION
921681801	AMAVITA	Word mark	12/07/2031	REGISTRATION
921681879	AMAVITA	Word mark	12/07/2031	REGISTRATION

1.6 Relevant effects of state regulation

921681933	AMAVITA	Word mark	12/07/2031	REGISTRATION
921681526	VITAT	Word mark	07/05/2022	REGISTRATION
921681666	VITAT	Word mark	10/26/2031	REGISTRATION
921681720	VITAT	Word mark	10/26/2031	REGISTRATION
921682026	VITATI	Word mark	10/26/2031	REGISTRATION
921682115	VITATI	Word mark	10/26/2031	REGISTRATION
921682174	VITATI	Word mark	10/26/2031	REGISTRATION
921682220	VITATI	Word mark	10/26/2031	REGISTRATION
921682298	VITATI	Word mark	10/26/2031	REGISTRATION
921682417	VITATI	Word mark	10/26/2031	REGISTRATION
921682603	VITATI	Word mark	10/26/2031	REGISTRATION
921682670	VITATI	Word mark	10/26/2031	REGISTRATION
922319537	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922319626	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922319693	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922319758	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922319790	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922319855	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922319910	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922319960	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922331006	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922331081	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922331170	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922331251	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922331367	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922331464	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922331634	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922331740	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922331790	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922331839	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922331901	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922331987	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922332452	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922332576	VITAT	Word and Device mark	02/15/2032	REGISTRATION
922332800	VITAT	Word and Device mark	02/15/2032	REGISTRATION
923543295	CUIDAÍ	Word and Device mark	08/09/2022	REGISTRATION
923543236	CUIDAÍ	Word and Device mark	08/09/2022	REGISTRATION
923543112	CUIDAÍ	Word and Device mark	08/09/2022	REGISTRATION
923543392	CUIDAÍ	Word and Device mark	08/09/2022	REGISTRATION
924256010	VITAT	Word mark	09/13/2021	APPLICATION
924031859	VITAT	Word mark	08/20/2021	APPLICATION
924031948	VITAT	Word and Device mark	08/20/2021	APPLICATION
924256362	VITAT	Word and Device mark	09/13/2021	APPLICATION
924256591	VITAT	Word mark	11/16/2022	REGISTRATION
924257083	VITAT	Word and Device mark	11/16/2022	REGISTRATION

1.6 Relevant effects of state regulation

924257393	VITAT	Word and Device mark	11/16/2022	REGISTRATION
924257679	VITAT	Word and Device mark	11/16/2022	REGISTRATION
924258110	VITAT	Word and Device mark	11/16/2022	REGISTRATION
924258179	VITAT	Word and Device mark	11/16/2022	REGISTRATION
924258403	VITAT MOVIMENTO	Word and Device mark	11/16/2022	REGISTRATION
924258527	VITAT CUIDADOS	Word and Device mark	11/16/2022	REGISTRATION
924258675	VITAT SONO	Word and Device mark	11/16/2022	REGISTRATION
924258837	VITAT EQUILÍBRIO	Word and Device mark	11/16/2022	REGISTRATION
924627905	CHÁ TECNONUTRI	Word and Device mark	01/10/2023	REGISTRATION
924628022	CHÁ TECNONUTRI	Word and Device mark	10/18/2021	APPLICATION
924629290	DS DIETA E SAÚDE	Word and Device mark	01/10/2023	REGISTRATION
924629584	DS DIETA E SAÚDE	Word and Device mark	01/10/2023	REGISTRATION
924629746	DS DIETA E SAÚDE	Word and Device mark	01/10/2023	REGISTRATION
924629835	DS DIETA E SAÚDE	Word and Device mark	01/10/2023	REGISTRATION
924629924	DS DIETA E SAÚDE	Word and Device mark	01/10/2023	REGISTRATION
924630027	WORKOUT	Word mark	10/18/2021	APPLICATION
924630205	WORKOUT	Word mark	10/18/2021	APPLICATION
924630256	WORKOUT	Word mark	01/10/2023	REGISTRATION
924630299	WORKOUT	Word mark	10/18/2021	APPLICATION
924630353	WORKOUT	Word mark	10/18/2021	APPLICATION
924630493	WORKOUT CORPORATE	Word mark	01/10/2023	REGISTRATION
912871083	CUCO HEALTH	Word and Device mark	11/27/2028	REGISTRATION
912871130	CUCO HEALTH	Word and Device mark	11/27/2028	REGISTRATION
912871180	CUCO HEALTH	Word and Device mark	11/27/2028	REGISTRATION
927669064	PRIMEIRA CAIXA	Word mark	08/15/2022	APPLICATION
927669129	PRIMEIRA CAIXA	Word mark	08/15/2022	APPLICATION
927669196	PRIMEIRA CAIXA	Word mark	08/15/2022	APPLICATION
928120740	PRIMEIRA CAIXA	Word and Device mark	09/23/2022	APPLICATION
928120791	PRIMEIRA CAIXA	Word and Device mark	09/23/2022	APPLICATION
928120848	PRIMEIRA CAIXA	Word and Device mark	09/23/2022	APPLICATION
930033477	bari+	Word and Device mark	04/06/2023	APPLICATION
930033485	bari+	Word and Device mark	04/06/2023	APPLICATION
920322255	SAFEPILL	Word and Device mark	04/20/2021	REGISTRATION
926804537	SAFEPILL	Word and Device mark	05/30/2022	APPLICATION
927295792	RD ADS	Word and Device mark	07/14/2022	APPLICATION
927960346	RD ADS	Word and Device mark	09/09/2022	APPLICATION
911700412	MANIPULAÊ	Word and Device mark	09/04/2018	REGISTRATION
910297258	AMPLIDRIVE	Word and Device mark	01/02/2018	REGISTRATION
911306935	AMPLIMED	Word and Device mark	08/28/2018	REGISTRATION
918789451	AMPLI	Word mark	07/26/2022	REGISTRATION
925229440	AMPLIMED	Word and Device mark	02/28/2023	REGISTRATION
925230170	AMPLIMED	Word and Device mark	02/28/2023	REGISTRATION
925230405	AMPLIMED	Word and Device mark	02/28/2023	REGISTRATION
925230553	AMPLIMED	Word and Device mark	02/28/2023	REGISTRATION
925230707	AMPLIMED	Word and Device mark	02/28/2023	REGISTRATION

1.6 Relevant effects of state regulation

927481626	AMPLI	Word mark	07/29/2022	APPLICATION
927481766	AMPLI	Word mark	07/29/2022	APPLICATION
911446974	HEALTHBIT	Word and Device mark	08/07/2018	REGISTRATION

RD national domains:

1.	NEEDSNATOS.COM.BR
2.	APPDROGARAIA.COM.BR
3.	BWELLVITAMINAS.COM.BR
4.	CAMINHARJUNTOS.COM.BR
5.	CARETECH.COM.BR
6.	CARETECHRD.COM.BR
7.	CONVERSAETICA.COM.BR
8.	CUIDARMAISDOSFUNCIONARIOS.COM.BR
9.	DESAFIOONOFRE.COM.BR
10.	DIALOGOSRD.COM.BR
11.	DROGARAIA-E-MAIL-MKT.COM.BR
12.	DROGARAIA-EMAIL-MARKETING.COM.BR
13.	DROGARAIA.COM.BR
14.	DROGARAIA.DEV.BR
15.	DROGARAIA.ECO.BR
16.	DROGARAIA.FAR.BR
17.	DROGARAIA.LOG.BR
18.	DROGARAIA.NET.BR
19.	DROGARAIA.ONG.BR
20.	DROGARAIA.TEC.BR
21.	DROGARAIA.TV.BR
22.	DROGARIA.COM.BR
23.	DROGARIAONOFRE.COM.BR
24.	DROGARIAONOFREELETRO.COM.BR
25.	DROGARIAVISON.COM.BR
26.	DROGASIL-E-MAIL-MKT.COM.BR
27.	DROGASIL-EMAIL-MARKETING.COM.BR
28.	DROGASIL-MKT-EMAIL.COM.BR
29.	DROGASIL.COM.BR
30.	DROGASIL.DEV.BR
31.	DROGASIL.ECO.BR
32.	DROGASIL.FAR.BR
33.	DROGASIL.LOG.BR
34.	DROGASIL.NET.BR
35.	DROGASIL.ONG.BR
36.	DROGASIL.TEC.BR
37.	DROGASIL.TV.BR
38.	DROGASRAIA.COM.BR

1.6 Relevant effects of state regulation

39.	E-RAIA.COM.BR
40.	E-RAIA.FAR.BR
41.	ELETRONOFRE.COM.BR
42.	EMAIL-MARKETING-DROGARAIA.COM.BR
43.	EMAIL-MARKETING-DROGASIL.COM.BR
44.	EMAILDROGARAIA.COM.BR
45.	EMAILDROGASIL.COM.BR
46.	EUSOUONOFRE.COM.BR
47.	FARMACIARAIA.COM.BR
48.	FARMAMUNDO.COM.BR
49.	FARMAMUNDO.FAR.BR
50.	FARMASIL.COM.BR
51.	FIDELIDADEONOFRE.COM.BR
52.	FONEFARMACIA.COM.BR
53.	GRUPORD.FAR.BR
54.	GUIADEMARCARAIA.COM.BR
55.	GUIADEMARCARD.COM.BR
56.	HIPERFARMACIA.COM.BR
57.	HIPERFARMACIARAIA.COM.BR
58.	HISTORIADAFARMACIA.COM.BR
59.	INTEGREA.COM.BR
60.	INTEGREA.FAR.BR
61.	KIDCARD.COM.BR
62.	LOJISTARD.COM.BR
63.	LUGARESDECUIDADOEMEMORIA.COM.BR
64.	LUGARESDECUIDADOEMEMORIARD.COM.BR
65.	MARKETPLACERD.COM.BR
66.	MKTONOFRE.COM.BR
67.	MUSEUDAFARMACIA.COM.BR
68.	MUSEUDOUNIVERSODAFARMACIA.COM.BR
69.	MUSEUFARMACIA.COM.BR
70.	NEEDSVITA.COM.BR
71.	NEEDSVITAVITAMINAS.COM.BR
72.	NEWSLETTER-DROGARAIA-MKT.COM.BR
73.	NEWSLETTER-DROGARAIA.COM.BR
74.	NEWSLETTER-DROGASIL-MKT.COM.BR
75.	NEWSLETTER-DROGASIL.COM.BR
76.	NUTRIGOOD.COM.BR
77.	ONOFRE.COM.BR
78.	ONOFRE.NET.BR
79.	ONOFREELETRONICOS.COM.BR
80.	ONOFREEMCASA.COM.BR
81.	ONOFREEMCASA.NET.BR
82.	ONOFRELETRONICOS.COM.BR
83.	ONOFRERECOMENDA.COM.BR

1.6 Relevant effects of state regulation

84.	PBMR.COM.BR
85.	PHARMACIARAIA.COM.BR
86.	PLUI.COM.BR
87.	PLUII.COM.BR
88.	PLUSCARD.COM.BR
89.	PORTALDAHISTORIADAFARMACIA.COM.BR
90.	PORTALHISTORIADAFARMACIA.COM.BR
91.	RAIA-DROGASIL.COM.BR
92.	RAIA.COM.BR
93.	RAIA.FAR.BR
94.	RAIA.NET.BR
95.	RAIABENEFICIOFARMACIA.COM.BR
96.	RAIACONVENIO.COM.BR
97.	RAIADELIVERY.COM.BR
98.	RAIADROGASIL.COM.BR
99.	RAIAEMCASA.COM.BR
100.	RAIAEMCASA.FAR.BR
101.	RAIAEMCASA.NET.BR
102.	RAIAEMPRESA.COM.BR
103.	RAIAEXPRESS.COM.BR
104.	RAIAEXPRESS.FAR.BR
105.	RAIAHIPERFARMACIA.COM.BR
106.	RAIAMED.COM.BR
107.	RAIANEEDS.COM.BR
108.	RAIAONLINE.COM.BR
109.	RAIAONLINE.NET.BR
110.	RAIAWEB.COM.BR
111.	RAIAWEB.FAR.BR
112.	RD.APP.BR
113.	RD.COM.BR
114.	RD.DEV.BR
115.	RD.ECO.BR
116.	RD.ONG.BR
117.	RD.TEC.BR
118.	RD.TV.BR
119.	RDADS.COM.BR
120.	RDDAY.COM.BR
121.	RDMARKETPLACE.COM.BR
122.	RDONLINE.COM.BR
123.	RDPHARMA.COM.BR
124.	RDSAUDEEMDIA.NET.BR
125.	RDVENTURES.COM.BR
126.	REMEDIOSBARATOS.COM.BR
127.	REMEDIOSBARATOS.NET.BR
128.	SAUDEEBELEZA.FAR.BR

1.6 Relevant effects of state regulation

129. SAUDERD.COM.BR
130. SEMANADAAPRENDIZAGEMRD.COM.BR
131. SENIORCARD.COM.BR
132. SERPLUS.COM.BR
133. TODOCUIDADOCONTA.COM.BR
134. TRISS.NET.BR
135. UNIVERS-PBM.COM.BR
136. UNIVERS-PME.COM.BR
137. VITAT.COM.BR
138. VIVANATZ.COM.BR
139. WEBFARMA.FAR.BR
140. WEBPHARMA.FAR.BR

RD international domains:

1. DROGA-RAIA.COM
2. DROGARAIA.CLUB
3. DROGARAIA.CO
4. DROGARAIA.INFO
5. DROGARAIA.ME
6. DROGARAIA.NET
7. DROGARAIA.ONLINE
8. DROGARAIA.SITE
9. DROGASIL.APP
10. DROGASIL.CLUB
11. DROGASIL.CO
12. DROGASIL.INFO
13. DROGASIL.ME
14. DROGASIL.NET
15. DROGASIL.ONLINE
16. DROGASIL.ORG
17. DROGASIL.SITE
18. PMEUNIVERS.COM
19. RDHOME.SITE
20. RDNOW.CO
21. RDNOW.INFO
22. RDONLINE.SITE
23. RDREVIEWS.COM
24. RDREVIEWS.SITE
25. RDTODOCUIDADOCONTA.COM
26. SAUDEEMDIARAIADROGASIL.COM
27. TODOCUIDADOCONTA.COM
28. TODOCUIDADOCONTA.ORG
29. TODOCUIDADOCONTARD.COM

1.6 Relevant effects of state regulation

30. UNIVERSPME.COM

Vitat domains:

1.	VITAT.CO
2.	VITAT.ME
3.	VITAT.LIFE
4.	VITAT.DIGITAL
5.	VITAT.APP
6.	VITAT.CLUB
7.	VITAT.VIP
8.	VITAT.WORK
9.	VITAT.ONLINE
10.	VITAT.SHOP
11.	VITAT.TECH

d. Financial contributions, indicating the respective amounts, made directly or through third parties:

(i) In favor of occupants of or candidates for political office

RD does not make financial contributions to occupants of or candidates for political office.

(ii) In favor of political parties

RD does not make financial contributions in favor of political parties.

(iii) To fund the exercise of activities to influence public policy decisions, notably in the content of normative acts

RD does not make financial contributions to fund the activity of influencing public policy decisions and/or the content of normative acts. However, it participates in two class associations that exist to give visibility of the industries they represent to the government. They are (i) IDV – Instituto para Desenvolvimento do Varejo [Retail Development Institute], which represents national general retail and to which pay a monthly fee of BRL 8,800.00 and other sharing of expenses, if any and (ii) Abrafarma – Associação Brasileira das Redes de Farmácias e Drogarias [Brazilian Association of Pharmacy and Drugstore Chains], which represents the pharmaceutical retail sector and for which we pay a monthly fee of BRL 22.00 per unit and other sharing of expenses, if any.

1.7 Relevant revenues in the country of the issuer's headquarters and abroad

1.7. For the countries where the issuer obtains substantial revenues, identify

a. Revenue from customers in the country of the issuer's headquarters and their share in the issuer's total net revenue:

There are no revenues in the Company from countries other than Brazil. Our activities are restricted to the national territory.

b. Revenue from customers in each foreign country and their share in the issuer's total net revenue:

There are no revenues in the Company from countries other than Brazil. Our activities are restricted to the national territory.

c. Revenue originating from foreign countries and their share in the issuer's total net revenue:

There are no revenues in the Company from countries other than Brazil. Our activities are restricted to the national territory.

1.8 Relevant effects of foreign regulation

1.8. In relation to the foreign countries disclosed in item 1.7, describe relevant impacts arising from the regulation of these countries on the issuer's business

We are not subject to foreign regulation.

1.9 Environmental, social and corporate governance (ESG) information

1.9. Regarding environmental, social, and corporate governance (ESG) information, please indicate:

a. whether the issuer discloses ESG information in an annual report or other document specifically for this purpose

RD has disclosed ESG information in its Annual and Sustainability Report since 2016. The documents can be accessed through this link <https://rd.com.br/en/sustainability/indicators-and-reports/>

b. the methodology or standard followed in the preparation of this report or document

RD uses the Global Reporting Initiative (GRI) methodology to prepare its Annual and Sustainability Reports. In 2022, in line with best practices, this publication was prepared in accordance with the GRI Standards (2021). In this document, we also follow the Integrated Reporting (IIRC) recommendations proposed by the Value Reporting Foundation and we report Sustainability Accounting Standards Board (SASB) indicators for the pharmaceutical retail sector. And the performance indicators are also correlated with the Sustainable Development Goals (SDGs) of the United Nations (UN).

In addition, 2022 was the first year in which we reported information in line with the recommendations of the Task Force on Climate Related Financial Disclosures (TCFD). Further information available in item 1.9.g of this form.

c. whether this report or document is audited or reviewed by an independent entity, identifying that entity, if applicable

The 2022 Annual and Sustainability Report was audited by KPMG, an independent entity. The scope of this audit was the limited assurance of non-financial information of the GRI – Standards criteria contained in the Annual and Sustainability Report. The letter of assurance can be found on page 134 of this link https://cdn.rd.com.br/prod/2023/07/c1530c09-rd_rel2022_en_06062023_-reshi_07.06.23.pdf

d. the page on the world wide web where the report or document can be found

RD's Annual and Sustainability Reports can be found at this link <https://rd.com.br/sustentabilidade/indicadores-e-relatorios/>

e. whether the report or document produced considers the disclosure of a materiality matrix and key ESG performance indicators, and what are the material indicators for the issuer

Yes, the 2022 Annual and Sustainability Report considers the disclosure of our materiality matrix and key ESG performance indicators for the Company.

1.9 Environmental, social and corporate governance (ESG) information

Our materiality analysis resulted in the following material topics:

Pillars	Material Topics 2022
Healthier people	Integral health and safety of employees
	Local development
	Healthy customers
Healthier business	Promotion of diversity and inclusion
	Personnel management
	Products and services
	Ethics, integrity and safety of operations
Healthier planet	Waste management and reverse logistics
	Resource consumption
	Actions for the climate

Material indicators for RD include all GRI indicators associated with material topics, such as: health and safety of our employees, economic performance, number of employees and third parties, diversity and inclusion, ethics and compliance practices and indicators of our Conversa Ética [Ethical Talk] Channel, qualification and training and environmental information (waste generation, greenhouse gas emissions, water and energy consumption), among others. These indicators can be consulted throughout the report and consolidated on page 108 of this link https://cdn.rd.com.br/prod/2023/07/c1530c09-rd_relata2022_en_06062023_-_reshi_07.06.23.pdf.

f. whether the report or document considers the Sustainable Development Goals (SDGs) established by the United Nations and what are the material SDGs for the issuer's business

Yes, the 2022 Annual and Sustainability Report considers the disclosure of our materiality matrix and key ESG performance indicators for the Company.

The analysis of the main environmental, social and corporate governance aspects resulted in the following material themes:

Pillars	Priority SDGs	Associated goals
Healthier people	SDG 3 - Health and well-being	3.4 and 3.8
	SDG 8 - Decent work and economic growth	8.5
Healthier business	SDG 3 - Health and well-being	3.4 and 3.8
	SDG 8 - Decent work and economic growth	8.5 and 8.8
	SDG 10 - Reduction of inequalities	10.2
	SDG 11 - Sustainable cities and communities	11.5
Healthier planet	SDG 12 - Responsible consumption and production	12.5 and 12.6
	SDG 7 – Affordable and clean energy	7.2
	SDG 11 - Sustainable cities and communities	11.6
	SDG 12 - Responsible consumption and production	12.2
	SDG 13 - Action to combat global climate change	13.1

g. whether the report or document takes into account the recommendations of the Task Force on Climate Related Financial Disclosures (TCFD) or financial disclosure recommendations from other recognized entities that are related to climate issues

Yes, in 2022 RD started reporting information in line with the recommendations of the Task Force on Climate Related Financial Disclosures (TCFD). This information can be found in our 2022 Annual and

1.9 Environmental, social and corporate governance (ESG) information

Sustainability Report, on pages 130 and 131, available at this link

https://cdn.rd.com.br/prod/2023/07/c1530c09-rd_rel2022_en_06062023_-reshi_07.06.23.pdf.

h. whether the issuer carries out greenhouse gas emission inventories, indicating, if applicable, the scope of inventoried emissions and the page on the World Wide Web where additional information can be found

Yes, RD carries out its inventory of greenhouse gas emissions. The scope of our inventory includes Scope 1, Scope 2, and Scope 3, with the following categories:

Scope	Emission Category
Scope 1	Stationary combustion
	Mobile combustion
	Fugitive emissions
Scope 2	Electric power
Scope 3	Goods and services purchased
	Capital assets
	Fuel and energy related activities not included in scope 1 and scope 2
	Upstream transport and distribution
	Waste generated in operations
	Business trips
	Employee commute (home-work)
	Downstream transport and distribution
	Use of goods and services sold
	End-of-life treatment of products sold
	Investments

Information regarding our inventory can be found on page 98 of our 2022 Annual and Sustainability Report.

1.10 Information on government-controlled companies

1.10. Indicate, if the issuer is a government-controlled company

Item not applicable. RD is not a government-controlled company.

1.11 Acquisition or disposal of relevant asset

Healthbit Performasys Tecnologia Inteligencia S.A. (“Healthbit”)

On March 09, 2021, the Company informed its shareholders, the market in general, and other interested parties that the share Purchase and Sale Agreement and Other Covenants was entered into with Healthbit's shareholders, for the acquisition by FIP RD Ventures of 50.75% of shareholding in the common stock, with call option for all remaining shares as of 2026.

On November 04, 2022, the Share Purchase and Sale Agreement and Other Covenants was entered into with Healthbit's shareholders, for acquisition of the remaining 49.25% of the common stock.

Healthbit is a technology startup focused on the use of big data to reduce health claims in large companies and to promote health and disease prevention for its employees.

Eloopz Serviços de Promoção de Vendas Ltda (“Eloopz”)

On September 16, 2022, the Company completed, through its subsidiary RD Ads Ltda., the acquisition of 100% of shareholding in Eloopz.

Eloopz is a technology startup that develops media solutions for retailers through the implementation and maintenance of hardware, mostly screens installed in physical stores, and software for the intelligent management of these assets. The investment in Eloopz will allow the Company to develop new publicity and advertising solutions, strengthening the advertising strategy of advertisers in physical and digital channels via RD Ads.

Safepill Comércio Varejista de Medicamentos Manipulados Ltda. (“SafePill”)

On November 23, 2022, the Company acquired a 100% shareholding in SafePill's common stock.

SafePill is a startup that has developed a solution to promote safer and more comfortable treatment for patients who use continuous medication. Medications are shipped monthly in personalized packaging, reducing the risk of discontinuing treatment, errors in consumption, and adverse drug interactions.

ZTO Tecnologia e Serviços de Informação na Internet Ltda (“Manipulaê”)

On November 28, 2022, the Company acquired a 100% shareholding in Manipulaê's common stock.

Manipulaê is a platform that facilitates the process of purchasing compounded drug formulas, where patients forward their medical prescription and receives their order. In the Company's portfolio, it complements the offer of medicines available to the customer.

Regarding the subject matter of this topic, details from previous years can be verified in past editions of the RD's Reference Form. For the matter in question, check item "8.1 - Extraordinary Business" of the 2021 FRE.

1.12 Corporate operations/Capital increase or reduction

1.12. Indicate merger, spin-off, consolidation, incorporation of shares, capital increase or reduction operations involving the issuer and the documents where more detailed information can be found

No records for the last fiscal year.

1.13 Shareholders' agreements

1.13. Indicate the execution, extinction or modification of shareholders' agreements and the documents where more detailed information can be found

On May 19, 2022, a shareholders' agreement was entered into among the members of Raia Block, with the purpose of reinforcing and regulating the joint exercise by these shareholders of the rights and duties regulated in the Raia Drogasil Shareholders' Agreement ("Raia Block Shareholders' Agreement").

On September 12, 2023, the First Amendment to the Bloco Raia Shareholders Agreement ("1st Amendment to the Bloco Raia Shareholders Agreement") was signed, to formalize the full adherence of a new signatory to the aforementioned agreement and the increase in the number of shares subject to trading restrictions.

The Company clarifies that, in addition to the Raia Block Shareholders' Agreement, the shareholders' agreement entered into on March 29, 2021 by the Galvão, Pires Oliveira Dias, and Pipponzi families ("Raia Drogasil Shareholders' Agreement") is also in effect.

The full text of the Raia Block Shareholders' Agreement, 1st Amendment to the Bloco Raia and also the Raia Drogasil Shareholders' Agreement is available on RD's Investor Relations website (<https://ri.rd.com.br>) and on the website of the CVM Consultation of Documents of Publicly-held Companies (cvm.gov.br).

1.14 Significant changes in the business conduction

1.14. Identify substantial changes in the conduction of the issuer's business

The company has not had significant changes in the way it conducts its business.

1.15 Relevant agreements entered into by the issuer and its subsidiaries

1.15. Identify the relevant agreements executed by the issuer and its subsidiaries not directly related with its operating activities

The company has no relevant agreements not related to its normal operations.

1.16 Other relevant information

1.16. Provide other information the issuer deems relevant

All relevant and pertinent information to the topic has already been disclosed in the previous items.

2.1 Financial and equity conditions

2. Officers' Comments

2.1. The officers should comment on

a. general financial and equity conditions

On December 31, 2022, there were 2,697 pharmacies in operation, spread over all Brazilian States, in addition to 5 4Bio units.

We are the largest drugstore chain in the country in sales and number of stores, according to the Abrafarma (Brazilian Association of Pharmacy and Drugstore Chains) ranking, released in 2022. The resources used for our activities, including the opening, modernization, and maintenance of stores come from the commercialization of branded drugs, generic drugs, OTC and perfumery, as well as from the provision of services to our customers.

As a result of the consistent evolution of the Company's operational results over the last years and of the comfortable situation of liquidity, we believe that the company has solid equity and financial conditions necessary to conduct the operation.

In addition, we maintained a stable situation of liquidity over the last years. At the end of 2022, our current liquidity rate was 1.50, compared to 1.31 in 2021, representing a 14.9% increase.

It is important to mention that, on December 31, 2022, our cash and cash equivalents reached BRL 433,541 thousand (Dec/21 – BRL 356,118 thousand), whereas the loans and financing of the company in the same period amounted to BRL 2,317,904 thousand (Dec/21 – BRL 1,505,222 thousand). Cash generation from operations financed almost all CAPEX for the year, allocated to opening new pharmacies (260 gross openings in the period), renovating existing units, in addition to projects related to information technology, logistics, and investments in subsidiaries for the creation of an integral health ecosystem and the development of new customer loyalty, engagement, and monetization solutions.

The shareholders' equity of the company on December 31, 2022 was BRL 5,402,941 thousand (Dec/21 – BRL 4,718,802 thousand), an increase of BRL 684,139 thousand or 14.5%.

The Company analyzes the liquidity rates with the purpose of identifying possible unbalances between the debts and the short-term receivables, as well as the necessity of raising of funds or availability of cash for future investments. The Management understands that the current levels of the liquidity rates are adequate. The Company follows them up and takes appropriate measures to maintain its good financial standing.

Indicator – IFRS 16	2022	2021
Current Liquidity ¹	1.50	1.31
General Liquidity ²	0.84	0.79

1) Current Liquidity¹ = (Current Assets)/(Current Liabilities)

2) General Liquidity² = (Current Assets + Noncurrent Receivables)/(Current Liabilities + Long-term Liabilities)

b. capital structure

Over the last years the Company has been financing itself mainly with own resources. Our gross indebtedness, at the end of 2022, amounted to BRL 2,317,904 thousand (Dec/21 – BRL 1,505,222 thousand), comprised mainly by long-term resources raised with the issue of debentures in comparison with a shareholder's equity of BRL 5,402,941 thousand (Dec/21 – BRL 4,718,802 thousand), and cash and cash equivalents of BRL 433,541 thousand (Dec/21 – BRL 356,118 thousand), data in IFRS 16.

2.1 Financial and equity conditions

Capital Structure (in BRL thousands) – IFRS 16	2022	VA	2021	VA
Net Equity (Shareholder's Equity)	5,402,941	69.98%	4,718,802	75.82%
Creditors' Equity (Short and Long-Term Loans and Financing)	2,317,904	30.02%	1,505,222	24.18%
Total	7,720,845	100.00%	6,224,024	100.00%

c. payment capacity in relation to the financial commitments assumed

Due to the financial structure already reported, the Management understands that the Company is fully capable of complying with all its financial commitments, as well as to meet all needs of working capital and investments scheduled.

On December 31, 2022, our current liabilities were BRL 6,367,168 thousand (Dec/21 – BRL 5,896,193 thousand), an amount lower than the current assets, which, on the same date, was BRL 9,577,068 thousand (Dec/21 – BRL 7,718,924), including the amounts of the cash and cash equivalents account, which represented BRL 433,541 (Dec/21 – BRL 356,118 thousand), data in IFRS 16.

On December 31, 2022, our short-term debt was BRL 186,356 thousand (Dec/21 – BRL 613,831 thousand), while 92.0% of our gross indebtedness, BRL 2,131,548 thousand (Dec/ 21 – BRL 891,391 thousand), was scheduled to fall due in the long term. Finally, it is worth mentioning that our debt is comprised mainly by resources from the debentures with market interest rates pegged to the CDI (Interbank Deposit Certificate).

d. sources of funding for working capital and investments in non-current assets used

The main source of liquidity of the Company is the generation of cash from operations. Over the last three fiscal years, the Company obtained resources through loans and debentures with the financial market, which were employed in the financing of its needs of working capital and short-term investment. For more detail, see item 2.1.f on the relevant loans and financing agreements.

e. sources of financing for working capital and investment in non-current assets that it intends to use as a means of covering liquidity shortfalls

Our loans and financing include the instruments described in letter (f) of this item 2.1. Notwithstanding the existence of the loans and financing described below, we believe we do not depend on resources from third parties for the performance of our businesses, taking into account our consistent cash generation and solid financial condition.

The Company will enter into new loans and financing transaction in the financial market when it identifies the need for additional resources to fund its expansion plan or with the purpose of improving the indebtedness profile.

f. Indebtedness levels and the characteristics of the debts, also mentioning:

i. material loans and financing agreements

On December 31, 2022, the Company had loans and financing which amounted to BRL 2,317,904 thousand (Dec/21 – BRL 1,505,222).

The principal amount of the loans is denominated in reais, with market interest rates linked to the CDI plus the bank's spread, of BRL 1,927,632 thousand, related to the 2nd, 3rd, 4th, 5th, 6th, and 7th issues of debentures, BRL 390,272 thousand in direct financial loans – Law No. 4131. The amount of the principal and interest of these loans are usually paid every six months, with due dates between 2023 and 2029.

The interest rates practiced in the credit facilities are specified in the table below:

2.1 Financial and equity conditions

Items of loans and financing	Average annual long-term interest rate	2022	2021
Amounts in thousands of BRL			
BNDES - Sub-credit		-	155
Others	-	-	155
Debentures		1,927,632	721,332
1st Issue of Debentures	104.75% of CDI	-	33,808
2nd Issue of Debentures	104.50% of CDI	45,943	135,773
3rd Issue of Debentures - CRIs	98.50% of CDI	256,264	250,947
4th Issue of Debentures	106.99% of CDI	301,211	300,804
5th Issue of Debentures	100% of CDI + 1.49% per annum	530,393	-
6th Issue of Debentures - CRIs	100% of CDI + 0.70% per annum	256,123	-
7th Issue of Debentures - CRIs	100% of CDI + 0.75% per annum	537,698	-
Loans		390,272	450,275
Direct Financial Loans - Law No. 4131	100.00% of CDI + 2.61%	311,974	307,163
Direct Financial Loans - Law No. 4131	100.00% of CDI + 3.30%	-	100,052
Direct Financial Loans - Law No. 4131	100.00% of CDI + 1.37%	77,966	-
Others	100.00% of CDI + 2.95%	332	43,060
Promissory notes		-	333,460
1st issue of promissory note	100.00% of CDI + 3.00%	-	333,460
Total		2,317,904	1,505,222
Current liabilities		186,356	613,831
Non-current liabilities		2,131,548	891,391

ii. other long-term relationships with financial institutions

We do not have other long-term relationships with financial institutions.

iii. debt subordination degree

The Managers of the Company inform that, over the last three fiscal years, there was no subordination level of the Company's debt and that this is determined in accordance with the provisions of the legislation in force (Law No. 11,101/05).

iv. any restrictions on the issuer, especially with regard to limits on indebtedness and contracting of new debts, distribution of dividends, divestiture, issuance of new securities, and disposal of ownership control, as well as if the issuer has been complying with these restrictions.

The Company's debentures amount to BRL 1,927,632 thousand in 2022 (Dec/21 BRL 721,332) are subject to compliance with the following restrictive clause ("covenants"):

- Net Debt/EBITDA: cannot be higher than 3.0 times.

The covenants are quarterly measured, and, on December 31, 2022 and 2021, said requirements were complied with. The non-compliance with the covenants for two consecutive quarters may be considered an event of default and, consequently, may have their early maturity declared.

2.1 Financial and equity conditions

The Company has loans and financing with other restrictive clauses (“covenants”), as included in the debentures deeds and in the agreements executed. On December 31, 2022, the Company was in conformity with all financial restrictions and rates established.

g. limits of use of the contracted funding and percentages already used

On the date of this Reference Form, the Company did not have any financing agreement whose disbursement has not been fully carried out.

h. significant changes in each item of the financial statements and cash flows

Fiscal year ended on December 31, 2022, compared with the fiscal year ended on December 31, 2021

Income Statement (in BRL thousands) - IFRS (State Registration) 16	2022	VA	2021	VA	HA
Net sales revenue	29,067,380	100.0%	24,127,002	100.0%	20.5%
Cost of goods sold	(20,257,912)	-69.7%	(16,920,834)	-70.1%	19.7%
Gross profit	8,809,468	30.3%	7,206,168	29.9%	22.2%
Operating (expenses) revenues					
With sales	(5,805,992)	-20.0%	(4,966,819)	-20.6%	16.9%
General and administrative	(1,249,847)	-4.3%	(912,404)	-3.8%	37.0%
Other operating revenues/(expenses)	86,516	0.3%	40,654	0.2%	112.8%
Equity in the results of subsidiaries	(821)	0.0%	(1,127)	0.0%	(27.2%)
	(6,970,144)	-24.0%	(5,839,696)	-24.2%	19.4%
Operating profit before the financial result	1,839,324	6.3%	1,366,472	5.7%	34.6%
Financial results					
Financial revenues	293,586	1.0%	80,016	0.3%	266.9%
Financial expenses	(939,701)	-3.2%	(459,226)	-1.9%	104.6%
	(646,115)	-2.2%	(379,210)	-1.6%	70.4%
Profits before income tax and social contribution	1,193,209	4.1%	987,262	4.1%	20.9%
Income tax and social contribution					
Current	(210,820)	-0.7%	(221,249)	-0.9%	(4.7%)
Deferred	32,579	0.1%	(1,880)	0.0%	(1832.9%)
	(178,241)	-0.6%	(223,129)	-0.9%	(20.1%)
Net profits of the fiscal year	1,014,968	3.5%	764,133	3.2%	32.8%
Attributable to the Company's shareholders	996,112	-	751,934	-	32.5%
Interest of Non-Controlling Shareholders	18,856	-	12,199	-	54.6%

Net sales revenue

2.1 Financial and equity conditions

We ended 2022 with BRL 29,067,380 thousand of net revenue, an increase of 20.5% versus the previous year (BRL 24,127,002 thousand in 2021). This variation results from the maturation of the stores opened over the last years, as well as of the organic expansion of the Company with the opening of 260 pharmacies and closing of 53 pharmacies in 2022.

Operating (expenses) revenues

On December 31, 2022 we recorded BRL 6,970,144 thousand in total expenses (BRL 5,839,696 thousand in 2021). An increase of BRL 1,130,448 thousand or 19.4%, due to the number of pharmacies and investments in the Company's administrative structure.

Financial results

On December 31, 2022, we recorded BRL 646,115 thousand in negative financial results (negative BRL 379,210 thousand in 2021). An increase of BRL 266,905 thousand or 70.4%, which results from the variation in the interest rate.

Income tax and social contribution

We recorded a reduction of BRL 44,888 thousand in the Income Tax and Social Contribution account, to BRL 178,241 thousand in 2022 (BRL 223.,129 in 2021), resulting from the increase in gains earned with ICMS tax benefits related to subsidy for investments in certain States.

Net Profit

We recorded a net profit of BRL 1,014,968 thousand in 2022 (BRL 764,133 thousand in 2021). The profit increased 32.8%, with a net adjusted margin of 3.5%, an increase of 0.4%.

Fiscal year ended on December 31, 2022, compared with the fiscal year ended on December 31, 2021

Statements of cash flows (in BRL thousands)	Dec/22	Dec/21	HA
Cash flows from operating activities			
Profits before Income Tax and Social Contribution	1,193,209	987,262	20.86%
Adjustments			
Depreciation and amortization	1,515,538	1,327,110	14.20%
Compensation plan with performance shares, net	22,604	15,086	49.83%
Interest on additional share call options	26,769	2,819	849.59%
Income from sale and write-off of property, plant, and equipment, and intangible assets	29,233	23,865	22.49%
Provision for lawsuits	64,670	42,029	53.87%
Provision for inventory losses	27,084	4,418	513.04%
(Reversal) provision for expected credit losses	7,245	7,732	(6.30%)
(Reversal) provision for adjournment of pharmacies	(1,072)	(105)	920.95%
Expenses net of interest on loans	274,962	89,957	205.66%
Interest expenses - Leases	258,640	235,667	9.75%
Amortization of transaction cost of debentures and promissory notes	4,639	4,321	7.36%
Equity in the results of subsidiaries	(820)	1,127	(172.76%)
Property lease discount	(1,105)	(6,390)	(82.71%)
	3,421,596	2,734,898	25.11%
Changes in assets and liabilities			
Customers and other accounts receivable	(583,602)	(161,869)	260.54%
Inventory	(1,035,341)	(896,809)	15.45%
Other current assets	12,121	(38,768)	(131.27%)
Long-term receivables	(69,009)	40,587	(270.03%)
Suppliers	728,351	341,316	113.39%

2.1 Financial and equity conditions

Suppliers - Drawee risk	(116,815)	49,438	(336.29%)
Salaries and social security charges	141,268	109,274	29.28%
Taxes, fees and contributions	(160,200)	(36,003)	344.96%
Other obligations	137,575	119,319	15.30%
Rents payable	10,985	21,128	(48.01%)
Others			
Interest paid	(258,674)	(64,861)	298.81%
Income Tax and Social Contribution Paid	(233,175)	(373,976)	(37.65%)
Interest paid - Leases	(258,640)	(235,667)	9.75%
Judicial claims - paid	(54,185)	(51,072)	6.10%
Net cash obtained in operating activities	1,682,255	1,556,935	8.05%
Cash flows from investment activities			
Acquisition and capital increase to investees, net of cash obtained in the acquisition	(40,000)	(12,636)	216.56%
Cash acquired in business combination	-	14,655	(100.00%)
Net assets acquired in business combination	-	(14,732)	(100.00%)
Acquisitions of property, plant, and equipment and intangible assets	(1,188,782)	(855,596)	38.94%
Receipts from sales of property, plant, and equipment	-	809	(100.00%)
Loans granted to subsidiaries	(800)	(18,450)	(95.66%)
Net cash applied in investment activities	(1,229,582)	(885,950)	38.79%
Cash flows from financing activities			
Banking loans and financing	1,460,248	338,234	331.73%
Payment of loans and financing	(668,493)	(517,646)	29.14%
Lease payments	(842,923)	(677,560)	24.41%
Interest on shareholders' equity and dividends paid	(324,082)	(265,025)	22.28%
Shares repurchase	-	(73,227)	(100.00%)
Net cash used in financing activities	(375,250)	(1,195,224)	(68.60%)
Net increase (decrease) in cash and cash equivalents	77,423	(524,239)	(114.77%)
Cash and cash equivalents on January 1	356,118	880,357	(59.55%)
Cash flow statement as of December 31	433,541	356,118	21.74%

Net increase in cash and cash equivalents

We presented a net increase in Cash and cash equivalents in the amount of BRL 77,427 thousand when compared to the net cash generation of BRL 433,541 thousand carried out in 2022, with the amount of BRL 356,118 thousand generated in 2021, which was an increase of 21.7%.

Net cash obtained in operating activities

The net cash generated from operating activities was in the amount of BRL 1,682,255 thousand on December 31, 2022, showing an increase of BRL 125,320 thousand or 8.0% when compared to the amount of BRL 1,556,935 thousand on December 31, 2021. The main variations were:

- (i) the increase of BRL 205,947 thousand or 20.9% in net income before income taxes and social contribution, which increased from BRL 987,262 thousand on December 31, 2021 to BRL 1,193,209 thousand on December 31, 2022, and the main events that justify this positive fluctuation were described in the explanations of the Income Statement;
- (ii) the increase of BRL 188,428 thousand in depreciation and amortization, which increased from BRL 1,327,110 thousand on December 31, 2021 to BRL 1,515,538 thousand on December 31, 2022 as a result of investments for expansion;

2.1 Financial and equity conditions

- (iii) increase of BRL 185,005 thousand in net interest expense on loans, from BRL 89,957 thousand on December 31, 2021 to BRL 274,962 thousand on December 31, 2022, which increase is mainly due to the variation in the interest rate;
- (iv) with the 20.5% increase in net sales in 2022, when compared to 2021, the balance of accounts receivable is positively affected, resulting in an oscillation in cash flow in the amount of BRL 421,733 thousand or 260.5%, when compared to the amount of BRL 583,602 thousand on December 31, 2022 in changes in assets - customers and other accounts receivable, against the amount of BRL 161,869 thousand on December 31, 2021.

Net cash applied in investment activities

The net cash used in investing activities was of BRL 1,229,582 thousand on December 31, 2022, showing an increase of BRL 343,634 thousand or 38.8% when compared to the amount of BRL 885,950 thousand on December 31, 2021. The main change observed was the increase of BRL 333,186 thousand in acquisitions of fixed and intangible assets, which changed from BRL 855,596 thousand on December 31, 2021 to BRL 1,188,782 thousand on December 31, 2022.

Net cash used in financing activities

The net cash used in financing activities was of BRL 375,250 thousand on December 31, 2022, presenting a reduction of BRL 819,974 thousand or 68.6% when compared to the amount of BRL 1,195,224 thousand on December 31, 2021. The most significant fluctuation was the increase of BRL 1,122,014 thousand in banking loans and financing, which changed from BRL 338,234 thousand on December 31, 2021 to BRL 1,460,248 thousand on December 31, 2022.

2.2 Operating and financial results

2.2. The officers should comment on:

a. results of the issuer's operations, especially:

i. description of any significant revenue elements

The Company generates revenue mainly in the sale of drugs (branded and generic), over the counter (OTC), non-drugs (perfumery, personal hygiene products, cosmetics and dermocosmetics) and services. Only for the purpose of managerial analyses, the Company separate its main sales revenues as follows:

Breakdown of Revenue (in BRL thousands)	2022	2021
Brand (% Retail Revenue)	41.9%	41.6%
Generics (% Retail Revenue)	11.6%	11.6%
OTC (% Retail Revenue)	22.4%	22.5%
Perfumery (% Retail Revenue)	23.9%	24.1%
Services (% Retail Revenue)	0.2%	0.3%
Total Retail	29,104,625	24,217,388
Subsidiaries and consolidation adjustments	1,845,939	1,388,296
Overall Total	30,950,564	25,605,684

ii. factors with a material impact on operating results

Overview of the Sector:

Brazil undergoes a process of population ageing, with relevant reflections on the health sector. From 2000 to 2022, the Brazilian pharmaceutical market grew by an average of 13.2% per year (CAGR), reaching BRL 171 billion at ex-factory prices, according to IQVIA. As the population ages, we believe that there will be an increase in the demand for medicines.

Although we are industry leaders, we ended 4Q22 with just 15.1% in market share, so there is still room for growth and consolidation. With a greater purchasing scale and ability to dilute expenses, we maintain competitive advantages in relation to smaller competitors.

b. relevant variations in revenue attributable to the introduction of new products and services, changes in volumes prices, exchange rates, and inflation:

In 2022, we inaugurated a total of 260 pharmacies, fully delivering our guidance for the year. We closed 53 stores, ending the period with 2,697 units in operation. In addition, investments made in the development of digital channels resulted in a 53% growth in sales through them, reaching the mark of BRL 3.2 billion in 2022, providing convenience for our customers, combined with greater engagement.

About price changes

We negotiate purchase agreements with suppliers frequently, which establish, for each line of product, commercial discounts on the Production Price and the payment conditions.

The Drugs' Factory Price is annually adjusted in April, based on the IPCA (Broad Consumer Price Index) by the Drugs Market Regulation Chamber (CMED), an inter-ministerial body responsible for the economic regulation of the drug market in Brazil and ANVISA (Brazilian Health Surveillance Agency), which exercises the role of Executive Secretary of the Chamber. CMED establishes drug pricing

2.2 Operating and financial results

limits, adopts rules that encourage competition in the industry, monitors the marketing, and applies penalties when its rules are breached.

In 2022, the average consumer price adjustment authorized by CMED was 10.89%. The average adjustment authorized by the CMED for 2021 was 8.21%.

In the case of Perfumery Products, our purchases are made directly from the manufacturers, and the commercial conditions are negotiated by the parties at market price.

c. relevant impacts of inflation, price variation of major inputs and products, exchange and interest rates on the issuer's operating and financial results:

Since all our liabilities and operating expenses are in reais, our operations results and financial condition are not directly affected by the variation of the Real x Dollar exchange rate. However, the exchange rate may affect the cost of our suppliers, which may transfer part of the increase of their costs through the reduction of commercial discounts practiced to the retail.

Likewise, the increase in inflation may cause the cost of goods to rise. For products that are not subject to federal price controls, in times of high inflationary pressure, we always seek to negotiate reasonable and balanced increases with our commercial partners in order to cause the weakest possible impact on demand.

The increase in the interest rate may impact in a negative manner the ability of the suppliers to offer us extended terms of payment and, thus, hinder our cash cycle.

We are subject to federal laws that impose price control to the majority of the pharmaceutical products that we sell. This price control could result in a lower profit margin than those usually realized by pharmaceutical products that are not subject to price control, affecting our profitability. It is not possible to predict whether the Federal Government change price controls in the future, which could adversely affect us.

2.3 Changes in the accounting practices/Modified opinions and emphases

2.3. The officers should comment on:

a. changes in accounting practices that have resulted in significant effects on the information provided in fields 2.1 and 2.2:

There are no standards, guidelines, or accounting pronouncements that became effective for the first time as of the fiscal year beginning on January 01, 2022. RD has not early adopted any other standard, interpretation, or amendment that has been issued but is not yet effective.

b. modifying opinions and emphasis in the auditor's report:

In the last three fiscal years, the independent auditor's reports were issued without modification, that is, they did not indicate reservations or emphasis of matter.

2.4 Relevant effects on the Financial Statements

2.4. The officers should comment on the material effects that the events below have caused or are likely to cause on the issuer's financial statements and results:

a. launch or disposal of an operating segment

No field of business was launched or disposed of.

b. establishment, acquisition, or sale of an equity interest

There was no incorporation, acquisition, or disposal of equity interest that has caused or may have a material effect on RD's financial statements.

c. extraordinary events or transactions

In August 2022, the Company acquired a 21.72% equity interest in Labi, through FIP RD Ventures. Labi complements the Company's services by offering laboratory tests, check-ups, and vaccines. Labi services will integrate Vitat's health journeys and complement the services offered in our Health Hubs.

On September 16, 2022, the Company completed, through its subsidiary RD Ads Ltda., the acquisition of 100% of the shareholding in Eloopz. Eloopz is a technology startup that develops media solutions for retailers through the implementation and maintenance of hardware, mostly screens installed in physical stores, and software for the intelligent management of these assets. The investment in Eloopz will allow the Company to develop new publicity and advertising solutions, strengthening the advertising strategy of advertisers in physical and digital channels via RD Ads.

In November 2022, the Company acquired 49.25% of HealthBit, now owning 100% of the company through FIP RD Ventures. Healthbit is a technology startup focused on the use of big data to reduce health claims in large companies and to promote health and disease prevention for its employees.

On November 23, 2022, the Company acquired a 100% shareholding in SafePill's common stock. SafePill is a startup that has developed a solution to promote safer and more comfortable treatment for patients who use continuous medication. Medications are shipped monthly in personalized packaging, reducing the risk of discontinuing treatment, errors in consumption, and adverse drug interactions.

On November 28, 2022, the Company acquired a 100% shareholding in Manipulaê's common stock. Manipulaê is a platform that facilitates the process of purchasing compounded drug formulas, where patients forward their medical prescription and receives their order. In the Company's portfolio, it complements the offer of medicines available to the customer.

2.5 Non-accounting measurements

2.5. If the issuer disclosed during the last fiscal year or wishes to disclose in this form any non-accounting measurements, such as EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) or EBIT (Earnings Before Interest and Taxes), the issuer must:

a. inform the value of non-accounting measures:

The Company discloses the non-accounting measurement EBITDA. The EBITDA was BRL 2,318.8 in 2022 and BRL 1,848.1 in 2021, data in IAS 17.

b. make reconciliation of reported values and the audited financial statements figures:

The table below presents our EBITDA for the last two fiscal years.

Consolidated (BRL million) - IAS 17	2022	2021
Net Profit	1,029.2	815.2
Financial income, net	401.0	155.4
Depreciation and amortization	701.1	627.0
Income tax and social contribution	185.9	249.4
Equity method	1.5	1.1
EBITDA	2,318.8	1,848.1
EBITDA Margin	7.5%	7.2%
Non-Recurring Revenue /Expenses ¹	-56.6	-40.9
Adjusted EBITDA	2,262.1	1,807.2
Adjusted EBITDA Margin	7.3%	7.1%
Gross sales revenue	30,950.6	25,605.7

¹ Non-recurring

2022: In 2022, we recorded a total of BRL 56.6 million in net non-recurring revenue. This includes BRL 8.8 million in social investments and donations, BRL 28.0 million in asset write-offs, mainly due to store closures, in addition to BRL 93.5 million in net revenue from tax effects from previous years and other non-recurring items.

2021: In 2021, we recorded a total of BRL 40.9 million in net non-recurring revenue. This includes non-recurring expenses of BRL 23.0 million for asset write-offs, mainly due to store closures and BRL 15.9 million in donations, more than offset by non-recurring revenues of BRL 73.9 million, arising from tax credits from previous periods, BRL 3.4 million from the change in the monetary adjustment rate on labor contingencies, and BRL 2.4 million from other non-recurring revenues.

c. explain why such measurement are reportedly more suitable for the proper understanding of the issuer's financial condition and result of operations

EBITDA and EBITDA margin are not measurements of profit, in accordance with accounting practices adopted in Brazil; they are measurements prepared by our management, reconciled in compliance with the provisions of CVM Ruling No. 527, of October 04, 2012, consisting of net profit for the fiscal year, plus income tax and social contribution, net financial result, and depreciation and amortization.

2.5 Non-accounting measurements

We consider the presentation of EBITDA to be useful as it is frequently used by capital market analysts, investors, and other parties interested in reviewing our operating performance, as well as comparing it with that of other companies.

EBITDA should not be considered a substitute for profit or operating revenue, an indicator of operating performance or cash flow, or used to measure the liquidity or debt amortization capacity.

The company understands that the Adjusted EBITDA facilitates the evaluation and projection of future results, using consistent numbers and disregarding specific events that occurred in a given period.

2.6 Events subsequent to the Financial Statements

2.6 Identify and comment on any subsequent events that have materially changed the conditions reflected in the last financial statements for complete fiscal years

Recently, the STF established an understanding that has an impact on the res judicata in tax matters, specifically the so-called continued legal relations. This decision, whose judgment has not yet been published, will affect not only the parties involved, and it is mandatory for the everyone else since it was issued under the general repercussion regime (Subjects 881 and 885).

We analyzed the final and unappealable individual decisions and, together with our legal advisors, we did not identify cases in which the Federal Supreme Court subsequently ruled in the opposite way, in an action with general repercussion.

2.7 Distribution of results

2.3. Officers must comment on the allocation of the company's results, indicating

a. rules on retained earnings

The Company's Bylaws establish that the remaining balance of the net profit, after the creation of the legal reserve and the payment of the mandatory dividend, be allocated to the reserve established by the Bylaws, with the purpose of reinforcing the Company's working capital. Note that its balance, added to the balances of the other Profit Reserves, except for the Contingency Reserve and the Unrealized Profits Reserve, cannot exceed one hundred percent (100%) of the common stock.

i. amounts of the retained income

On April 19, 2023, an Ordinary Shareholders' Meeting was held at which the Company's shareholders approved the allocation of net profits for the fiscal year ended on December 31, 2022, as follows: a) BRL 49,805,623.09 for the Legal Reserve Account; b) BRL 224,900,960.43, for the Account of the Reserve created by the Bylaws; c) BRL 223,681,041.24 for the Tax Incentive Reserve Account.

ii. percentages in relation to total declared profits

The Company's shareholders approved at the Ordinary Shareholders' Meeting, held on April 19, 2023, the percentage of net profit for the year ended December 31, 2022 of 5% to be allocated to the Legal Reserve Account; and 22.50% of net profit for the fiscal year to be allocated to the Account of the Reserve created by the Bylaws.

b. rules on dividend distributions

Pursuant to the Company's Bylaws, holders of shares of any type will receive, in each fiscal year, a minimum dividend of 25% of adjusted net profit, calculated pursuant to corporate law.

c. periodicity for dividend distributions

Payment of dividends and interest on equity is made twice a year, in December of the year itself and in May of the following year.

d. any dividend distribution restrictions imposed by law or special regulations applying to the issuer, or otherwise prescribed by contract or by administrative, judicial or arbitral decisions

There was no restriction on the distribution of dividends in the last three fiscal years.

e. If the issuer has a formally approved income allocation policy, inform the agency responsible for approval, date of approval and, if the issuer publishes the policy, locations on the World Wide Web where the document can be consulted

The Company has a profit allocation policy approved at the Board of Directors' meeting held on December 14, 2017, which can be consulted on the CVM website and on the Investor Relations website.

2.8 Relevant items not evidenced in the financial statements

2.8. The officers must describe the relevant items not evidenced in the issuer's financial statements, indicating:

a. the off-balance-sheet assets and liabilities directly or indirectly owned by the issuer, such as:

i. written-off receivables portfolios over which the entity holds risks and liabilities, indicating the respective liabilities

We do not hold assets and liabilities that are not recorded in our balance sheet.

ii. agreements for future purchase and sale of products or services

We do not hold assets and liabilities that are not recorded in our balance sheet.

iii. unfinished construction contracts

We do not hold assets and liabilities that are not recorded in our balance sheet.

iv. future financing receipt contracts

We do not hold assets and liabilities that are not recorded in our balance sheet.

b. other items not evidenced in the financial statements

There are no other items not evidenced in the financial statements.

2.9 Comments on items not evidenced

2.9. For each off-balance-sheet item not stated in the financial statements in item 2.8 above, the officers should comment on:

a. how such items change or may change the issuer's revenue, expenses, operating income, financial expenses, or other items in the issuer's financial statements

In accordance with the applicable accounting standards, there are no transactions or operations not evidenced in the financial statements that may significantly impact the Company.

b. nature and purpose of the transaction

In accordance with the applicable accounting standards, there are no transactions or operations not evidenced in the financial statements that may significantly impact the Company.

c. nature and amount of the obligations undertaken and the rights generated in favor of the issuer as a result of the transaction

In accordance with the applicable accounting standards, there are no transactions or operations not evidenced in the financial statements that may significantly impact the Company.

2.10 Business plans

2.10. The officers should state and comment on the major points in the issuer's business plan, focusing on:

a. investments, including:

i. quantitative and qualitative description of current and expected investments

The Company's investments are mostly directed to network expansion, renovation and modernization of stores. In 2022, BRL 1,020.6 million were invested, of which BRL 431.8 million were allocated for the opening of new pharmacies, BRL 166.4 million for the renovation of existing units, and BRL 422.4 million for infrastructure projects. Investment in infrastructure included BRL 238.3 million in technology projects, BRL 158.8 million in logistics, and BRL 25.3 million in other projects.

Finally, BRL 146.9 million were invested in affiliates in order to build our integral health ecosystem.

Projects (in millions of BRL)	2022	2021
Network expansion	431.8	377.5
Renovation of stores	166.4	155.3
Infrastructure	422.4	315.0
Capex	1,020.6	847.8
Investments in affiliates	146.9	137.4
Total investments	1,167.5	985.2

ii. sources of investment financing

The main source of financing for investments is the generation of cash in the Company's operation, supplemented by long-term credit facilities with banks and issuance of debentures, for example.

iii. material divestments in progress and planned divestments

There has been no divestment in the last three years and there is no planned divestment.

b. if already disclosed, indicate the acquisition of plants, equipment, patents and other assets that may have a material impact on the issuer's production capacity

There was no acquisition of plants, equipment, patents or other assets, in addition to those already described in the item above, that could materially influence the Company's production capacity.

c. new products and services, indicating

i. description of research in progress and already disclosed

We do not have research in progress.

ii. total expenditures by the issuer in research activities to develop new products or services

2.10 Business plans

We do not have expenditures in development of new products or services.

iii. projects under development and already disclosed

In 2020, we announced our new Strategy, based on 3 pillars: the New Pharmacy, the Marketplace and the Health Platform.

New Pharmacy focuses on the re-signification of the pharmacy as a health hub, adding to retail a range of pharmaceutical services, as well as a multichannel experience, digitally connected through applications and websites, complementing the traditional physical experience.

Marketplace is an environment that connects millions of RD customers to third-party sellers, which now offer a broad assortment of health and well-being products on RD platforms. While customer finds in RD a much more complete assortment, it gives sellers access to a strong base of customers who visit RD channels frequently.

The Health Platform is an ecosystem that was born to develop solutions to support our customers' health journey, transforming them into a daily and accessible experience. It will connect different health links, both those existing (such as retail and pharmaceutical services of the Raia and Drogasil chains), as well as new capabilities offered by startups, including those already invested by RD Ventures.

This is a long-term strategy and continues throughout the current year.

iv. total expenditures by the issuer in development activities for new products or services

We have not developed new products and services.

d. opportunities included in the issuer's business plan related to ESG issues

The Company understands that improvements related to ESG topics facilitate the continuity of the business and, therefore, it actively seeks to make advances related to sustainability in an objective manner.

In an event promoted in May 2021, we announced the Caminhar Juntos [Walk Together] plan, an executive program with 35 goals to be achieved by 2030, aligned with the UN Sustainable Development Goals (SDGs), and organized in the dimensions of Healthier People, aiming to improve the health of 50 million people, Healthier Business, seeking to empower 350,000 individuals economically, and Healthier Planet, aiming to transform RD into a net zero and zero landfill company.

The 35 goals can be consulted on our website at the address below:

<https://rd.com.br/sustentabilidade/compromissos-2030/>

Each year's achievements can be monitored through the Annual and Sustainability Reports, available on the Internet at the address below: <https://rd.com.br/sustentabilidade/indicadores-e-relatorios/>

2.11 Other factors that significantly influenced operating performance

2.11. Comment on other factors that could have a material impact on operating results but not identified or addressed elsewhere in this section

There are no other factors that had a material impact on the Company's operating results that have not been identified or addressed elsewhere in this section.

3.1 Disclosed projections and premises

3.1. For each projection, identify

a. object of the projection

Raia Drogasil S.A. projects the total number of units to be opened over the calendar year. This projection is made on an aggregated basis for the brands Droga Raia and Drogasil.

It is important to note that this number considers gross openings, not taking into account possible unit closings. Therefore, the net increase in units may differ from the sum of initial units and gross openings in the period.

b. covered period and validity term

The projection comprises and is valid for years 2023, 2024, and 2025.

c. projection premises, identifying those that may be influenced by the Company's management and those beyond its control

The projections were prepared in the light of our past experience and consider our expectations regarding our operations, especially considering:

- (i) the expansion strategy;
- (ii) the financial capacity to support investments;
- (iii) the ability to obtain attractive commercial points with adequate return expectations;
- (iv) the ability to implement new units, including our engineering structure and the availability of qualified employees within our career plan to operate such units;
- (v) other circumstances inherent to the expansion activities.

We understand that we have control over a large part of these variables. It is worth mentioning that the projections are estimates, and that they do not represent a promise of performance, so that they may be revised (positively or negatively).

The pharmaceutical market in Brazil has been growing at very expressive rates in the last ten years. This growth is the result of a combination of a number of factors. The ageing of the population, due to the increase in people's life expectancy, is the main factor. According to the Brazilian Institute of Geography and Statistics (IBGE), the elderly population over 65 years of age will reach the mark of 58 million people in 2060, 180% more than in 2020.

d. values of underlying indicators

YEAR	PROJECTION	REVISION	ACHIEVED
2016	165 openings	200 openings	212 openings
2017	195 openings	200 openings	210 openings
2018	240 openings	-	240 openings
2019	240 openings	-	240 openings
2020	240 openings	-	240 openings
2021	240 openings	-	240 openings
2022	240 openings	260 openings	260 openings
2023	260 openings	270 openings	-
2024	260 openings	from 280 to 300 openings	-
2025	260 openings	from 280 to 300 openings	-

3.2 Follow-up of projections

3.2. If the issuer has disclosed, during the latest three fiscal years, projections over the evolution of its indicators

a. inform those being replaced with new projections contained in the form and those being repeated in the form

According to a Material Fact released on November 8, 2023, we revised the projection of gross openings for the years 2023, 2024 and 2025. For the year 2023, we increased the projection from 260 gross openings to 270. For the years 2024 and 2025, the projection has been revised to a number between 280 and 300 gross openings per year.

b. as for projections related to past periods, compare the projected data and the actual performance of indicators, clearly explaining the reasons for any deviations from the projections

Year	Projection	Achieved
2016	200 openings	212 openings
2017	200 openings	210 openings
2018	240 openings	240 openings
2019	240 openings	240 openings
2020	240 openings	240 openings
2021	240 openings	240 openings
2022	260 openings	260 openings

In 2016 and 2017 we surpassed the planned openings. This led us to expand the projections to 240 openings in 2018, 2019, 2020, and 2021, which were fully achieved. For the year 2022, the projection was also revised, according to the material fact disclosed on October 27, 2021, increasing from 240 to 260 gross openings, a number fully reached by the end of 2022.

c. as for projections related to ongoing periods, inform whether the projections remain valid on the date of delivery of the form and, if applicable, explain why they were abandoned or replaced

According to the Material Fact published on November 8, 2023, we increased the projection for the year 2023 to 270 gross openings. Furthermore, according to such document, the projection for the years 2024 and 2025 was revised to a quantity between 280 and 300 gross openings per year, due to expectations regarding the Company's operations, including the projection assumptions indicated in item 3.1 .c of this form.

On the form submission date, the projection remains valid.

4.1 Description of risk factors

4.1 - Describe the risk factors with effective potential to influence the investment decision, observing the categories below and, within them, the decreasing order of relevance

With the aim of modernizing the risk management process and making it more adherent to the best market practices (ISO 31000:2018, COSO ERM, IBGC and IIA methodologies), in addition to being aligned with the strategic objectives of RD, in 2022 we completely restructured our Risk Matrix, justifying the increments and alterations of the risk factors presented to the market in the Reference Form of previous years, taking into account the criteria of CVM Resolution 80.

a. to the issuer:

Our expansion depends, first and foremost, on our ability to successfully open and operate new units.

Our ability to successfully open and operate new units depends on a number of factors, many of which are beyond our control. Among the factors that depend on our performance is our ability to identify strategic locations to install units. It is a review process that requires gathering and evaluating location and population information, marketing to determine if there will be customer demand for consumption of our products in the chosen locations, and we need to be successful in negotiating acceptable leases and building the branch at economically viable cost.

Our ability to grow our business could be impaired if convenient locations cannot be found and if lease negotiations are not favorable to us. We compete with other retailers and merchants to find suitable locations for our units. The various regulations applicable to the types of units that we intend to build may represent an obstacle to our ability to identify suitable locations and influence the construction price of our units.

The opening of new units will also require maintaining inventory levels of products at acceptable costs, in order to meet the needs of new units, and also hiring, training, and maintaining employees, especially pharmacists, managers, and attendants.

New or newly opened units may not reach the level of revenue and profitability compared to our older units, either in our estimated timeframe or generally. In addition, our new units or newly opened units may adversely affect the revenue and profitability of our existing units by causing customers to transfer from the old branch to the new one.

We may be adversely affected if there are failures to open new units, due to delays in the construction schedule, due to factors related to the weather, essential licenses and qualified service providers, since if the Company works with companies that are not sufficiently committed in guaranteeing the safety of its own employees (although we have a specific area for evaluating and monitoring our suppliers in various areas), the Company may be held liable for any accidents that may occur in its workplaces, generating labor liabilities and potentially impact the Expansion strategy.

In addition, as our business expands, we need a highly skilled workforce. The service area in units represents the majority of our total employee turnover, therefore we believe that success will depend essentially on our continued ability to attract and retain qualified employees and partners.

All the aspects listed above could negatively impact our expansion strategy, as well as our revenue and ability to provide high standard services to our customers.

We are subject to risks associated to non-compliance with the LGPD (General Data Protection Law) and may be adversely affected by the imposition of fines or other types of sanctions.

4.1 Description of risk factors

Law 13,709, known as the General Data Protection Law (LGPD), sanctioned on August 14, 2018, regulates practices related to the processing of personal data in general and no longer in a sparse and sectoral manner, as the right to privacy and protection of data was regulated in Brazil until then.

Failure to comply with any provisions set forth in the LGPD has the following risks: (i) the filing of individual or collective lawsuits claiming compensation for damages resulting from violations, based not only on the LGPD, but on the sparse and sectoral legislation on data protection still in effect, or the exercise of any right arising from the LGPD; and (ii) the imposition of penalties set forth in the Consumer Protection Code and Civil Rights Framework for the Internet by some consumer protection bodies, as they are already acting in that sense, even before LGPD's date of effectiveness and the effective structuring of ANPD, especially in cases of security incidents that result in undue access to personal data.

For our operations, we have controls in relation to our customers' data and failures in the protection of personal data processed by our Company and the inadequacy to the applicable legislation can lead to high fines, disclosure of the incident to the market, deletion of personal data from the base, and even the suspension or prohibition of our activities, which could negatively affect our reputation, results and, consequently, the value of our shares.

We are subject to cybersecurity incidents or attacks on the infrastructure necessary to keep our systems up and running, which could result in operational, reputational, and financial damage.

Our operations depend on the performance of information management and data processing systems. Our activities and our results depend on the availability, integrity, and serviceability of data centers and other information systems, including point-of-sale systems, communication systems, centralized logistics systems, and other software applications used to control the inventories of our logistics centers.

Cybersecurity incidents may result in misappropriation of information from the Company and/or our customers and suppliers, and, consequently, the leakage of data from our operations and/or our customers and suppliers, thus causing damage to the Company's reputation and costs of dealing with the incident.

Failures, breaches, or disruptions in our information technology systems could impact our operations and negatively impact our business.

Information technology is an important part of our business and we rely heavily on systems to support our operations, manage our business data, and increase efficiency in the distribution and inventory management process. We also use information technology to process financial information and operating results for internal reporting and to comply with tax laws and regulations. In addition, we rely on information technology for digital marketing and electronic communications among our distribution centers, personnel, customers, and suppliers.

Like other companies, our information technology systems may be vulnerable to interruptions, including in the process of updating or replacing software, databases, among other components, natural disasters, terrorist attacks, telecommunications failures, computer viruses, cyber-attacks, hackers, unauthorized access, among other security issues. We implement technology security measures, as well as disaster coverage plans to mitigate our exposure to these risks, but these measures may not be sufficient. Failure to prevent security breaches, including breaches that prevent our systems from working as intended, could cause transaction errors, process inefficiencies, lost sales, negatively impact our business partners, customers, and our reputation.

We could be materially and adversely affected if our supply chain is interrupted, whether in the event that our distribution centers suffer material damage or are closed, or in the interruption of the supply of products by our suppliers.

4.1 Description of risk factors

We operate through 12 distribution centers located in ten states: São Paulo, Rio de Janeiro, Minas Gerais, Paraná, Goiás, Pernambuco, Bahia, Ceará, Rio Grande do Sul, and Mato Grosso, the latter having its operations started in 2023. If these distribution centers suffer any substantial damage, including damage caused by natural disasters, environmental damage, fire or flood, as well as if our distribution activity is reduced or interrupted due to strikes or lasting interruptions in the supply of electric power or shortages of diesel, we may incur a significant increase in costs and increased time for processing and distribution of our products to our stores, in addition, the coverage limit of our insurance policy may not be sufficient.

Such events may cause shortages in our distribution centers, resulting in a material adverse effect on our activity, originating a relevant loss of sales and results.

Negative impact on our image and reputation in the market.

We have a strong image related to solid corporate governance and are known as a company focused on people, health, and well-being. Any negative reflection on our image could have an impact on our business results, as well as our ability to implement our growth strategy.

We must comply with the laws and regulations applicable to our business. While we will act to ensure compliance with anti-corruption laws and sanctions regulations that apply to us, there is no guarantee that prosecution will be sufficient or that our employees, directors, officers, partners, agents, and service providers will not act in violation of our values for which we or they can be held accountable.

Risk associated with non-renewal of rental of properties for units.

The Company has property lease agreements with terms and validity between one and twenty years, with the possibility of renewal. According to the provisions of Law 8,245-91 (Tenancy Law), the company is assured the right to renew contracts that have been signed with a duration equal to or greater than 5 years, and must file an Action for Compulsory Renewal of Lease Agreement in court within the period between 6 and 12 months prior to expiration whenever it has not been renewed by consensus between the parties.

We have a significant number of lease agreements in force, with the right to renew established by the Tenancy Law, and it is important to note that, even in the case of agreements lasting more than 5 years, they may not be renewed if the owner requests the property to transfer goodwill existing for more than one year in which the owner, his or her spouse, ascendants, or descendants, are holders of a majority of the common stock, and provided that this business is of a branch different from that of the lessee.

Changes to the rules, provisions, and instructions of the Novo Mercado and the Arbitration Chamber may directly impact our Company.

The Company, its shareholders, managers, members of the Audit Committee undertake to resolve, by means of arbitration, any and all disputes or conflicts that may arise between them, especially in connection with, or arising out of, application, validity, effectiveness, construal, violation and effects thereof, of the provisions set forth in the Brazilian Corporate Laws, in the Company's Bylaws, in the standards enacted by the National Monetary Council, by the Central Bank of Brazil, and by the Securities Commission, as well as in the other standards applicable to the operation of the capital market in general, in addition to those included in the Novo Mercado Listing Regulations, in the Novo Mercado Participation Agreement, and in the Arbitration Rules of *Câmara de Arbitragem do Mercado* (Market Arbitration Chamber).

A global economic recession or slowdown, reflected in Brazil with rising unemployment and lower commercial activity, both during pandemics and after the outbreak subsides, has the potential to reduce the demand for our products.

4.1 Description of risk factors

As a result, pandemics such as Covid19 may adversely affect our business, financial condition, results of operations, liquidity, and cash flows. After the Covid19 outbreak subsides, we, including our subsidiaries and acquired companies, could have materially adverse impacts on our business as a result of the national and global economic impact. We have no guarantee that other regional and/or global outbreaks will not happen again, which could impact demand for our products and pricing policy. We cannot say that we will be able to take the necessary actions to prevent a negative impact on our business.

Increased competitiveness in the market in which we operate, whether due to the appearance of new competitors or the expansion and sophistication of the operations of existing competitors, could negatively affect our market share.

Competition may adversely affect us, as we operate in highly competitive markets and compete with national, regional, and local pharmacy chains. Some of our competitors have a large number of units in Brazil, as well as significant market presence, name recognition, distribution network, marketing, and other resources. We also compete with independent drugstores, telephone prescription services and other retailers, such as supermarkets and convenience stores. In addition, in the future, our competitors may open new pharmacies, and other retailers may enter the market in which we operate and become our competitors.

Competition is characterized by many factors, including product variety, advertising, price, quality, service, location, reputation, means of purchase, credit availability, and new services available to customers. We compete with pharmacy chains and other retailers with respect to product variety to meet consumer preferences. If we fail to anticipate and match consumer preferences, our revenue could be harmed and market share could be lost to our competitors.

The volatility and illiquidity of the Brazilian securities market may substantially limit investors' ability to sell our shares at the price and time they desire.

Investment in securities traded in emerging markets, such as Brazil, frequently involves higher risk if compared to other global markets, and these investments are generally considered to be more speculative. The Brazilian securities market is substantially smaller, less liquid and more concentrated, and may be more volatile than the main global securities markets. The volatility and illiquidity of the Brazilian securities market may considerably limit our shareholders' ability to sell our shares at the price and time they desire.

Any change in investor interest in Brazilian assets, for whatever reason, may adversely affect the price of said assets. In Brazil, there is the possibility of reduction in the purchasing power of the population, reducing the sales volume of our operations with a direct impact on the Company's economic result.

Raising additional funds through an offering of shares may dilute investors' shareholding in our Company.

We may, in the future, raise funds through public or private issuance of debt securities, convertible or not into shares, or shares. The raising of additional funds through the issuance of shares or securities convertible into shares may, pursuant to the provisions of the Brazilian Corporate Laws, be carried out excluding the preemptive rights of our shareholders, including investors in our shares, and may therefore dilute the shareholding of the investors in our shares.

Holders of our shares may not receive dividends.

4.1 Description of risk factors

According to Law No. 6,404 of December 15, 1976, or the Brazilian Corporate Laws and to our Bylaws, our shareholders are entitled to a minimum dividend of at least 25.0% of our annual net profit, as determined and adjusted. Such net profit adjustments for purposes of calculating the dividends base include contributions to several reserves that effectively reduce the amount available for payment of dividends. Despite the requirement of the compulsory dividend, we can opt for not paying dividends to our shareholders in any fiscal year, if our Board of Directors determines that such distributions are not advisable given our financial condition or the need to use such resources in our operations.

b. to its shareholders, in particular the controlling shareholders

Our managers and other eligible collaborators may participate in the Long-Term Incentive Program with Restricted Shares, which is closely related to the performance of the price of the shares issued by us.

A portion of the remuneration of our management and key employees is linked to the Long-Term Incentive Program based on Restricted Shares, if such program is discontinued, under any circumstances, this could lead to a misalignment of interests between the management, shareholders and Company, due to the eventual search for shorter-term results that would value the shares issued by the Company in immediate periods, without building long-term value.

Additional information can be consulted in the Compensation Policy of the Statutory Executive Office disclosed on March 30, 2021.

c. to its subsidiaries and affiliated companies

Our revenue may be impacted if investments in other companies have a lower than expected return.

Part of the RD strategy includes developing a health and wellness ecosystem, which can involve investing in existing companies or creating new companies. The construction of this ecosystem and possible investments may present a financial return lower than expected, which may impact the company's consolidated results.

d. to its managers

The interests of our controlling shareholders may conflict with the interests of our minority shareholders.

We have managers who are also shareholders of the Company. The fact described may, eventually, lead to the taking of measures that conflict with the interests of our other shareholders or which do not result in an improvement in our operational results, and they may be interested in carrying out acquisitions, disposals of assets, partnerships, seeking financing, or make decisions that may conflict with the interests of our other shareholders.

e. to its suppliers

It is not possible to fully guarantee that our suppliers will not be involved in irregular practices.

4.1 Description of risk factors

We cannot guarantee that suppliers do not have problems in relation to the outsourcing of the production chain, inadequate health and safety conditions, or that they do not use these irregular practices to reduce expenses and costs. If our suppliers are involved in these or similar practices, our reputation could be harmed and, consequently, the perception of our customers and investors could be negatively affected, and they could be held liable for the labor and social-security obligations of third-party suppliers.

We depend on third parties for the manufacture of medicines and products.

All products available in our units and websites are manufactured by third parties, through contracts. The loss or termination of these contracts with third parties or our inability to renew them or negotiate new contracts with other suppliers at equivalent prices could adversely affect our commercial and financial performance.

f. its customers

Pharmacies are inherently subject to the risk that consumption of their products and services could cause injury, illness, or death, and our insurance coverage may not be adequate to cover any damages suffered by customers.

Pharmacies are exposed to certain risks inherent to the sale and distribution of pharmaceutical products and other health-related products, as well as the provision of pharmaceutical services. Furthermore, errors in the sale of such pharmaceutical products and in the provision of pharmaceutical services could lead to serious injury or death.

Civil liability claims may be brought against us in connection with any of the pharmaceutical or other products we sell and services we provide, and we may be required to suspend or discontinue our activities and the sale of certain products or the provision of certain services, or even to recall products sold by us.

Additionally, the limit of our insurance coverage may not be adequate to protect us from future claims arising from liability for products sold by us or services provided by us, and we may not be able to maintain insurance coverage with adequate conditions for these risks.

If any lawsuits regarding liability for products sold by us or services provided by us result in unfavorable judgments for our Company, we may incur damages to our reputation and financial indemnities that may not be fully covered by our insurance, which may adversely affect us.

g. to the economic sectors where the issuer operates

The growing consolidation of the retail sector in Brazil may put pressure on our margins and operating results.

The retail sector in which we operate has undergone a consolidation process in recent years. As a result, we have larger, more sophisticated competitors with increasing bargaining power, able to operate with reduced inventory and resist price increases, in addition to demanding lower prices and increased promotion programs. If we do not respond effectively to these trends, the pace of our sales growth could slow down or we could be forced to lower our prices or increase our promotional expenses, which could affect our results.

h. regulations applying to sectors where the issuer acts

The pharmaceutical industry is subject to a large number of regulations.

4.1 Description of risk factors

The pharmaceutical industry is subject to a large number of federal, state, and municipal regulations for the operation and safety standards of the Ministry of Health, ANVISA and state and municipal agencies, as well as laws and regulations regarding aspects of protection of the environment, health and safety, including the display, handling, and disposal of hazardous substances. There can be no guarantee that the regulatory agencies or the judiciary will recognize that the Company is fully complied with the provisions of the laws and regulations.

Our operations may be influenced by specific regulations for the states and metropolitan areas in which we operate.

Our operations may be influenced by regulations specific to the states and metropolitan areas in which we operate, such as zoning laws and marketing restrictions. In particular, due to the fact that a significant portion of our units are located in the greater São Paulo metropolitan region, any additional or more onerous regulations or restrictions imposed by the state of São Paulo or the municipality of São Paulo could have an adverse effect on our business.

Untimely compliance or non-compliance with applicable regulations may result in the imposition of civil and criminal sanctions, causing an adverse effect on the maintenance of our business, including: suspension of payments related to government programs; loss of government-mandated certifications; loss of authorization to participate in or our exclusion from government reimbursement programs; loss of license to operate one or more stores or to carry out certain commercial activities; or significant fines or financial penalties, could adversely affect us.

In addition, changes to these regulations may restrict our existing operations, limit the expansion of our business, and require expansion of systems and operational changes that may be difficult to implement.

Changes in our production chain could have an adverse effect on our business.

Factors related to the pharmaceutical industry that could have an adverse effect on our business include:

- Changes in pharmaceutical product distribution policy or procedures related to pricing, sales, inventory, distribution, and supply;
- Changes in distribution methods for pharmaceutical products;
- Amendments to laws or regulations relating to the pharmaceutical sector;
- Imposition of additional or more restrictive price controls on pharmaceutical products; and
- Increased sales of pharmaceutical products by Brazilian supermarkets.

Future changes in the pharmaceutical industry could adversely affect the supply, demand, and marketing of our products and services, restrict our ability to conduct business in our current and future market, with a consequent adverse effect on us.

We are subject to federal laws that impose price control to the majority of the pharmaceutical products that we sell.

The prices we can charge on these products are subject to the limit annually adjusted in accordance with the terms of the federal law to reflect the changes in inflation. This price control has resulted in a lower profits margin in pharmacy than those usually realized in the pharmaceutical products that are not subject to price control, affecting our profitability. We cannot guarantee that the Federal Government will not impose additional or more restrictive price controls for pharmaceutical products in the future, which may adversely affect us.

4.1 Description of risk factors

Increases in personnel expenses due to new regulatory requirements or unfavorable labor negotiations may adversely affect us.

Compliance with new laws, regulations by the competent authorities, or unfavorable labor negotiations may lead to increases in our operating expenses, such as: (i) salary increments; (ii) increase in the number of employees in units, in the Distribution Center, and in the administrative center; (iii) replacement of other professionals by pharmacists; (iv) increase in other expenses related to sales in stores; and (v) handling and control in our Distribution Center.

We cannot guarantee that these possible additional costs will not be passed on in our prices. If such transfers do not occur, these cost increases could impact our profitability and adversely affect us.

i. to the foreign countries where the issuer acts

We currently do not operate in foreign countries.

Introductory text for items “j. social matters”, “k. environmental matters”, and “l. climate matters, including physical and transition risks”.

In addition to the Risk Committees and the Audit Committee periodically monitoring the company's risks, the Sustainability Committee (with duties to advise the Board of Directors) also monitors risks related to social matters (j), environmental matters (k), and climate matters, including physical and transition risks (l). The company is responsible for achieving the goals established in its 2030 Sustainability Commitments, however unusual social, environmental, and climate change events may compromise the achievement of these goals.

j. social matters

Actions or omissions or connivance carried out by third parties, employees, and customers that may have a negative effect on socially conscious practices and compliance with dignified working conditions.

In 2022, we improved our Risk Management process and included the mapping of social risks and their impacts, resulting in risk factors that could impact the health and safety of our employees and third parties; the promotion of inclusion, diversity, and equity; dignified employment relationships; the protection of children, young people, and the elderly; the eradication of child labor, slave labor, or forced labor and any violation of human rights.

Despite these preventive measures, we cannot guarantee, given the scope of our activities, that there may not be any violation, whether by an employee, third party, or supplier, who will be subject to the appropriate measures.

k. environmental matters

Amendment to the environmental laws and other environmental matters could adversely impact our operations.

Legislation on environmental matters may change unpredictably, which may require adjustments by the Company that require investments and adaptations in the way it operates, which may impact the achievement of the goals established in the 2030 Sustainability Strategy.

Other environmental issues are related to the consumption and use of natural resources: water, electric power, and fossil fuels, the scarcity of which can impact the operation, increasing costs,

4.1 Description of risk factors

decreasing the comfort of customers and employees in our facilities and, in extreme cases, causing the interruption of operations until access to these resources is restored.

I. climate matters, including physical and transition risks

Matters related to climate change may adversely impact our operations.

The company is exposed to physical risks, which may impact the integrity of physical structures and the safety of our employees and customers, due to changes in precipitation patterns and extreme variability in weather patterns, effects of climate change, which may lead to periods of water shortage in the regions where our pharmacies and Distribution Centers are located, which could impact and compromise our operations.

Regarding transition risks, if adequate management of GHG emissions is not carried out, aiming to contain the effects of climate change, there may be a loss of credibility with investors, with consequent financial and reputational impacts, in addition to regulatory risks of regulatory nature, which can be implemented in unpredictable ways.

m. other matters not included in the previous items

All risk factors were covered in the previous items.

4.2 Indication of the five (5) main risk factors

4.2. Indicate the five (5) main risk factors, among those listed in field 4.1, regardless of the category they fall into

In item 4.1, we presented the risk factors that the company considers relevant. Next, we have the top risks:

1. Our expansion depends, first and foremost, on our ability to successfully open and operate new units.
2. We are subject to risks associated to non-compliance with the LGPD (General Data Protection Law) and may be adversely affected by the imposition of fines or other types of sanctions.
3. We are subject to cybersecurity incidents or attacks on the infrastructure necessary to keep our systems up and running, which could result in operational, reputational, and financial damage.
4. Failures, breaches, or disruptions in our information technology systems could impact our operations and negatively impact our business.
5. We could be materially and adversely affected if our supply chain is interrupted, whether in the event that our distribution centers suffer material damage or are closed, or in the interruption of the supply of products by our suppliers.

Our expansion depends, first and foremost, on our ability to successfully open and operate new units.

Our ability to successfully open and operate new units depends on a number of factors, many of which are beyond our control. Among the factors that depend on our performance is our ability to identify strategic locations to install units. It is a review process that requires gathering and evaluating location and population information, marketing to determine if there will be customer demand for consumption of our products in the chosen locations, and we need to be successful in negotiating acceptable leases and building the branch at economically viable cost.

Our ability to grow our business could be impaired if convenient locations cannot be found and if lease negotiations are not favorable to us. We compete with other retailers and merchants to find suitable locations for our units. The various regulations applicable to the types of units that we intend to build may represent an obstacle to our ability to identify suitable locations and influence the construction price of our units.

The opening of new units will also require maintaining inventory levels of products at acceptable costs, in order to meet the needs of new units, and also hiring, training, and maintaining employees, especially pharmacists, managers, and attendants.

New or newly opened units may not reach the level of revenue and profitability compared to our older units, either in our estimated timeframe or generally. In addition, our new units or newly opened units may adversely affect the revenue and profitability of our existing units by causing customers to transfer from the old branch to the new one.

We may be adversely affected if there are failures to open new units, due to delays in the construction schedule, due to factors related to the weather, essential licenses and qualified service providers, since if the Company works with companies that are not sufficiently committed in guaranteeing the safety of its own employees (although we have a specific area for evaluating and monitoring our suppliers in various areas), the Company may be held liable for any accidents that may occur in its workplaces, generating labor liabilities and potentially impact the Expansion strategy.

In addition, as our business expands, we need a highly skilled workforce. The service area in units represents the majority of the total turnover of our employees, so we believe that success will essentially depend on our continued ability to attract and retain qualified employees and partners.

All the aspects listed above could negatively impact our expansion strategy, as well as our revenue and ability to provide high standard services to our customers.

We are subject to risks associated to non-compliance with the LGPD (General Data Protection Law) and may be adversely affected by the imposition of fines or other types of sanctions.

Law 13,709, known as the General Data Protection Law (LGPD), sanctioned on August 14, 2018, regulates practices related to the processing of personal data in general and no longer in a sparse and sectoral

4.2 Indication of the five (5) main risk factors

manner, as the right to privacy and protection of data was regulated in Brazil until then.

Failure to comply with any provisions set forth in the LGPD has the following risks: (i) the filing of individual or collective lawsuits claiming compensation for damages resulting from violations, based not only on the LGPD, but on the sparse and sectoral legislation on data protection still in effect, or the exercise of any right arising from the LGPD; and (ii) the imposition of penalties set forth in the Consumer Protection Code and Civil Rights Framework for the Internet by some consumer protection bodies, as they are already acting in that sense, even before LGPD's date of effectiveness and the effective structuring of ANPD, especially in cases of security incidents that result in undue access to personal data.

For our operations, we have controls in relation to our customers' data and failures in the protection of personal data processed by our Company and the inadequacy to the applicable legislation can lead to high fines, disclosure of the incident to the market, deletion of personal data from the base, and even the suspension or prohibition of our activities, which could negatively affect our reputation, results and, consequently, the value of our shares.

We are subject to cybersecurity incidents or attacks on the infrastructure necessary to keep our systems up and running, which could result in operational, reputational, and financial damage.

Our operations depend on the performance of information management and data processing systems. Our activities and our results depend on the availability, integrity, and serviceability of data centers and other information systems, including point-of-sale systems, communication systems, centralized logistics systems, and other software applications used to control the inventories of our logistics centers.

Cybersecurity incidents may result in misappropriation of information from the Company and/or our customers and suppliers, and, consequently, the leakage of data from our operations and/or our customers and suppliers, thus causing damage to the Company's reputation and costs of dealing with the incident.

Failures, breaches, or disruptions in our information technology systems could impact our operations and negatively impact our business.

Information technology is an important part of our business and we rely heavily on systems to support our operations, manage our business data, and increase efficiency in the distribution and inventory management process. We also use information technology to process financial information and operating results for internal reporting and to comply with tax laws and regulations. In addition, we rely on information technology for digital marketing and electronic communications among our distribution centers, personnel, customers, and suppliers.

Like other companies, our information technology systems may be vulnerable to interruptions, including in the process of updating or replacing software, databases, among other components, natural disasters, terrorist attacks, telecommunications failures, computer viruses, attacks cybernetics, hackers, unauthorized access, among other security

4.2 Indication of the five (5) main risk factors

issues. We implement technology security measures, as well as disaster coverage plans to mitigate our exposure to these risks, but these measures may not be sufficient. Failure to prevent security breaches, including breaches that prevent our systems from working as intended, could cause transaction errors, process inefficiencies, lost sales, negatively impact our business partners, customers, and our reputation.

We could be materially and adversely affected if our supply chain is interrupted, whether in the event that our distribution centers suffer material damage or are closed, or in the interruption of the supply of products by our suppliers.

We operate through 12 distribution centers located in ten states: São Paulo, Rio de Janeiro, Minas Gerais, Paraná, Goiás, Pernambuco, Bahia, Ceará, Rio Grande do Sul, and Mato Grosso, the latter having its operations started in 2023. If these distribution centers suffer any substantial damage, including damage caused by natural disasters, environmental damage, fire or flood, as well as if our distribution activity is reduced or interrupted due to strikes or lasting interruptions in the supply of electric power or shortages of diesel, we may incur a significant increase in costs and increased time for processing and distribution of our products to our stores, in addition, the coverage limit of our insurance policy may not be sufficient.

Such events may cause shortages in our distribution centers, resulting in a material adverse effect on our activity, resulting in a relevant loss of sales and results.

4.3 Description of main market risks

The Company seeks protection for the main risks that may adversely and significantly impact the objectives outlined by the Senior Management, our activities expose us to various financial risks, such as market risk, credit risk, and liquidity risk. The risk management program focuses on the unpredictability of financial and operating markets and seeks to minimize potential adverse effects on financial performance. The Board of Directors establishes principles for risk management, as well as for specific areas, such as interest rate risk, credit risk, use of non-derivative financial instruments, and investment of excess cash.

(a) Market Risk

Foreign exchange risk

All asset and liability operations of the Group (Raia Drogasil and Subsidiaries) are carried out in reais (BRL), with no risk due to exchange variations.

Interest rate risk

The exposure of the Group (Raia Drogasil and Subsidiaries) to interest rate risk mainly refers to obligations subject to variable rates.

The Company's loans and financing are pegged to the CDI + bank spread. Financial investments are contracted based on the CDI variation, which does not entail major risks in relation to interest rates, as their variations are not relevant. The Management understands that the risk of significant changes in earnings and cash flows is low and constantly evaluates the best way to raise funds.

(b) Credit risk

Credit risks are related to our financial assets, which are cash and cash equivalents, financial investments and accounts receivable.

Cash and cash equivalents and financial investments are handled only with financial institutions of recognized solidity.

The extension of credit on sales of goods follows a policy aimed at minimizing default. In the fiscal year ended December 31, 2022, sales with installment payments represented 61% (57% - Dec/2021) in the Controlling Shareholder and 63% (59% - Dec/2021) for the consolidated, and 89% of this total (94% - Dec/2021) in the Controlling Shareholder and 82% (87% - Dec/2021) in the consolidated are related to credit card sales, which, based on the history of losses, present very low risk. The remaining 11% (6% - Dec/2021) and 18% (13% - Dec/2021) for the consolidated are credits with Drug Benefit Programs ("PBM's"), which agreements present low risk, given the customer selectivity.

The Company has loans with a contractual clause that requires the maintenance of financial indicators, having as main operation with clauses of this nature being simple unsecured Debentures, with the 2nd issue on April 02, 2018 and the 3rd issue on March 13, 2019, the 4th issue on June 17, 2019, 5th issue on January 25, 2022, 6th issue on March 7, 2022, and 7th issue on June 26, 2022. Below is a summary of the financial index (Covenants) provided for, according to public offering documents registered with the CVM:

Financial Net Debt/EBITDA smaller than or equal to 3.0.

(c) Liquidity risk

The Management of the Group (Raia Drogasil and Subsidiaries) continuously monitors the necessary liquidity forecasts to ensure that there is sufficient cash to meet operational needs. Excess cash is invested in financial assets with appropriate maturities in order to

4.3 Description of main market risks

guarantee the necessary liquidity for compliance with its obligations. The company's substantial indebtedness may limit its ability to obtain additional financing for working capital.

The objective of the Group (Raia Drogasil and Subsidiaries) in terms of capital management is to maintain its investment capacity, enabling its growth process to be viable and offering an adequate return to its shareholders.

It is the policy of the Group (Raia Drogasil and Subsidiaries) not to leverage its capital structure with loans and financing, with the exception of debentures with rates adequate to the levels of profitability of the Group (Raia Drogasil and Subsidiaries).

Thus, the financial leverage ratio is the result of dividing net cash or net debt by shareholders' equity. Net cash or net debt results from the sum of financing subtracted from total cash and cash equivalents, as shown below:

	Amounts in thousands	
	2022	2021
Capital management items		
Long and short term loans	2,317,904	1,505,222
(-) Cash and cash equivalents	(433,541)	(356,118)
Net debt	1,884,363	1,149,104
Shareholders' Equity attributable to shareholders of the Controlling Shareholder	5,340,862	4,677,114
Interest of non-controlling shareholders	62,079	41,129
Total shareholders' equity	5,402,941	4,718,243
Total Capital	7,287,304	5,867,347
Financial leverage index (%)	25.86%	19.58%
Net debt adjusted with leasing liabilities	2022	2021
Net debt	1,884,363	1,149,104
Lease liabilities	3,740,008	3,672,898
Adjusted net debt	5,624,371	4,822,002
Total shareholders' equity	5,402,941	4,718,243
Total adjusted Capital	11,027,312	9,540,245
Adjusted financial leverage index (%)	51.00%	50.54%

(d) Counterparty Risk

On December 31, 2022, the Company had BRL 433,541 thousand in cash and cash equivalents, and these funds are allocated in financial institutions of recognized solidity.

4.3 Description of main market risks

Unrest in the economy, fraud and mismanagement can affect institutions' financial ability to honor their obligations. In the event of a counterparty's lack of credit, the Company may have significant losses on the funds contributed to the financial institution.

(e) Sensitivity analysis

The Company prepares a sensitivity analysis of financial instruments indexed to interest rates, to which the Company is exposed. Currently, all of the Company's loans and financing are indexed to the CDI, and given the economy's basic interest rate stability (Selic), we understand that there is no need to analyze scenarios where there is an increase in the interest curve, given that any market analysis foresees a reduction in the basic interest rate as from the second half of 2023.

4.4 Relevant non-confidential proceedings

4.4. Describe the judicial, administrative or arbitral proceedings to which the issuer or its subsidiaries are a party, broken down into civil, environmental, tax, labor and other areas, which are:

(i) not subject to secrecy, and (ii) relevant for the businesses of the issuer or its subsidiaries, indicating:

The Company defines as a criterion for considering the proceedings as relevant the potential disbursement of an amount related to 0.25% of its Shareholders' Equity, with a base date of December 31, 2022, given that such reference is adopted in its Bylaws for the approval of certain acts by the governance bodies. This amount totals BRL 13.6 million, which shall be verified in the event of loss of each of the aforementioned proceedings, after the appropriate administrative or judicial instances have been exhausted.

We present below a brief description of the most relevant proceedings to which we are a party, according to their nature.

Civil Aspects

There are no civil lawsuits that represent a relevant contingency for the Company in December 2022, according to the previously evaluated criteria.

Additionally, despite not being considered relevant, the Company informs that, on December 31, 2022, it was a defendant in four hundred and ninety-six (496) civil lawsuits of a consumer nature with diverse subject matters, such as: compensation for undue protest of instruments, consumption relationship (defective products, incorrect sale of medicines), theft of customer objects by third parties in our establishments, GDPL, among others. The proceedings that represented potential liabilities totaled, on that date, the approximate amount of BRL 14.4 million.

The amounts provisioned for the civil lawsuits described above total BRL 0.9 million, given that the amounts of judicial deposits in December 2022 totaled BRL 2.6 million.

Labor Aspects

There are no labor claims that represent a relevant contingency for the Company in December 2022, according to the previously evaluated criteria.

Additionally, despite not being considered relevant, the Company informs that, on December 31, 2022, it was a defendant in three thousand, five hundred and sixty (3,560) labor claims with various claims, such as: overtime, holidays, function bonus of 40%, premium for unhealthy work, among others, totaling an accounting provision of BRL 94 million. The amounts of judicial deposits to be withdrawn in December totaled BRL 5.5 million and there are BRL 3.2 million in judicial guarantees.

Tax Aspects

On December 31, 2022, the Company was a defendant in 360 administrative and judicial proceedings of a tax nature. The proceedings that represented potential liabilities totaled, on that date, the approximate amount of BRL 487.5 million.

As an internal practice adopted by us, we provision amounts referring to probable contingencies, which is why we have provisioned the amount of BRL 11.8 million.

Among the tax proceedings that represented a relevant contingency for the Company in December 2022 due to the respective amount, the following stand out:

4.4 Relevant non-confidential proceedings

(I) IRPJ and CSLL

ADMINISTRATIVE PROCEEDINGS No. 13864.720-004/2018-27	
a. Court	Brazilian Federal Revenue Office
b. Instance	Administrative Council of Tax Appeals - CARF
c. Filing date	02/08/2018
d. Parties in the proceedings	AUTHORITY: Brazilian Federal Revenue Office; DEFENDANT: Raia Drogasil S.A.
e. Amounts, assets, or rights	BRL 141,128,841.04, in December/2022.
f. Main facts	This is a tax deficiency notice drawn up to charge a fine due to the alleged incorrect completion of the EFDs-Contributions for the year 2013.
g. Summary of decisions on the merits	Objection filed in February 2018. In February 2019, a decision on partial granting was handed down to exclude the requirements for the calculation periods between 01/2013 to 04/2013. In March 2019, a voluntary appeal was filed.
h. Stage of proceeding	2 nd administrative instance
i. Chances of loss	Remote
j. Reason why the proceeding is relevant	Criterion provided for in the 1st paragraph of this item
k. Analysis of the impact in case of an unfavorable outcome	BRL 141,128,841.04, in December/2022.

ADMINISTRATIVE PROCEEDINGS No. 16561.720022/2019-92	
a. Court	Brazilian Federal Revenue Office
b. Instance	Administrative Council of Tax Appeals - CARF
c. Filing date	05/30/2019
d. Parties in the proceedings	AUTHORITY: Brazilian Federal Revenue Office; DEFENDANT: Drogaria Onofre S.A.
e. Amounts, assets, or rights	BRL 13,755,318.62, in December/2022.
f. Main facts	This is an administrative proceeding resulting from tax deficiency notices drawn up for the collection of corporate income tax (IRPJ) and social contribution on net income (CSLL), relating to the base years from 2014 to 2017, accrued with late payment interest, aggravated fine imposed at the initiative of the authority, and isolated fine.
g. Summary of decisions on the merits	The challenge was filed in July 2019. Awaiting trial of the voluntary appeal filed in February 2020.
h. Stage of proceeding	2 nd administrative instance
i. Chances of loss	Possible
j. Reason why the proceeding is relevant	Criterion provided for in the 1st paragraph of this item
k. Analysis of the impact in case of an unfavorable outcome	BRL 13,755,318.62, in December/2022.

4.4 Relevant non-confidential proceedings

(II) Treasury Office of the State of São Paulo

TAX DEFICIENCY NOTICE No. 4.020.867/9	
a. Court	Treasury Office of the State of São Paulo
b. Instance	Tax Court of the State of São Paulo (TIT)
c. Filing date	07/19/2013
d. Parties in the proceedings	AUTHORITY: Treasury Office of the State of São Paulo DEFENDANT: Raia Drogasil S.A.
e. Amounts, assets, or rights	BRL 19,114,129.13, in December/2022.
f. Main facts	This is a Tax Deficiency Notice and Imposition of Fines through which the collection of ICMS is required due to the lack of proof of the right to reimbursement of the ICMS withheld in excess due to tax substitution, related to the assessment periods of April, May, and June 2008 plus 50% fine.
g. Summary of decisions on the merits	The challenge was filed in September 2013. The voluntary appeal was lodged in December 2014. On April 07, 2021, a decision was issued upholding the tax deficiency notice. On December 27, 2021, a special appeal was filed. Appeal judgment pending.
h. Stage of proceeding	3 rd administrative instance
i. Chances of loss	Remote
j. Reason why the proceeding is relevant	Criterion provided for in the 1st paragraph of this item
k. Analysis of the impact in case of an unfavorable outcome	BRL 19,114,129.13 in December/2022.

TAX DEFICIENCY NOTICE No. 4.119.544/9	
a. Court	Treasury Office of the State of São Paulo
b. Instance	Tax Court - SP
c. Filing date	12/17/2018
d. Parties in the proceedings	AUTHORITY: Treasury Office of the State of São Paulo DEFENDANT: Raia Drogasil S.A.
e. Amounts, assets, or rights	BRL 32,722,587.68, in December/2022
f. Main facts	This is a tax deficiency notice issued for alleged undue crediting of ICMS in the periods of 02/2013, 03/2013, 08/2013, 09/2013, and 11/2013, as well as for alleged errors in the bookkeeping for the period from 01/2013 to 12/2013 and alleged duplicate credit on 11/2013. CAT ORDINANCE 17/1999.
g. Summary of decisions on the merits	The objection was filed in January 2019. In October 2019, a decision was issued upholding the tax deficiency notice. In November 2019, the ordinary appeal was filed. In September 2020, the appeal was denied, and the tax deficiency notice was upheld. In October 2020, a special appeal was filed. Special appeal judgment pending.
h. Stage of proceeding	3 rd administrative instance

4.4 Relevant non-confidential proceedings

i. Chances of loss	Remote
j. Reason why the proceeding is relevant	Criterion provided for in the 1st paragraph of this item
k. Analysis of the impact in case of an unfavorable outcome	BRL 32,722,587.68, in December/2022

TAX DEFICIENCY NOTICE No. 4.113.786/3	
a. Court	Treasury Office of the State of São Paulo
b. Instance	Tax Court - SP
c. Filing date	10/15/2018
d. Parties in the proceedings	AUTHORITY: Treasury Office of the State of São Paulo DEFENDANT: Raia Drogasil S.A.
e. Amounts, assets, or rights	BRL 33,958,934.29 in december/2022
f. Main facts	This is a tax deficiency notice drawn up for the collection of ICMS and fine for alleged errors in EFD tax bookkeeping in the years 2013 to 2017
g. Summary of decisions on the merits	The challenge was filed in November 2018. In January 2019, decision upholding the tax deficiency notice. In February 2019, an ordinary appeal was filed. In February 2019, the ordinary appeal was denied. In November 2019, a special appeal was filed. We are awaiting judgment of the special appeal.
h. Stage of proceeding	3 rd administrative instance
i. Chances of loss	Remote
j. Reason why the proceeding is relevant	Criterion provided for in the 1st paragraph of this item
k. Analysis of the impact in case of an unfavorable outcome	BRL 33,958,934.29 in December/2022

TAX DEFICIENCY NOTICE No. 4.113.795/4	
a. Court	Treasury Office of the State of São Paulo
b. Instance	Tax Court - SP
c. Filing date	10/04/2018
d. Parties in the proceedings	AUTHORITY: Treasury Office of the State of São Paulo DEFENDANT: Raia Drogasil S.A.
e. Amounts, assets, or rights	BRL 49,552,372.36 in December/2022
f. Main facts	This is a tax deficiency notice relating to the alleged joint liability in the collection of ICMS on goods received from suppliers, for the period from 01/2014 to 12/2015.
g. Summary of decisions on the merits	The challenge was filed in November 2018. In May 2019, a judgment was rendered upholding the tax deficiency notice. In June 2019, a voluntary appeal was filed. In August 2019, a decision was rendered denying the voluntary appeal. In May 2021, the presentation of oral arguments in the judgment of May 2021 was requested. Postponement of judgment to produce more evidence. Awaiting compliance with the production of evidence for new trial.
h. Stage of proceeding	2 nd administrative instance
i. Chances of loss	Remote

4.4 Relevant non-confidential proceedings

j. Reason why the proceeding is relevant	Criterion provided for in the 1st paragraph of this item
k. Analysis of the impact in case of an unfavorable outcome	BRL 49,552,372.36 in December/2022

4.5 Total amount provisioned for relevant non-confidential proceedings

4.5. State the total amount provisioned, if any, for the proceedings described in item 4.4:

On December 31, 2022, RD had BRL 11,832 thousand provisioned for probable tax proceedings, considered individually relevant indicated in item 4.4 above. As for civil and labor proceedings, there are no lawsuits considered individually relevant by the Company.

4.6 Relevant confidential proceedings

4.6. For relevant confidential proceedings to which the issuer or its subsidiaries are a party and not disclosed in item 4.4, analyze their impact in case of an unfavorable outcome and inform the amounts involved

There is no additional information on relevant confidential processes to which we are party and was not disclosed in item 4.4.

4.7 Other relevant contingencies

4.7. Describe other relevant contingencies not covered by the preceding items

There are no other relevant contingencies not covered by the preceding items.

5.1 Description of the risk management and market risk management

Regarding the risks indicated in items 4.1 and 4.3, please inform:

a. If the issuer has a formal risk management policy, highlighting, if so, the body that approved it and its approval date and, if not, the reasons why the issuer has not adopted a policy.

We have a Corporate Risk Management Policy duly formalized and approved by the Board of Directors on December 14, 2017 and updated on July 29, 2022.

The risk factors presented in item 4.1 are constantly evaluated by the Executive Office and the Audit Committee and periodically reported to the Board of Directors, in addition to the mechanisms adopted for managing the Company's risks.

b. The objectives and strategies of the risk management policy, if any, including:

The Policy defines the guidelines for the Company's risk management and guidelines for the processes of identification, evaluation, handling, monitoring, and communicating risks related to the business objectives, incorporating the vision of risks into decision-making and strategic planning, in order to align RD governance with good market practices. The policy provides a common language, aiming to align, disseminate, and encourage the risk management culture in the Company.

Our methodological approach is based on ISO 31000, COSO ERM, and IBGC, also considering the concepts proposed in the Three Lines Model, created by the IIA.

The IIA's Three-Line Model ensures segregation of direct responsibility in three levels:

- (i) First Line (business area): manage the risks in its area, take actions to mitigate risks, and know them.
- (ii) Second Line (Risk Management and Internal Controls): support the first line, with complementary expertise including continuous improvement of risk management practices.
- (iii) Third Line: objective and independent risk management assessment, control and governance processes.

i. Risks against which protection is sought

With the different actions of our segment and the complexity of our structure for carrying out our operations, we understand the company's exposure to different risks, which may vary and include, but are not limited to, the aspects listed below, grouped into strategic, financial, operational, compliance, cyber, and ESG risks.

- **Strategic:** risks that may interrupt the achievement of objectives and the execution of the planned strategy.
- **Financial:** risks that affect the capital and market structure, in such a way as to compromise execution of the Company's strategy.
- Market risks are included in the corporate risk matrix, however the "Market Risks Policy" is considered for technical decisions on the subject.
- **Operational:** event that may interrupt the achievement of objectives related to the operation of the business, usually resulting from the inadequacy or failure of internal processes and/or people.
- **Compliance:** possibility of sanctions due to non-compliance or inadequate treatment of external standards (laws, regulations, recommendations, and guidelines from Brazilian or foreign regulatory and self-regulatory entities).
- **Cyber:** vulnerabilities that could impact the business, such as financial losses resulting from virtual attacks, or even incidents resulting from errors or negligence caused internally at the Company, which result in data leakage and other damages related to the confidentiality of information.
- **ESG:** environmental, social, and governance risks that affect the company's processes.

5.1 Description of the risk management and market risk management

ii. *Hedge instruments*

The Risk Management and Internal Controls area operates at different levels of the Company, including the Board of Directors, its Advisory Committees, the Executive Office, the Management, and all their professionals.

In 2022, a review of the corporate risk matrix was carried out, in a structured process of analysis and mapping of new risks.

An assessment of the identified risks was carried out, using as parameters the potential impact on the business and the probability of the risks materializing. Therefore, the classification is carried out through the combination of impact and probability, resulting in the new risk map defined by the risk area and validated with the Audit Committee and Board of Directors, together with the relevant areas.

For the impact rule, **quantitative** criteria (Financial), according to the Company's risk appetite, and **qualitative** criteria (Image & Reputation, Health & Safety, Operational, Environmental, Social and Governance/Compliance) are used, in accordance with the objectives expressed in the Strategic Planning and the main Business notes, in agreement with the management. The impact of risk can be classified into 4 scales, namely: **Very High, High, Medium, and Low**.

For the Impact ruler **quantitative** (Financial), according to the Company's risk appetite, and **qualitative**

To compose the probability analysis, **historical data** and the existence of mitigating mechanisms (**controls**) are used, as being the criteria for evaluating and classifying the possibility of materialization of risks. The probability of materialization of risks can be classified into four scales: **Very High, High, Medium, and Low**.

As a result of this assessment, the risks that directly or indirectly impact the company's strategic planning are identified, thus identifying the priority risks that need treatment and management, being the basis for decision-making.

The treatment and monitoring of risks are carried out periodically, being reported at the Risk Management Committee (Committee reporting to the Statutory Executive Office), where the risks that directly or indirectly impact the Company's strategic planning are addressed, also reporting periodically to the Audit Committee, an advisory body to the Board of Directors.

iii. *Corporate structure of Risk Management*

The Risk Management Executive Management, subordinated to the Controllership Office, which reports to the Financial and Administrative Vice-Presidency, has a multidisciplinary team with proven experience in the subject, with the following main responsibilities:

- Disseminate knowledge about risks and risk management to employees, with the purpose of disseminating the risk management culture.
- Propose guidelines for the Company's corporate risk management structure (methodology, processes, systems, among others).
- Establish and keep up to date the Risk Management Policy, as well as proper information reporting mechanisms and standards. Review and propose changes to risk management procedures whenever necessary.
- Ensure that risk managers identify, mitigate, and monitor the Company's risks, as well as the integrity of internal controls.
- Periodically evaluate the action plans, carrying out necessary tests and adjustments, according to meetings with risk managers, and establishing deadlines and persons responsible for the execution and reporting of mitigating actions.
- Improve the risk appetite calculation methodology, assessing the probability and impact of the Company's mapped risks.
- Collaborate, together with the Executive Office, Vice-Presidency, Presidency, Risk Management Committees, Audit Committee, and Board of Directors, in the discussion on the definition of the Company's acceptable risk appetite. Coordinate and monitor the risk identification and assessment process with the

5.1 Description of the risk management and market risk management

Company's executives.

- Update and review risk factors periodically and whenever there are updates to the strategic plan and/or when relevant facts occur.
- Keep the Company's Risk Map up to date.
- Monitor and report changes in the criticality of risks to the Risk Management Committee, Audit Committee and Board of Directors.
- Submit to the Risk Management Committee and Audit Committee the risks to be prioritized and the proposed action plans.
- Make periodic reports to the Risk Management Committee and Audit Committee on risk management.
- Evaluate the company's Risk Map with an independent, consolidated, and integrated view, as well as the risk appetite and recommend adjustments and necessary updates to the Audit Committee.

We have an integrated risk management structure, with the main reporting bodies being the Board of Directors and the Audit Committee. In addition, the company has an Internal Audit area, responsible for assessing the effectiveness of the risk management process, with responsibilities highlighted in:

Board of Directors: (i) Monitor the operationalization mechanisms related to risk management, aligning the coherence of financial policies with the strategic guidelines and the risk profile of the business; ii) Approve the guidelines of the Company's risk management corporate governance structure (methodology, policies, processes, systems, among others), when duly recommended by the Audit Committee; iii) Monitor compliance with established methodologies, mitigating actions and action plans for inherent risks, especially those that go beyond the Company's risk appetite; iv) Support actions to raise awareness among managers and employees about the importance of risk management and the responsibility assigned to those involved in managing the company's risks; v) Ensuring the proper management of this policy, as well as the effectiveness and continuity of its application.

Audit Committee: (i) Resolve on the risk management process (methodology, processes, systems, policy, reporting mechanisms, among others), request adjustments, if necessary, and recommend to the Board of Directors; ii) Report to the Board of Directors exceptions to the Risk Management process guidelines and other matters deemed relevant; iii) Monitoring the planning of the Risk Management Department and requesting adjustments if necessary, monitoring the execution of the work and ensuring the quality and effectiveness of the process, evaluating and monitoring exposures and risk management in general for the Company (and investees when they mean potential impact for the Company); (iv) Appraise and monitor the Company's risk management and exposure; v) Evaluate whether management is adopting the necessary controls to manage very high risks or any other that it deems relevant.

Internal Audit: It is an independent, objective assessment and consulting activity that aims to add value and improve an organization's operations. It assists the organization to achieve its objectives, through a systematic and disciplined approach to assess and improve the effectiveness of risk management, control and governance processes. By definition, the mission of Internal Audit (IA) is to provide an objective and independent assessment in order to enhance and protect organizational value by providing risk-based assurance, advisory, and insight.

(c) Suitability of the operational structure and internal controls to verify the effectiveness of the policy adopted.

The Company has a Risk Management and Internal Controls area that advises the Executive Office, the Audit Committee, the Risk Committee, and the Board of Directors in the evaluation of internal controls, aiming to verify the adequacy of these controls and current activities with the practices and risk management guidelines established by the Company.

5.1 Description of the risk management and market risk management

The Risk and Internal Controls Executive Management is responsible for monitoring the risk management model and ensuring that it is carried out according to the defined methodology, ensuring guidelines and goals, and ensuring that the necessary resources are allocated for the proper functioning of the area. It is also the area's responsibility to provide support in the development of processes and procedures, training, and forms of communication that allow dissemination of the risk management culture in the Company.

5.2 Description of internal controls

a. the main internal control practices and the level of efficiency of such controls, indicating any imperfections and the measures adopted to correct them

The Company maintains internal controls in order to provide its shareholders with a good degree of efficiency and security regarding the reliability of its statements and other financial information, based, for this purpose, on accounting rules issued by nationally recognized bodies and entities, such as the pronouncements of the Accounting Pronouncements Committee ("CPC") previously approved and countersigned by the Securities Commission - CVM and the accounting standards issued by the Federal Accounting Council - CFC.

Aiming to ensure that the financial statements are prepared in a reliable manner, consistently reflecting its operational and financial processes, and prepared in accordance with the necessary requirements, the Company adopts several practices and internal controls that guarantee the transparency and reliability of its financial statements.

The internal control assessment process provides for joint action with the business areas to map processes, consequently risk assessment and possible assessment of compliance of these controls with normative documents and applicable regulations. The purpose of this work is to mitigate the risks that may affect the Company's ability to initiate, authorize, register, process and disclose relevant information in the financial statements, using as a criterion the Internal Control - Integrated framework - 2013 - issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").

The Company's management has not identified material changes in its internal control over financial reporting that occurred during the fiscal year ended December 31, 2022 that materially affected or are likely to materially affect its internal control over financial reporting.

- **Record of Financial Transactions:**

Operations are recorded using the SAP ERP system. This feature enables the Company to integrate all its data and processes into a single system. Furthermore, the monitoring of financial balances is carried out daily by the finance area, which is responsible for controlling all the Company's financial movements and reporting them to the Managers. The Controllership and Finance area also assesses the reasonableness of the balances of all financial transactions and, in the event of material inconsistencies, justifications and adjustments are requested from the respective areas.

In addition, a monthly accounting closing checklist is made available on the Company's network so that the areas involved can report the month's operations and activities. The Accounting area monitors the checklist to ensure that all accounting closing activities have been completed and that the accounting closing for the month can be finalized. In addition, the Controllership area also performs the analysis of changes in balance sheet and income accounts. All significant variations in the balance sheet and income accounts are analyzed to check the consistency of the justifications.

- **Accounting Closing Policy:**

The Company has a corporate policy that aims to establish guidelines and direct actions to all those involved in the Accounting Closing process, aiming at the preparation and disclosure of information to the Senior Management, Committees, External Audit, and control bodies.

- **Schedule of the Financial Statements:**

The Company's financial reports are prepared and disclosed on a quarterly basis, in accordance with the applicable regulations. These reports are prepared based on the Company's consolidated balance sheet, Income Statement, DMPL, cash flow, DVA, accompanying notes, and management performance/report. The preliminary version of the financial reports is reviewed by the Controllership and Accounting areas, which review the reasonableness of the balances presented and the accompanying notes. The revision is documented in writing in the draft and filed in the Accounting Area.

The process of disseminating the culture of internal controls at RD included the adoption of the following actions:

- Initial communication to the departments involved.
- Contextualization, involvement, and transfer of responsibility to departments during the review of implementation plans and evaluation of operational effectiveness of internal controls.

5.2 Description of internal controls

- Conducting workshops on awareness of the function of Internal Controls in the context of RD, explaining how the entire company is responsible for maintaining the internal controls environment. With the restructuring of the Risk Management and Internal Controls area and the execution of the last actions, the internal controls environment at RD has consistently evolved to a standardized level, where activities are designed, implemented, consistently applied, and properly documented.

(b) Organizational structures involved

The Company has an organizational structure of internal controls to ensure the preparation of reliable financial statements composed of the Risk and Internal Controls Executive Management, subordinated to the Controllershship Executive Office, which reports to the Financial and Administrative Vice-Presidency with the respective monitoring of the Audit Committee, Board of Directors, and Audit Committee. It is important to mention that the Internal Audit, which includes in its duties, without limitation, objective analysis of evidence, the purpose of offering independent assessments to the Audit Committee, the management, and external parties on the adequacy and effectiveness of governance processes, risk management, and internal controls.

- **Board of Directors:**
As one of the main components of the corporate governance system, the Board of Directors makes decisions according to the Company's interests, which are expressed through resolution and vote of the majority of the Directors, not conferring to its members, individually, any attribution in the Management of RD. As described in the Internal Rules of the Board of Directors, it is responsible for monitoring the Company's control structure, as well as monitoring the work of the independent external audit, regarding verification of compliance with the financial statements, recommendations for correcting accounting irregularities, assessing the quality of internal controls, including policies and authority limits and risks related to accounting treatments or disagreements regarding methods and criteria adopted by the Company.
- **Audit Committee:**
It is incumbent upon the Audit Committee to give an opinion on the annual management report, adding information deemed necessary or useful for resolution at a Shareholders' Meeting. In addition to ensuring that the Company adopts good corporate governance practices.
- **Audit Committee:**
It is the function of the Audit Committee to monitor the work of the areas of internal audit, internal controls, risk management areas, and the Compliance Program, in addition to reporting to the Board, annually, the summary report of the Committee covering the meetings held and the main matters discussed, highlighting the recommendations, in addition to the quarterly report on its activities.
- **Internal Audit:**
It is an independent, objective assessment and consulting activity that aims to add value and improve an organization's operations. It assists the organization to achieve its objectives, through a systematic and disciplined approach to assess and improve the effectiveness of risk management, control and governance processes. By definition, the mission of Internal Audit (IA) is to provide an objective and independent assessment in order to enhance and protect organizational value by providing risk-based assurance, advisory, and insight.
- **Executive Office:**
It is incumbent upon the chief executive officer and the vice chief executive officers to manage the Company and coordinate the other officers, including implementing the guidelines determined by the Board of Directors and rendering accounts to this body. The Chief Executive Officer, the vice chief executive officers, and the officers establish a transparent relationship with interested parties, providing those involved with information of interest to them, ensuring compliance with the code of conduct, as well as corporate policies.

5.2 Description of internal controls

- **Risk Management and Internal Controls:**

Act proactively in monitoring the applicable standards and in recommending the improvement of controls, policies, and procedures, in line with good market practices. Establish Company's internal controls policies; review processes and assess risks that may impact the Company's objectives. Support the development of corporate policies and procedures. Promote adherence to the standards established by the management. Support the definition of roles and responsibilities. Develop and improve internal control policies and practices. Identify changes that may impact the Company's risk appetite and control environment. Provide guidance and training on risk management and internal controls. Monitor the adequacy and effectiveness of the internal controls environment.

(c) If and how the efficiency of internal controls is supervised by the management of the issuer, indicating the position of the persons in charge for said monitoring

The Company has an area dedicated to the subject of internal controls, composed of Analysts, Senior Analysts, Internal Controls Coordinator, and Executive Manager of Internal Controls, with multidisciplinary training and proven experience in the subject. The Management promotes the assessment of all controls with the effective participation of all Vice-Presidencies and Executive Offices involved in the processes. Currently, there is a periodic report in relation to the risks monitored by the Executive Office to the Audit Committee and also to the Board of Directors. The Company periodically develops work with the aim of formalizing strategies and policies and assigning responsibilities. The scope of this work also includes determining the size of the organizational structure necessary for that purpose.

(d) Deficiencies and recommendations on internal controls as pointed out in the detailed report, prepared and forwarded to the issuer by the independent auditor, pursuant to the rules issued by CVM regarding the registration and exercise of the activity of independent auditing

In the audit report for the fiscal year ended December 31, 2022, no deficiencies were detected regarding the internal control environment.

(e) Comments of the officers regarding the deficiencies pointed out in the substantiated report prepared by the independent auditor and the actions taken to correct them

N/A

Exhibit A - Significant Deficiencies (DS)

N/A

5.3 Integrity program

a. Whether the issuer has rules, policies, procedures or practices aimed at the prevention, detection and remediation of deviations, frauds, irregularities and unlawful acts practiced against the government, identifying if affirmative:

i. main integrity mechanisms and procedures adopted and their adequacy to the profile and risks identified by the issuer, informing how frequently the risks are reassessed and the policies, procedures and practices are adapted;

The Integrity Program, described in item 5.1, is based on the following principles:

Senior management commitment and support:

The management reaffirms its commitment to ethics, doing what is right, transparently and honestly, whatever the situation. Publicly reaffirming the importance of RD's values and guidelines with examples of good conduct, broadly declaring in presentations and meetings the Company's commitment to its values, principles, beliefs, and especially to ethics.

Structuring of rules and instruments:

Aligned with the RD Culture, the Company disclosed the Code of People – Ethics and Conduct at RD in order to outline the guidelines that will mainly guide its managers, employees, and business partners. It has developed the Ethics Conversation Channel in order to preserve and strengthen the Company's image and mitigate possible unlawful acts in due time, preserving the confidentiality of information, anonymity, and non-retaliation of the employee.

Compliance Committees:

The ethical principles defined by RD are shared by everyone at the Company. The senior management periodically assesses matters and occurrences on the Ethics Conversation Channel and adopts the appropriate procedures. RD's Compliance Team is responsible for promoting the program. The committees are divided as follows:

Audit Committee: On a half-yearly basis, the Committee monitors the indicators, the actions carried out, and the main themes carried out during the year. This Committee reports to the Company's Board of Directors.

Ethics Committee: On a bimonthly basis, the Committee monitors the indicators, the area's actions, and provides guidance on actions that demand more attention, as well as assisting in the resolution on sensitive topics, if necessary. This Commission is composed of the following: Chief Executive Officer, Vice President of People and Culture and Sustainability, Vice President of Operations, Vice President of Finance, and General Counsel.

Ethical Affairs Commission: On a weekly basis, the Commission decides on sensitive cases investigated by the Compliance team. This Commission is composed of several Officers of the Company as a way of covering the main areas of activity in the company's operations. The members of the Commission are: 7 permanent directors and 5 alternate directors, with a term of 12 months to 24 months. After the 12-month period, new elections are held among the members of the executive office for renewal of the Commission.

The sensitive cases reported and decided by the Committees are: Harassment, Discrimination, Fraud, Corruption, Physical or Verbal Aggression, intimate relationship with direct subordination, inappropriate sexual conduct, among others.

Profile and risk analysis:

Periodically, the Company evaluates the risk factors that may impact the business, as well as the protective measures, with the aim of avoiding, mitigating, accepting, or transferring the risk, through periodical

5.3 Integrity program

reviews by the internal audit. The risks and respective action plans are reported to the Audit Committee.

Compliance Policies:

In addition to the Code of People, the Ethical Conversation Channel Policy and the Integrity Program, the Company has structured Compliance policies that deal with the topic of prevention, detection, and remediation of fraud and unlawful acts committed against the Government, such as: Anti-Corruption, Anti-Fraud and Relationship with Public Agents Policy and Conflict of Interest Policy, duly published on the CVM, Investor Relations Website and repeatedly communicated to the internal public.

For suppliers, the Company also has a Supplier Code of Conduct, with governance rules for contracting and also provisions regarding the Anti-Corruption Policy and expected behavior in the commercial relationship.

The Company has a capacitation portal with training related to the Code of People and the Policies mentioned herein, for employees, managers, directors, suppliers, and also for interns, apprentices, and temporary workers.

ii. organizational structures involved in the monitoring of operations and efficiency of internal integrity mechanisms and procedures, indicating their attributions, whether their creation has been formally approved, issuer's bodies to which they report, and the mechanisms to ensure the independence of its directors, if any;

The Company has a dedicated area responsible for promoting the Ethics and Compliance Program. The Committees reported above act with autonomy, independence, and impartiality and periodically report to the Company's Chief Executive Officer. The Company's senior management supports changes and corrections in the Integrity Program, aiming at better management of risk events and receives periodic information on the area's actions.

The Audit Committee acts impartially through the organizational structure that supports the Integrity Program and which has access to the highest decision-making body of the company. With the support of the Board of Directors, the Presidency leads the Ethics Committee, as part of the organizational structure of this program.

iii. whether the issuer has a formally approved code of ethics or conduct, indicating:

The Code of People – Ethics and Conduct in RD was approved at a meeting of the Board of Directors on October 26, 2018.

- *whether it applies to all officers, members of the audit committee, members of the board of directors and employees and also encompasses third parties, such as suppliers, service providers, intermediaries and associates*

The Code of People – Ethics and Conduct at RD was instituted and has the purpose of outlining the guidelines that will direct, mainly, its managers, officers, directors, committee members, employees, interns, service providers, and suppliers of the Company to adopt, in their daily work, behaviors and attitudes guided by ethics and the basic values outlined herein, aiming to preserve and strengthen the Company's image before society, its customers, suppliers, and investors, partners and other stakeholders, in order to achieve high ethical standards.

Each of the Collaborators, Officers, and Directors is responsible for complying with and ensuring that their acts and behavior always consider the People's Code – Ethics and Conduct at RD, and anyone who violates the provisions of the Code is subject to the applicable disciplinary measures. Thus, it is everyone's duty to know, understand, and practice the recommendations provided

5.3 Integrity program

in this Code, respecting the values on which they are inspired, preserving an environment guided by honesty and loyalty.

The Company also has a Code of Conduct for Suppliers specifically for suppliers, with governance rules for contracting and also a forecast regarding the Anti-Corruption Policy and expected behavior in the commercial relationship, it being understood that all documents mentioned herein are published on the website www.ri.rd.com.br

- *sanctions applicable in case of violation of the code or other standards related to the matter, identifying the document where these sanctions are set out*

The sanctions, when applicable to collaborators, are those provided for in the CLT (Consolidation of Labor Laws) and in the Code of People – Ethics and Conduct at RD. In addition, the Company has a Disciplinary Sanctions Policy that guides managers and members of the Committees in the decision-making process when acts that violate the Code of People and other Company policies occur. The sanctions follow a scale depending on the complexity of the conduct, starting with oral and written warnings, suspensions, and dismissal. For our suppliers and service providers, sanctions may vary from notification to termination of the contract.

- *the body that approved the code, date of approval and, in case the issuer discloses the code of conduct, any websites where the document may be consulted*

The Code of People – Ethics and Conduct at RD was approved by the Board of Directors on October 26, 2018 and can be consulted on RD's Investor Relations (IR) page, the CVM website, and the Company's internal communication media.

b. Whether the issuer has a reporting channel, indicating which one, if affirmative:

- *whether the reporting channel is internal or is in the hands of third parties:*

The Ethics Conversation Channel, RD's reporting channel, is in charge of third parties that guarantee the anonymity of the whistleblower. It is available 24 hours a day, including Saturdays, Sundays, and holidays.

- *whether the channel is open to receive complaints from third parties or only receives complaints from employees:*

The Ethics Conversation Channel is free to receive any type of report and from any person (including third parties), in cases where the whistleblower is aware of specific data or facts about someone who has benefited to the detriment of others or the Company itself or in the event of a clear violation of the stipulations of this Code, he or she shall file a report through:

Phone: 0800 778 9009

Email: contato@conversaetica.com.br

Website: www.conversaetica.com.br

- *whether there are mechanisms of anonymity and protection to complainants in good faith:*

Registered reports are received by a third-party company, which guarantees the anonymity of the whistleblower, so that the leadership and the accused are not aware of the whistleblower's data, consolidates and directs the information for due treatment within RD. RD uses the principle of non-retaliation against the employee through the use of the Channel, protecting the whistleblower from arbitrary dismissals. This principle is duly provided for in the Code of People and also in the Ethics Conversation Channel Policy.

- *issuer's body in charge of investigating complaints:*

5.3 Integrity program

Calls of a sensitive nature are investigated by the Compliance team and reported to the Ethical Affairs Committee for a decision. General calls, of a lesser degree of complexity, are dealt with by the officers of the denounced area, if they are not involved or cited. In the case of calls involving Company executives, these are dealt with by the respective leader above.

c. Number of confirmed cases of deviations, fraud, irregularities and unlawful acts practiced against the government in the last three (3) fiscal years and corrective measures adopted

We had no cases of deviation, corruption, fraud, irregularities, or practical unlawful acts against the public administration.

d. In case the issuer does not have rules, policies, procedures or practices aimed at the prevention, detection and remediation of deviations, frauds, irregularities and unlawful acts practiced against the government, please identify the reasons for which the issuer did not adopt controls in this respect

Not Applicable. RD has an Anti-Corruption, Anti-Fraud and Relationship with Public Agents Policy duly structured and conveyed to third parties and internal public. (<https://ri.rd.com.br>).

5.4 Significant changes

In relation to the last fiscal year, there were no changes in the main market risks. Regarding the monitoring of risks adopted by the Company, as informed in item 5.1, we reviewed the risk management process in 2022 and the monitoring of the risks already previously mapped and the new ones identified occurs periodically with a report to independent bodies: Audit Committee and Board of Directors.

5.5 Other relevant information

5.5. Provide other information the issuer deems relevant

There is no other relevant information regarding this item.

6.1/2 Shareholding position

CONTROLLING SHAREHOLDER / INVESTOR					
SHAREHOLDER					
Shareholder's CPF/CNPJ	Nationality-State	Adherence to shareholders agreement	Controlling shareholder	Last amendment	
Shareholder Residing Abroad	Name of the Legal Representative or Attorney-in-Fact		Type of person	Individual Taxpayer's Register (CPF)/Corporate Taxpayer ID (CNPJ) enrollment number	
Details of shares					
Number of common shares	Common shares %	Number of preferred shares	Preferred shares %	Total number of shares	Total shares %
CONTROLLER / INVESTOR			Shareholder's CPF/CNPJ		Composition of Common Stock
ALBERTO WRIGHT PIPPONZI					
227.271.318-10	Brazil	Yes	Yes	06/01/2023	
No					
5,028,467	0.293	0	0.000	5,028,467	0.293
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock	
TOTAL	0	0,000			
ALEXANDRE DE ZAGOTTIS					
270.158.038-28	Brazil	Yes	Yes	04/30/2024	
No					
5,288,747	0.308	0	0.000	5,288,747	0.308
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock	
TOTAL	0	0,000			
ANDRE ALMEIDA PIPPONZI					
274.953.688-02	Brazil	Yes	Yes	03/25/2024	
No					
12,606,295	0.734	0	0.000	12,606,295	0.734
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock	
TOTAL	0	0,000			

6.1/2 Shareholding position

CONTROLLING SHAREHOLDER / INVESTOR						
SHAREHOLDER						
Shareholder's CPF/CNPJ	Nationality-State	Adherence to shareholders agreement	Controlling shareholder	Last amendment		
Shareholder Residing Abroad	Name of the Legal Representative or Attorney-in-Fact		Type of person	Individual Taxpayer's Register (CPF)/Corporate Taxpayer ID (CNPJ) enrollment number		
Details of shares						
Number of common shares	Common shares %	Number of preferred shares	Preferred shares %	Total number of shares	Total shares %	
CONTROLLER / INVESTOR				Shareholder's CPF/CNPJ	Composition of Common Stock	
ANTONIO CARLOS PIPPONZI						
454.326.788-53	Brazil	Yes	Yes	05/24/2023		
No						
17,188,697	1.001	0	0.000	17,188,697	1.001	
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock		
TOTAL	0	0,000				
BlackRock, Inc. (See item 6.6)						
00.000.000/0000-00	U.S.A	No	No	11/28/2023		
Yes	BLACKROCK, INC.		Legal Entity	00.000.000/0000-00		
86,991,112	5.063	0	0.000	86,991,112	5.063	
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock		
TOTAL	0	0,000				
Bruno Wright Pipponzi						
221.182.778-06	Brazil	Yes	Yes	04/09/2024		
No						
6,960,303	0.405	0	0.000	6,960,303	0.405	
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock		
TOTAL	0	0,000				

6.1/2 Shareholding position

CONTROLLING SHAREHOLDER / INVESTOR					
SHAREHOLDER					
Shareholder's CPF/CNPJ	Nationality-State	Adherence to shareholders agreement	Controlling shareholder	Last amendment	
Shareholder Residing Abroad	Name of the Legal Representative or Attorney-in-Fact	Type of person	Individual Taxpayer's Register (CPF)/Corporate Taxpayer ID (CNPJ) enrollment number		
Details of shares					
Number of common shares	Common shares %	Number of preferred shares	Preferred shares %	Total number of shares	Total shares %
CONTROLLER / INVESTOR			Shareholder's CPF/CNPJ		Composition of Common Stock
Cristiana Almeida Pipponzi					
285.220.788-58	Brazil	Yes	Yes	11/30/2023	
No					
16,201,901	0.943	0	0.000	16,201,901	0.943
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock	
TOTAL	0	0,000			
EUGENIO DE ZAGOTTIS					
186.783.418-90	Brazil	Yes	Yes	04/12/2024	
No					
13,953,771	0.812	0	0.000	13,953,771	0.812
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock	
TOTAL	0	0,000			
FUNDO DE INVEST DE ACOES ARAUCARIA SEGUNDO					
10.326.747/0001-98	Brazil	No	Yes	05/24/2023	
No					
1,383,616	0.081	0	0.000	1,383,616	0.081
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock	
TOTAL	0	0,000			

6.1/2 Shareholding position

CONTROLLING SHAREHOLDER / INVESTOR						
SHAREHOLDER						
Shareholder's CPF/CNPJ	Nationality-State	Adherence to shareholders agreement	Controlling shareholder	Last amendment		
Shareholder Residing Abroad	Name of the Legal Representative or Attorney-in-Fact		Type of person	Individual Taxpayer's Register (CPF)/Corporate Taxpayer ID (CNPJ) enrollment number		
Details of shares						
Number of common shares	Common shares %	Number of preferred shares	Preferred shares %	Total number of shares	Total shares %	
CONTROLLER / INVESTOR				Shareholder's CPF/CNPJ	Composition of Common Stock	
GI Investimentos e Participacoes Ltda						
05.318.060/0001-70	Brazil	Yes	Yes	05/24/2023		
No						
97,074,681	5.650	0	0.000	97,074,681	5.650	
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock		
TOTAL	0	0,000				
MARCELLO DE ZAGOTTIS						
270.229.108-20	Brazil	Yes	Yes	04/04/2024		
No						
13,425,625	0.781	0	0.000	13,425,625	0.781	
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock		
TOTAL	0	0,000				
MARIA EUGÊNIA LAFER GALVÃO						
076.308.458-12	Brazil	Yes	Yes	05/24/2023		
No						
6,909,864	0.402	0	0.000	6,909,864	0.402	
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock		
TOTAL	0	0,000				

6.1/2 Shareholding position

CONTROLLING SHAREHOLDER / INVESTOR					
SHAREHOLDER					
Shareholder's CPF/CNPJ	Nationality-State	Adherence to shareholders agreement	Controlling shareholder	Last amendment	
Shareholder Residing Abroad	Name of the Legal Representative or Attorney-in-Fact	Type of person	Individual Taxpayer's Register (CPF)/Corporate Taxpayer ID (CNPJ) enrollment number		
Details of shares					
Number of common shares	Common shares %	Number of preferred shares	Preferred shares %	Total number of shares	Total shares %
CONTROLLER / INVESTOR				Shareholder's CPF/CNPJ	Composition of Common Stock
MARTA ALMEIDA PIPPONZI					
225.035.128-79	Brazil	Yes	Yes	12/19/2023	
No					
13,843,966	0.806	0	0.000	13,843,966	0.806
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock	
TOTAL	0	0,000			
PAULO SERGIO COUTINHO GALVAO FILHO					
040.443.368-57	Brazil	Yes	Yes	04/23/2024	
No					
11,897,170	0.692	0	0.000	11,897,170	0.692
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock	
TOTAL	0	0,000			
RODRIGO WRIGHT PIPPONZI					
221.378.728-03	Brazil	Yes	Yes	09/22/2023	
No					
6,872,086	0.400	0	0.000	6,872,086	0.400
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock	
TOTAL	0	0,000			

6.1/2 Shareholding position

CONTROLLING SHAREHOLDER / INVESTOR					
SHAREHOLDER					
Shareholder's CPF/CNPJ	Nationality-State	Adherence to shareholders agreement	Controlling shareholder	Last amendment	
Shareholder Residing Abroad	Name of the Legal Representative or Attorney-in-Fact	Type of person	Individual Taxpayer's Register (CPF)/Corporate Taxpayer ID (CNPJ) enrollment number		
Details of shares					
Number of common shares	Common shares %	Number of preferred shares	Preferred shares %	Total number of shares	Total shares %
CONTROLLER / INVESTOR				Shareholder's CPF/CNPJ	Composition of Common Stock
ROSALIA PIPPONZI RAIA DE ALMEIDA PRADO					
154.088.518-69	Brazil	Yes	Yes	10/02/2023	
No					
9,037,199	0.526	0	0.000	9,037,199	0.526
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock	
TOTAL	0	0,000			
SCHRODER'SCHRODER INVESTMENT MANAGEMENT BRASIL LTDA. (See item 6.6)					
92.886.662/0001-29	Brazil	No	No	05/16/2024	
No					
85,929,944	5.002	0	0.000	85,929,944	5.002
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock	
TOTAL	0	0,000			
WELLS HOLDING LIMITED					
32.107.155/0001-18	Malta	Yes	Yes	10/10/2023	
Yes	José Sampaio Correa Sobrinho		Individual	495.082.618-20	
196,770,448	11.453	0	0.000	196,770,448	11.453
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock	
TOTAL	0	0,000			
SHARES HELD IN TREASURY - Date of last change: 05/24/2023					
2,881,869	0.168	0	0.000	2,881,869	0.168

OTHERS					
1,107,761,439	64.479	0	0.000	1,107,761,439	64.479
TOTAL					
1,718,007,200	100.000	0	0.000	1,718,007,200	100.000

6.1/2 Shareholding position

CONTROLLING SHAREHOLDER / INVESTOR						
SHAREHOLDER						
Shareholder's CPF/CNPJ	Nationality-State	Adherence to shareholders agreement	Controlling shareholder	Last amendment		
Shareholder Residing Abroad	Name of the Legal Representative or Attorney-in-Fact		Type of person	Individual Taxpayer's Register (CPF)/Corporate Taxpayer ID (CNPJ) enrollment number		
Details of shares						
Number of common shares	Common shares %	Number of preferred shares	Preferred shares %	Total number of shares	Total shares %	
CONTROLLER / INVESTOR				Shareholder's CPF/CNPJ	Composition of Common Stock	
FUNDO DE INVEST DE ACOES ARAUCARIA SEGUNDO				10.326.747/0001-98		
MARIA EUGÊNIA LAFER GALVÃO						
076.308.458-12	Brazil	Yes	Yes	05/24/2023		
No						
607,823	48.671	0	0.000	607,823	48.671	
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock		
TOTAL	0	0,000				
PAULO SERGIO COUTINHO GALVAO FILHO						
040.443.368-57	Brazil	Yes	Yes	05/24/2023		
No						
641,029	51.329	0	0.000	641,029	51.329	
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock		
TOTAL	0	0,000				
SHARES HELD IN TREASURY - Date of last change: 05/24/2023						
0	0.000	0	0.000	0	0.000	
OTHERS						
0	0.000	0	0.000	0	0.000	
TOTAL						
1,248,852	100.000	0	.000	1,248,852	100.000	

6.1/2 Shareholding position

CONTROLLING SHAREHOLDER / INVESTOR						
SHAREHOLDER						
Shareholder's CPF/CNPJ	Nationality-State	Adherence to shareholders agreement	Controlling shareholder	Last amendment		
Shareholder Residing Abroad	Name of the Legal Representative or Attorney-in-Fact		Type of person	Individual Taxpayer's Register (CPF)/Corporate Taxpayer ID (CNPJ) enrollment number		
Details of shares						
Number of common shares	Common shares %	Number of preferred shares	Preferred shares %	Total number of shares	Total shares %	
CONTROLLER / INVESTOR				Shareholder's CPF/CNPJ	Composition of Common Stock	
GL INVESTIMENTOS E PARTICIPACOES LTDA.				05.318.060/0001-70		
MARIA EUGÊNIA LAFER GALVÃO						
076.308.458-12	Brazil	Yes	Yes	05/24/2023		
No						
48,537,341	50.000	0	0.000	48,537,341	50.000	
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock		
TOTAL	0	0,000				
PAULO SERGIO COUTINHO GALVAO FILHO						
040.443.368-57	Brazil	Yes	Yes	05/24/2023		
No						
48,537,341	50.000	0	0.000	48,537,341	50.000	
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock		
TOTAL	0	0,000				
SHARES HELD IN TREASURY - Date of last change: 05/24/2023						
0	0.000	0	0.000	0	0.000	
OTHERS						
0	0.000	0	0.000	0	0.000	
TOTAL						
97,074,682	100.000	0	.000	97,074,682	100.000	

6.1/2 Shareholding position

CONTROLLING SHAREHOLDER / INVESTOR						
SHAREHOLDER						
Shareholder's CPF/CNPJ	Nationality-State	Adherence to shareholders agreement	Controlling shareholder	Last amendment		
Shareholder Residing Abroad	Name of the Legal Representative or Attorney-in-Fact	Type of person	Individual Taxpayer's Register (CPF)/Corporate Taxpayer ID (CNPJ) enrollment number			
Details of shares						
Number of common shares	Common shares %	Number of preferred shares	Preferred shares %	Total number of shares	Total shares %	
CONTROLLER / INVESTOR				Shareholder's CPF/CNPJ	Composition of Common Stock	
WELLS HOLDING LIMITED				32.107.155/0001-18		
CARLOS PIRES OLIVEIRA DIAS						
578.464.058-53	Brasil	No	No	03/21/2024		
No						
98,385,224	100.000	0	0.000	98,385,224	100.000	
Class of Share	Number of shares	Shares %	Shares (%) of the class	Shares (%) of the common stock		
TOTAL	0	0,000				
SHARES HELD IN TREASURY - Date of last change:						
0	0.000	0	0.000	0	0.000	
OTHERS						
0	0.000	0	0.000	0	0.000	
TOTAL						
98,385,224	100.000	0	0.000	98,385,224	100.000	

6.3 Capital distribution

Date of last meeting / Date of last amendment	04/17/2024
Number of shareholders who are individuals	53,700
Number of shareholders that are legal entities	213
Number of institutional investors	1,481

Outstanding Shares

Outstanding shares corresponding to all shares of the issuer with the exception of those owned by the controlling shareholder, any person related to the controlling shareholder, the issuer's manager and shares held in treasury.

Number of common shares	1,279,770,315	74.492%
Number of preferred shares	0	0.000%
Total	1,279,770,315	74.492%


6.4 Interest in companies

Corporate Name	Corporate Taxpayer ID (CNPJ)	Issuer's interest (%)
DR. CUCO DESENVOLVIMENTO DE SOFTWARE LTDA	23.000.392/0001-94	100
4 BIO MEDICAMENTOS S.A.	07.015.691/0001-46	85
AMPLISOFTWARE TECNOLOGIA LTDA.	21.661.781/0001-35	100
HEALTHBIT PERFORMASYS TECNOLOGIA E INTELIGENCIA S.A.	22.416.310/0001-24	100
RD VENTURES FUNDO DE INVESTIMENTO EM PARTICIPAÇÕES - MULTIESTRATÉGIA	39.581.447/0001-37	100
STIX FIDELIDADE E INTELIGÊNCIA S.A.	31.688.927/0001-90	33.33
VITAT SERVIÇOS EM SAÚDE LTDA	06.186.457/0001-19	100
LABI EXAMES S.A.	27.579.749/0001-91	25
ELOOPZ SERVICOS DE PROMOCAO DE VENDAS LTDA	28.735.776/0001-79	100
SAFEPIII COMÉRCIO VAREJISTA DE MEDICAMENTOS MANIPULADOS LTDA	36.839.003/0001-60	100
ZTO TECNOLOGIA E SERVICOS DE INFORMAGAO NA INTERNET S.A	26.255.154/0001-18	100
RD ADS LTDA	40.440.353/0001-27	100

6.5 Organizational Chart of shareholders and economic group

6.5 Insert the organizational chart of the issuer's shareholders and economic group in which it is inserted:

Organizational chart and composition of the group on April 30, 2024:



6.6 Other relevant information

6.6. Provide other information the issuer deems relevant

The shareholding indicated in items 6.1 and 6.2 of the Reference Form corresponds to the consolidated percentage of managed portfolios and/or investment funds managed/administrated by each of the managers/administrators indicated in items 6.1 and 6.2 and, according to correspondence sent to the Company, such managed portfolios and/or investment funds managed/administrated by each of the managers/administrators jointly own more than five percent (5%) of the Company's share capital.

On June 3, 2022, the company **J.P. Morgan Chase & Co.** informed, in compliance with Article 12 of CVM Resolution No. 44, that it held, on June 02, 2022, an amount of 84,537,049 shares, equivalent to approximately 5.11% of the total number of shares.

On October 10, 2023, the company **J.P. Morgan Chase & Co.** informed, in compliance with Article 12 of CVM Resolution No. 44, that it held, on October 09, 2023, an amount of 85,882,614 shares, equivalent to approximately 4.99% of the total number of shares.

On October 13, 2023, the company **J.P. Morgan Chase & Co.** informed, in compliance with Article 12 of CVM Resolution No. 44, that it held, on October 12, 2023, an amount of 86,284,554 shares, equivalent to approximately 5.02% of the total number of shares.

On October 30, 2023, the company **J.P. Morgan Chase & Co.** informed, in compliance with Article 12 of CVM Resolution No. 44, that it held, on October 27, 2023, an amount of 85,853,062 shares, equivalent to approximately 4.99% of the total number of shares.

On November 08, 2023, the company **Schroder Investment Management Brasil Ltda.** informed, in compliance with Article 12 of CVM Resolution No. 44, that it held, on November 07, 2023, an amount of 85,648,123.56 shares, equivalent to approximately 4.985% of the total number of shares.

On November 08, 2023, the company **BlackRock, Inc.** informed, in compliance with Article 12 of CVM Resolution No. 44, that it held, on November 28, 2023, an amount of 86,991,112 shares (equivalent to approximately 5.063% of total shares), as well as other 1,977,608 deliverable derivative instruments underlying Company's shares (equivalent to approximately 0.115% of total shares).

On May 17, 2024, the company **Schroder Investment Management Brasil Ltda.** informed, in compliance with Article 12 of CVM Resolution No. 44, that it held, on May 16, 2024, an amount of 85,929,944 shares (equivalent to approximately 5.001% of total shares).

Regarding the subject matter of this topic, details from previous years can be verified in past editions of the RD Reference Form. For the matter in question, see section "15. Control and economic group / 15.8 - Other relevant information - Control and economic group" of FRE 2021.

7.1 Main characteristics of the issuer's management bodies and audit committee

The Board of Directors and Executive Office are responsible for the management of the Company, being governed by the provisions of the Brazilian Corporate Laws and by the Bylaws of Raia Drogasil S.A.

a. main characteristics of the policies on the appointment and filling out of vacant positions, if any, and, if the issuer discloses them, the online addresses where the document may be consulted:

The selection criteria for directors are established in the Policy for Appointing and Completing Members of the Board of Directors, Committees, and Executive Office, which was revised at the Board of Directors' meeting on May 03, 2022 ("Policy"), available at Company's Investor Relations website at <https://ri.rd.com.br/list.aspx?idCanal=ebcBJMy5wkUA4JCROsKQLg==>.

The Policy aims to establish minimum requirements and procedures to be followed for nominating members to the Board of Directors ("Board"), its advisory Committees ("Committees"), and the Statutory Executive Office ("Executive Office") of Raia Drogasil S.A. ("RD" or "Company").

Under the terms of the Policy, the nomination of a candidate for member of the Board of Directors shall consider the following cumulative criteria: (a) Compatible technical, professional, and academic qualification; (b) Alignment with the RD's purpose, values, and culture, as well as the Code of People; (c) Absence of conflicting interests with RD; (d) Not hold offices in companies that may be deemed competitors of RD; (e) Unblemished reputation and ethical conduct in line with RD principles; (f) Knowledge and/or experience in sustainability will be considered positive differentiation attributes; and (g) If the nominee is considered as an independent member, there shall be a statement from the nominee attesting to their compliance with the independence criteria established in the Novo Mercado Rules.

The proposal for nominating Board members for reelection should consider the director's good performance during the period, his/her experience, participation, contribution, attendance at meetings during the previous term, the body's efficiency and the complementarity of its functions, as well as pointing out possible points of improvement in its composition.

Nominations of candidates for members of the Board of Directors, Committees, and Executive Office shall be preceded by an analysis and opinion by the People Committee, which, within its attributions, will assess compliance with the criteria and requirements of the policy.

Shareholders may appoint members to the Board of Directors, provided that the provisions of Law No. 6,404/76, of CVM Instructions 367/02 and 480/09 are observed, who shall be submitted for approval at the Shareholders' Meeting.

b. whether there are mechanisms for assessing the performance of the board of directors and of each body or committee that reports to the board of directors, informing, if so:

i. the periodicity of the assessment and its scope

7.1 Main characteristics of the issuer's management bodies and audit committee

RD adopts an annual assessment process for the Board, Committees, and Governance Office, conducted by an external and independent consultant. The methodology includes interviews, online questionnaires, and sample monitoring of meetings, addressing, among other issues, the composition and operation of the Board, planning, rituals, and dynamics, compliance and risks, value creation, and performance. As of 2023, the process will be subject to individual evaluation by its members and the Chairman.

The process of evaluating the performance of the Company's Statutory and non-statutory Executive Office takes place annually based on individual goals and performance.

ii. methodology adopted and main criteria used in the assessment

The process of assessing the performance of statutory and non-statutory officers is aligned with their strategies and set of short- and long-term goals for the Company. The targets cover all processes and business areas, also considering socio-environmental criteria (ESG), are divided among the statutory officers and broken down to non-statutory ones. Monitoring is done monthly in management meetings. After the end of the year, a complete assessment is made of the level of achievement of the objectives and goals of the executive offices and the Company and the officers are assessed by the Board of Directors through the People Committee.

The evaluation process of the Board of Directors in 2022 was carried out through analysis of the company's strategy and corporate governance system, interviews with directors and committee members, in addition to monitoring meetings and assessment of the dynamics adopted.

The evaluation processes of the Board and Committees and of the Executive Office are monitored by the People Committee which, in the end, analyzes its results, which are discussed with all parties involved for subsequent submission of action plans, which aim at the continuous improvement of governance processes and the development cycle of managers.

iii. whether any consultancy or external advisory services were hired

To assess the performance of the Board, Committees, and Executive Office, a specialized consulting firm was retained, which conducted the evaluation process and presented a final report contemplating the results and recommendations that, after being evaluated by the People Committee, were shared and discussed with the board members.

c. rules for identification and administration of conflicts of interests:

The Company has a Conflict of Interests Policy, approved at the RCA of October 26, 2018 and in accordance with Law 6,404/76, any member of the company's board of directors is prohibited from voting at any Meeting or Board meeting, or from acting in any transaction or business in which they have conflicting interests with those of the company.

Additionally, the internal rules of the Board of Directors provide that, in order to achieve its mission, the Board shall be guided by certain guidelines, including the prevention and management of situations of conflict of interests, misalignments of vision, and differences of opinion that may jeopardize the prevalence of the Company's interests and its perpetuity.

d. per body:

7.1 Main characteristics of the issuer's management bodies and audit committee

The following data were obtained through a survey carried out with advice from the consulting firm +Diversidade in February/2023, which resulted in the adhesion of 64% of the members of the Board of Directors, 75% of the consultants of the Advisory Committees to the Board, 63% of the members of the Statutory Executive Office, 71% of the Non-Statutory Executive Office, and 100% of the members of the Audit Committee.

i. total number of members, grouped by self-declared gender identity

Body	Men	Women	Total
Board of Directors	7	3	10
Statutory Executive Office	4	1	5
Audit Committee	6	2	8
Advisors to the Advisory Committees to the Board	2	2	4
Non-Statutory Executive Office	26	13	39

ii. total number of members, grouped by self-declared color or racial identity

Body	White	Brown	Black	Others
Board of Directors	10	0	0	0
Statutory Executive Office	5	0	0	0
Audit Committee	7	1	0	0
Advisors of the Advisory Committees to the Board	4	0	0	0
Non-Statutory Executive Office	37	2	0	0

iii. total number of members grouped by other diversity features that the issuer deems relevant

With a focus on executing the strategy aimed at the health and sustainability of the business, RD values the diversity of knowledge, academic background, and generational profile of the members of the Board of Directors.

With regard to training, the members of the Board have degrees in Business Administration, Economics, Communication, and Engineering.

Additionally, when it comes to their self-declared previous experiences, 35% of the board members have expertise in the retail sector, 15% in the technology area, 10% in industry and health, 15% in the financial market, 5% in the infrastructure sector, and 10 % in the service sector.

Another factor worth mentioning is the generational diversity among the Board members, which adds multiplicity of views and balance in discussions due to the different degrees of seniority and complementarity of skills. The RD Board is made up of professionals aged between 40 and 72 years old.

e. if any, specific goals the issuer has regarding gender diversity, color, or race, or other features, among members of its management bodies and audit committee:

7.1 Main characteristics of the issuer's management bodies and audit committee

RD adopts diversity goals aimed at leadership positions, the fulfillment of which impacts the variable compensation of executives.

f. the role of management bodies in the assessment, management, and oversight of climate-related risks and opportunities:

At RD we believe that contributing to a healthier society is also taking care of the planet. Therefore, we seek to improve our management and mitigate the impacts of our activities with a focus defined as a priority and with the greatest impact: waste and climate change. Our commitments in the "Healthier Planet" pillar include reducing and mitigating our impacts related to the emission of Greenhouse Gases (GHG) and the generation and disposal of waste, reinforcing how we can combine our growth with the management of risks and impacts, transforming our processes and promoting education and qualification in the value chain.

These actions are actively monitored and evaluated by the Board of Directors, through the Audit and Sustainability Committees, with periodic reports to the Board's collegiate body.

According to the Internal Rules, the Audit Committee is responsible for assessing and monitoring exposures and risk management in general, which include climate risks under the terms of RD's Risk Management Policy.

Additionally, the Sustainability Committee monitors and discusses actions to mitigate climate impacts, which are considered in its annual work plan, included in the RD's sustainability commitments and in the goals of the Sustainability Executive Office. We also point out that compliance with sustainability goals impacts the variable compensation of RD executives.

7.1 D Description of the main characteristics of the management bodies and audit committee

Number of members per declaration of gender

	Female	Male	Non-binary	Others	Prefer not to answer
Executive Office	1	4	0	0	0
Board of Directors - Permanent Members	3	7	0	0	0
Board of Directors - Alternate Members	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
Audit Committee - Permanent Members	0	4	0	0	0
Audit Committee - Alternate Members	2	2	0	0	0
Total = 23	6	17	0	0	0

Number of members per declaration of color and race

	Yellow	White	Black	Brown	Indigenous	Others	Prefer not to answer
Executive Office	0	5	0	0	0	0	0
Board of Directors - Permanent Members	0	10	0	0	0	0	0
Board of Directors - Alternate Members	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
Audit Committee - Permanent Members	0	3	0	1	0	0	0
Audit Committee - Alternate Members	0	4	0	0	0	0	0
Total = 23	0	22	0	1	0	0	0

7.2 Information related to the board of directors

a. permanent bodies and committees reporting to the board of directors:

RD's corporate governance structure has as its main body the Board of Directors, guardian of the Company's culture and values, which is responsible for the general guidance of the business.

Its Advisory Committees and the Executive Office report to the Board.

Executive Office

The Executive Office is responsible for the executive management and execution of RD's strategy. The Officers are elected by the Board of Directors, and the Executive Office may be composed of at least five and at most eleven Officers.

The Executive Office is currently composed of the Chief Executive Officer (CEO) and Vice-Presidencies dedicated to key themes of our strategy: Financial and Administrative; Health Business; Corporate Planning, IR and M&A; Digital Transformation; Commercial and Marketing; People, Culture and Sustainability; Unit Operations, Multichannel and Expansion. This executive leadership group is composed of 7 men and 1 woman.

The Executive Office shall: a) coordinate and manage the corporate business; b) abiding by and having others abide by the provisions of the Brazilian Corporate Laws, of the Novo Mercado Rules, and Bylaws; c) organizing and submitting to the Ordinary Shareholders' Meeting, every year, the financial statements and Management Report, accompanied by the opinion of the Board of Directors, Audit Committee, and independent auditors; d) opening, closing, and using bank accounts; e) proposing the purchase, disposal, transfer, encumbrance, or lease of real property; f) settling, assigning, or waiving rights not related to Company's real property; g) appointing attorneys-in-fact or at-law on behalf of the Company; h) purchasing, disposing, encumbering, or leasing real property of the Company, within the limits set by these Bylaws; i) authorizing and entering into transactions and agreements that create obligations, encumber, or hold the Company liable, within the limits set by these Bylaws; j) deciding to open, close, or change branches, warehouses, distribution centers, offices, or representations in the country or abroad at an Executive Office's meeting; l) deciding on any matter that does not fall within the exclusive responsibility of the Shareholders' Meeting or the Board of Directors, as well as on dissensions among its members.

Advisory Committees to the Board of Directors (non-statutory bodies):

The Board of Directors has the support of committees the function of which is to deal in a more in-depth and attentive manner with complex and strategic issues, providing support in relevant business decisions. These bodies are composed of directors and external consultants (experts).

The Board has been assisted by the Committees since mid-2011. The duties, names, and composition are revised in due course, according to the needs and opportunities of the business.

The **People Committees** shall: (i) Monitor projects and processes related to people, ensuring their alignment with the organization's strategic vision; (ii) Discuss and propose compensation and incentive policies for employees and managers, as well as call option plans and/or stock options for managers; (iii) Discuss and propose criteria for assessing performance and skills

7.2 Information related to the board of directors

for employees and managers; (iv) Formulate and monitor the organization's performance, productivity, and management indicators; (v) support the Chairman of the Board in preparing and monitoring the succession plan for the Chief Executive Officer; (vi) conduct, together with the Chairman of the Board and with the support of the Board Secretary, the annual performance evaluation process of the board of directors, its committees, and the governance office; and (vii) analyze and give an opinion on the nominations of candidates for members of the Statutory Executive Office, the Board of Directors and the respective Advisory Committees, assessing adherence to the criteria and requirements established in the Company's Nomination Policy.

The **Finance Committee** shall: (i) Monitor compliance with the budget and results; (ii) Assist the Board in analyzing the economic and global situation and its potential effects on the Company's financial position; (iii) Examine, discuss, and make recommendations to the Board of Directors regarding the financial policy proposed by the Executive Office; (iv) Review the financial statements and other information to be transmitted to the market.

Note: The duties of the Finance Committee were reviewed by the Board of Directors at a meeting on February 22, 2022, for alignment with the duties assigned to the Audit Committee.

The **Strategy and Health Committee** shall: (i) Develop and propose to the Board of Directors policies related to business strategy, operational improvement, digital transformation, and transformation of a company focused on customers; (ii) Make recommendations and monitor the implementation of policies, strategies, and actions aimed at increasing the Company's competitiveness; (iii) Monitor and report on the development of approved strategic guidelines; (iv) Monitor the implementation of the operating model, considering the technology guidelines, data analytics, agile company, and customer insight; (v) Monitor the Governance and transformation management model, considering processes, people, and innovation culture; (vi) Develop and propose success indicators to monitor the digital strategy; and (vii) promote corporate innovation for healthcare business initiatives.

The **Sustainability Committee** shall: (i) Develop and propose to the Board of Directors guidelines and commitments related to the sustainable development of the Company and its subsidiaries, considering risks and opportunities for value creation; (ii) Discuss and monitor the preparation and application of short-, medium-, and long-term socio-environmental programs and actions, as well as the impacts generated; and (iii) Develop and propose to the Board of Directors, as well as monitor sustainability goals for the variable compensation of the Executive Office.

Audit Committee

In February 2022, the Board of Directors of RD approved the installation of the Audit Committee, an advisory body with permanent operation and non-statutory nature, composed of 3 members, all independent, led by Maria Fernanda Teixeira and composed of Sylvia Leão (independent director) and Pedro Zan (corporate accounting specialist).

It is incumbent upon the Audit Committee, in short, to issue an opinion on the retainment, monitor the work, and evaluate the independent auditor, evaluate the financial statements, monitor the work of the areas of internal audit, internal controls, risk management, and the Compliance Program, in addition to report to the Board, annually, the summary report of the Committee contemplating the meetings held and the

7.2 Information related to the board of directors

main subjects discussed, highlighting the recommendations, in addition to the quarterly report of its activities.

The Audit Committee has its own Internal Rules, approved by the Board of Directors on February 22, 2022 and published to the market. The full text can be consulted on the RD Investor Relations website at <https://ri.rd.com.br>.

Internal Audit

RD has an Internal Audit structure led by a manager and made up of a team of seven qualified auditors. The area reports directly to the Audit Committee and carries out activities that include, but are not limited to, objective analysis of evidence with the purpose of offering independent assessments to management and external parties on the adequacy and effectiveness of governance processes, risk management, and controls of the Company. The Internal Audit work plan is carried out based on an Annual Plan, approved by the Audit Committee and aligned with the Board of Directors. This plan consists of risk assessment activities consistent with RD strategy and regulatory activities. The work of the Internal Audit is based on internal procedures and international standards for professional practice issued by The Institute Of Internal Auditors (IIA).

b. how the board of directors assesses the independent audit work, indicating whether the issuer has a policy on contracting extra audit service from an independent accounting firm and, in case the issuer discloses the policy, websites where the document can be consulted:

RD's Board of Directors chooses and periodically supervises the work of the external auditor and, if necessary, dismisses them. The Audit Committee monitors and inspects the work. It meets with the independent auditors at least quarterly to discuss the annual audit plan, monitor the work, discuss the main audit points, and analyze any recommendations. The retainment of an independent audit is in line with the standards established in the applicable law, as well as with the Company's Procurement Policy. Additionally, RD has a formal policy for retaining extra-audit services approved by the Board of Directors in an RCA held on October 26, 2018, available for consultation on the CVM website and investor relations website (Bylaws and Policies - RD | Investor Relations). Any contracting needs are evaluated promptly by the Company's Management, considering all aspects required to guarantee the maintenance of the independence of the external auditors, in addition to the conditions provided for in the Procurement Policy.

Additionally, the choice of independent auditors shall be previously assessed by the Audit Committee and approved by the Board of Directors.

c. if any, channels created so that complaints related to ESG themes and practices and compliance can reach the board of directors:

All stakeholders can contact the RD Sustainability area through the email address sustentabilidade@rd.com.br.

The questions received are monitored and evaluated by the sustainability team, and if they are qualified

7.2 Information related to the board of directors

as critical, they are reported to the Sustainability Committee of the Board of Directors.

Additionally, any reports can be sent through the Ethics Conversation Channel. In this channel, the information recorded will be received by an independent company, which ensures total secrecy of your report and your identity.

Ethics Conversation is an exclusive communication channel for reporting conduct that is in noncompliance with the Code of Ethical Conduct, policies and good practices of RD, in addition to making records that deal with corruption, fraud, and other nonconformities provided for in the Brazilian Federal Anti-Corruption Law (No. 12,846/2013) and other relevant legislation. <https://canalconfidencial.com.br/conversaetica/>

7.3 Members and professional experience of the management and audit committee

Name: ADEILDO PAULINO **CPF:** 953.644.398-87 **Occupation:** Accountant **Date of Birth:** 10/04/1958

Professional Experience: He holds a Master's degree in Accounting and Actuarial Sciences from Pontifical Catholic University of São Paulo and a post-graduation degree in Financial Management from Economic Sciences College of São Paulo. Current sitting member of the Audit Committee of five (5) companies in the field of management of eucalyptus forests to supply wood for sale to the pulp and paper industry, former Member of the Audit Committee of ABECS (Brazilian Association of Credit Card and Service Companies), and of the Audit Committee of Seicho-No-Ie in Brazil. Partner at BRW Consultoria since January 2009 and Member of the Audit Committee of Raia Drogasil S.A.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Fiscal Council	04/17/2023	Until the OSM of 2025	Fiscal Council (Permanent) Elected by Controlling Shareholder	04/18/2024	Yes	04/14/2022

Name: ANTÔNIO CARLOS COELHO **CPF:** 030.285.708-74 **Occupation:** Accountant **Date of Birth:** 06/14/1963

Professional Experience: He holds a degree in Accounting from Guarulhos Integrated Schools [Faculdades Integradas de Guarulhos] (FIG) and an MBA in Finance from Administration Institute Foundation (FIA). He developed his career at Drogasil, now Raia Drogasil. From 1996 to 2010, he was Controllership Manager, from 2010 to 2012 he was Deputy Controllership Officer, and from 2012 to 2013 he was Finance and Controllership Officer. He was elected Vice Chief Financial and Administrative Officer on 09/30/2013, a position he currently holds. In the Company's investees, he serves as Board Member of 4Bio Medicamentos S.A.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Executive Office	05/03/2023	05/02/2025	11 - Vice Chief Executive Officer/Superintendent	05/03/2023	Yes	09/30/2013

Name: ANTONIO CARLOS PIPPONZI **CPF:** 454.326.788-53 **Occupation:** Engineer **Date of Birth:** 08/18/1952

Professional Experience: Chairman of the Board of Directors and member of the Health and Strategy, People and Finance Committees of Raia Drogasil S.A. He holds a degree in Civil Engineering from the Polytechnic School of the University of São Paulo (POLI-USP) and a post-graduate degree in Business Administration from Getulio Vargas Foundation (EAESP FGV-SP). He represents the founding family of Droga Raia, and held executive positions from 1977 to 2011, until the merger of the Company, accumulating decades of experience in the industry.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Board of Directors	04/19/2023	Until the OSM of 2025	20 - Chairman of the Board of Directors	04/20/2023	Yes	11/10/2011

Name: BRUNO WRIGHT PIPPONZI **CPF:** 221.182.778-06 **Occupation:** Business administrator **Date of Birth:** 07/13/1981

Professional Experience: He holds a degree in Dentistry from the University of São Paulo (USP) and a post-graduation degree in Business Administration from Getulio Vargas Foundation (CEAG FGV-SP). Works at Raia Drogasil S.A. since 2011 and has held the following positions: Planning and Expansion Manager, Expansion Officer, Planning and Operational Efficiency Officer. Currently, he is Vice President of Health Business at Raia Drogasil S.A. In the Company's investees, he serves as Board Member of Healthbit Performasys Tecnologia and Amplissoftware Tecnologia LTDA

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Executive Office	05/03/2023	05/02/2025	11 - Vice Chief Executive Officer/Superintendent	05/03/2023	Yes	04/28/2021

Name: CARLOS PIRES OLIVEIRA DIAS **CPF:** 578.464.058-53 **Occupation:** Economist **Date of Birth:** 05/24/1951

Professional Experience: Member of the Board of Directors of Raia Drogasil S.A. Businessman and economist with a degree from Mackenzie University, he represents one of the founding families of Drogasil, accumulating decades of experience in pharmaceutical retail.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Board of Directors	04/19/2023	Until the OSM of 2025	22- Board of Directors (Permanent)	04/20/2023	Yes	11/10/2011

Name: CRISTIANA ALMEIDA PIPPONZI **CPF:** 285.220.788-58 **Occupation:** Business administrator **Date of Birth:** 12/22/1974

Professional Experience: Member of the Board of Directors. She leads the Health and Strategy, and the Sustainability Committees and is also a member of the Finance and People Committees of Raia Drogasil S.A. She holds a degree in Business Administration from the School of Economics and Management at the University of São Paulo, and an MBA from INSEAD, France. She has worked with e-commerce projects at E&Y and was Marketing, Institutional Communication, and Sustainability Officer at Droga Raia.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Board of Directors	04/19/2023	Until the OSM of 2025	22- Board of Directors (Permanent)	04/20/2023	Yes	11/30/2012

Name: EUGENIO DE ZAGOTTIS **CPF:** 186.783.418-90 **Occupation:** Administrator **Date of Birth:** 11/21/1970

Professional Experience: He holds a degree in Business Administration from Getulio Vargas Foundation (EAESP FGV-SP) and an MBA degree from the University of Michigan Business School. From 1998 to 2000, he worked at McKinsey & Company, and from 1992 to 1996 he worked at Arthur Andersen as a consultant. He joined Raia S.A. in 2000, and was responsible for the Executive Office for Commercial Projects and later for the Commercial Executive Office. He was also responsible for the Corporate Planning, Institutional Relations, Proprietary Trademarks, and Institutional Sales areas. Eugênio is also a member of the Board of Abrafarma - Associação Brasileira Redes Farmácias e Drogarias [Brazilian Association of the Pharmacy and Drugstore Chains]. In the Company's investees, he serves as Board Member of ZTO Tecnologia e Serviços de Informação na Internet LTDA., 4Bio Medicamentos S.A., Stix Fidelidade e Inteligencia S.A., and RD Ads LTDA.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Board of Directors	04/30/2024	Until the OSM of 2025	27 - Board of Directors (Permanent)	05/10/2024	Yes	05/10/2024

Name: EDUARDO AZEVEDO MARQUES DE ALVARENGA **CPF:** 299.155.458-43 **Occupation:** Electronic Engineer **Date of birth:** 07/31/1978

Professional Experience: Independent member and member of the Strategy and Health Businesses Committees. Electronic Engineer graduated from Instituto Mauá de Tecnologia. He founded E+Tech, specialized in creating and developing technology for POS and outdoor media, served as Director of Digital Business at Grupo Abril and CEO of Eletromídia. He is currently a member of Eletromídia's Board of Directors and member of the Strategy Committee.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Board of Directors	04/19/2023	Until the OSM of 2025	27 - Independent Board of Directors (Permanent)	04/20/2023	Yes	04/19/2023

Name: FLAVIO DE MORAES CORREIA **CPF:** 270.804.998-44 **Occupation:** Administrator **Date of Birth:** 01/03/1974

Professional Experience: Graduated in Business Administration from PUC-SP, with an MBA from HEC Paris and extension programs at Harvard and FGV. A senior executive with extensive experience in business leadership. Currently holding the position of Director of Investor Relations and Corporate Affairs at RD Saúde, having also played a significant role as Director of Omnichannel/E-commerce, where he led a 15-fold growth in activity over a two-year period. He accumulates 20 years of experience in Strategy, Finance, Online and Offline Operations, and Management in Retail and the Financial Market, notably as a partner at Península, successfully involved in the acquisition, development, and IPO of Carrefour Brazil. He also worked at publicly traded companies Grupo Pão de Açúcar and Carrefour.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Executive Office	04/30/2024	05/02/2025	Investor Relations Director	05/10/2024	Yes	05/10/2024

Name: FERNANDO KOZEL VARELA **CPF:** 171.185.568-58 **Occupation:** Engineer **Date of Birth:** 05/29/1970

Professional Experience: Holds a Bachelor's degree in Electrical Engineering from the Polytechnic School of the University of São Paulo (POLI-USP) and a specialization degree in Business Administration from Getulio Vargas Foundation (FGV-SP). He attended an MBA course from the University of Pittsburgh, at the American Chamber, in São Paulo. He started his career at Arthur Andersen and in 1996 joined Raia S.A as Project Manager. On 11/10/2011 he was appointed Vice President of Digital Transformation at Raia Drogasil S.A.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Executive Office	05/03/2023	05/02/2025	11 - Vice Chief Executive Officer/Superintendent	05/03/2023	Yes	11/10/2011

Name: FLÁVIO DA SILVEIRA DOS ANJOS **CPF:** 175.790.198-17 **Occupation:** Business Administrator **Date of Birth:** 08/16/1978

Professional Experience: Graduated in Business Administration from Unisant'Anna, in Theology from the Biblical Theological Seminary, postgraduate in Leadership from the South American Theological Faculty, and holds an MBA in Financial Management, Controller, and Auditing from the Getúlio Vargas Foundation (FGV). Flávio has 30 years of experience in finance and business administration. Specialized in Financial Planning, Accounting and Tax Management, Corporate Governance, M&A, Treasury and Administrative Management, he has worked as Financial Manager at Bell Micro Products, Controller at Megaware Industrial Ltda., Financial Consultant at Wert Capital Business Advisory, and Financial Director at Tellus Comércio Imp. E Exp. Ltda. He is currently a Director at Companhia Agricola e Pastoril Fazenda Rio Pardo and Financial Consultant at the company Revisora Paulista-Contabilidade.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Fiscal Council	04/17/2024	Until the OSM of 2025	46 - Fiscal Council (Alternate)	04/18/2024	No	04/17/2024

Name: GILBERTO LERIO **CPF:** 269.714.378-53 **Occupation:** Accountant **Date of Birth:** 08/26/1950

Professional Experience: He holds a degree in Accounting from the University of the City of São Paulo and in Legal Sciences from the University of Guarulhos. During the last five years he has served as: (1) Member of the Board of Directors of Galvão Engenharia S/A, which operates in the provision of engineering and industrial construction services; (2) Alternate member of the Audit Committee of Telefônica, a company operating in the telecommunications industry; (3) Member of the Audit Committee of Brascod Comércio Importação e Exportação Ltda.; (4) Member of the Board of Directors of Protende Sistemas e Métodos de Construções Ltda; (5) Member of the Board of Directors of Plastifluor Industria Comercio de Vedações Ltda.; and (6) Member of the Audit Committee of Raia Drogasil S.A., a publicly-held company whose main activity is the retail trade of pharmaceuticals, perfumery, and the like.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Fiscal Council	04/17/2024	Until the OSM of 2025	43 - Fiscal Council (Permanent) Elected by Controlling Shareholder	04/18/2024	Yes	10/09/1995

Name: Ivanyra Maura de Medeiros Correia **CPF:** 009.092.797-48 **Occupation:** Production Engineering **Date of Birth:** 10/23/1967

Professional Experience: Graduated in production engineering from the Federal University of Rio de Janeiro, with an MBA from The Wharton School, and certified as a board member and fiscal council member by the IBGC. Currently, she is a member of the Finance, Audit, and Risk Committee of Grupo Baumgart, a member of the Audit Committee of Eletronuclear, and a Board Member of PIOB, an international body overseeing international auditing standards. Previously, she served as External Fiscal Council Member of Banco Bradesco S.A. for four years, Independent Board Member of Serpro, Board Member of Zurich Resseguradora S.A., Chairman of the Fiscal Council of Statkraft Energias Renováveis S.A., Chairman of the Fiscal Council of Brasileira Participações S.A. (BNDESPar and AES), Alternate Board Member of Invepar S.A., and Alternate Fiscal Council Member of Tecnisa.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Fiscal Council	04/17/2024	Until the OSM of 2025	43 - Fiscal Council (Alternate) Elected by Minority Shareholders	04/18/2024	Yes	04/17/2024

Name: MARCELLO DE ZAGOTTIS **CPF:** 270.229.108-20 **Occupation:** Administrator **Date of Birth:** 11/01/1975

Professional Experience: He holds a degree in Business Administration from Getulio Vargas Foundation (FGV-SP) and an MBA with honors from the University of Michigan Business School. He began his career in corporate consulting at Accenture and Arthur D. Little, and later worked as a Category Manager at Borders Bookstores. He joined Raia S.A in 2001, having held the position of Manager from February 2001 to April 2003, and returned in August 2006 as Sales Officer. On 11/10/2011, he was appointed Commercial and Marketing Vice-President of Raia Drogasil S.A. In the Company's investees, he serves as Board Member of 4Bio Medicamentos S.A., Safepill Comércio Varejista de Medicamentos Manipulados LTDA. and ZTO Tecnologia e Serviços de Informação na Internet LTDA.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Executive Office	05/03/2023	05/02/2025	11 - Vice Chief Executive Officer/Superintendent	05/03/2023	Yes	11/10/2011

Name: MARCILIO D'AMICO POUSADA **CPF:** 066.548.318-02 **Occupation:** Business administrator **Date of Birth:** 08/02/1963

Professional Experience: He holds a degree in Business Administration from Armando Álvares Penteado Foundation (FAAP), president of Saraiva from 2005 to 2013, and from 2000 to 2005 he was founding president of OfficeNet in Brazil. Officer of Non-food Products at Sam’s Club, part of the Walmart Group, where he worked from 1994 to 1999. Pousada began his career at Mappin and C&A. He is currently the Chief Executive Officer of Raia Drogasil since July 2013. In the Company's investees, he serves as Member of the Board of Directors of Stix Fidelidade e Inteligência S.A.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Executive Office	05/03/2023	05/02/2025	Chief Executive Officer/Superintendent	05/03/2023	Yes	07/01/2013

Name: MARCO AMBROGIO CRESPI BONOMI **CPF:** 700.536.698-00 **Occupation:** Economist **Date of Birth:** 05/06/1956

Professional Experience: Independent member of the Board of Directors and Vice-Chairman of the Board of Directors, leader of the Health and Strategy Committee and member of the Finance and People Committees of Raia Drogasil S.A. He holds a degree in Economics from Armando Álvares Penteado Foundation (FAAP-SP), studied Financial Executive Improvement at Getulio Vargas Foundation (FGV), and Capital Markets at New York University (NYU). He acted as Member of the Board of Directors of Itaú Unibanco Holding S.A. and is currently also Vice-Chairman of the Board of Directors of Porto Seguro S.A. He has solid experience in finance and innovation.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Board of Directors	04/19/2023	Until the OSM of 2025	25 – Vice-Chairman Independent Member of the Board of Directors	04/20/2023	Yes	05/23/2018

Name: MARIA SUSANA DE SOUZA**CPF:** 399.000.104-34**Occupation:** Psychologist**Date of Birth:** 08/24/1964

Professional Experience: She holds a degree in Organizational Psychology and a specialization degree in Human Resources Management and Planning from the Catholic University of Pernambuco. She attended the Management Development Program at IESE, Universidad de Navarra, in Barcelona. She worked at Walmart/Bompreço from 1997 to 2010, where she held different leadership positions in Human Resources, and in recent years she was at the head of the Executive Office of Organizational Development and Diversity. She joined Makro South America, a company of the Dutch SHV group, from 2010 to 2014, where she led Human Resources strategies in the region. At Raia Drogasil since April 2014, she holds the position of Vice President for People, Culture and Sustainability.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Executive Office	05/03/2023	05/02/2025	11 - Vice Chief Executive Officer/Superintendent	05/03/2023	Yes	04/09/2015

Name: MÁRIO ANTONIO LUIZ CORRÊA**CPF:** 063.857.108-15**Occupation:** Accountant and Manager**Date of Birth:** 12/29/1944

Professional Experience: During the last five years he has served as: (1) Officer in charge of the financial and accounting area of GL Holdings S/A., whose main activity is the management of own assets and participation in other companies, whether business or civil, national or foreign, as a partner, shareholder or quotaholder; (2) Officer in charge of the financial and accounting area of GL Agropecuária Ltda., whose main activity is the agricultural production on its own or third parties lands, and the sales of its products, being able to participate in other companies as a shareholder or quotaholder; (3) Officer in charge of the financial and accounting area of Gepel Rural S/A., whose main activity is the agricultural and forestry exploitation; (4) Officer in charge of the financial and accounting area of Tantra Participações Ltda., whose main activity is the management of its own assets and participation in other companies, whether business or civil, as partner, shareholder or quotaholder; (5) acted as a member of the Audit Committee of companies of Grupo Klabin S/A. (Celucat S/A, Papelão Ondulado do Nordeste S/A - PONSÁ and Bacell S/A); and (6) currently an alternate member of the Audit Committee of Raia Drogasil S.A.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Fiscal Council	04/17/2024	Until the OSM of 2025	46 - Fiscal Council (Alternate) Elected by Controlling Shareholder	04/18/2024	Yes	04/14/2022

Name: PAULO SÉRGIO BUZAID TOHMÉ **CPF:** 143.925.478-84 **Occupation:** Lawyer **Date of Birth:** 12/28/1967

Professional Experience: Lawyer, holding a degree in Law from Mackenzie University and a graduation degree in Procedural Law, in recent years, he has worked as: (1) partner of Leão and Tohmé Advogados Associados (1994-2011); (2) alternate member of the Audit Committee of Raia Drogasil S.A.; and (3) member of the Audit Committee of companies of Klabin Group S/A. He is currently Chairman of the Audit Committee of Raia Drogasil S.A.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Fiscal Council	04/17/2024	Until the OSM of 2025	43 - Fiscal Council (Permanent) Elected by Controlling Shareholder	04/18/2024	Yes	04/11/2011

Name: PAULO SÉRGIO COUTINHO GALVÃO FILHO **CPF:** 040.443.368-57 **Occupation:** Administrator **Date of Birth:** 07/17/1960

Professional Experience: Member of the Board of Directors and of the Health and Strategy Committee of Raia Drogasil S.A., representing one of the founding families of Drogasil, accumulating decades of experience in pharmaceutical retail. He holds a degree in Business Administration from the Pontifical Catholic University of São Paulo (PUC-SP) and a Harvard degree from the Owner/President Management program. He currently also serves as a member of the Board of Directors of Klabin S.A. and Fundação Bial de São Paulo.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Board of Directors - Permanent Members	04/19/2023	Until the OSM of 2025	22- Board of Directors (Permanent)	04/20/2023	Yes	11/10/2011

Name: PHILIPP PAUL MARIE POVEL **CPF:** 416.239.878-06 **Occupation:** Business administrator **Date of Birth:** 11/09/1982

Professional Experience: Independent member of the Board of Directors and member of the Strategies and Health Committee. A serial entrepreneur, investor, co-founder, and CEO of Dafiti Group, he has solid experience in the retail sector with focus on e-commerce and innovation.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Board of Directors - Permanent Members	04/19/2023	Until the OSM of 2025	27 - Independent Board of Directors (Permanent)	04/20/2023	Yes	04/30/2021

Name: PLÍNIO VILLARES MUSETTI **CPF:** 954.833.578-68 **Occupation:** Engineer **Date of Birth:** 01/27/1954

Professional Experience: Member of the Board of Directors, member of the Finance Committee, and of the Sustainability and People Committees of Raia Drogasil S.A. He holds degrees in Civil Engineering and Business Administration from Mackenzie University, and attended the “Program for Management Development” at the Harvard Business School. He has solid experience gained in national and multinational companies, including positions as CEO of Elevadores Atlas, partner at JP Morgan Partners, and Executive President of Satipel Industrial.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Board of Directors - Permanent Members	04/19/2023	Until the OSM of 2025	22- Board of Directors (Permanent)	04/20/2023	Yes	11/10/2011

Name: RENATO CEPOLLINA RADUAN **CPF:** 213.837.378-94 **Occupation:** Engineer **Date of Birth:** 05/31/1975

Professional Experience: He holds a degree in naval engineering from POLI-USP and an MBA degree from Insead, France. Between 2010 and 2013, he served as Vice President of Marketing, Category Management, and Pricing. In 2009 he was leader of the Retail and Consumer Goods Division (Officer/Principal) at Roland Berger Strategy Consultants. He was leader of the Management Consulting Division for Retail in Latin America (Senior Manager) between 2005 and 2008. Since 2013, he has been serving as Vice-President of Store Operations, Multichannel, and Expansion at Raia Drogasil. In the Company's investees, he serves as Board Member of Safepill Comércio Varejista de Medicamentos Manipulados Ltda. and ZTO Tecnologia e Serviços de Informação na Internet LTDA.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Executive Office	05/03/2023	05/02/2025	11 - Vice Chief Executive Officer/Superintendent	05/03/2023	Yes	04/29/2013

Name: RENATO PIRES OLIVEIRA DIAS **CPF:** 269.999.988-17 **Occupation:** Administrator **Date of Birth:** 03/08/1978

Professional Experience: Member of the Board of Directors and of the People Committee of Raia Drogasil S.A. He holds a degree in Business Administration from FMU, and represents one of the founding families of Drogasil, accumulating solid experience in pharmaceutical retail.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Board of Directors - Permanent Members	04/19/2023	Until the OSM of 2025	22- Board of Directors (Permanent)	04/20/2023	Yes	11/10/2011

Name: SYLVIA DE SOUZA LEÃO WANDERLEY **CPF:** 731.199.977-49 **Occupation:** Social Communication **Date of birth:** 03/09/1962

Professional Experience: Independent member of the Board of Directors, leader of the People Committee and member of the Auditing, Sustainability, Health and Strategy Committees at Raia Drogasil S.A. She holds a degree in Social Communication, with an Executive MBA in Business Administration from COPPEAD - UFRJ, and attended specialization courses at MIT – Massachusetts Institute of Technology – Sloan School of Management and Dom Cabral Foundation. She worked for over 30 years in the Retail market, focusing on the areas of Marketing, Sales, Operations, and Human Resources.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Board of Directors	04/19/2023	Until the OSM of 2025	27 - Independent Board of Directors (Permanent)	04/20/2023	Yes	04/30/2021

Name: VIVIAN DO VALLE SOUZA LEÃO MIKUI **CPF:** 088.036.718-03 **Occupation:** Lawyer **Date of Birth:** 04/03/1962

Professional Experience: She holds a degree in Business Administration from the Mackenzie University, a Law degree from the United Metropolitan Colleges (FMU), and a Social Communication degree from Higher School of Advertising and Marketing [Escola Superior de Propaganda e Marketing] (ESPM). She was a Member of the Audit Committee of Klabin S/A for 16 years, and also a member of the board of directors of Klabin, and she is a partner at Leão e Tohmé Advogados Associados since 2001. She is an alternate member of the Audit Committee of Raia Drogasil S.A.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Fiscal Council	04/17/2024	Until the OSM of 2025	46 - Fiscal Council (Alternate) Elected by Controlling Shareholder	04/18/2024	Yes	04/08/2020

Name: ZEILA THOALDO CANTERI **CPF:** 856.866.039-87 **Occupation:** Accountant **Date of Birth:** 06/12/1973

Professional Experience: Graduated in Accounting, certified in internal auditing by the IIA (Certified Internal Auditor), and serving as a member of the audit committee by the IBGC, with a well-established career spanning experience in governance, auditing, operational risk management, regulatory affairs, technology, and integrated risk, having worked for market-leading companies such as EY, HSBC, and Bradesco. Over the past 5 years, she has served as Executive Superintendent of Internal Control and Operational Risk at Banco Bradesco S/A.

Management Bodies:

Management Body	Election Date	Term of office	Elective position held	Date of investiture	Elected by the controlling shareholder	Start date of the first term of office
Fiscal Council	04/17/2024	Until the OSM of 2025	46 - Fiscal Council (Permanent) Elected by Minority Shareholders	04/18/2024	No	04/17/2024

7.4 Committees composition

Name: ANTONIO CARLOS PIPPONZI **CPF:** 454.326.788-53 **Occupation:** Engineer **Date of Birth:** 08/18/1952

Professional Experience: Chairman of the Board of Directors and member of the Health and Strategy, People and Finance Committees of Raia Drogasil S.A. He holds a degree in Civil Engineering from the Polytechnic School of the University of São Paulo (POLI-USP) and a post-graduate degree in Business Administration from Getulio Vargas Foundation (EAESP FGV-SP). He represents the founding family of Droga Raia, and held executive positions from 1977 to 2011, until the merger of the Company, accumulating decades of experience in the industry.

Committees:

Type of committee	Type of audit	Position held	Date of investiture	Term of office	Description of other committees	Election date	Elected by the controlling shareholder	Start date of the first term of office
Financial Committee		Committee Member (Sitting Member)	05/03/2023	Until the OSM of 2025		05/03/2023	Yes	08/09/2012
Other Committees		Committee Member (Sitting Member)	05/03/2023	Until the OSM of 2025	People Committee	05/03/2023	Yes	11/24/2011

Name: CRISTIANA ALMEIDA PIPPONZI **CPF:** 285.220.788-58 **Occupation:** Business administrator **Date of Birth:** 12/22/1974

Professional Experience: Member of the Board of Directors, leader of the Strategies and Health and Sustainability Committees, and also a member of the People Committees of Raia Drogasil S.A. She holds a degree in Business Administration from the School of Economics and Management at the University of São Paulo, and an MBA from INSEAD, in France. She has worked with e-commerce projects at E&Y and was Marketing, Institutional Communication, and Sustainability Officer at Droga Raia.

Committees:

Type of committee	Type of audit	Position held	Date of investiture	Term of office	Description of other committees	Election date	Elected by the controlling shareholder	Start date of the first term of office
Other Committees		Committee Member (Sitting Member)	05/03/2023	Until the OSM of 2025	People Committee	05/03/2023	Yes	04/29/2013

Name: EUGENIO DE ZAGOTTIS **CPF:** 186.783.418-90 **Occupation:** Administrator **Date of Birth:** 11/21/1970

Professional Experience: Board member, leader of the Finance Committee, and member of the Health and Strategy Committee of RD Saúde since May/2024. He holds a degree in Business Administration from Getulio Vargas Foundation (EAESP FGV-SP) and an MBA degree from the University of Michigan Business School. From 1998 to 2000, he worked at McKinsey & Company, and from 1992 to 1996 he worked at Arthur Andersen as a consultant. He joined Raia S.A. in 2000, and was responsible for the Executive Office for Commercial Projects and later for the Commercial Executive Office. He was also responsible for the Corporate Planning, Institutional Relations, Proprietary Trademarks, and Institutional Sales areas. Eugênio is also a member of the Board of Abrafarma - Associação Brasileira Redes Farmácias e Drogarias [Brazilian Association of the Pharmacy and Drugstore Chains]. In the Company's investees, he serves as Board Member of ZTO Tecnologia e Serviços de Informação na Internet LTDA., 4Bio Medicamentos S.A., Stix Fidelidade e Inteligencia S.A., and RD Ads LTDA.

Committees:

Type of committee	Type of audit	Position held	Date of investiture	Term of office	Description of other committees	Election date	Elected by the controlling shareholder	Start date of the first term of office
Financial Committee		Committee Member (Sitting Member)	05/10/2024	Until the OSM of 2025		04/30/2024	Yes	05/10/2024

Name: MARCO AMBROGIO CRESPI BONOMI **CPF:** 700.536.698-00 **Occupation:** Economist **Date of Birth:** 05/06/1956

Professional Experience: Independent member of the Board of Directors and Vice-Chairman of the Board of Directors, leader of the Health and Strategy Committee and member of the Finance and People Committees of Raia Drogasil S.A. He holds a degree in Economics from Armando Álvares Penteado Foundation (FAAP-SP), studied Financial Executive Improvement at Getulio Vargas Foundation (FGV), and Capital Markets at New York University (NYU). He acted as Member of the Board of Directors of Itaú Unibanco Holding S.A. and is currently also Vice-Chairman of the Board of Directors of Porto Seguro S.A. He has solid experience in finance and innovation.

Committees:

Type of committee	Type of audit	Position held	Date of investiture	Term of office	Description of other committees	Election date	Elected by the controlling shareholder	Start date of the first term of office
Other Committees		Committee Member (Sitting Member)	05/03/2023	Until the OSM of 2025	People Committee	05/03/2023	Yes	04/29/2019
Financial Committee		Committee Member (Sitting Member)	05/03/2023	Until the OSM of 2025		05/03/2023	Yes	05/03/2022

Name: MARIA FERNANDA DOS SANTOS TEIXEIRA **CPF:** 765.087.908-97 **Occupation:** Administrator **Date of Birth:** 08/10/1952

Professional Experience: Leader of the Audit Committee and member of the Finance Committee of Raia Drogasil S.A. She holds a degree in Business from the Methodist University, with specialization in Marketing/Economics from Getulio Vargas Foundation (FGV). She attended specializations courses at Harvard, INSEAD, MIT, and Thunderbird. She is currently a member of the Board of Directors of Claranet Technology S.A., member of the Auditing Committee of Grupo SIMPAR – Holding, and VAMOS Group, and Chairman of the Board of Directors of Pérola S.A. - Nutrien Fertilizantes (Global largest). She has acted as: Chairperson of the Diversity Committee at IBGC, CEO at Integrow, joined the First Data Corporation as President of First Data Brasil and Vice President of Operations - Latin America. She was the Latin America Chairperson at ICT Group Corporation, Vice President (COO) of Operations - Latin America at EDS – Electronic Data Systems, and Leader of several technology areas at General Motors Brazil.

Committees:

Type of committee	Type of audit	Position held	Date of investiture	Term of office	Description of other committees	Election date	Elected by the controlling shareholder	Start date of the first term of office
Other Committees		Chairperson of the Committee	05/03/2023	Until the OSM of 2025	Audit Committee	05/03/2023	Yes	02/22/2022
Financial Committee		Committee Member (Sitting Member)	05/03/2023	Until the OSM of 2025		05/03/2023	Yes	05/03/2023

Name: PEDRO GUILHERME ZAN **CPF:** 010.972.568-98 **Occupation:** Accountant **Date of Birth:** 06/29/1960

Professional Experience: Member of the Audit Committee (as specialist in Corporate Accounting) and Finance Committee at Raia Drogasil S.A. He holds an Accounting degree from the Economic Sciences School of São Paulo (1983) and an MBA from Insper (2006). He is a partner and owner of KMG Apoio Administrativo S.A since September 2020. In the last 5 years, he also held the following positions: General Controllership Manager at Klabin S.A.

Committees:

Type of committee	Type of audit	Position held	Date of investiture	Term of office	Description of other committees	Election date	Elected by the controlling shareholder	Start date of the first term of office
Other Committees		Committee Member (Sitting Member)	05/03/2023	Until the OSM of 2025	Audit Committee	05/03/2023	Yes	02/22/2022
Financial Committee		Committee Member (Sitting Member)	05/03/2023	Until the OSM of 2025		05/03/2023	Yes	05/03/2023

Name: PLÍNIO VILLARES MUSETTI **CPF:** 954.833.578-68 **Occupation:** Engineer **Date of Birth:** 01/27/1954

Professional Experience: Member of the Board of Directors, member of the Finance, Sustainability and People Committees of Raia Drogasil S.A. He holds degrees in Civil Engineering and Business Administration from Mackenzie University, and attended the “Program for Management Development” at the Harvard Business School. He has solid experience gained in national and multinational companies, including positions as CEO of Elevadores Atlas, partner at JP Morgan Partners, and Executive President of Satipel Industrial.

Committees:

Type of committee	Type of audit	Position held	Date of investiture	Term of office	Description of other committees	Election date	Elected by the controlling shareholder	Start date of the first term of office
Financial Committee		Chairperson of the Committee	05/03/2023	Until the OSM of 2025		05/03/2023	Yes	08/09/2012
Other Committees		Committee Member (Sitting Member)	05/03/2023	Until the OSM of 2025	People Committee	05/03/2023	Yes	11/24/2011

Name: RENATO PIRES OLIVEIRA DIAS **CPF:** 269.999.988-17 **Occupation:** Administrator **Date of Birth:** 03/08/1978

Professional Experience: Member of the Board of Directors and of the People Committee of Raia Drogasil S.A. He holds a degree in Business Administration from FMU, and represents one of the founding families of Drogasil, accumulating solid experience in pharmaceutical retail.

Committees:

Type of committee	Type of audit	Position held	Date of investiture	Term of office	Description of other committees	Election date	Elected by the controlling shareholder	Start date of the first term of office
Other Committees		Committee Member (Sitting Member)	05/03/2023	Until the OSM of 2025	People Committee	05/03/2023	Yes	04/28/2020

Name: SYLVIA DE SOUZA LEÃO WANDERLEY **CPF:** 731.199.977-49 **Occupation:** Social Communication **Date of birth:** 03/09/1962

Professional Experience: Independent member of the Board of Directors, leader of the People Committee and member of the Auditing, Sustainability, Strategies and Health Committees at Raia Drogasil S.A. She holds a degree in Social Communication, with an Executive MBA in Business Administration from COPPEAD - UFRJ, and attended specialization courses at MIT – Massachusetts Institute of Technology – Sloan School of Management and Dom Cabral Foundation. She worked for over 30 years in the Retail market, focusing on the areas of Marketing, Sales, Operations, and Human Resources.

Committees:

Type of committee	Type of audit	Position held	Date of investiture	Term of office	Description of other committees	Election date	Elected by the controlling shareholder	Start date of the first term of office
Other Committees		Chairperson of the Committee	05/03/2023	Until the OSM of 2025	People Committee	05/03/2023	Yes	05/07/2021
Other Committees		Committee Member (Sitting Member)	05/03/2023	Until the OSM of 2025	Audit Committee	05/03/2023	Yes	02/22/2022

7.5 Family relations

Name	CPF	Business name of the issuer or subsidiary	CNPJ	Type of relationship to the administrator of the issuer or subsidiary
Position				
<u>Issuer or subsidiary's administrator</u>				
EUGENIO DE ZAGOTTIS	186.783.418-90	RAIA DROGASIL S.A.	61.585.865/0001-51	
Member of the Board of Directors (Permanent)				
<u>Related person</u>				
MARCELLO DE ZAGOTTIS	270.229.108-20	RAIA DROGASIL S.A.	61.585.865/0001-51	Brother or Sister (1st degree by consanguinity)
Vice President of Business and Marketing				
<u>Note</u>				

<u>Issuer or subsidiary's administrator</u>				
EUGENIO DE ZAGOTTIS	186.783.418-90	RAIA DROGASIL S.A.	61.585.865/0001-51	
Member of the Board of Directors (Permanent)				
<u>Related person</u>				
MARCELLO DE ZAGOTTIS	270.229.108-20	4 BIO MEDICAMENTOS S.A.	07.015.691/0001-46	Brother or Sister (1st degree by consanguinity)
Member of the Board of Directors (subsidiary)				
<u>Note</u>				

<u>Issuer or subsidiary's administrator</u>				
EUGENIO DE ZAGOTTIS	186.783.418-90	RAIA DROGASIL S.A.	61.585.865/0001-51	
Member of the Board of Directors (Permanent)				
<u>Related person</u>				
MARCELLO DE ZAGOTTIS	270.229.108-20	RAIA DROGASIL S.A.	61.585.865/0001-51	Brother or Sister (1st degree by consanguinity)
Controlling shareholder (member of the controlling block)				
<u>Note</u>				

<u>Issuer or subsidiary's administrator</u>				
EUGENIO DE ZAGOTTIS	186.783.418-90	RAIA DROGASIL S.A.	61.585.865/0001-51	
Member of the Board of Directors (Permanent)				

7.5 Family relations

Name	CPF	Business name of the issuer or subsidiary	CNPJ	Type of relationship to the administrator of the issuer or subsidiary
Position				
Related person				
MARCELLO DE ZAGOTTIS	270.229.108-20	SAFEPILL COMÉRCIO VAREJISTA DE MEDICAMENTOS MANIPULADOS LTDA	36.839.003/0001-60	Brother or Sister (1st degree by consanguinity)
Member of the Board of Directors (subsidiary)				
Note				
<hr/>				
Issuer or subsidiary's administrator				
EUGENIO DE ZAGOTTIS	186.783.418-90	RAIA DROGASIL S.A.	61.585.865/0001-51	
Member of the Board of Directors (Permanent)				
Related person				
MARCELLO DE ZAGOTTIS	270.229.108-20	ZTO TECNOLOGIA E SERVICOS DE INFORMAGAO NA INTERNET S.A	26.255.154/0001-18	Brother or Sister (1st degree by consanguinity)
Member of the Board of Directors (subsidiary)				
Note				
<hr/>				
Issuer or subsidiary's administrator				
BRUNO WRIGHT PIPPONZI	221.182.778-06	RAIA DROGASIL S.A.	61.585.865/0001-51	
Vice President of Health Business				
Related person				
ANTONIO CARLOS PIPPONZI	454.326.788-53	RAIA DROGASIL S.A.	61.585.865/0001-51	Son or Daughter (1st degree by consanguinity)
Chairman of the Board of Directors (Sitting Member)				
Note				
<hr/>				
Issuer or subsidiary's administrator				
BRUNO WRIGHT PIPPONZI	221.182.778-06	RAIA DROGASIL S.A.	61.585.865/0001-51	

7.5 Family relations

Name	CPF	Business name of the issuer or subsidiary	CNPJ	Type of relationship to the administrator of the issuer or subsidiary
Position				
Vice President of Health Business				
Related person				
ANTONIO CARLOS PIPPONZI	454.326.788-53	RAIA DROGASIL S.A.	61.585.865/0001-51	Son or Daughter (1st degree by consanguinity)
Controlling shareholder (member of the controlling block)				
Note				
<hr/>				
Issuer or subsidiary's administrator				
RENATO PIRES OLIVEIRA DIAS	269.999.988-17	RAIA DROGASIL S.A.	61.585.865/0001-51	
(Sitting) Member of the Board of Directors				
Related person				
CARLOS PIRES OLIVEIRA DIAS	578.464.058-53	RAIA DROGASIL S.A.	61.585.865/0001-51	Son or Daughter (1st degree by consanguinity)
Controlling shareholder (member of the controlling block)				
Note				
<hr/>				
Issuer or subsidiary's administrator				
MARCELLO DE ZAGOTTIS	270.229.108-20	RAIA DROGASIL S.A.	61.585.865/0001-51	
Vice President of Business and Marketing				
Related person				
EUGENIO DE ZAGOTTIS	186.783.418-90	HEALTHBIT PERFORMASYS TECNOLOGIA E INTELIGENCIA S.A.	22.416.310/0001-24	Brother or Sister (1st degree by consanguinity)
Chairman of the Board of Directors (Parent Company)				
Note				
<hr/>				
Issuer or subsidiary's administrator				
MARCELLO DE ZAGOTTIS	270.229.108-20	RAIA DROGASIL S.A.	61.585.865/0001-51	
Vice President of Business and Marketing				
Related person				

7.5 Family relations

Name	CPF	Business name of the issuer or subsidiary	CNPJ	Type of relationship to the administrator of the issuer or subsidiary
Position EUGENIO DE ZAGOTTIS Member of the Board of Directors (subsidiary)	186.783.418-90	AMPLISOFTWARE TECNOLOGIA LTDA.	21.661.781/0001-35	Brother or Sister (1st degree by consanguinity)
Note				
<hr/>				
Issuer or subsidiary's administrator				
MARCELLO DE ZAGOTTIS Vice President of Business and Marketing	270.229.108-20	RAIA DROGASIL S.A.	61.585.865/0001-51	
Related person				
EUGENIO DE ZAGOTTIS Chairman Member of the Board of Directors (subsidiary)	186.783.418-90	4 BIO MEDICAMENTOS S.A.	07.015.691/0001-46	Brother or Sister (1st degree by consanguinity)
Note				
<hr/>				
Issuer or subsidiary's administrator				
MARCELLO DE ZAGOTTIS Vice President of Business and Marketing	270.229.108-20	RAIA DROGASIL S.A.	61.585.865/0001-51	
Related person				
EUGENIO DE ZAGOTTIS Controlling shareholder (member of the controlling block)	186.783.418-90	RAIA DROGASIL S.A.	61.585.865/0001-51	Brother or Sister (1st degree by consanguinity)
Note				
<hr/>				
Issuer or subsidiary's administrator				
MARCELLO DE ZAGOTTIS Vice President of Business and Marketing	270.229.108-20	RAIA DROGASIL S.A.	61.585.865/0001-51	
Related person				
EUGENIO DE ZAGOTTIS	186.783.418-90	SAFEPILL COMÉRCIO VAREJISTA DE MEDICAMENTOS MANIPULADOS LTDA	36.839.003/0001-60	Brother or Sister (1st degree by consanguinity)

7.5 Family relations

Name	CPF	Business name of the issuer or subsidiary	CNPJ	Type of relationship to the administrator of the issuer or subsidiary
------	-----	---	------	---

Chairman Member of the Board of Directors
(subsidiary)

Note

Issuer or subsidiary's administrator

MARCELLO DE ZAGOTTIS Vice President of Business and Marketing	270.229.108-20	RAIA DROGASIL S.A.	61.585.865/0001-51	
--	----------------	--------------------	--------------------	--

Related person

EUGENIO DE ZAGOTTIS Member of the Board of Directors (subsidiary)	186.783.418-90	ZTO TECNOLOGIA E SERVICOS DE INFORMAGAO NA INTERNET S.A	26.255.154/0001-18	Brother or Sister (1st degree by consanguinity)
---	----------------	--	--------------------	---

Note

Issuer or subsidiary's administrator

MARCELLO DE ZAGOTTIS Vice President of Business and Marketing	270.229.108-20	RAIA DROGASIL S.A.	61.585.865/0001-51	
--	----------------	--------------------	--------------------	--

Related person

EUGENIO DE ZAGOTTIS Member of the Board of Directors (subsidiary)	186.783.418-90	FULL NINE DIGITAL CONSULTORIA S.A.	30.120.829/0001-99	Brother or Sister (1st degree by consanguinity)
---	----------------	------------------------------------	--------------------	---

Note

Issuer or subsidiary's administrator

MARCELLO DE ZAGOTTIS Vice President of Business and Marketing	270.229.108-20	RAIA DROGASIL S.A.	61.585.865/0001-51	
--	----------------	--------------------	--------------------	--

Related person

7.5 Family relations

Name	CPF	Business name of the issuer or subsidiary	CNPJ	Type of relationship to the administrator of the issuer or subsidiary
Position EUGENIO DE ZAGOTTIS Member of the Board of Directors (subsidiary)	186.783.418-90	STIX FIDELIDADE E INTELIGÊNCIA S.A.	31.688.927/0001-90	Brother or Sister (1st degree by consanguinity)
Note				
<hr/>				
Issuer or subsidiary's administrator				
MARCELLO DE ZAGOTTIS Vice President of Business and Marketing	270.229.108-20	RAIA DROGASIL S.A.	61.585.865/0001-51	
Related person				
EUGENIO DE ZAGOTTIS Member of the Board of Directors (subsidiary)	186.783.418-90	LABI EXAMES S.A.	27.579.749/0001-91	Brother or Sister (1st degree by consanguinity)
Note				
<hr/>				
Issuer or subsidiary's administrator				
ANTONIO CARLOS PIPPONZI Chairman of the Board of Directors (Parent Company)	454.326.788-53	RAIA DROGASIL S.A.	61.585.865/0001-51	
Related person				
BRUNO WRIGHT PIPPONZI Health Officer	221.182.778-06	VITAT SERVIÇOS EM SAÚDE LTDA	06.186.457/0001-19	Son or Daughter (1st degree by consanguinity)
Note				
<hr/>				
Issuer or subsidiary's administrator				
ANTONIO CARLOS PIPPONZI Chairman of the Board of Directors (Parent Company)	454.326.788-53	RAIA DROGASIL S.A.	61.585.865/0001-51	
Related person				
BRUNO WRIGHT PIPPONZI	221.182.778-06	HEALTHBIT PERFORMASYS TECNOLOGIA E INTELIGENCIA S.A.	22.416.310/0001-24	Son or Daughter (1st degree by consanguinity)

7.5 Family relations

Name	CPF	Business name of the issuer or subsidiary	CNPJ	Type of relationship to the administrator of the issuer or subsidiary
Position				
Member of the Board of Directors				
<u>Note</u>				

<u>Issuer or subsidiary's administrator</u>				
ANTONIO CARLOS PIPPONZI	454.326.788-53	RAIA DROGASIL S.A.	61.585.865/0001-51	
Chairman of the Board of Directors (Parent Company)				
<u>Related person</u>				
BRUNO WRIGHT PIPPONZI	221.182.778-06	AMPLISOFTWARE TECNOLOGIA LTDA.	21.661.781/0001-35	Son or Daughter (1st degree by consanguinity)
Member of the Board of Directors				
<u>Note</u>				

<u>Issuer or subsidiary's administrator</u>				
ANTONIO CARLOS PIPPONZI	454.326.788-53	RAIA DROGASIL S.A.	61.585.865/0001-51	
Chairman of the Board of Directors (Parent Company)				
<u>Related person</u>				
BRUNO WRIGHT PIPPONZI	221.182.778-06	RAIA DROGASIL S.A.	61.585.865/0001-51	Son or Daughter (1st degree by consanguinity)
Controlling shareholder (member of the controlling block)				
<u>Note</u>				

<u>Issuer or subsidiary's administrator</u>				
CARLOS PIRES OLIVEIRA DIAS	578.464.058-53	RAIA DROGASIL S.A.	61.585.865/0001-51	
(Sitting) Member of the Board of Directors				
<u>Related person</u>				
RENATO PIRES OLIVEIRA DIAS	269.999.988-17	RAIA DROGASIL S.A.	61.585.865/0001-51	Son or Daughter (1st degree by consanguinity)
(Sitting) Member of the Board of Directors				
<u>Note</u>				

Identification	CPF/CNPJ	Type of relationship of the Manager with the related person	Type of related person
Position/Role			
Note			

7.6 Subordination, service provision or control relationships

Identification	CPF/CNPJ	Type of relationship of the Manager with the related person	Type of related person
Position/Role			
Fiscal Year 12/31/2022			
<u>Issuer's Manager</u>			
ANTÔNIO CARLOS COELHO Financial and Administrative Vice President	030.285.708-74	Control	Direct Subsidiary
<u>Related Person</u>			
4 BIO MEDICAMENTOS S.A. Member of the Board of Directors	07.015.691/0001-46		
<u>Note</u>			

<u>Issuer's Manager</u>			
EUGENIO DE ZAGOTTIS Member of the Board of Directors (Permanent)	186.783.418-90	Control	Direct Subsidiary
<u>Related Person</u>			
4 BIO MEDICAMENTOS S.A. Member of the Board of Directors	07.015.691/0001-46		
<u>Note</u>			

<u>Issuer's Manager</u>			
MARCELLO DE ZAGOTTIS Vice President of Business and Marketing	270.229.108-20	Control	Direct Subsidiary
<u>Related Person</u>			
4 BIO MEDICAMENTOS S.A. Member of the Board of Directors	07.015.691/0001-46		
<u>Note</u>			

7.7 Managers' agreements/insurance

We have a D&O insurance policy, with coverage of BRL 100 million for losses and damages resulting from a claim filed against our managers during the policy period or during the complementary or supplementary period, if purchased, which results from the practice of any Harmful Act by the Insured as a result of their capacity as our Manager.

Harmful act is the Culpable Unlawful Act committed by an Insured, in the exercise of their management duties in the company, and which causes Damage to Third Parties, resulting in formal administrative and/or judicial proceedings against the Insured, as well as in arbitration proceedings, in the performance of the duties inherent to their office or position in our Company, as well as any claim against these persons made exclusively due to their function.

The total amount of insurance premium paid in 2023 is BRL 169 thousand. This policy is valid until March 30, 2024 and provides for the payment and/or reimbursement of amounts, respectively, due or paid by us to third parties by way of compensation for damages caused by the acts described above.

7.8 Other Relevant Information

Type	Date of the Meeting	Summary of the Agenda	2 ^a Call notice	Opening Quorum
AGEO	04/19/2023	<p>in EGM: (i) approval of the Company's common stock increase through capitalization of part of the balance of the Profit Reserve Established by the Bylaws, assigning new shares to the shareholders, as bonus; and (ii) if the item above is approved, amendment to article 4 of the Company's Bylaws to reflect the capital increase; and in OSM: (iii) review of management accounts, analysis, discussion, and voting on the financial statements for the fiscal year ended December 31, 2022; (iv) allocation of the net profit assessed in the fiscal year ended December 31, 2022; (v) definition of the number of members for the Company's Board of Directors;</p> <p>(vi) election of members of the Company's Board of Directors; (vii) determination of the annual global compensation of managers of the Company; (viii) election of the members of the Audit Committee and their respective alternates; and (ix) determination of the compensation of the members of the Audit Committee.</p>	Not applicable	OSM: 84.93% ESM: 86.55%
AEGM	04/14/2022	<p>in EGM: (i) amendment to the Bylaws of the Company to: (i.1) include a provision that shareholders and managers shall act in the interest of the Company and society with good sustainability practices, social responsibility and governance; (i.2) allow the meetings of the Board of Directors and the Executive Office to have as secretary a person to be nominated by the chairman of the meeting in question; (i.3) change the approval authority of the Board of Directors for certain transactions, execution of agreements, set of permanent and intangible assets and goodwill; (i.4) adjust the wording of the authority of the Board of Directors for approval of transactions with related parties; (i.5) change the approval authority of the Board of Directors for voting instructions rights in subsidiaries regarding certain matters; (i.6) allow the creation of commissions by the Board of Directors; and (i.7) clarify that any accumulation of office as Chief Executive Officer and member of the Board of Directors, due to the vacancy in office as Chief Executive Officer, shall be temporary; and (ii) restatement of the Company's Bylaws; and in OSM: (iii) review of the management accounts, examination, discussion, and voting on the financial statements for the fiscal year ended December 31, 2021, accompanied by the Management Report and the Independent Auditor's Report, published in the edition of "O Estado de S. Paulo" on February 23, 2022, as well as the Audit Committee's Opinion; (iv) destination of the net profit of the fiscal year ended December 31, 2021, confirming the appropriations of interest on equity and distribution of interim dividends previously resolved by the Board of Directors, which shall be imputed to the mandatory dividend; (v) determination of the annual global compensation of managers of the Company; (vi) determination of the number of members that will comprise the Audit Committee of the Company; (vii) election of the members of the Audit Committee and respective alternates; and (viii) determination of the compensation of the members of the Audit Committee.</p>	Not applicable	OSM: 81.69% ESM: 82.12%

7.8 Other Relevant Information

EGM	11/18/2021	approve the acquisition, by the Company, of shares representing the entire common stock of Dr. Cuco Desenvolvimento de Software Ltda. ("Cuco Health"), enrolled with the CNPJ/ME under No. 23.000.392/0001-94 and at the Board of Trade of the State of São Paulo under State Registration (NIRE) 35232657067, with headquarters at Alameda Vicente Pinzon, nº 54, Vila Olímpia, in the city of São Paulo, State of São Paulo, CEP 04547-130, in compliance with the provisions of item II and paragraph 1 of article 256 of Law 6,404/76	Not applicable	79.30%
AEGM	04/30/2021	In ESM: (i) amendment to and restatement of the Company's Bylaws; In OSM: (iii) review of management accounts, analysis, discussion, and voting on the financial statements for the fiscal year ended December 31, 2020, accompanied by the Management Report and the Independent Auditor's Report; (iv) allocation of the net profit assessed in the fiscal year ended December 31, 2020; (v) definition of the number of members of the Company's Board of Directors; (vi) election of the members of the Board of Directors; (vii) determination of the annual global compensation of managers of the Company; (viii) determination of the number of members that will comprise the Audit Committee of the Company; (ix) election of the members of the Audit Committee and respective alternates; and (x) determination of the compensation of the members of the Audit Committee.	Not applicable	OSM: 78.62% ESM: 81.72%
EGM	09/15/2020	(i) Split of all shares issued by the Company, at the proportion of five (5) common shares for each share of the same type existing on September 18, 2020, without changing the common stock, with the consequent amendment to the main section and paragraph five of Article 4 of the Company's Bylaws; (ii) amendment to paragraph four of Article 11 of the Company's Bylaws; (iii) amendment to Article 14 of the Company's Bylaws; (iv) restatement of the Company's Bylaws; and (v) approval of the Stock Granting Restricted Plan	Not applicable	81.11%
AEGM	04/08/2020	In OSM: (i) review of management accounts, analysis, discussion, and voting on the financial statements for the fiscal year ended December 31, 2019, accompanied by the Management Report and the Independent Auditor's Report; (ii) allocation of the net profit assessed in the fiscal year ended December 31, 2019; (iii) determination of the annual global compensation of managers of the Company; (iv) instatement the Audit Committee; (v) once instated, determination of the number of members that will comprise the Audit Committee of the Company; (vi) election of the members of the Audit Committee and their respective alternates; (vii) determination of the compensation of the members of the Audit Committee; in EGM: (viii) amendment to and restatement of the Company's Bylaws.	Not applicable	OSM: 79.14% ESM: 79,06%
EGM	08/01/2019	Proposed incorporation of Drogaria Onofre Ltda.	Not applicable	63.14%
AEGM	04/10/2019	In OSM: (a) review of management accounts, analysis, discussion, and voting on the financial statements for the fiscal year ended December 31, 2018, accompanied by the Management Report, Independent Auditor's Report; (b) allocation of net profit for the fiscal year; (c) definition of the number of members for the Board of Directors; (d) election and reelection, as the case may be, of the permanent and alternate members of the Board of Directors and confirmation of the members who meet the requirements of independent director set forth in the Novo Mercado Listing Regulations of B3 S.A. - Brasil, Bolsa, Balcão; (e) determination	Not applicable	OSM: 74.13% ESM: 74.81%

7.8 Other Relevant Information

		<p>of the annual global compensation of managers of the Company; and (f) considering the request for installation of the Audit Committee for the 2019 fiscal year by the controlling shareholder, determination of the number of members to compose the Company's Audit Committee, election and reelection, as the case may be, of the permanent and alternate members of the Audit Committee, as well as determination of their compensation; and in EGM: (g) increase in the Company's common stock, through capitalization of part of the Statutory Reserve without issuing new shares; and (h) if item "g" is approved at the Extraordinary Shareholders' Meeting, the consequent amendment to the main section of Article 4 of the Company's Bylaws.</p>		
--	--	---	--	--

Interactions between the Board of Directors and the Audit Committee

The members of the audit committee participate in the Board of Directors' meetings whenever matters are resolved on which the Audit Committee shall render an opinion, in line with the provisions of art. 163 of Law 6,404/76. In the 2020 fiscal year, the joint meeting was held on February 19, when the financial statements for the fiscal year ended December 31, 2019 were approved, with the participation of representatives of the independent auditors.

Executive Office

We emphasize that the percentage of participation in the meetings by the members of the Executive Office does not apply, since it is not a collegiate body.

Note regarding item 7.1.

The data informed in item 7.1. was obtained through a survey carried out with the assistance by the consultancy firm +Diversidade in February/2023, which resulted in the adhesion of 64% of the members of the Board of Directors, 75% of the consultants of the Advisory Committees to the Board, 63% of the members of the Statutory Executive Office, 71% of the Non-Statutory Executive Office, and 100% of the members of the Audit Committee.

8.1 Compensation policy or practice

8.1. Describe the policy or practice adopted for compensation of the board of directors, Officers appointed by the bylaws and other officers, audit committee, committees provided for in the bylaws and audit, risk, financial and compensation committees, addressing the following aspects

a. objectives of the compensation policy or practice, informing whether the compensation policy has been formally approved, the body responsible for its approval, the date of approval and, if issuer discloses the policy, locations on the Internet where the document may be consulted

The compensation policy for the Company's Executive Office Appointed by the Bylaws was approved through a formal and transparent procedure, as recommended by the People Committee at a meeting of the Board of Directors held on March 30, 2021, and can be consulted on the Company's website (<https://ri.rd.com.br>) and CVM's website. This policy is premised on the standardization of compensation rules and procedures, serving as a professional and impersonal guide in decision-making, in order to:

- Attract, develop and retain professionals with real capacity to meet the needs and priorities of the Company in the market
- Manage and control expenses with people
- Establish the necessary positions for the Company regarding the compatibility between the activities carried out, required training and mandatory experiences
- Fix consistent and competitive compensation for services rendered

The Company's compensation practice for the Statutory and Non-Statutory Executive Office is aligned with market practices (market research compared to companies in the same segment, size, billing, among others) and the management and corporate governance system. The compensation strategy emphasizes our commitment to attracting and retaining good executives, including competitive salaries, profit sharing, and long-term incentives.

Compensation is established based on market research and the Company's strategic alignment, for all bodies described except members of the Audit Committee based on the Law.

The members of the Board of Directors are compensated based on market research carried out by specialized consulting companies, have a monthly fixed compensation and an additional compensation when they participate in committees, all within the limits approved by the Shareholders' Meeting.

The Members of the Audit Committee are compensated based on the Brazilian Corporate Laws, i.e., Law 6,404, article 162, paragraph 3.

b. practices and procedures adopted by the board of directors to determine the individual compensation of the board of directors and the Executive Office, indicating:

i. Issuer's bodies and committees that are part of the decision-making process, identifying the manner in which they participate

The compensation practices of the members of the Board of Directors and Executive Office Appointed by the Bylaws are led by the Board of Directors with the assistance of the People Committee and specialized consulting firms. It being understood that it is incumbent upon the People Committee to carry out the survey of information and comparison of market practices, together with the specialized consultancy, for the presentation of the matter to the Board for the purpose of discussing and reviewing the Company's annual compensation methodology in periodical meetings on the subject.

8.1 Compensation policy or practice

ii. criteria and methodology used to set the individual compensation, indicating if studies were used to verify the market practices and, if so, the comparison criteria and scope of these studies

Compensation is established based on market research (selection of large companies that have structured policies and good practices in human capital management, with good employment conditions at all organizational levels and which have a balanced compensation composition), covering companies in retail and other sectors, carried out by specialized consultants.

iii. frequency and how the board of directors evaluates the adequacy of the issuer's compensation policy

The Board of Directors periodically re-discusses the Company's Policy and compensation practices, including its adherence to market research.

c. composition of the compensation

i. A description of the elements that form the compensation, including, in relation to each of them:

- *Their goals and alignment to short, medium, and long-term interests of the issuer:*

Board of Directors: Members of the Board of Directors receive fixed monthly fees following market standards. The fees are the same for all members, except for the fees of the Chairman of the Board, which are differentiated in view of his duties, responsibilities and time demands.

The members of the Board of Directors participating in the Advisory Committees to the Board of Directors have a fixed compensation for their participation in each Committee.

Statutory Executive Office: Members of the statutory executive office receive fixed monthly fees in addition to direct and indirect benefits (such as medical care, dental care extensible to the dependents, and life insurance) within market standards, as well as bonuses according to the evaluations of the results achieved, whose objectives are to generate alignment and competitiveness with the market. Officers Appointed by the Bylaws may also receive stock-based compensation and variable compensation, linked to short-, medium- and long-term goals. The bonuses and the share plan aim to encourage officers to align with the Company's larger objectives.

Fixed compensation plays the role of alignment with the market so that executives focus on the exercise of their activities. Short-, medium- and long-term variable compensation is linked to the results obtained, so that executives are rewarded for this, including when they exceed the results.

Audit Committee: The members of the Audit Committee receive a fixed compensation equivalent to at least ten percent (10%) of an officer's compensation, considering for the calculation the average monthly compensation of the officers.

8.1 Compensation policy or practice

- *Their proportion in the global compensation of the last 3 fiscal years:*

	2020	2021	2022
Statutory Executive Office			
- Annual Fixed Fees	30%	30%	24%
- Direct and Indirect Benefits	1%	1%	1%
- Others (INSS)	6%	5%	5%
- Annual Variable Compensation	31%	29%	30%
- Stock-Based Compensation	32%	35%	40%
- Post-Employment Benefits	0%	0%	0%
Non-Statutory Executive Office			
- Annual Fixed Fees	47%	45%	44%
- Direct and Indirect Benefits	5%	5%	4%
- Others (INSS and FGTS)	20%	17%	18%
- Annual Variable Compensation	16%	16%	17%
- Stock-Based Compensation	12%	17%	17%
- Post-Employment Benefits	0%	0%	0%
Board of Directors			
- Fixed Fees	100%	100%	100%
Audit Committee			
- Fixed Fees	100%	100%	100%
Committees			
- Fixed Fees	100%	100%	100%

- *The calculation and adjustment methodology:*

The Board of Directors establishes the fixed compensation adjustment values, always within the limit approved by the Ordinary Shareholders' Meeting. The values of the variable compensation, applicable to the officers appointed by the Bylaws, are determined according to the budget and its execution.

The compensation of managers, including members of the Advisory Committees to the Board of Directors, is compared from time to time with market practices (selection of large companies that have structured policies and good practices in human capital management, with good employment conditions at all organizational levels and that have a balanced composition of compensation), through salary surveys carried out through specialized consultancies, in addition to monitoring inflation for the period, evaluating the need for adjustment in the compensation components.

- *The main performance indicators taken into account, including, if applicable, ESG-related indicators.*

For fixed compensation, the Company relies on market research and does not use specific performance indicators. Variable compensation has evaluation components with respective indicators:

1. Company goals (financial, customers, engagement, and sustainability);
2. Area goals (specific to each area);
3. Individual goals (performance/succession evaluation); and

The socio-environmental component takes into account goals related to the development of commitments of RD's 2030 strategy. Each year, we prioritize 3 to 4 commitments and set intermediary goals to be achieved.

- ii. *Reasons that justify the composition of the compensation*

8.1 Compensation policy or practice

We have adopted a compensation composition model that focuses a significant share of the total compensation in variable components (both short and long term). The existence of variable compensation practices, including share-based compensation, allows to share the risk and our profit with our main executives, which are features of a transparent policy aimed at achieving lasting results that enable our continuance and the creation of value that is reflected in the market price of our shares.

iii. Existence of members not compensated by the issuer and the reason for such fact

The Company has no members who are not compensated.

d. existence of compensation supported by subsidiaries, controlled companies or direct or indirect controllers

There is no remuneration supported by subsidiaries, controlled companies or controlling shareholders.

e. existence of any compensation or benefit linked to the occurrence of a given corporate event, such as the disposal of issuer's ownership control

There is no compensation or benefit bound to the occurrence of a specific corporate event.

8.2 Total compensation per body**Total compensation for the Fiscal Year as of December 31, 2022 - Annual Values**

	Board of Directors	Statutory Executive Office	Audit Committee	Total
Total number of members	11	8	4	23.00
No. of compensated members	11	8	4	23.00
Annual fixed compensation				
Salary or compensation	4,281,169.00	12,461,449.00	618,400.00	17,361,018.00
Direct and indirect benefits	0.00	357,942.00	0.00	357,942.00
Participations in committees	4,292,047.00	0.00	0.00	4,292,047.00
Others	0.00	0.00	0.00	0.00
Description of other fixed compensation	Salary or compensation = Fees.	Salary or compensation = Fees.	Salary or compensation = Fees.	
Variable compensation				
Bonus	0.00	10,301,066.00	0.00	10,301,066.00
Profit sharing	0.00	0.00	0.00	0.00
Participation in meetings	0.00	0.00	0.00	0.00
Commissions	0.00	0.00	0.00	0.00
Others	0.00	0.00	0.00	0.00
Description of other variable compensation				
Post-employment	0.00	0.00	0.00	0.00
Removal from office	0.00	0.00	0.00	0.00
Based on shares (including options)	0.00	20,490,749.00	0.00	20,490,749.00
Note				
Total compensation	8,573,216.00	43,611,206.00	618,400.00	52,802,822.00

8.2 Total compensation per body**Total Compensation for the Fiscal Year as of December 31, 2021 - Annual Values**

	Board of Directors	Statutory Executive Office	Audit Committee	Total
Total number of members	10.50	8	4	22.50
No. of compensated members	10.50	8	4	22.50
Annual fixed compensation				
Salary or compensation	3,816,650.00	11,339,540.00	550,401.00	15,706,591.00
Direct and indirect benefits	0.00	420,295.00	0.00	420,295.00
Participations in committees	3,940,475.00	0.00	0.00	3,940,475.00
Others	0.00	0.00	0.00	0.00
Description of other fixed compensation	Salary or compensation = Fees.	Salary or compensation = Fees.	Salary or compensation = Fees.	
Variable compensation				
Bonus	0.00	7,232,295.00	0.00	7,232,295.00
Profit sharing	0.00	0.00	0.00	0.00
Participation in meetings	0.00	0.00	0.00	0.00
Commissions	0.00	0.00	0.00	0.00
Others	0.00	0.00	0.00	0.00
Description of other variable compensation				
Post-employment	0.00	0.00	0.00	0.00
Removal from office	0.00	0.00	0.00	0.00
Based on shares (including options)	0.00	13,163,593.00	0.00	13,163,593.00
Note				
Total compensation	7,757,125.00	32,155,723.00	550,401.00	40,463,249.00

8.2 Total compensation per body**Total Compensation for the Fiscal Year as of December 31, 2020 - Annual Values**

	Board of Directors	Statutory Executive Office	Audit Committee	Total
Total number of members	9	7.75	3.75	20.50
No. of compensated members	9	7.75	3.75	20.50
Annual fixed compensation				
Salary or compensation	3,304,362.00	10,840,635.00	497,893.00	14,642,890.00
Direct and indirect benefits	0.00	373,871.00	0.00	373,871.00
Participations in committees	3,508,717.00	0.00	0.00	3,508,717.00
Others	0.00	0.00	0.00	0.00
Description of other fixed compensation	Salary or compensation = Fees.	Salary or compensation = Fees.	Salary or compensation = Fees.	
Variable compensation				
Bonus	0.00	7,610,455.00	0.00	7,610,455.00
Profit sharing	0.00	0.00	0.00	0.00
Participation in meetings	0.00	0.00	0.00	0.00
Commissions	0.00	0.00	0.00	0.00
Others	0.00	0.00	0.00	0.00
Description of other variable compensation				
Post-employment	0.00	0.00	0.00	0.00
Removal from office	0.00	0.00	0.00	0.00
Based on shares (including options)	0.00	11,554,441.00	0.00	11,554,441.00
Note				
Total compensation	6,813,079.00	30,379,402.00	497,893.00	37,690,374.00

8.3 Variable Compensation

Fiscal Year: 12/31/2022

	Board of Directors	Statutory Executive Office	Audit Committee	Total
Total number of members	11	8	4	23.00
No. of compensated members	11	8	4	23.00
IN RELATION TO BONUS				
Minimum amount provided for in the compensation plan	0.00	0.00	0.00	0.00
Maximum amount provided for in the compensation plan	0.00	15,552,117.00	0.00	15,552,117.00
Amount provided for in the compensation plan, if the established targets were met	0.00	10,368,078.00	0.00	10,368,078.00
Amount actually recognized in the fiscal year	0.00	10,301,066.00	0.00	10,301,066.00
IN RELATION TO PROFIT SHARING				
Minimum amount provided for in the compensation plan	0.00	0.00	0.00	0.00
Maximum amount provided for in the compensation plan	0.00	0.00	0.00	0.00
Amount provided for in the compensation plan, if the established targets were met	0.00	0.00	0.00	0.00
Amount actually recognized in the fiscal year	0.00	0.00	0.00	0.00

Fiscal Year: 12/31/2021

	Board of Directors	Statutory Executive Office	Audit Committee	Total
Total number of members	10.50	8	4	22.50
No. of compensated members	10.50	8	4	22.50
IN RELATION TO BONUS				
Minimum amount provided for in the compensation plan	0.00	0.00	0.00	0.00
Maximum amount provided for in the compensation plan	0.00	14,995,937.00	0.00	14,995,937.00
Amount provided for in the compensation plan, if the established targets were met	0.00	9,997,291.00	0.00	9,997,291.00
Amount actually recognized in the fiscal year	0.00	7,232,295.00	0.00	7,232,295.00
IN RELATION TO PROFIT SHARING				
Minimum amount provided for in the compensation plan	0.00	0.00	0.00	0.00
Maximum amount provided for in the compensation plan	0.00	0.00	0.00	0.00
Amount provided for in the compensation plan, if the established targets were met	0.00	0.00	0.00	0.00
Amount actually recognized in the fiscal year	0.00	0.00	0.00	0.00

Fiscal Year: 12/31/2020

	Board of Directors	Statutory Executive Office	Audit Committee	Total
Total number of members	9	7.75	3.75	20.50
No. of compensated members	9	7.75	3.75	20.50
IN RELATION TO BONUS				
Minimum amount provided for in the compensation plan	0.00	0.00	0.00	0.00
Maximum amount provided for in the compensation plan	0.00	13,152,023.00	0.00	13,152,023.00
Amount provided for in the compensation plan, if the established targets were met	0.00	8,768,016.00	0.00	8,768,016.00
Amount actually recognized in the fiscal year	0.00	7,610,455.00	0.00	7,610,455.00
IN RELATION TO PROFIT SHARING				
Minimum amount provided for in the compensation plan	0.00	0.00	0.00	0.00
Maximum amount provided for in the compensation plan	0.00	0.00	0.00	0.00
Amount provided for in the compensation plan, if the established targets were met	0.00	0.00	0.00	0.00
Amount actually recognized in the fiscal year	0.00	0.00	0.00	0.00

8.4 Share-based compensation plan

8.4. As for the share-based compensation plan for the board of directors and executive office, during the last fiscal year and forecasted for the current fiscal year, describe:

a. general terms and conditions

Plan approved in 2014

The Plan in force at the Company was approved at the Extraordinary Shareholders' Meeting held on April 23, 2014 ("Plan"). Officers appointed by the Bylaws and other officers and employees of the Company or other companies under its control may be elected as Beneficiaries of Performance Shares under the Plan. The Plan will be managed by the Board of Directors, with the assistance of the People Committee. Annually, or whenever it deems appropriate, the Board of Directors will approve the granting of Performance Shares, electing the Beneficiaries in favor of which the Company will dispose of the Performance Shares under the Plan, establishing the terms and conditions for the acquisition of rights related to the Performance Shares. The Board of Directors may condition the granting of a portion of Performance Shares to the investment by the Beneficiary in the acquisition of shares issued by the Company with the use of its variable compensation, and such Performance Shares must also be subject to the rules for the acquisition of rights established.

In addition, the Board of Directors may subordinate the vesting of rights related to the Performance Shares to certain conditions, as well as impose restrictions on the transfer, and may also reserve to the Company repurchase options and/or rights of first refusal in the event of the disposal by the Beneficiary of such Performance Shares. For the purpose of satisfying the granting of Performance Shares under the Plan, the Company, subject to the law and regulation in force, will dispose of shares held in treasury, by means of a private transaction. The Beneficiaries will only acquire the rights to the Performance Shares to the extent that they remain continuously bound as managers or employees of the Company or another company under its control, for the period between the Date of Granting and the dates specified below, as follows: (a) one-third (1/3) after the 2nd anniversary of the Date of Granting; (b) one-third (1/3) after the 3rd anniversary of the Date of Granting; and (c) one-third (1/3) after the 4th anniversary of the Date of Granting. While the rights to the Performance Shares are not fully acquired, under the terms and conditions set forth, the Beneficiary may not pledge, sell, assign, dispose or transfer, directly or indirectly, the Performance Shares.

Plan approved in 2020 – Performance Shares

The Plan in force at the Company was approved at the Extraordinary Shareholders' Meeting held on September 15, 2020 ("Plan"). Officers and employees of the Company, or another company under its control, may be elected as Beneficiaries of the Performance Share Plan, provided that upon approval by the Company's Board of Directors.

The Plan is managed by the Board of Directors, which may have an advisory committee created or appointed by the Board of Directors to advise it in the management of the Plan. Nevertheless, any decision will be incumbent on the Board of Directors. Provided that the general conditions of the Plan are respected, the Board of Directors shall have full powers to take all measures required and appropriate for management of the Plan including: (a) creation and application of general standards related to the granting of Performance Shares, under the Plan, and settlement of doubts concerning interpretation of the Plan; (b) the election of the Beneficiaries and the authorization to grant Performance Shares in their favor, establishing all goals and conditions for the acquisition of rights related to the Performance Shares under this Plan, as well as the modification of such conditions when necessary or convenient, observing the terms and principles of this Plan and the provisions of the respective Granting Agreements; (c) the authorization to transfer treasury shares to satisfy the granting of the Performance Shares, under the Plan and CVM Ruling 77, or, in the event that there are no treasury shares, settle the obligation to deliver the Performance Shares in cash; (d) define the WACC to be included in each Granting Agreement. The Board of Directors may, at its discretion, change or modify such goals to avoid distortions arising from unforeseen events and/or scenarios; and (e) make any arrangements required for the administration of the Plan. In the performance of its duties, the Board of Directors will only be subject to the limits established by law, in the regulations of the Securities Commission and in this Plan, it being understood that the Board of

8.4 Share-based compensation plan

Directors may treat Beneficiaries who are in a similar situation differently, not being obliged by any rule of isonomy or analogy to extend to all the conditions that it considers applicable only to one or some participants.

The Beneficiaries may not dispose of, transfer, sell, rent, encumber or otherwise trade fifty percent (50%) of the Performance Shares received from the Company for a period of one (1) year, counted from the date of transfer of the Performance Shares by the Company to the Beneficiary ("Lock-Up"). After this Lock-Up period, said Performance Shares will be free and clear of any restrictions, and the Beneficiary may freely trade such shares. The Beneficiary must keep the Performance Shares with the bookkeeping bank and outside the B3 trading environment and, to the extent possible, such shares must be recorded with the bookkeeping bank to provide for the Lock-Up. The Company may, at any time, request proof of compliance with the Lock-Up obligation by the Beneficiary and require the adoption of certain procedures that enable the monitoring and control of the Lock-Up. For the avoidance of doubt, in case the Participant is dismissed, for any reason, upon receipt of the Performance Shares, the portion of the Performance Shares subject to the Lock-Up will remain subject to the Lock-Up.

b. approval date and responsible body

Plan approved in 2014

Approved at Extraordinary Shareholders' Meeting held on April 23, 2014.

Plan approved in 2020 – Performance Shares

Approved at Extraordinary Shareholders' Meeting held on September 15, 2020.

c. maximum number of covered shares

Plan approved in 2014

The maximum number of shares that may be granted in the scope of the Plan shall not exceed two percent (2%) of the shares representing the total common stock of the Company, and this limit will be used for at least five (5) years.

Plan approved in 2020 – Performance Shares

Within the scope of the Performance Share Granting Plan ("Performance Shares"), shares issued by the Company representing up to two percent (2%) of the Company's common stock may be delivered to the Beneficiaries.

d. maximum number of options to be granted

Plan approved in 2014

The Plan includes the grant of shares, and not of share options.

Plan approved in 2020 – Performance Shares

The Plan includes the grant of shares, and not of share options.

e. conditions for acquisition of shares

Plan approved in 2014

The Beneficiaries will only acquire the rights to the Performance Shares to the extent that they remain continuously bound as managers or employees of the Company or another company under its control, for the period between the Date of Granting and the dates specified below, as follows: (a) one-third (1/3) after the 2nd anniversary of the Date of Granting; (b) one-third (1/3) after the 3rd anniversary of the Date of Granting; and (c) one-third (1/3) after the 4th anniversary of the Date of Granting.

8.4 Share-based compensation plan

Plan approved in 2020 – Performance Shares

Annually, the Company's Board of Directors will define the Beneficiaries to which the Performance Shares will be granted and the target number of Performance Shares that will be granted to each Beneficiary ("Target Number"), and the Beneficiary's right to effectively receive the Performance Shares granted will only be fully acquired if the following conditions are cumulatively met:

(a) the Beneficiary remains continuously bound, as manager or employee, to the Company or to a company under its control, as the case may be, during the period of four (4) years counted from the date of granting of the Performance Shares ("Vesting Period"); and (b) the price of the Company's share on B3 (weighted by trading volume) in the ninety (90) trading sessions prior to the last day of the Vesting Period must be greater than ninety percent (90%) of the Reference Price, adjusted by the WACC adjusted to reflect the distribution of dividends and interest on the stockholders' equity realized in the Vesting Period. "Reference Price" will correspond to the average price of the share on B3 (weighted by the trading volume) in the ninety (90) trading sessions prior to January 1 of the year in which the Target Number is granted.

If the conditions contained in items (a) and (b) above are met, the Beneficiary will be entitled to a percentage of the Target Number granted, depending on the quadrant of achievement of the target contained in item (b) above, according to the matrix below. In any event, the maximum number of Performance Shares to which the Beneficiary will be entitled may not exceed one hundred and twenty percent (120%) of the Target Number granted.

Share price at the end of the Vesting Period Vs. Reference Price, adjusted by WACC	Percentage of Target Quantity that will be entitled to Beneficiary
Less than 90%	0%
Between 90% and 94.99%	70%
Between 95% and 99.99%	85%
Between 100% and 104.99%	100%
Between 105% and 110%	105%
Over 110%	120%

f. acquisition or strike pricing criteria

Plan approved in 2014

The Plan provides for the granting of shares and not stock options. The shares will be granted as payment of the variable compensation to which the elected participants are entitled, therefore, there is no strike price.

Plan approved in 2020 – Performance Shares

Not applicable. The Performance Share Plan establishes that, when the Vesting Period has elapsed, and provided that all the conditions set forth in the Plan are met, the shares will be transferred by the Company to the Beneficiary, without payment of any strike price.

g. acquisition or strike pricing criteria

Plan approved in 2014

As described in item 8.1, the Company relies on market research to compare practices, including compensation periods, for purposes of competitiveness of the compensation package.

Additionally, deadlines are linked to executive retention strategies.

Plan approved in 2020 – Performance Shares

Not applicable. The Performance Share Plan establishes that, when the Vesting Period described in the Performance Share Plan is exceeded, and provided that all the conditions set forth in the Plan are met, the shares will be transferred by the Company to the Beneficiary, without payment of any strike price.

8.4 Share-based compensation plan

h. method of settlement

Plan approved in 2014

The shares granted by the plan, once all the requirements provided for in the contract signed between the Company and the executive are fulfilled, are transferred from treasury to the executive.

Plan approved in 2020 – Performance Shares

Under the Performance Share Plan, the Company will transfer shares held in treasury, by means of a private transaction, at no cost to the Beneficiaries, pursuant to CVM Ruling 87. In the event that there are no treasury shares and/or if acquiring shares on the market is not possible due to legal or regulatory restrictions, the Board of Directors may choose to settle the delivery of the performance shares in cash.

i. shares transfer restrictions

Plan approved in 2014

While the rights to the Performance Shares are not fully acquired, under the terms and conditions set forth, the Beneficiary may not pledge, sell, assign, dispose or transfer, directly or indirectly, the Performance Shares.

Plan approved in 2020 – Performance Shares

The Beneficiaries may not dispose of, transfer, sell, rent, encumber or otherwise trade fifty percent (50%) of the Performance Shares received from the Company for a period of one (1) year, counted from the date of transfer of the Performance Shares by the Company to the Beneficiary (“Lock-Up”). After this Lock-Up period, said Performance Shares will be free and clear of any restrictions, and the Beneficiary may freely trade such shares.

j. criteria and events that, upon their occurrence, will result in suspension, change or termination of the plan

Plan approved in 2014

Amendment: Any relevant legal amendment to the rules of the joint-stock companies, to the publicly-held companies, to the labor laws, and/or the tax effects of a restricted share grant plan may lead to full revision of this Plan. Termination: The Plan may be terminated at any time by decision of the Company’s Shareholders’ Meeting.

Plan approved in 2020 – Performance Shares

The Performance Share Plan may be terminated at any time by decision of the Shareholders’ Meeting, it being understood that grants of Performance Shares made before said Performance Share Plan termination will remain effective. Any amendment to the legislation and regulations applicable to the Company may give rise to the full review of the Performance Share Plan.

k. effects of a manager’s exit from the issuer’s bodies on his rights provided in the share-based compensation plan

Plan approved in 2014

If, at any time, the Beneficiary leaves the Company:

(i) by their own initiative or (ii) due to dismissal with cause: The rights not yet fully acquired on the date of termination will be automatically terminated, by operation of law, regardless of prior notice or warning, with no right to indemnification.

(iii) due to dismissal without cause: The rights not yet fully acquired will observe the deadlines set in the Plan, and their early exercise will be possible, to the Board of Directors’ discretion.

8.4 Share-based compensation plan

(iv) due to retirement, death, or permanent disability: Early exercise of rights not yet fully acquired under the Plan.

Plan approved in 2020 – Performance Shares

If, at any time, the Beneficiary leaves the Company:

- (i) (a) of its own free will, by way of voluntary resignation or resignation from the office of manager; or
- (b) at the discretion of the Company, upon (b.1) dismissal with cause under the legislation in force or (b.2) removal from his position as manager with cause arising from (i) violation of his legal and/or statutory duties or assignments, (ii) motivated termination of the contract governing the relationship between the Company and the Beneficiary; (iii) criminal conviction related to intentional crimes; (iv) dishonest or fraudulent acts against the Company or its subsidiaries ; (v) any act or omission arising from intent or fault of the Beneficiary and that is detrimental to the business, image, or financial situation of the Company, its shareholders, or its subsidiaries; (vi) harassment or serious violation of the Company's policies and codes: the Beneficiary will lose any and all rights related to the Performance Shares granted and not yet received from the Company, which will be automatically extinguished on the date of Dismissal, by operation of law, regardless of prior notice or notification and without the right to any indemnity to the Beneficiary, so that the Performance Shares will be automatically canceled; (ii) at the discretion of the Company, upon dismissal without cause or without the managers having committed any act resulting in removal with cause or dismissal with cause under the terms of item (i) above: the Beneficiary will be entitled to receive, at the end of the Vesting Period, a pro rata amount of the Target Number of Performance Shares granted under the respective Granting Agreement, proportional to the number of days elapsed during the Vesting Period, in the proportion of $X/1460$, where "X" is the number of days elapsed between the start date of the Vesting Period and the date of Dismissal, provided that, however, the effective amount of Performance Shares that the Beneficiary will be entitled to receive is subject to the achievement of the performance target contained in item 8.1(b) of the Performance Share Plan, according to the performance matrix contained in item 8.1 of the Performance Share Plan, to be applied to the Target Number on a pro rata basis to which the Beneficiary is entitled.

Any fractional shares will be rounded up and the Beneficiary will only receive said Performance Shares to which he is entitled on the same date initially provided for in the Granting Agreement and in the Plan, that is, after the Vesting Period has elapsed, observing the legal deductions and withholding, as provided in item 11.7 of the Performance Share Plan;(iii) due to the Beneficiary's retirement: if the Company and the Beneficiary agree that the Dismissal is due to the Beneficiary's retirement, the Beneficiary will be entitled to receive (a) within sixty (60) days from the date of formalization of the Dismissal, fifty percent (50%) of the Target Number of Performance Shares granted under the respective Granting Agreement, so that fifty percent (50%) of the Target Number granted to the Beneficiary will become immediately vested, regardless of the course of the Vesting Period; and (b) after a period of twelve (12) months from the date of formalization of the Dismissal, fifty percent (50%) of the Target Number granted under the respective Granting Agreement, provided that the Beneficiary complies with the non-competition and non-soliciting obligations to be fixed in the instrument governing the Dismissal. In this case, the performance condition contained in item 8.1(b) above will not be applied, so that the number of Performance Shares to be delivered will be equivalent to the Target Number, subject to the legal deductions, as provided in item 11.7 of the Performance Share Plan;

(iv) due to death or permanent disability: the Beneficiary or his estate or heir(s), as applicable, will be entitled to receive the entire Target Number granted under the respective Granting Agreement, so that the Performance Shares granted to the Beneficiary will become immediately vested, regardless of the expiration of the Vesting Period, and the Company must deliver said Performance Shares within sixty (60) days from the Dismissal. In the event provided for herein, the performance condition of item 8.1(b) of the Restricted Share Grant Plan shall not apply, so that the number of Restricted Shares to be delivered shall be equivalent to the Target Number, subject to the legal deductions.

Notwithstanding the provisions of item 8.1 of the Restricted Share Grant Plan, the Board of Directors may, in its sole discretion, whenever it deems that the Interests of the Company shall be better met by such measure, establish rules different from those provided for in item 8.1 above, conferring

8.4 Share-based compensation plan

differentiated treatment to a particular Beneficiary, provided that such treatment does not harm the Beneficiary in question.

8.5 Share-based compensation (Stock options)

Reasons for not completing the table:

The share-based compensation plans include the grant of shares, and not of stock options.

8.6 Granting of stock options

8.6. Regarding each stock option granted in the last 3 fiscal years and that estimated for the current fiscal year, of the board of directors and the executive office appointed by the bylaws, prepare a table with the following content:

The Plan includes the grant of shares, and not of share options.

8.7 Outstanding options

8.7. As for outstanding options held by the board of directors and executive office at the end of the latest fiscal year, prepare a table with the following content:

The Plan includes the grant of shares, and not of share options.

8.8 Options exercised and shares delivered

8.8. Regarding the exercised options related to the share-based compensation of the board of directors and of the executive office appointed by the bylaws over the last 3 fiscal years, prepare a table with the following content:

The Plan includes the grant of shares, and not of share options.

8.9 Potential dilution for grant of shares

8.9. Regarding the stock-based compensation as shares to be delivered directly to the beneficiaries, recognized in the results of the last 3 fiscal years and that estimated for the current fiscal year of the board of directors and the executive office appointed by the bylaws, prepare a table with the following content:

- a. body;
- b. total number of members;
- c. number of compensated members;
- d. potential dilution if all shares are granted to the beneficiaries.

	2020	2021	2022	2023 – Forecast
Statutory Executive Office				
Total number of members	7.75	8	8	8
No. of compensated members	7.75	8	8	8

Only members of the Executive Office Appointed by the Bylaws have a variable share-based compensation.

There is no dilution in the event of granting of all shares to the beneficiaries since the shares granted are already held in the Company's treasury.

8.10 Grant of shares

8.10. Regarding each granting of shares made in the last 3 fiscal years and that estimated for the current fiscal year, of the board of directors and executive office appointed by the bylaws, prepare a table with the following content:

- a. body;
- b. total number of members;
- c. number of compensated members;
- d. date of granting;
- e. number of shares granted;
- f. deadline for the delivery of shares;
- g. lock-up period for transfer of shares;
- h. fair value of shares on the date of granting;
- i. multiplication of the number of shares granted by the fair value of the shares on the granting date.

About the Company’s Long-Term Incentive Program with Performance Shares approved on April 23, 2014. Below we have the information pertaining to the grants made during the last 3 fiscal years to members of its statutory executive office:

	2020				2021				2022				2023 – Forecast			
	1 st Tranche	2 nd Tranche	3 rd Tranche	Total	1 st Tranche	2 nd Tranche	3 rd Tranche	Total	1 st Tranche	2 nd Tranche	3 rd Tranche	Total	1 st Tranche	2 nd Tranche	3 rd Tranche	Total
Total number of members	7.00				8.00				8.00				8.00			
No. of compensated members	7.00	7.00	7.00	7.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00
Date of granting	03/01/2020	03/01/2020	03/01/2020	-	03/01/2021	03/01/2021	03/01/2021	-	03/01/2022	03/01/2022	03/01/2022	-	03/01/2023	03/01/2023	03/01/2023	-
Number of shares granted	195,485	195,485	195,485	586,455	147,096	147,096	147,096	441,288	178,319	178,319	178,319	534,957	249.627	249.627	249.626	748.880
Maximum term for delivery of shares	03/01/2022	03/01/2023	03/01/2024	-	03/01/2023	03/01/2024	03/01/2025	-	03/01/2024	03/01/2025	03/01/2026	-	03/01/2025	03/01/2026	03/01/2027	-

8.10 Grant of shares

Lock-up period for transfer of the shares	03/01/2022	03/01/2023	03/01/2024	-	03/01/2023	03/01/2024	03/01/2025	-	03/01/2024	03/01/2025	03/01/2026	-	03/01/2025	03/01/2026	03/01/2027	-
Fair value of shares on the date of granting	24.89	24.89	24.89		22.72	22.72	22.72	-	23.90	23.90	23.90	-	23.90	23.90	23.90	
Multiplication of the number of shares granted by the fair value of the shares on the granting date	4,865,622	4,865,622	4,865,622	14,596,865	3,342,021	3,342,021	3,342,021	10,026,063	4,261,824	4,261,824	4,261,824	12,785,472	5,966,085	5,966,085	5,966,085	17,898,232

About the Performance Share Program approved on September 15, 2020. Below we have the information pertaining to the grants made during the last 3 fiscal years to members of its statutory executive office:

	2021 Grant	2022 Grant	2023 Grant – Forecast
Total number of members	8	8	8
No. of compensated members	8	8	8
Date of granting	01/01/2021	01/01/2022	01/01/2023
Number of shares granted	302,990	381,554	435,443
Deadline for the delivery of shares	01/01/2025	01/01/2026	01/01/2027
Lock-up period for transfer of shares	01/01/2026	01/01/2027	01/01/2028
Fair value of shares on the date of granting	33.99	31.18	31.18

8.10 Grant of shares

Multiplication of the number of shares granted by the fair value of shares on the date of granting	10,298,630	11,896,854	13,577,113
---	------------	------------	------------

8.11 Shares Delivered

Fiscal Year: 12/31/2022

	Board of Directors	Statutory Executive Office	Fiscal Council
Total number of members		8	
No. of compensated members		8	
No. of shares		530,666	
Weighted average purchase price		19,28	
Weighted average market price of the purchased shares		23,36	
Multiplication of the total number of shares by the difference between the weighted average purchase price and the weighted average market price of the purchased shares		-2,165,117.28	

Fiscal Year: 12/31/2021

	Board of Directors	Statutory Executive Office	Fiscal Council
Total number of members		8	
No. of compensated members		8	
No. of shares		729,965	
Weighted average purchase price		10.60	
Weighted average market price of the purchased shares		23.23	
Multiplication of the total number of shares by the difference between the weighted average purchase price and the weighted average market price of the purchased shares		-9,219,457.95	

Fiscal Year: 12/31/2020

	Board of Directors	Statutory Executive Office	Fiscal Council
Total number of members		7.75	
No. of compensated members		7.75	
No. of shares		838,780	
Weighted average purchase price		10.60	
Weighted average market price of the purchased shares		23.98	
Multiplication of the total number of shares by the difference between the weighted average purchase price and the weighted average market price of the purchased shares		-11,222,876.40	

8.12 Share/option pricing

8.12. A summary containing the information needed to understand the data disclosed in items 8.5 through 8.11, such as an explanation of the shares and options pricing method, stating at least:

The Plan includes the grant of shares, and not of share options. Pertinent information listed below.

- a. **pricing method;**
- b. **data and assumptions used in the pricing model, including weighted average share price, strike price, expected volatility, life term of the option, expected dividends and the risk-free interest rate;**
- c. **method and assumptions adopted to consider the expected effects of early exercise;**
- d. **method for ascertaining the expected volatility;**
- e. **whether any other characteristic of the option was taken into consideration when ascertaining its fair value.**

Regarding the Long-Term Incentive Program with Restricted Shares approved on April 23, 2014, the reference price per restricted share, for the purposes of determining the target quantity that will be granted to each Beneficiary, shall be equivalent to the average share price on B3 (weighted by trading volume) in the last thirty trading sessions prior to the granting.

Regarding the Performance Shares Program approved on September 15, 2020, given that the payment shall be made upon the achievement of price targets per share, to determine the fair value of the shares, we carried out a probability simulation by applying the Monte Carlo Method ("Monte Carlo Simulation – SMC"). 10,000 simulations were performed considering the assumptions below:

	2020 Grant	2021 Grant	2022 Grant
Date of Granting	Jan/2020	Jan/2021	Jan/2022
Vested Date	Dec/2023	Dec/2024	Dec/2025
St - Reference price	BRL 20.46	BRL 24.21	BRL 23.80
u - %WACC	10.00%	12.00%	13.80%
q - Dividend Yield%	0.72%	0.95%	0.95%
r(T-t) - Rf	5.69%	5.64%	10.51%
d – Volatility*	29.36%	32.41%	33.78%
Variance/2	4.31%	5.25%	5.70%
Fair Value	BRL 13.19	BRL 33.99	BRL 31.18

* Historical volatility was calculated based on the return of the last 1,000 closing prices of the Company's shares (RADL3) on B3.

** There is no possibility of early settlement and we have no stock options granted.

8.13 Interests held, per body

8.13. State the number of shares, membership units (quotas), and other securities convertible into shares or membership units issued in Brazil or abroad by the issuer, its direct or indirect controlling companies, subsidiaries, or companies under common control, held by members of the board of directors, executive office appointed by the bylaws, or audit committee, grouped per body:

Body*	Number of Shares	%
Board of Directors	47,071,989	2.85%
Statutory Executive Office	35,175,922	2.13%
Audit Committee	10,063	0.00%

* Position as of December 31, 2022

8.14 Welfare plans

8.14. As for current pension plans available to the board of directors' members and executive officers appointed by the bylaws, provide a chart itemizing:

We have granted no pension plans to members of the Board of Directors and the Statutory Executive Officers.

8.15 Minimum, average and maximum compensation

Annual values

	Statutory Executive Office			Board of Directors			Audit Committee		
	12/31/2022	12/31/2021	12/31/2020	12/31/2022	12/31/2021	12/31/2020	12/31/2022	12/31/2021	12/31/2020
No. of members	8	8	7.75	11	10.50	9	4	4	3.75
No. of compensated members	8	8	7.75	11	10.50	9	4	4	3.75
Highest Real compensation amount	11,738,155.00	10,980,753.00	10,283,840.00	1,581,750.00	1,619,830.00	1,891,337.00	154,600.00	137,600.00	133,352.00
Lowest Real compensation amount	3,097,631.00	2,142,988.00	729,652.00	329,862.00	309,750.00	588,467.00	154,600.00	137,600.00	97,838.00
Average Real compensation amount	5,451,401.00	4,019,465.00	3,919,923.00	779,383.00	738,774.00	757,009.00	154,600.00	137,600.00	132,771.00

Note

Statutory Executive Office	
12/31/2021	The lowest compensation amount excludes members who were in office for less than 12 months

Board of Directors	
--------------------	--

Audit Committee	
12/31/2021	The lowest compensation amount excludes members who were in office for less than 12 months

8.16 Compensation/indemnity mechanisms

8.16. Describe contract arrangements, insurance policies, or other instruments containing mechanisms for compensation or indemnification of managers in case of removal or retirement, stating the financial consequences for the issuer

We have no compensation or indemnification mechanisms for managers in the event of removal from office or retirement.

8.17 Percentage of related parties in the compensation

8.17. As for the last 3 fiscal years and the forecast for the current fiscal year, state the percentage of the total compensation of each body as recognized in the issuer's results related to members of the board of directors, of the executive office appointed by the bylaws, or of the audit committee who are related to the direct or indirect controlling shareholders, as defined in the accounting rules dealing with this issue:

	Compensatio n 2020	Compensatio n 2021	Compensatio n 2022	Compensation 2023 forecast
Statutory Executive Office	23%	29%	30%	31%
Board of Directors	63%	52%	49%	49%
Audit Committee	0%	0%	0%	0%

8.18 Compensation - Other functions

8.18. As for the last 3 fiscal years and the forecast for the current fiscal year, state the amounts recognized in the issuer's results as compensation of members of the board of directors, of the executive office appointed by the bylaws, or of the audit committee, grouped per body, for reasons other than their positions, e.g., commissions and advisory or consulting services rendered:

The members of the Board of Directors making up the Advisory Committees to the Board of Directors receive additional compensation for their participation.

	2020	2021	2022	2023 FORECAST
Board of Directors	3,508,717	3,940,475.00	4,292,047.30	5,199,272
Statutory Executive Office	-	-	-	-
Audit Committee	-	-	-	-

8.19 Recognized compensation of the controlling shareholder/subsidiary

8.19. As for the latest three fiscal years and the forecast for the current fiscal year, state the amounts recognized in the results of the issuer's direct or indirect controlling shareholders, companies under common control, and subsidiaries, as compensation of members of the issuer's board of directors, executive office appointed by the bylaws, or audit committee, grouped per body, and explaining why such amounts were attributed to such individuals

No member of the Board of Directors, the Statutory Executive Office or the Audit Committee had their compensation recognized in the results of the issuer's controlling shareholders, companies under common control and subsidiaries.

8.20 Other relevant information**8.20. Other relevant information**

Year	Social Charges	Board of Directors	Statutory Executive Office	Audit Committee	Overall Total
2023	Fixed annual compensation - the National Social Security System (INSS)	2,040,960	3,074,478	149,235	5,264,673
	Variable annual compensation - INSS	0	8,235,327	0	8,235,327
2022	Fixed annual compensation - INSS	1,714,643	2,492,176	123,680	4,330,499
	Variable annual compensation - INSS	0	5,335,815	0	5,335,815
2021	Fixed annual compensation - INSS	1,551,425	2,267,859	110,080	3,929,364
	Variable annual compensation - INSS	0	3,708,798	0	3,708,798
2020	Fixed annual compensation INSS	1,362,615	2,168,079	99,579	3,630,273
	Variable annual compensation - INSS	0	4,109,223	0	4,109,223

Auditors - 9.1/9.2 Identification and Compensation

Auditor CVM Code	004715		
Trade Name	Type of Auditor	CPF/CNPJ	
ERNST AMP; YOUNG AUDITORES INDEPENDENTES	Legal	61.366.936/0001-25	
Date of service engagement	Start date of the provision of service		
03/24/2022	04/01/2022		
Cost of services provided			
<p>(i) Carry out the audit and issue an independent auditor's report on the individual and consolidated financial statements for the fiscal year ending December 31, 2022 of Raia Drogasil S.A. and subsidiaries ("Raia Drogasil"), prepared in accordance with accounting practices adopted in Brazil and international financial reporting standards (IFRS); (ii) Carry out a review and issue a review of the independent auditor's report on the individual and consolidated quarterly information for the periods ending March 31, June 30, and September 30, 2022 of Raia Drogasil S.A. and subsidiaries, prepared in accordance with accounting practices adopted in Brazil and international financial reporting standards (IFRS); (iii) Carry out a review and issue an independent auditor's report on compliance with contractual clauses in accordance with the established conditions, mentioned below, present in the agreements signed by Raia Drogasil S.A., for the periods ending March 31, June 30, September 30, and December 31, 2022.</p>			
Total amount of independent auditors compensation separated by service in the last fiscal year			
<p>The total compensation of the independent auditors for fiscal year 2022 was BRL 1,514 thousand related to (i) audit of the Company's individual and consolidated financial statements for the fiscal years ended December 31, 2022 in accordance with BRGAAP and international accounting standards - International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB"); and (ii) review of the Company's quarterly information for the periods ended March 31, 2022, June 30, 2022, and September 30, 2022, signed on March 07, 2022.</p>			
Justification for the replacement			
Not applicable			
Reason presented by the auditor in case of disagreement with the justification			
Not applicable			

9.3 Independence and conflict of interests of auditors

9.3. Provide other information the issuer deems relevant

The company informs that its Policy for Contracting Extra Audit Services, approved in the Board of Directors' Meeting of October 26, 2018, establishes the procedures to be adopted to avoid the existence of a conflict of interest and loss of independence of its independent auditors, so that they can provide their services objectively and issue an impartial opinion on the Company's Financial Statements. The evaluation of the contracting of extra audit services observes the following criteria:

- I. Do not impact the auditor's independence;
- II. Are approved by the Board of Directors;
- III. Are within the scope of their professional authority.

Such principles are based on the fact that independent auditors should not audit their own work, cannot perform management functions, shall not advocate for their customer or provide any other services that are considered prohibited by the applicable standards, thus maintaining Independence in the work done. This document can be consulted on the website ri.rd.com.br

The company informs that it did not contract extra audit services, so there was no need to carry out conflict of interest procedures for the year 2022.

9.4 Other relevant information

9.4. Provide other information the issuer deems relevant

The company informs that there is no other relevant information that has not be disclosed in the other items of this Reference Form.

10.1 Human resources description

Number of employees by gender declaration

	Female	Male	Non-binary	Others	Prefer not to answer
Leadership	2282	1348	0	0	0
Non-leadership	31768	17641	0	0	0
Total = 53,039	34050	18989	0	0	0

Number of employees by color or race statement

	Yellow	White	Black	Brown	Indigenous	Others	Prefer not to answer
Leadership	75	1384	346	1113	17	0	695
Non-leadership	764	11728	3787	10885	166	0	22.079
Total = 53,039	839	13112	4133	11998	183	0	22774

Number of employees by position and age group

	Less than 30 years old	From 30 to 50 years old	More than 50 years old
Leadership	885	2653	92
Non-leadership	34202	13805	1402
Total = 53,039	35087	16458	1494

Number of employees by position and geographic location

	North	Northeast	Mid-West	Southeast	South	Abroad
Leadership	120	433	305	2413	359	0
Non-leadership	1498	7158	4759	30872	5122	0
Total = 53,039	1618	7591	5064	33285	5481	0

Number of employees by geographic location and gender

	Female	Male	Non-binary	Others	Prefer not to answer
North	1010	608	0	0	0
Northeast	4423	3168	0	0	0
Mid-West	3445	1619	0	0	0
Southeast	21455	11830	0	0	0
South	3717	1764	0	0	0
Abroad	0	0	0	0	0
Total = 53,039	34050	18989	0	0	0

Number of employees by geographic location and color or race

	Yellow	White	Black	Brown	Indigenous	Others	Prefer not to answer
North	25	317	133	346	6	0	791
Northeast	120	1688	638	2112	33	0	3.000
Mid-West	78	1100	372	1178	20	0	2.316
Southeast	524	8502	2596	7264	104	0	14.295
South	92	1505	394	1098	20	0	2.372
Abroad	0	0	0	0	0	0	0
Total = 53,039	839	13112	4133	11998	183	0	22774

Number of employees by geographic location and age group

	Less than 30 years old	From 30 to 50 years old	More than 50 years old
North	1283	297	38
Northeast	5102	2325	164
Mid-West	3418	1570	76
Southeast	21553	10652	1080
South	3731	1614	136
Abroad	0	0	0
Total = 53,039	35087	16458	1494

10.1 Human resources description

10.1. Describe issuer's human resources, providing the following information

a. number of employees (total and per groups), based on the activity performed, geographic location, and diversity indicators which, within each hierarchical level of the issuer, encompass:

The information related to items 10.1.a.(i), 10.1.a.(ii), and 10.1.a.(iii) is provided in the structured table of item 10.1.a. Below we provide additional details for a better understanding of the data.

i. self-declared gender identity;

Our Gender-related data is obtained from the documentation forwarded by employees upon admission, with the gender assigned at birth or in cases of transgender people whose documentation has been rectified.

Regarding the LGBTI+ population, we have additional data obtained from the last Diversity Census, carried out in 2021. Among the total number of employees and respective gender breakdowns (shown in structured table 10.1.a), transgender and non-binary people are included, presented separately as shown below, and who are included in the total number of employees.

Transgender People: 469 people

Non-Binary People: 97 people

As a strategy, the recurrence of this Census is biannual and we will have a new edition in May 2023.

Since January 2023, RD has a structured process so that transgender people have the right to use their social name in their corporate access, regardless of document rectification, which allows us to broaden the understanding of our internal public in this regard. The gender self-declaration process will be incorporated into the color and race identity survey starting this year, on an annual basis.

ii. self-declared color or racial identity;

The reported data reflect self-declaration of color and race by 58% of the total internal public. This process started in March/2022 with active employees and all people hired from September/2022 make the self-declaration at the time they are hired. This process is carried out annually, and a new edition is being planned. Non-respondents (22,363 people) were considered in the "prefer not to answer" column, completing the total number of RD employees.

iii. age range;

RD presents a great generational diversity in its business units, although the average age of the internal public is 28 years old. The total population of people aged 50 or over is 3%, and among leadership positions, they represent 2.5%. This indicator is part of the 2030 Sustainability Goals, which is "Double the representation of 50+ people at RD, compared to 2020".

iv. other diversity indicators that the issuer deems relevant.

Other Diversity indicators that are relevant and are part of the 2030 Goals are:

Achieve gender equality in all functional categories at the headquarters, units, and distribution centers – in addition to the reported data, we have the following measurements in this area:

10.1 Human resources description

- Participation of women in Middle Leadership positions: 44.1%
- Participation of women in Senior Leadership positions: 29.3%

Having representation of at least 50% of black people in leadership positions - in addition to the reported data, we have the following measurements in this area:

- Black and brown people in Leadership Positions: 40.3%
- Black and brown people in Operational Leadership positions: 43.3%

On December 31, 2022, our workforce consisted of 53,039 employees, distributed across the Distribution Center, Corporate, Multichannel, Marketplace, Cuco, RDAs, and Droga Raia and Drogasil Units areas.

Distribution Center	5,761
BA	326
CE	312
GO	592
MG	269
MT	107
PE	284
PR	358
RJ	412
RS	271
SP	2,830
Multichannel	460
SP	460
New Businesses	38
SP	38
Marketplace	56
SP	56
Raia and Drogasil Units	44,181
AC	52
AL	383
AM	295
AP	64
BA	1,589
CE	1,095
DF	1,311
ES	920
GO	1,662
MA	524
MG	2,904
MS	740
MT	640
PA	746
PB	348

10.1 Human resources description

PE	1,687
PI	258
PR	2,156
RJ	3,219
RN	343
RO	173
RR	46
RS	1,470
SC	1,226
SE	442
SP	19,634
TO	254
Corporate	2,543
SP	2,395
RJ	22
PE	21
PR	17
GO	15
BA	15
MG	15
RS	13
DF	9
CE	8
SC	5
ES	4
MS	3
MT	1
Overall Total	53,039

i. Employees by age group

Age Groups	Headcount
Over 50	1,579
45 to 50	1,401
40 to 45	2,729
35 to 40	4,930
30 to 35	8,396
25 to 30	14,515
20 to 25	17,205
15 to 20	2,284
Total	53,039

b. number of outsourced employees (total; per group based on core activity; per territory)

10.1 Human resources description

On December 31, 2022, we registered a total of 2,266 outsourced employees, as shown in the table below:

2022	Number of Employees		
	State	Security	Cleaning
AC	0	3	3
AL	0	12	12
AM	0	11	11
AP	0	4	4
BA	14	67	81
CE	12	54	66
DF	0	45	45
ES	5	33	38
GO	21	74	95
MA	0	24	24
MG	13	126	139
MS	10	33	43
MT	14	37	51
PA	4	31	35
PB	0	11	11
PE	43	63	106
PI	0	11	11
PR	22	96	118
RJ	66	113	179
RN	1	12	13
RO	0	10	10
RR	0	2	2
RS	19	90	109
SC	2	57	59
SE	0	15	15
SP	219	760	979
TO	0	11	11
Total	465	1801	2266

c. Turnover rate

The parent company's employee turnover rate, ended December 31, 2022, was 37%, with a monthly average turnover of 3.1%. For December 31, 2021 it was 35% with a monthly average turnover of 2.9%. For December 31, 2020 it was 30% with a monthly average turnover of 2.5%.

10.2 Relevant changes

10.2. Comment about any relevant changes in relation to the numbers disclosed in item 10.1 above

On December 31, 2022 we reached the mark of more than 53 thousand employees (50 thousand in 2021, 44 thousand in 2020, 41 thousand in 2019). The 5.7% increase in the number of our employees is due to the expansion of number of company units, as well as the increase in the number of customers served in our units.

10.3 Employee compensation policies and practices

a. Salaries and Variable Compensation policy

Seeking to align strategic interests, company and individual objectives with a more competitive compensation in relation to the market, we have developed a fixed compensation policy that includes competitiveness analyzes and also an annual adjustment provided for in the Collective Bargaining Agreement. For the analysis of market competitiveness, we use external and specialized consultants with recognized technical competence to verify practices and policies with companies that are market reference

As for variable compensation, we have a robust plan that aligns all statutory goals and objectives with the degree of contribution of each area and employees, where the gain is based on market references so that we are competitive and share the gains and risks of our results.

Profit Sharing Program

We also have the Profit Sharing Program ("PPR") for which all employees of the Company are eligible, and the main objective of which is to value the performance of its employees during the fiscal year. This program has been in place since 2005 and applies to all Company employees.

b. Benefits Policy

Our employees are eligible for the Benefit Program according to their position and collective bargaining agreements or at the Company's discretion. Such benefits are available to our employees from the moment of their admission, or according to the rules determined for the respective benefit.

All our employees are eligible for the following benefits: medical assistance, life insurance, dental plan, transportation voucher, meal allowance, and pharmacy agreement (purchase of medicines at a discount).

c. characteristics of stock-based compensation plans for non-management employees.

i. Groups of beneficiaries

The Plan in force at the Company was approved at the Extraordinary Shareholders' Meeting held on April 23, 2014 ("Plan"). Officers appointed by the Bylaws and other officers and employees of the Company or other companies under its control may be elected as Beneficiaries of Performance Shares under the Plan.

The Plan in force at the Company was approved at the Extraordinary Shareholders' Meeting held on September 15, 2020 ("Plan"). Officers and employees of the Company, or another company under its control, may be elected as Beneficiaries of the Performance Share Plan, provided that upon approval by the Company's Board of Directors.

ii. Conditions for exercise

Described in item 8.4.a of this form, read plan approved in 2014.

iii. Strike prices

Described in item 8.4.a of this form, read plan approved in 2014.

iv. Exercise terms

Described in item 8.4.a of this form, read plan approved in 2014.

10.3 Employee compensation policies and practices

v. number of shares allocated to the plan

As of December 31, 2022, the share-based compensation plans that benefit our non-management employees involve 3,843,552 shares issued by us, as shown in the table below:

Fiscal Year	Number of Shares Granted	Number of Shares Granted with the split (*)
2014	56,238	281,190
2015	77,527	387,635
2016	83,891	419,455
2017	101,414	507,070
2018	33,088	165,440
2019	89,889	449,445
2020	109,496	547,480
2021	74,971	374,857
2022	142,196	710,980
TOTAL	768,710	3,843,552

*The Company approved at the Extraordinary Shareholders' Meeting held on September 15, 2020, the split of its shares, in the proportion of five common shares for each share of the same type; The table above shows the number of shares granted without the effect and with the effect of the split.

d. Ratio between (i) the highest individual compensation (considering the compensation composition, with all items described in field 8.2.d) recognized in the result of the issuer in the last fiscal year, including the compensation and the manager appointed by the bylaws, if applicable; and (ii) the median of the individual compensation of issuer's employees in Brazil, ignoring the highest individual compensation, as recognized in the results of the last fiscal year.

The ratio between the highest individual compensation over the median individual compensation of employees who contributed/remained throughout the 2022 fiscal year (January/22 to December/22) was 332.65 times.

Our calculation includes the total individual compensation of RD employees, therefore excluding apprentices, interns, directors, and statutory employees. Compensation is made up of fixed and variable elements (fixed salary, 13th salary, vacation, PPR – profit-sharing program and long-term incentive Vested).

10.4 Relationship between issuer and unions

10.4. Describe the relations between issuer and the unions, indicating whether there have been stoppages and strikes over the last 3 fiscal years

We have not recorded any strikes at the Company since the consolidation of Droga Raia and Drogasil in 2011, and there was also no record of strikes prior to the consolidation. We have a good relationship with our employees and the unions that represent them. Collective bargaining agreements are signed with unions and renegotiated annually.

We are represented by the Sindicato do Comércio Varejista de Produtos Farmacêuticos (Pharmaceuticals Retail Trade Union) in each State and our employees are represented by 274 unions.

The unions to which the Company's employees belong are:

Union by State	Number of employees
ACRE	
Sindicato dos Empregados no Comércio do Acre (AC) [Union of Trade Employees of Acre]	44
Sindicato dos Farmacêutico do Acre (AC) [Union of Pharmacists of Acre]	18
ALAGOAS	
Empregados Comércio de Arapiraca (AL) [Trade Employees of Arapiraca]	27
Empregados Comércio de Alagoas (AL) [Trade Employees of Alagoas]	246
Farmacêuticos de Alagoas (AL) [Pharmacists of Alagoas]	114
AMAZONAS	
Trab e Empr do Com Drog Produtos Farmacêuticos do Amazonas (AM) [Workers and Trade Employees Pharmacies and Pharmaceuticals of Amazonas]	213
Farmacêuticos do Amazonas (AM) [Pharmaceuticals of Amazonas]	79
AMAPÁ	
Sindicato dos Empregados no Comércio de Macapá (AP) [Union of Trade Employees of Macapá]	44
Sindicato dos Farmacêuticos do Estado do Amapá (AP) [Union of Pharmacists of the State of Amapá]	18
BAHIA	
Práticos de Farmácia de Salvador (BA) [Pharmacy Practitioners in Salvador]	1133
Empregados no Comércio de Itabuna (BA) [Trade Employees of Itabuna]	35
Empregados no Comércio de Vitoria da Conquista (BA) [Trade Employees of Vitoria da Conquista]	49
Empregados no Comércio de Feira de Santana (BA) [Trade Employees of Feira de Santana]	120
Farmacêuticos da Bahia (BA) [Pharmacists of Bahia]	395
Empregados no Comércio de Ilhéus (BA) [Trade Employees of Ilhéus]	28
Empregados no Comércio de Juazeiro (BA) [Trade Employees of Juazeiro]	26
Condutores da Bahia (BA) [Drivers of Bahia]	20
Empregados no Comércio de Alagoinhas (BA) [Trade Employees of Alagoinhas]	10
Empregados no Comércio de Eunápolis (BA) [Trade Employees of Eunápolis]	11
Empregados Comércio Teixeira de Freitas (BA) [Trade Employees of Teixeira de Freitas]	9
Sindicato dos Empregados Santo Antonio de Jesus (BA) [Union of Employees of Santo Antonio de Jesus]	13
Sindicato dos Comercários de Barreiras e Região Oeste da Bahia (BA) [Trade Union of Barreiras and Western Region of Bahia]	9
Sindicato dos Empregados no Comércio Varejista de Cruz das Almas (BA) [Union of Employees in the Retail Trade of Cruz das Almas]	8
Sindicato dos Empregados no Comércio de Serrinha (BA) [Union of Trade Employees of Serrinha]	10

10.4 Relationship between issuer and unions

Sindicato dos Empregados no Comércio de Paulo Afonso e Região (BA) [Union of Trade Employees of Paulo Afonso and Region]	9
Sindicato dos Empregados no Comércio de Brumado e Região (BA) [Union of Trade Employees of Brumado and Region]	10
Sindicato dos Empregados no Comércio de Valença (BA) [Union of Trade Employees of Valença]	10
Sindicato dos Empregados no Comércio de Porto Seguro (BA) [Union of Employees in Porto Seguro]	9
Empregados no Comércio de Jequié (BA) [Trade Employees in Jequié]	21

CEARÁ

Empregados no Comércio de Fortaleza (CE) [Trade Employees in Fortaleza]	605
Farmacêuticos do Ceara (CE) [Pharmacists of Ceará]	312
Empregados no Comércio de Maracanaú (CE) [Trade Employees in Maracanaú]	351
Empregados no Comércio e Serv de Sobral (CE) [Trade Employees and Services of Sobral]	29
Empregados no Comércio de Juazeiro do Norte (CE) [Trade Employees in Juazeiro do Norte]	25
Empregados no Comércio de Caucaia e Região (CE) [Trade Employees in Caucaia and Region]	16
Sindicato Empregados no Comércio de Eusébio (CE) [Union of Trade Employees of Eusébio]	18
Sindicato dos Empregados no Comércio de Crateus (CE) [Union of Trade Employees of Crateus]	8
Sindicato Empregados no Comércio de Quixadá e Região (CE) [Union of Trade Employees of Quixadá and Region]	8
Sindicato Empregados no Comércio de Iguatu (CE) [Union of Trade Employees of Iguatu]	8
Sindicato dos Empregados no Comércio de Limoeiro do Norte (CE) [Union of Trade Employees of Limoeiro do Norte]	9
Sindicato dos Empregados no Comércio de Russas (CE) [Union of Trade Employees of Russas]	6
Empregados no Comércio de Crato (CE) [Trade Employees in Crato]	16
Sindicato dos Empregados no Comércio de Pacajus (CE) [Union of Trade Employees of Pacajus]	9

FEDERAL DISTRICT

Práticos de Farmácia do Distrito Federal (DF) [Pharmacy Practitioners of the Federal District]	965
Farmacêuticos de Brasília (DF) [Pharmacists of Brasilia]	327

ESPÍRITO SANTO

Práticos de Farmácia do Espírito Santo (ES) [Pharmacy Practitioners of Espírito Santo]	685
Farmacêuticos do Espírito Santo (ES) [Pharmacists of Espírito Santo]	233

GOIÁS

Farmacêuticos de GO) [Pharmacists of Goiás]	411
Empregados no Comércio de Jatai (GO) [Trade Employees of Jatai]	26
Empregados no Comércio de Anápolis (GO) [Trade Employees of Anápolis]	77
Transporte Rodoviário de Goiás (GO) [Road Transport of Goiás]	39
Empregados no Comércio de Itumbiara (GO) [Trade Employees of Itumbiara]	43
Empregados no Comércio de Rio Verde (GO) [Trade Employees of Rio Verde]	64
Práticos de Farmácia de Goiás (GO) [Pharmacy Practitioners of Goiás]	1591

MARANHÃO

Farmacêuticos do Maranhão - São Luís (MA) [Pharmacists of Maranhão - São Luís]	120
Empregados no Comércio de São Luís (MA) [Trade Employees of São Luís]	262
Empregados no Comércio de Imperatriz (MA) [Trade Employees of Imperatriz]	56
Farmacêuticos do Maranhão -Imperatriz (MA) [Pharmacists of Maranhão]	25
Sindicato dos Empregados no Comércio de Timon e Região Leste (MA) [Union of Employees n Trade of Timon and Eastern Region]	10

10.4 Relationship between issuer and unions

Sindicato dos Empregados no Comércio de Bacabal (MA) [Union of Trade Employees of Bacabal]	9
Empregados no Comércio de Açailândia (MA) [Trade Employees of Açailândia]	8
Sindicato dos Empregados no Comércio de Santa Inês (MA) [Union of Trade Employees of Santa Inês]	9
Sindicato dos Empregados no Comércio de Caxias (MA) [Union of Trade Employees of Caxias]	7
Sindicato dos Empregados no Comércio de Barra do Corda (MA) [Union of Trade Employees of Barra do Corda]	8
Sindicato dos Farmacêuticos de Barra do Corda (MA) [Union of Pharmacists of Barra do Corda]	3
Sindicato dos Empregados no Comércio de São José de Ribamar (MA) [Union of Trade Employees of São José de Ribamar]	8

MINAS GERAIS

Práticos de Farmácia de Minas Gerais - BH, Contagem e Região (MG) [Pharmacy Practitioners of Minas Gerais - BH, Contagem and Region]	1052
Farmacêuticos de Minas Gerais (MG) [Pharmacists of Minas Gerais]	745
Práticos de Farmácia de Minas Gerais - Interior (MG) [Pharmacy Practitioners of Minas Gerais - Countryside]	841
Práticos de Farmácia de Uberlândia (MG) [Pharmacy Practitioners of Uberlândia]	233
Empregados no Comércio de Governador Valadares (MG) [Trade Employees of Governador Valadares]	39
Práticos de Farmácia de Minas Gerais - Juiz de Fora (MG) [Pharmacy Practitioners of Minas Gerais]	88
Práticos de Farmac. e dos Empreg. no Com. de Ipatinga (MG) [Pharmacy Practitioners and Trade Employees of Ipatinga]	22
Práticos de Farmácia de Minas Gerais - Cataguazes (MG) [Pharmacy Practitioners of Minas Gerais - Cataguazes]	14
Práticos de Farmácia de Minas Gerais - Conselheiro Lafaiete (MG) [Pharmacy Practitioners of Minas Gerais - Conselheiro Lafaiete]	40
Práticos de Farmácia de Minas Gerais - Barbacena (MG) [Pharmacy Practitioners of Minas Gerais - Barbacena]	21
Práticos de Farmácia de Minas Gerais - Ituiutaba (MG) [Pharmacy Practitioners of Minas Gerais - Ituiutaba]	23
Práticos de Farmácia de Minas Gerais - São Joao Del Rei (MG) [Pharmacy Practitioners of Minas Gerais - São Joao Del Rei]	20
Práticos de Farmácia de Minas Gerais -Sete Lagoas (MG) [Pharmacy Practitioners of Minas Gerais - Sete Lagoas]	33
Empregados no Comércio de Teófilo Otoni e Região (MG) [Trade Employees of Teófilo Otoni and Region]	8

MATO GROSSO

Empregados no Comércio de Mato Grosso (MT) [Trade Employees of Mato Grosso]	552
Farmacêuticos de Mato Grosso (MT) [Pharmacists of Mato Grosso]	215

MATO GROSSO DO SUL

Farmacêuticos do Mato Grosso do Sul (MS) [Pharmacists of Mato Grosso do Sul]	182
Práticos de Farmácia de Mato Grosso do Sul (MS) [Pharmacy Practitioners of Mato Grosso do Sul]	570

PARÁ

Práticos de Farmácia do Pará (PA) [Pharmacy Practitioners of Pará]	546
Farmacêuticos de Belém (PA) [Pharmacists of Belém]	210

PARAÍBA

Empregados Comércio de Joao Pessoa (PB) [Trade Employees of Joao Pessoa]	179
Farmacêuticos de João Pessoa (PB) [Pharmacists of João Pessoa]	81
Farmacêuticos de Campina Grande (PB) [Pharmacists of Campina Grande]	23
Empregados Com de Campina Grande (PB) [Trade Employees of Campina Grande]	50
Sindicato dos Trabalhadores no Com. e Serviços de Patos e Região (PB) [Union of Workers in Trade and Services of Patos and Region]	11

10.4 Relationship between issuer and unions

PERNAMBUCO	
Farmacêuticos do Estado de Pernambuco (PE) [Pharmacists of the State of Pernambuco]	501
Empregados no Comércio de Recife (PE) [Trade Employees of Recife]	721
Empregados no Com de Jaboatao dos Guararapes (PE) [Trade Employees of Jaboatao dos Guararapes]	329
Condutores de Recife e Região Metrop (PE) [Drivers of Recife and Metropolitan Region]	29
Empregados no Comércio de Garanhuns (PE) [Trade Employees of Garanhuns]	13
Empregados no Comércio de Petrolina (PE) [Trade Employees of Petrolina]	75
Empregados no Comércio das Cidades do Paulista e Região (PE) [Trade Employees of the Cities of Paulista and Region]	62
Empregados Comércio de Vitoria de Santo Antao (PE) [Trade Employees of Vitoria de Santo Antao]	17
Empregados Comércio de Camaragibe, São Lourenço da Mata e Região (PE) [Trade Employees of Camaragibe, São Lourenço da Mata and Region]	19
Empregados no Com do Cabo de Santo Agostinho (PE) [Trade Employees of Cabo de Santo Agostinho]	18
Empregados no Comércio de Serra Talhada (PE) [Trade Employees of Serra Talhada]	21
Empregados no Comércio de Limoeiro e Carpina (PE) [Trade Employees of Limoeiro and Carpina]	11
Empregados do Com. de Toritama Santa Cruz do Capibaribe e Surubim (PE) [Trade Employees of Toritama Santa Cruz do Capibaribe and Surubim]	10
Empregados no Comércio de Araripina (PE) [Trade Employees of Araripina]	16
Empregados no Comércio Belo Jardim (PE) [Trade Employees of Belo Jardim]	8
Empregados no Comércio de Olinda (PE) [Trade Employees of Olinda]	59
Empregados no Comércio de Caruaru (PE) [Trade Employees of Caruaru]	52
Empregados no Comércio de Bezerros (PE) [Trade Employees of Bezerros]	17
PIAUI	
Sindicato dos Empregados no Comércio e Serviços de Teresina (PI) [Union of Trade Employees and Services of Teresina]	179
Sindicato dos Farmacêuticos do Estado do Piauí (PI) [Union of Pharmacists of the State of Piauí]	76
Sindicato dos Empregados no Comércio de Floriano (PI) [Union of Trade Employees of Floriano]	10
PARANÁ	
Empregados no Comércio de Curitiba (PR) [Trade Employees of Curitiba]	1019
Empregados no Comércio de Apucarana (PR) [Trade Employees of Apucarana]	28
Empregados no Comércio de Campo Mourão (PR) [Trade Employees of Campo Mourão]	27
Práticos de Farmácia Cascavel e Região Oeste (PR) [Pharmacy Practitioners in Cascavel and West Region]	173
Empregados no Comércio de Cianorte (PR) [Trade Employees of Cianorte]	28
Empregados no Comércio de Guarapuava (PR) [Trade Employees of Guarapuava]	37
Empregados no Comércio de Londrina (PR) [Trade Employees of Londrina]	262
Empregados no Comércio de Maringá (PR) [Trade Employees of Maringá]	123
Empregados no Comércio de Paranaguá (PR) [Trade Employees of Paranaguá]	38
Empregados no Comércio de Paranavaí (PR) [Trade Employees of Paranavaí]	25
Empregados no Comércio de Ponta Grossa (PR) [Trade Employees of Ponta Grossa]	122
Empregados no Comércio de Umuarama (PR) [Trade Employees of Umuarama]	35
Farmacêuticos de Curitiba (PR) [Pharmacists of Curitiba]	329
Sind. Farmacêuticos Est. Paraná - Maringá (PR) [Union of Pharmacists of the State of Paraná - Maringá]	51
Farmacêuticos de Londrina e Região (PR) [Pharmacists of Londrina and Region]	108
Farmacêuticos de Paranavaí (PR) [Pharmacists of Paranavaí]	10
Farmacêuticos de Cascavel e Região (PR) [Pharmacists of Cascavel and Region]	64
Empregados no Comércio de Pato Branco (PR) [Trade Employees of Pato Branco]	19

10.4 Relationship between issuer and unions

Condutores do Paraná (PR) [Drivers of Paraná]	24
Empregados no Comércio de Francisco Beltrão (PR) [Trade Employees of Francisco Beltrão]	15
Empregados no Com de Cornélio Procópio (PR) [Trade Employees of Cornélio Procópio]	10

RIO DE JANEIRO

Farmacêuticos do Estado do Rio de Janeiro (RJ) [Pharmacists of the State of Rio de Janeiro]	427
Empregados no Comércio de Barra Mansa (RJ) [Trade Employees of Barra Mansa]	26
Empregados no Comércio de Cabo Frio (RJ) [Trade Employees of Cabo Frio]	107
Empregados no Comércio de Campos de Goytaguases (RJ) [Trade Employees of Campos de Goytaguases]	102
Empregados no Comércio de Duque de Caxias (RJ) [Trade Employees of Duque de Caxias]	479
Empregados no Comércio de Macaé (RJ) [Trade Employees of Macaé]	63
Farmacêuticos de Niterói e São Gonçalo (RJ) [Pharmacists of Niterói and São Gonçalo]	84
Empregados no Comércio de Niterói (RJ) [Trade Employees of Niterói]	207
Empregados no Comércio de Nova Friburgo (RJ) [Trade Employees of Nova Friburgo]	34
Empregados no Comércio de Petrópolis (RJ) [Trade Employees of Petrópolis]	67
Empregados no Comércio de Resende (RJ) [Trade Employees of Resende]	35
Empregados no Comércio de Teresópolis (RJ) [Trade Employees of Teresópolis]	63
Empregados no Comércio de Nova Iguaçu e Nilópolis (RJ) [Trade Employees of Nova Iguaçu and Nilópolis]	89
Práticos de Farmácia do Rio de Janeiro (RJ) [Pharmacy Practitioners of Rio de Janeiro]	1491
Empregados no Comércio de Volta Redonda (RJ) [Trade Employees of Volta Redonda]	72
Farmacêuticos de Volta Redonda (RJ) [Pharmacists of Volta Redonda]	14
Empregados no Comércio de Rio das Ostras (RJ) [Trade Employees of Rio das Ostras]	30
Farmacêuticos de Petrópolis (RJ) [Pharmacists of Petrópolis]	21
Farmacêuticos de Macaé (RJ) [Pharmacists of Macaé]	15
Farmacêuticos de Teresópolis (RJ) [Pharmacists of Teresópolis]	21
Farmacêuticos de Barra Mansa (RJ) [Pharmacists of Barra Mansa]	8
Farmacêuticos de Nova Iguaçu (RJ) [Pharmacists of Nova Iguaçu]	19
Farmacêuticos de Cabo Frio (RJ) [Pharmacists of Cabo Frio]	27
Empregados no Comércio de São Joao do Meriti (RJ) [Trade Employees of São João do Meriti]	21
Empregados no Comércio de Itaperuna (RJ) [Trade Employees of Itaperuna]	18
Empregados no Comércio de Três Rios (RJ) [Trade Employees of Três Rios]	11
Farmacêuticos de Nilópolis (RJ) [Pharmacists of Nilópolis]	3
Farmacêuticos de Resende e Itatiaia (RJ) [Pharmacists of Resende and Itatiaia]	7
Empregados no Com. de Itaborai, Rio Bonito, Marica e Saquarema (RJ) [Trade Employees of Itaborai, Rio Bonito, Marica, and Saquarema]	51
Trab Com de Bens e Serv Barra do Pirai e Valença Angra dos Reis (RJ) [Workers in Trade and Services of Barra do Pirai and Valença Angra dos Reis]	30

RIO GRANDE DO NORTE

Farmacêuticos do Rio Grande do Norte (RN) [Pharmacists of Rio Grande do Norte]	88
Práticos de Farmácia de Rio Grande do Norte (RN) [Pharmacy Practitioners of Rio Grande do Norte]	254

RIO GRANDE DO SUL

Empregados no Comércio de Canoas (RS) [Trade Employees of Canoas]	63
Empregados no Comércio de Porto Alegre (RS) [Trade Employees of Porto Alegre]	400
Empregados no Comércio de Passo Fundo (RS) [Trade Employees of Passo Fundo]	45
Empregados no Comércio de São Leopoldo (RS) [Trade Employees of São Leopoldo]	68

10.4 Relationship between issuer and unions

Empregados no Comércio de Santa Cruz do Sul (RS) [Trade Employees of Santa Cruz do Sul]	23
Farmacêuticos de Passo Fundo (RS) [Pharmacists of Passo Fundo]	15
Farmacêuticos do Rio Grande do Sul (RS) [Pharmacists of Rio Grande do Sul]	394
Empregados no Comércio de Novo Hamburgo (RS) [Trade Employees of Novo Hamburgo]	52
Empregados no Comércio de Bento Goncalves (RS) [Trade Employees of Bento Goncalves]	20
Empregados no Comércio de Lajeado (RS) [Trade Employees of Lajeado]	23
Empregados no Comércio de Caxias do Sul (RS) [Trade Employees of Caxias do Sul]	76
Empregados no Comércio de Erexim (RS) [Trade Employees of Erexim]	16
Empregados no Comércio de Gravataí (RS) [Trade Employees of Gravataí]	295
Empregados no Comércio de Farroupilha (RS) [Trade Employees of Farroupilha]	8
Empregados no Comércio de Santa Maria (RS) [Trade Employees of Santa Maria]	46
Empregados no Comércio de Pelotas (RS) [Trade Employees of Pelotas]	20
Empregados no Comércio de Rio Grande (RS) [Trade Employees of Rio Grande]	17
Empregados no Comércio do Ijuí (RS) [Trade Employees of Ijuí]	6
Empregados no Comércio de Santa Rosa (RS) [Trade Employees of Santa Rosa]	12
Empregados no Comércio de Bagé (RS) [Trade Employees of Bagé]	9
Empregados no Comércio de Guaíba (RS) [Trade Employees of Guaíba]	10
Empregados no Comércio de Uruguaiana (RS) [Trade Employees of Uruguaiana]	21
Empregados Comércio de Sapiranga (RS) [Trade Employees of Sapiranga]	7
Sindicato dos Empregados no Com. de Santo Antonio Patrulha (RS) [Union of Trade Employees of Santo Antonio Patrulha]	9
Sindicato no Comércio dos Empregados de Viamão (RS) [Trade Union of Employees of Viamão]	8
Sindicato dos Empregados no Comércio de Montenegro (RS) [Union of Trade Employees of Montenegro]	8
Sindicato dos Empregados no Comércio de Venâncio Aires (RS) [Union of Trade Employees of Venâncio Aires]	8
Sindicato dos Empregados no Comércio de Vacaria (RS) [Union of Trade Employees of Vacaria]	7
Sindicato dos Empregados no Comércio de São Gabriel (RS) [Union of Trade Employees of São Gabriel]	9
Sindicato dos Empregados no Comércio de Capão da Canoa (RS) [Union of Trade Employees of Capão da Canoa]	17
Sindicato dos Empregados no Comércio de São Borja (RS) [Union of Trade Employees of São Borja]	8
Sindicato dos Empregados no Comércio de Carazinho (RS) [Union of Trade Employees of Carazinho]	5
Sindicato dos Empregados no Comércio de Canela (RS) [Union of Trade Employees of Canela]	10
Empregados no Comércio de Alvorada (RS) [Trade Employees of Alvorada]	18
Sindicato dos Empregados no Comércio de Alegrete (RS) [Union of Trade Employees of Alegrete]	6

RONDONIA

Sindicato dos Farmacêuticos do Estado de Rondônia (RO) [Union of Pharmacists of the State of Rondônia]	48
Sindicato dos Trab em Drogarias do Município de Porto Velho (RO) [Union of Workers in Pharmacies in the Municipality of Porto Velho]	46
Empregados no Comércio de Rondonia - Sitracom (RO) [Trade Employees of Rondonia]	58

RORAIMA

Sindicato Empregados no Comércio de Roraima (RR) [Union of Trade Employees of Roraima]	35
Sindicato dos Farmacêuticos de Roraima (RR) [Union of Pharmacists of Roraima]	15

SANTA CATARINA

Empregados no Comércio de Canoinhas (SC) [Trade Employees of Canoinhas]	8
Empregados no Comércio de Araranguá (SC) [Trade Employees of Araranguá]	11
Empregados no Comércio de Florianópolis (SC) [Employees in Trade of Florianópolis]	204

10.4 Relationship between issuer and unions

Empregados no Comércio de Balneário Camboriú (SC) [Employees in Trade of Balneário Camboriú]	75
Empregados no Comércio de Itajaí (SC) [Trade Employees of Itajaí]	47
Empregados no Comércio de Blumenau (SC) [Trade Employees of Blumenau]	56
Empregados no Comércio de Brusque (SC) [Trade Employees of Brusque]	40
Empregados no Comércio de Chapeco (SC) [Trade Employees of Chapeco]	39
Empregados no Comércio de Concordia (SC) [Trade Employees of Concordia]	12
Empregados no Comércio de Jaraguá do Sul (SC) [Trade Employees of Jaraguá do Sul]	34
Empregados no Comércio de Joinville e Região (SC) [Trade Employees in Joinville and Region]	91
Empregados no Comércio de Lages (SC) [Trade Employees of Lages]	26
Empregados no Comércio de São José e Região (SC) [Trade Employees in São José and Region]	64
Empregados no Comércio de Rio do Sul (SC) [Trade Employees of Rio do Sul]	25
Empregados no Comércio de São Bento do Sul (SC) [Trade Employees of São Bento do Sul]	9
Empregados no Comércio de Tubarão (SC) [Trade Employees of Tubarão]	23
Farmacêuticos de Itajaí (SC) [Pharmacists of Itajaí]	70
Farmacêuticos de Santa Catarina (SC) [Pharmacists of Santa Catarina]	242
Empregados no Comércio de Criciúma (SC) [Trade Employees of Criciúma]	43
Empregados no Comércio de Joaçaba (SC) [Trade Employees of Joaçaba]	12
Empregados no Comércio de Palhoça e Região (SC) [Trade Employees of Palhoça and Region]	36
Empregados no Comércio de Itapema (SC) [Trade Employees of Itapema]	31
Sindicato dos Empregados no Comércio de Caçador (SC) [Union of Trade Employees of Aracaju (SC)]	10
Sindicato Empregados no Com. Porto União (SC) [Union of Trade Employees of Porto União]	8

SERGIPE

Farmacêuticos de Sergipe (SE) [Pharmacists of Sergipe]	140
Empregados Comércio de Aracaju (SE) [Trade Employees of Aracaju]	283
Sindicato dos Empregados no Comércio de Nossa Senhora do Socorro (SE) [Union of Trade Employees of Nossa Senhora do Socorro]	12

SÃO PAULO

Práticos de Farmácia de São Paulo (SP) [Pharmacy Practitioners in São Paulo]	11476
Empregados no Comércio de Cotia e Região (SP) [Trade Employees of Cotia and Region]	134
Empregados no Comércio de Araçatuba (SP) [Trade Employees of Araçatuba]	48
Empregados no Comércio de Araraquara (SP) [Trade Employees of Araraquara]	127
Empregados no Comércio de Assis (SP) [Trade Employees of Assis]	61
Empregados no Comércio de Barretos (SP) [Trade Employees of Barretos]	50
Empregados no Comércio de Catanduva (SP) [Trade Employees of Catanduva]	53
Empregados no Comércio de Fernandópolis (SP) [Trade Employees of Fernandópolis]	28
Empregados no Comércio de Franca (SP) [Trade Employees of Franca]	103
Empregados no Comércio de Garça (SP) [Trade Employees of Garça]	14
Empregados no Comércio de Itapetininga Tatuí e Região (SP) [Trade Employees of Itapetininga Tatuí and Region]	96

10.4 Relationship between issuer and unions

Empregados no Comércio de Ituverava (SP) [Trade Employees of Ituverava]	42
Empregados no Comércio de Jaboticabal (SP) [Trade Employees of Jaboticabal]	32
Empregados no Comércio de Jales (SP) [Trade Employees of Jales]	31
Empregados no Comércio de Lins (SP) [Trade Employees of Lins]	58
Empregados no Comércio de Marília (SP) [Trade Employees of Marília]	106
Empregados no Comércio de Matão (SP) [Trade Employees of Matão]	45
Empregados no Comércio de Mogi das Cruzes (SP) [Trade Employees of Mogi das Cruzes]	133
Empregados no Comércio de Ourinhos (SP) [Trade Employees of Ourinhos]	63
Empregados no Comércio de São João da Boa Vista (SP) [Trade Employees of São João da Boa Vista]	70
Empregados no Comércio de São Carlos e Região (SP) [Trade Employees of São Carlos and Region]	153
Empregados no Comércio de Sorocaba (SP) [Trade Employees of Sorocaba]	396
Empregados no Comércio de Tupã (SP) [Trade Employees of Tupã]	31
Empregados no Comércio de Votuporanga (SP) [Trade Employees of Votuporanga]	32
Práticos de Farmácia de Americana (SP) [Pharmacy Practitioners of Americana]	2265
Práticos de Farmácia de Santos e Região (SP) [Pharmacy Practitioners of Santos and Region]	891
Práticos de Farmácia de Presidente Prudente (SP) [Pharmacy Practitioners of Presidente Prudente]	210
Práticos de Farmácia de São José dos Campos (SP) [Pharmacy Practitioners of São José dos Campos]	743
Práticos de Farmácia de São José do Rio Preto (SP) [Pharmacy Practitioners of São José do Rio Preto]	288
Farmacêuticos de São Paulo (SP) [Pharmacists of São Paulo]	4168
Práticos de Farmácia de Bauru e Região (SP) [Pharmacy Practitioners of Bauru and Region]	256
Farmacêuticos de São Paulo - ABC (SP) [Pharmacists of São Paulo - ABC]	242
Práticos de Farmácia Jaú e Região (SP) [Pharmacy Practitioners Jaú and Region]	71
Práticos de Farmácia de Ribeirão Preto (SP) [Pharmacy Practitioners of Ribeirão Preto]	866
Empregados Comércio de Birigui (SP) [Trade Employees of Birigui]	53
Práticos de Farmácia de Osasco e Região (SP) [Pharmacy Practitioners of Osasco and Region]	1363
Farmacêuticos de Osasco (SP) [Pharmacists of Osasco]	147
Empregados no Comércio de Franco da Rocha e Região (SP) [Trade Employees of Franco da Rocha and Region]	41
Sindicato dos Empregados no Comércio de Itapeva (SP) [Union of Trade Employees of Itapeva]	9
Sindicato dos Empregados no Comércio de Registro [Union of Trade Employees of Registro]	2
TOCANTINS	
Empregados Comércio Estado do Tocantins (TO)	155
Farmacêuticos do Estado do Tocantins (TO)	85
Overall Total	52.565

10.5 Other relevant information

All information relevant to this topic was disclosed in the items above.

11.1 Rules, policies and practices

11.1. Describe the rules, policies, and practices of issuer regarding transactions with related parties, as defined by the accounting rules that refer to this matter, indicating, where there is a formal policy adopted by the issuer, the body responsible for its approval, date of approval and, in case the issuer discloses the policy, the websites where the document may be consulted

In line with the recommendations of the Brazilian Code of Corporate Governance, and also with the Novo Mercado Rules, the Company has a Policy for Transactions with Related Parties, approved at a meeting of the Board of Directors on October 26, 2018, revised on new meetings held on March 30, 2021, February 22, 2022, and May 03, 2023.

RDs Policy on Transactions with Related Parties seeks to:

- (i) establish rules to ensure that transactions involving related parties and situations with a potential conflict of interest be conducted under market conditions, in accordance with current standards and best corporate governance practices, and always in the best interest of the Company; and
- (ii) ensure that all decisions that may confer a private benefit on any of its managers, family members, entities, or persons related to them be taken with total fairness, transparency, respecting the interests of the Company and its shareholders.

The Company, through its Executive Office and the Board of Directors, assisted by the Audit Committee, acts to ensure that any and all Related Party Transactions carried out by the Company be contractually formalized, observing the following criteria:

- (i) Be in market conditions at the time of approval;
- (ii) the terms of the transaction and the purpose of the transaction shall be included in the respective agreement;
- (iii) the terms and conditions of the Policy shall be fully observed; and
- (iv) the Related Party may not have access to information related to the transaction or participate in resolutions related to the matter.

The Executive Office, the Audit Committee, and the Board of Directors of the Company have access to all documents related to the respective Transaction with Related Parties, as well as any opinions or technical opinions on the subject, so that they can base their analysis, as well as verify the compliance with the Policy's principles.

When analyzing Transactions with Related Parties, the Company's Executive Office and Board of Directors, assisted by the Audit Committee, verify whether such transactions will be carried out under commutative conditions and in compliance with market conditions. In its analysis, it shall observe the following points:

- (i) if there are clear reasons that justify the execution of the Transaction with the Related Party;
- (ii) if the transaction is carried out on terms at least equally favorable to the Company than those generally available in the market or those offered to or by a third party unrelated to the Company, in equivalent circumstances;
- (iii) the results of evaluations carried out or opinions issued by a specialized and independent company, if any;
- (iv) whether or not a competitive process has been carried out for said contracting and its result; and
- (v) the pricing methodology used and other possible alternative ways of pricing the transaction.

11.1 Rules, policies and practices

Prior to the approval of Transactions with Related Parties, the body responsible for approving the Transaction with Related Parties may request market alternatives for the transaction in question, adjusted for the risk factors involved.

The Executive Office or the Board of Directors may only approve the Transaction with a Related Party if it concludes that it is equitable, commutative, and carried out in the best interest of the Company, and it may, at its sole discretion and in compliance with this Policy, condition the approval of the Transaction with a Related Party on any changes it deems necessary. Transactions between Related Parties to be entered into by the Company shall be submitted by the Board of Directors for approval by the General Shareholders' Meeting, if they involve the sale or contribution of assets with a value corresponding to more than ten percent (10%) of the total value of all the Company's assets, contained in the latest Financial Statements disclosed.

The Company shall annually carry out a mapping, through self-declaration by the managers, to monitor, identify, and deal with any situations that may characterize transactions between related parties.

The full Policy is available on RD's Investor Relations website (<https://ri.rd.com.br>) and in the Empresas.NET System.

11.2 Transactions with related parties

Related party	Transacti on date	Amount involved in the Transaction Real	Existing balance	Amount corresponding to the interest Real	Duration	Interest rate charged
Regimar Comercial S.A.	04/22/2003	32,000.00	15,000.00		Indefinite term	0.000000
Relationship with the issuer	Companies held by the children of Mr. Carlos Pires Oliveira Dias, member of the Board of Directors and shareholder, who is the usufructuary of the respective shares.					
Subject matter of the agreement	Agreement for the supply by our Company to Regimar S.A. through products sold by us through our units, internet, and delivery.					
Guarantee and insurance	None					
Termination	At any time, by any of the parties, without the imposition of any penalty, upon prior written notice, accompanied by the respective proof of receipt, presented at least 60 days in advance of the date of termination.					
Nature and reason for the transaction	Not applicable					
Issuer's contractual position	Creditor					
Heliomar Ltda.	12/23/2003	394,000.00	30,000.00		Expires on August 1, 2023	0.000000
Relationship with the issuer	Company controlled by Mr. Carlos Pires Oliveira Dias, member of the Board of Directors and shareholder, and by his brother, Mr. Jose Pires Oliveira Dias Neto.					
Subject matter of the agreement	Property lease agreement for the opening of a unit located at Avenida Robert Kennedy, 3.377, lotes 9, 9A e 10B, quadra 4, in the city of São Paulo, SP.					
Guarantee and insurance	Insurance against fire risk, for the real value of the construction of the property.					
Termination	For expropriation or breach of contract. After 24 months of effectiveness, the agreement may be terminated by the Company without any charges or penalties, provided that 30 days' notice is given.					
Nature and reason for the transaction	Not applicable					
Issuer's contractual position	Debtor					
Editora Mol Ltda	02/14/2008	3,457,000.00	203,000.00		Indefinite term	0.000000
Relationship with the issuer	Mr. Rodrigo Pipponzi, member of Editora Mol and signatory to the Shareholders' Agreement					

11.2 Transactions with related parties

Related party	Transacti on date	Amount involved in the Transaction Real	Existing balance	Amount corresponding to the interest Real	Duration	Interest rate charged
Subject matter of the agreement	Editora MOL is a social business specialized in generating income for social organizations (NGOs) through content projects (books, magazines, calendars, guides, etc.). The objective of the contract between RD and Editora Mol is the social investment project, through the purchase and sale of the charity magazines "Sorria" and "Todos", as well as the transfer of the amount raised to social organizations (NGOs). We buy the magazine from the publisher and resell it in our units for the same purchase price, so the Company does not make gains or losses with this transaction. The amounts collected from the sale of magazines are transferred to Mol, which deducts the taxes levied on the transaction and the operating cost of the publishing house. Therefore, the entire net amount is donated in full by Editora Mol to social organizations (NGOs) such as: Support Group for Adolescents and Children with Cancer (GRAACC) and the Ayrton Senna Institute (IAS), among others.					
Guarantee and insurance	None					
Termination	The agreement may be terminated at the request of one of the parties, 30 days in advance.					
Nature and reason for the transaction	Not applicable					
Issuer's contractual position	Debtor					
Cfly Consultoria e Gestão Empresarial Ltda.	08/09/2017	0.00	232,000.00		Indefinite term	0.000000
Relationship with the issuer	Mr. Carlos Eduardo Ribeiro do Valle Filho, member of the company in question, is married to Maria Regina Pires Ribeiro do Valle, daughter of Mr. Carlos Pires Oliveira Dias, member of the Board of Directors and shareholder.					
Subject matter of the agreement	Aircraft Management and Operation (Operational Advisory Services, Compliance, Financial, Maintenance Coordination, and Technical Maintenance Control (CTM)).					
Guarantee and insurance	None					
Termination	The provision of services may be interrupted at any time, upon 30-day prior notice.					
Nature and reason for the transaction	Not applicable					
Issuer's contractual position	Creditor					
Ribeiro Filho, Pires Oliveira Dias e Freire Advogados	12/22/1994	5,176,000.00	141,000.00		Indefinite term	0.000000
Relationship with the issuer	Mr. Cláudio Pires Oliveira Dias Didier Fecarrotta, partner of the law firm in question, is the nephew of Mr. Carlos Pires Oliveira Dias, member of the Board of Directors and shareholder.					
Subject matter of the agreement	Agreement for the provision of legal services.					
Guarantee and insurance	None					
Termination	The provision of services may be interrupted at any time, upon 30-day prior notice, without any penalty or indemnity.					

11.2 Transactions with related parties

Related party	Transacti on date	Amount involved in the Transaction Real	Existing balance	Amount corresponding to the interest Real	Duration	Interest rate charged
Nature and reason for operation	Not applicable					
Issuer's contractual position	Debtor					
Heliomar Ltda.	05/16/2003	5,000.00	1,000.00		Indefinite term	0.000000
Relationship with the issuer	Company controlled by Mr. Carlos Pires Oliveira Dias, member of the Board of Directors and shareholder, and his brother, Mr. José Pires Oliveira Dias Neto.					
Subject matter of the agreement	Agreement for the supply by our Company to Heliomar S.A. of products sold by us through our units, internet, and delivery.					
Guarantee and insurance	None					
Termination	At any time, by either party, without the imposition of any penalty, upon prior written notice, accompanied by the respective proof of receipt, presented at least 30 days in advance of the termination date.					
Nature and reason for the transaction	Not applicable					
Issuer's contractual position	Creditor					
Antonio Carlos Pipponzi	08/31/2015	133,000.00	10,000.00		Until June 01, 2022	0.000000
Relationship with the issuer	Mr. Antonio Carlos Pipponzi is the Chairman of the Board of Directors and signatory to the Shareholders' Agreement					
Subject matter of the agreement	Property lease agreement for the opening of a store located in the city of São Carlos and Santo Andre, SP.					
Guarantee and insurance	Insurance against fire risk, for the real value of the construction of the property.					
Termination	In the event of expropriation or noncompliance with contractual obligations.					
Nature and reason for the transaction	Not applicable					
Issuer's contractual position	Debtor					
Rosalia Pipponzi Raia	08/31/2015	133,000.00	10,000.00		Until June 01, 2022	0.000000
Relationship with the issuer	Ms. Rosalia Pipponzi is a shareholder and signatory to the Shareholders' Agreement					
Subject matter of the agreement	Property lease agreement for the opening of a store located in the city of São Carlos and Santo Andre, SP.					
guarantee and insurance	Insurance against fire risk, for the real value of the construction of the property.					
Termination	In the event of expropriation or noncompliance with contractual obligations.					

11.2 Transactions with related parties

Related party	Transacti on date	Amount involved in the Transaction Real	Existing balance	Amount corresponding to the interest Real	Duration	Interest rate charged
Nature and reason for operation	Not applicable					
Issuer's contractual position	Debtor					
Cristiana Almeida Pipponzi	08/31/2015	44,000.00	4,000.00		Until June 1, 2022	0.000000
Relationship with the issuer	Mrs. Cristiana Almeida Pipponzi is a member of the Board of Directors and signatory to the Shareholders' Agreement					
Subject matter of the agreement	Property lease agreement for the opening of a store located in the city of São Carlos and Santo Andre, SP.					
guarantee and insurance	Insurance against fire risk, for the real value of the construction of the property.					
Termination	In the event of expropriation or noncompliance with contractual obligations.					
Nature and reason for the transaction	Not applicable					
Issuer's contractual position	Debtor					
André Almeida Pipponzi	08/31/2015	44,000.00	4,000.00		Until June 01, 2022	0.000000
Relationship with the issuer	Mr. André Almeida Pipponzi is a signatory to the Shareholders' Agreement					
Subject matter of the agreement	Property lease agreement for the opening of a store located in the city of São Carlos and Santo Andre, SP					
guarantee and insurance	Insurance against fire risk, for the real value of the construction of the property.					
Termination	In the event of expropriation or noncompliance with contractual obligations.					
Nature and reason for the transaction	Not applicable					
Issuer's contractual position	Debtor					
Marta Almeida Pipponzi	08/31/2015	44,000.00	4,000.00		Until June 01, 2022	0.000000
Relationship with the issuer	Ms. Marta Almeida Pipponzi is a signatory to the Shareholders' Agreement					
Subject matter of the agreement	Property lease agreement for the opening of a store located in the city of São Carlos and Santo Andre, SP.					
guarantee and insurance	Insurance against fire risk, for the real value of the construction of the property					
Termination	In the event of expropriation or noncompliance with contractual obligations.					
Nature and reason for the transaction	Not applicable					

11.2 Transactions with related parties

Related party	Transacti on date	Amount involved in the Transaction Real	Existing balance	Amount corresponding to the interest Real	Duration	Interest rate charged
Issuer's contractual position						
	Debtor					
Ribeiro Filho, Pires Oliveira Dias e Freire Advogados	12/22/1994	0.00	20,000.00		Indefinite term	0.000000
Relationship with the issuer	Mr. Cláudio Pires Oliveira Dias Didier Fecarrota, partner of the law firm in question, is the nephew of Mr. Carlos Pires Oliveira Dias, member of the Board of Directors and shareholder.					
Subject matter of the agreement	Agreement for the provision of legal services.					
Guarantee and insurance	Not applicable					
Termination	The provision of services may be interrupted at any time, upon 30-day prior notice, without any penalty or indemnity.					
Nature and reason for the transaction	Not applicable					
Issuer's contractual position						
	Creditor					
Editora Mol Ltda	02/14/2008	0.00	0.00		Indefinite term	0.000000
Relationship with the issuer	Mr. Rodrigo Pipponzi, member of Editora Mol, is a shareholder and son of the Chairman of the Board of Directors, Mr. Antonio Carlos Pipponzi.					
Subject matter of the agreement	Sales made under the agreement for the supply by the Company to Editora Mol of products sold by us through our units, internet, and delivery.					
guarantee and insurance	None					
Termination or extinction	At any time, by any of the parties, without the application of any penalty, upon prior written notice, accompanied by the respective proof of receipt, presented at least 60 days in advance of the date of termination.					
Nature and reason for the transaction	Not applicable					
Issuer's contractual position						
	Creditor					
Cfly Consultoria e Gestão Empresarial Ltda.	08/09/2017	3,139,000.00	73,000.00		Indefinite term	0.000000
Relationship with the issuer	Mr. Carlos Eduardo Ribeiro do Valle Filho, member of the company in question, is married to Maria Regina Pires Ribeiro do Valle, daughter of Mr. Carlos Pires Oliveira Dias, member of the Board of Directors and shareholder.					
Subject matter of the agreement	Aircraft Management and Operation (Operational Advisory Services, Compliance, Financial, Maintenance Coordination, and Technical Maintenance Control (CTM).					
Guarantee and insurance	Not applicable					

11.2 Transactions with related parties

Related party	Transacti on date	Amount involved in the Transaction Real	Existing balance	Amount corresponding to the interest Real	Duration	Interest rate charged
Termination	At any time, by either party, without the imposition of any penalty, upon prior written notice, accompanied by the respective proof of receipt, presented at least 30 days in advance of the termination date.					
Nature and reason for operation	Not applicable					
Issuer's contractual position	Debtor					
Stix Fidelidade e Inteligência S.A.	11/27/2019	14,208,000.00	4,322,000		Indefinite term	0.000000
Relationship with the Issuer	Affiliate					
Subject matter of the agreement	Accounts receivable and accounts payable transactions related to the STIX points program.					
Guarantee and insurance	Not applicable					
Termination or extinction						
Nature and reason for operation	Not applicable					
Issuer's contractual position	Creditor					
CI&T Softwares S.A	04/30/2021	27,349,000.00	3,234,000		Up to March 2023	0.000000
Relationship with the issuer	Shareholder/Member of the Board of Directors as from May 2021					
Subject matter of the agreement	Transactions related to information technology consulting services. One of the agreements was entered into in March 2020 with CI&T Comércio de Hardware e Software Ltda. and the other in November 2020 with CI&T Softwares SA, with the purpose of consulting for digital transformation and squads.					
Guarantee and insurance	Not applicable					
Termination or extinction						
Nature and reason for operation	Not applicable					
Issuer's contractual position	Debtor					
Stix Fidelidade e Inteligência S.A.	11/27/2019	51,552,000.00	11,452,000		Indefinite term	0.000000
Relationship with the Issuer	Affiliate					
Subject matter of the agreement	Accounts receivable and accounts payable transactions related to the STIX points program.					
Guarantee and insurance	Not applicable					

11.2 Transactions with related parties

Related party	Transacti on date	Amount involved in the Transaction Real	Existing balance	Amount corresponding to the interest Real	Duration	Interest rate charged
Termination or extinction						
Nature and reason for operation						
	Not applicable					
Issuer's contractual position						
	Debtor					
Sensedia S.A.	12/01/2022	1,378,000.00	1,300,000			
Relationship with the issuer						
	Shareholder/Member of the Board of Directors as from May 2021					
Subject matter of the agreement						
	The balances and transactions refer to services agreements related to the implementation of digital transformation.					
Guarantee and insurance						
	Not applicable					
Termination or extinction						
Nature and reason for the transaction						
	Not applicable					
Issuer's contractual position						
	Debtor					
Full Nine Digital Consulting (Conecta Lá)	07/07/2021	185,000.00	1,320,000			0.000000
Relationship with the Issuer						
	Affiliate					
Subject matter of the agreement						
	Loan transaction carried out between Raia Drogasil S..A (lender) and Full Nine Digital Consultoria - Conecta Lá (borrower) in the amounts of BRL 700 and BRL 400 with adjustment calculated by the CDI 3.50% p.a.					
guarantee and insurance						
	None					
Termination or extinction						
Nature and reason for the transaction						
	Not applicable					
Issuer's contractual position						
	Creditor					

11.2 Items 'n.' and o.'

11.2. With the exception of transactions falling into article 3, II, “a”, “b”, and “c”, of Exhibit 30-XXXIII, provide information about transactions with related parties that, under accounting standards, are subject to compulsory disclosure on the issuer’s individual or consolidated financial statements and which were executed during the last fiscal year or are otherwise effective in the current fiscal year:

Name of the related parties	n. Measures taken to treat conflicts of interests	o. Demonstration of the arm’s length basis of the agreed conditions or appropriate compensatory payment
Regimer Comercial S.A.	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	The commercial conditions offered by the Company are the same offered in the market
Heliomar Ltda.	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	Transaction value in line with the report prepared by the Company
Editora Mol Ltda	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	Mol's business model negotiated with RD is on a more favorable basis than those negotiated by Mol with the market
Cfly Consultoria e Gestão Empresarial Ltda.	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	Transaction value under market conditions, according to BID carried out by the Company
Ribeiro Filho, Pires Oliveira Dias e Freire Advogados	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	Transaction value under market conditions, according to BID carried out by the Company
Heliomar Ltda.	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	The commercial conditions offered by the Company are the same offered in the market
Antonio Carlos Pipponzi	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	The transaction amounts are below the amount determined in the report prepared by the Company
Rosalia Pipponzi Raia	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	The transaction amounts are below the amount determined in the report prepared by the Company

11.2 Items 'n.' and o.'

Cristiana Almeida Pipponzi	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	The transaction amounts are below the amount determined in the report prepared by the Company
André Almeida Pipponzi	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	The transaction amounts are below the amount determined in the report prepared by the Company
Marta Almeida Pipponzi	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	The transaction amounts are below the amount determined in the report prepared by the Company
Ribeiro Filho, Pires Oliveira Dias e Freire Advogados	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	Transaction value under market conditions, according to BID carried out by the Company
Editora Mol Ltda	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	The commercial conditions offered by the Company are the same offered in the market
Cfly Consultoria e Gestão Empresarial Ltda.	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	Transaction value under market conditions, according to BID carried out by the Company
Stix Fidelidade e Inteligência S.A. (x)	N/A	The amount charged by Stix from RD is lower than market conditions
CI&T Softwares S.A	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	Transaction value under market conditions, according to BID carried out by the Company
Stix Fidelidade e Inteligência S.A. (x)	N/A	The amount charged by Stix from RD is lower than market conditions
Sensedia S.A.	Any persons with a possible conflict of interest have neither participated in the negotiation nor in the approval	Transaction value under market conditions, according to BID carried out by the Company
Full Nine Digital Consultoria (Conecta Lá)	N/A	Transaction value under market conditions, according to BID carried out by the Company

11.3 Other relevant information

Provide other information the issuer deems relevant

There is no other relevant information.

12.1 Information on common stock

Type of Capital		Issued Capital	
Date of authorization or approval	Paying-up term	Capital value	
04/19/2023	0	4,000,000,000.00	
Number of common shares	Number of preferred shares	Total number of shares	
1,718,007,200	0	1,718,007,200	
Other securities convertible into shares			
Instru ment		Conditions for conversion	
0		0	

Type of Capital		Subscribed Capital	
Date of authorization or approval	Paying-up term	Capital value	
04/19/2023	0	4,000,000,000.00	
Number of common shares	Number of preferred shares	Total number of shares	
1,718,007,200	0	1,718,007,200	

Type of Capital		Paid-in Capital	
Date of authorization or approval	Paying-up term	Capital value	
04/19/2023		4,000,000,000.00	
Number of common shares	Number of preferred shares	Total number of shares	
1,718,007,200	0	1,718,007,200	

Type of Capital	Authorized Capital	
Date of authorization or approval	Paying-up term	Capital value
04/19/2023		0.00
Number of common shares	Number of preferred shares	Total number of shares
2,000,000,000	0	2,000,000,000

12.2 Foreign issuers - Rights and rules

12.2. Foreign issuers must describe the rights of each class and type of share issued and the rules of their home country and the country in which the shares are held in custody regarding:

a. right to dividends:

Not applicable.

b. voting rights:

Not applicable.

c. convertibility into another class or type of share, stating::

i. conditions: Not applicable.

ii. effects on the common stock: Not applicable.

d. rights to reimbursement of capital:

Not applicable.

e. right to participation in a public tender offer for disposal of controlling stake:

Not applicable.

f. restrictions on circulation:

Not applicable.

g. conditions for changing the rights assured by such securities:

Not applicable.

h. possibility of redemption, indicating:

i. redemption events: Not applicable.

ii. redemption amount calculation formula: Not applicable.

i. events for cancellation of registration, as well as rights of security holders in this situation:

Not applicable.

j. events in which the security holders will have the right of first refusal in the subscription of shares, securities backed by shares or equity convertible securities, as well as the respective conditions for the exercise of said right, or the events in which this right is not guaranteed, as the case may be:

Not applicable.

k. other relevant characteristics:

Not applicable.

12.3 Other securities issued in Brazil

Security	Debentures
Identification of the security	3rd Issue Debentures (Single Series) - CRI
Issue date	03/13/2019
Maturity date	03/13/2026
Number	250,000
Total amount (BRL)	250,000,000.00
Outstanding Debt Balance	256,154,312.12
Circulation restriction	No
Convertibility	No
Possibility of redemption	Yes
Event and calculation of the redemption value	The Company may, at its sole discretion, at any time from and including March 13, 2022, promote the early redemption of all Debentures (partial redemption being prohibited), with the consequent cancellation of such Debentures, by sending a notice at least four (4) Business Days in advance of the actual redemption date to the Debenture Holder and Bookkeeping Agent, with a copy to the Fiduciary Agent of the Debentures, upon payment of the balance of the Unit Par Value of the Debentures, plus (i) the Compensation, calculated on a <i>pro rata temporis</i> basis from the first Payment Date or the immediately preceding Compensation Payment Date, as the case may be, to the actual payment date; and (ii) the Premium, set forth in Clauses 8.1.2 of the Private Indenture of the 3rd Issue of Debentures.

12.3 Other securities issued in Brazil

Debt securities characteristics	The Debentures shall be issued in the registered and book-entry form, without the issue of share certificates, it being understood, for all legal purposes, that the ownership of the Debentures shall be evidenced by a statement of a deposit account issued by the Bookkeeping Agent. The Debentures shall be simple, therefore not convertible into shares issued by the Company. The Debentures shall be unsecured, under the terms of article 58, main section of the Brazilian Corporate Laws, without security interest and without preemptive right, and they shall have a maturity term of two thousand, five hundred and fifty-seven (2,557) days as from the Debentures Issue Date, falling due, therefore, on March 13, 2026 and over the Unit Par Value of the Debentures or balance of the Unit Par Value of the Debentures, as the case may be, interest at the rate of ninety-eight integers and fifty-hundredths percent (98.50%) shall be levied on the accrued variation of the DI Rate, calculated exponentially and cumulatively on a <i>pro rata temporis</i> basis per Business Days elapsed, from the first Payment Date or the immediately preceding Compensation Payment Date, as applicable, to the actual payment date.
Conditions for changing the rights assured by such securities	Without prejudice to the specific quorums set forth in this Indenture and in the applicable law, the Debenture Holders may, at any time, hold a general meeting, as set forth in article 71 of the Brazilian Corporate Laws, in order to resolve on matters of interest to the Debenture Holders; Debenture holder general meetings may be called by the Company, by the Fiduciary Agent of the Debentures, or by the Debenture Holder.
Other relevant characteristics	See item 12.9

Security	Debentures
Identification of the security	Debentures of the 4th Issue (Single series)
Issue date	06/17/2019
Maturity date	06/17/2027
Number	300,000
Total amount (BRL)	300,000,000.00
Outstanding Debt Balance	300,920,832.90
Circulation restriction	Yes
Restriction description	Pursuant to CVM Instruction 476, the Debentures are subject to restrictions on trading provided for in said instruction and, for this reason, they may only be traded on the regulated securities markets after ninety (90) days have elapsed from each subscription or acquisition. Until the subscription and payment of the Debentures, the Professional Investor shall sign a statement attesting, among others, to be aware that: (i) the offer has not been registered with the CVM; and (ii) the Debentures are subject to the trading restrictions set forth in this Disclosure Material, in the Indenture and in the applicable regulations. Additionally, as provided for in article 3 of said instruction, the Restricted Offer will only be presented to a maximum of seventy-five (75) Professional Investors, and may be subscribed by a maximum of fifty (50) Professional Investors. The Debentures may only be traded after ninety (90) days have elapsed from their subscription by the Professional Investor. The distribution of this Disclosure Material is carried out in a numbered and controlled manner by the Lead Underwriter
Convertibility	No
Possibility of redemption	Yes

12.3 Other securities issued in Brazil

Event and calculation of the redemption value	The Issuer may, at its sole discretion, carry out, at any time from (and including) June 17, 2021, the optional early redemption of all Debentures (partial optional early redemption being prohibited), with the consequent cancellation of such Debentures. The amount to be paid in relation to each of the Debentures subject to the Optional Early Redemption will be the Unit Par Value or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated on a <i>pro rata temporis</i> basis from the Compensation Payment Date immediately prior to the date of actual payment ("Optional Early Redemption Amount"), plus a premium, which cannot be negative, levied on the Optional Early Redemption Amount, according to the formula: ("Optional Early Redemption Premium")
Debt securities characteristics	The Debentures shall be issued in the registered and book-entry form, without the issue of share certificates, it being understood, for all legal purposes, that the ownership of the Debentures shall be evidenced by a statement of the Debentures issued by the Bookkeeping Agent and additionally, for those Debentures electronically held in custody at B3, as the case may be, it shall issue a statement in the name of the Debenture Holder, which will be used as proof of ownership of such Debentures. The Debentures shall be simple, that is, not convertible into shares issued by the Issuer. The Debentures will be unsecured, under the terms of article 58, main section, of the Brazilian Corporate Laws, without guarantee and without preference, will have a term of maturity of eight (8) years from the Issue Date, expiring, therefore, on June 17, 2027 and on the Unit Par Value or the balance of the Unit Par Value, as the case may be, interest will be levied corresponding to the accrued variation of a certain percentage, to be defined in accordance with the Bookbuilding Procedure, and, in any case, limited to one hundred and six and ninety-nine hundredths percent (106.99%) of the accrued variation of the average daily rates of the DI - Interfinancial Deposit for one day, "over extra-group", expressed as a percentage to the year, based on two hundred and fifty-two (252) Business Days, calculated and published daily by B3.
Conditions for changing the rights assured by such securities	Without prejudice to the specific quorums established in this Indenture and in the applicable legislation, the resolutions of the General Meetings of Debenture Holders will depend on the approval of Debenture Holders holding at least two thirds (2/3) of the Outstanding Debentures, on the first call, and two thirds (2/3) of the Debentures of those present, on second call, provided that they represent at least fifty percent (50%) plus one of the Outstanding Debentures. The events of alteration (i) of the Compensation, (ii) of the Compensation Payment Dates, (iii) of the Maturity Date, (iv) of the values, amounts, and amortization dates of the principal of the Debentures; (v) clauses related to the Early Redemption Offer; (vi) of the quorums foreseen in the Issuance Indenture; and/or (vii) of the Events of Early Maturity, including, in the case of resignation or temporary forgiveness, will depend on the approval of Debenture Holders representing at least seventy-five percent (75%) of the Outstanding Debentures, on the first call, or seventy-five percent (75%) of the Debentures of those present, on second call, provided that they represent at least fifty percent (50%) plus one of the Outstanding Debentures.
Other relevant characteristics	See item 12.9

Security	Debentures
Identification of the security	Debentures of the 5th Issue (Single series)
Issue date	01/25/2022
Due date	01/25/2029
Number	500,000

12.3 Other securities issued in Brazil

Total amount (BRL)	500,000,000.00
Outstanding Debt Balance	528,154,015.33
Circulation restriction	Yes
Restriction description	Pursuant to CVM Instruction 476, the Debentures are subject to restrictions on trading provided for in said instruction and, for this reason, they may only be traded on the regulated securities markets after ninety (90) days have elapsed from each subscription or acquisition. Until the subscription and payment of the Debentures, the Professional Investor shall sign a statement attesting, among others, to be aware that: (i) the offer has not been registered with the CVM; and (ii) the Debentures are subject to the trading restrictions set forth in this Disclosure Material, in the Indenture and in the applicable regulations. Additionally, as provided for in article 3 of said instruction, the Restricted Offer will only be presented to a maximum of seventy-five (75) Professional Investors, and may be subscribed by a maximum of fifty (50) Professional Investors. The Debentures may only be traded after ninety (90) days have elapsed from their subscription by the Professional Investor. The distribution of this Disclosure Material is carried out in a numbered and controlled manner by the Lead Underwriter
Convertibility	No
Possibility of redemption	Yes
Event and calculation of the redemption value	The Issuer may, at its sole discretion, carry out, at any time from (and including) January 25, 2026, the optional early redemption of all Debentures (partial optional early redemption being prohibited), with the consequent cancellation of such Debentures. The amount to be paid in relation to each of the Debentures subject to the Optional Early Redemption will be the Unit Par Value or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated on a <i>pro rata temporis</i> basis from the Compensation Payment Date immediately prior to the date of actual payment ("Optional Early Redemption Amount"), plus a premium, which cannot be negative, levied on the Optional Early Redemption Amount, according to the formula: ("Optional Early Redemption Premium").
Debt securities characteristics	The Debentures shall be simple, that is, not convertible into shares issued by the Issuer. The Debentures shall be unsecured, under the terms of article 58, main section of the Brazilian Corporate Laws, without security interest and without preemptive right. Subject to the provisions of this Indenture, the Debentures shall have a maturity term of seven (7) years as from the Issue Date, therefore falling due on January 25, 2029 ("Due Date").
Conditions for changing the rights assured by such securities	Without prejudice to the specific quorums set forth in this Indenture and in the applicable law, the Debenture Holders may, at any time, hold a general meeting, as set forth in article 71 of the Brazilian Corporate Laws, in order to resolve on matters of interest to the Debenture Holders; Debenture holder general meetings may be called by the Company, by the Fiduciary Agent of the Debentures, or by the Debenture Holder.
Other relevant characteristics	See item 12.91

Security	Debentures
Identification of the security	Debentures of the 6th Issue (Single Series) - CRI
Issue date	03/07/2022
Due Date	03/05/2027

12.3 Other securities issued in Brazil

Number	250,000
Total amount (BRL)	250,000,000.00
Outstanding Debt Balance	256,088,140.18
Circulation restriction	No
Convertibility	No
Possibility of redemption	Yes
Event and calculation of the redemption value	The Issuer may, at its sole discretion, carry out, at any time from (and including) April 07, 2025, the optional early redemption of all Debentures (partial optional early redemption being prohibited), with the consequent cancellation of such Debentures. The amount to be paid in relation to each of the Debentures subject to the Optional Early Redemption will be the Unit Par Value or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated on a <i>pro rata temporis</i> basis from the Compensation Payment Date immediately prior to the date of actual payment ("Optional Early Redemption Amount"), plus a premium, which cannot be negative, levied on the Optional Early Redemption Amount, according to the formula: ("Optional Early Redemption Premium")
Debt securities characteristics	The Debentures shall be simple, that is, not convertible into shares issued by the Issuer. The Debentures shall be unsecured, under the terms of article 58, main section of the Brazilian Corporate Laws, without security interest and without preemptive right. Subject to the provisions of this Debenture Indenture, the Debentures shall have a maturity term of one thousand eight hundred and twenty-four (1,824) days as from the Issue Date, therefore falling due on March 05, 2027 ("Due Date").
Conditions for changing the rights assured by such securities	Without prejudice to the specific quorums set forth in this Indenture and in the applicable law, the Debenture Holders may, at any time, hold a general meeting, as set forth in article 71 of the Brazilian Corporate Laws, in order to resolve on matters of interest to the Debenture Holders; Debenture holder general meetings may be called by the Company, by the Fiduciary Agent of the Debentures, or by the Debenture Holder.
Other relevant characteristics	See item 12.9

Security	Debentures
Identification of the security	Debentures of the 7th Issue (Single Series) - CRI
Issue date	06/26/2022
Due Date	06/25/2029
Number	550,000
Total amount (BRL)	550,000,000.00
Outstanding Debt Balance	539,372,393.55
Circulation restriction	No
Convertibility	No
Possibility of redemption	Yes

12.3 Other securities issued in Brazil

Event and calculation of the redemption value	The Issuer may, at its sole discretion, carry out, at any time from (and including) July 26, 2026, the optional early redemption of all Debentures (partial optional early redemption being prohibited), with the consequent cancellation of such Debentures. The amount to be paid in relation to each of the Debentures subject to the Optional Early Redemption will be the Unit Par Value or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated on a <i>pro rata temporis</i> basis from the Compensation Payment Date immediately prior to the date of actual payment ("Optional Early Redemption Amount"), plus a premium, which cannot be negative, levied on the Optional Early Redemption Amount, according to the formula: ("Optional Early Redemption Premium").
Debt securities characteristics	The Debentures shall be simple, that is, not convertible into shares issued by the Issuer. The Debentures shall be unsecured, under the terms of article 58, main section of the Brazilian Corporate Laws, without security interest and without preemptive right. Subject to the provisions of this Debenture Indenture, the Debentures shall have a maturity term of two thousand five hundred and fifty-six (2,556) days as from the Issue Date, therefore falling due on June 25, 2029 ("Due Date").
Conditions for changing the rights assured by such securities	Without prejudice to the specific quorums set forth in this Indenture and in the applicable law, the Debenture Holders may, at any time, hold a general meeting, as set forth in article 71 of the Brazilian Corporate Laws, in order to resolve on matters of interest to the Debenture Holders; Debenture holder general meetings may be called by the Company, by the Fiduciary Agent of the Debentures, or by the Debenture Holder.
Other relevant characteristics	See item 12.9

Security	Debentures
Identification of the security	Debentures of the 8th Issue (Single Series) - CRI
Issue date	09/15/2023
Due Date	09/11/2025
Number	350,000
Total amount (BRL)	350,000,000.00
Outstanding Debt Balance	360,056,655.55
Circulation restriction	No
Convertibility	No
Possibility of redemption	Yes

12.3 Other securities issued in Brazil

Event and calculation of the redemption value	The Issuer may, at its sole discretion, carry out, at any time from October 15, 2024 (including) for the First Series Debentures, the optional early redemption of all First Series Debentures (Partial Optional Early Redemption being prohibited, with the consequent cancellation of such Debentures ("Discretionary Optional Early Redemption"). The amount to be paid in relation to each of the Debentures subject to the Discretionary Optional Early Redemption will be the Nominal Unit Value or the balance of the Nominal Unit Value, plus the Remuneration calculated <i>pro rata temporis</i> from the First Payment Date or the Payment Date of Immediately previous remuneration, as applicable, until the date of effective payment, without prejudice to the payment of the respective Late Payment Charges and Expenses, when applicable, and any other amounts eventually owed by the Issuer under the terms of this Debenture Issuance Deed and/ or any of the other Transaction Documents, if applicable ("Discretionary Optional Early Redemption Value"), plus a premium, levied on the Discretionary Optional Early Redemption Value, according to the formula: ("Discretionary Optional Early Redemption Premium").
Debt securities characteristics	The Debentures will be simple, that is, not convertible into shares issued by the Issuer. The Debentures will be unsecured, in accordance with article 58, caput, of the Brazilian Corporate Laws, without guarantee and without preference. The First Series Debentures will have a maturity period of 727 (seven hundred and twenty-seven) days from the Issuance Date, therefore expiring on September 11, 2025 ("Due Date of the First Series Debentures").
Conditions for changing the rights assured by such securities	Without prejudice to the specific quorums set forth in this Indenture and in the applicable law, the Debenture Holders may, at any time, hold a general meeting, as set forth in article 71 of the Brazilian Corporate Laws, and applying, where appropriate, the provisions of CVM Resolution No. 81, of March 29, 2022, as in force ("CVM Resolution 81"), in order to deliberate on matters of interest to the Debenture Holder ("General Meeting of Debenture Holders"). The General Meeting of Debenture Holders can be called by the Issuer or the Debenture Holder.
Other relevant characteristics	See item 12.9

Security	Debentures
Identification of the security	Debentures of the 8th Issue (Single Series) – CRI (2nd Series)
Issue date	09/15/2023
Due Date	09/13/2027
Number	150,000
Total amount (BRL)	150,000,000.00
Outstanding Debt Balance	152,812,285.11
Circulation restriction	No
Convertibility	No
Possibility of redemption	Yes

12.3 Other securities issued in Brazil

Event and calculation of the redemption value	The Issuer may, at its sole discretion, carry out, at any time from October 15, 2025 (including) for the Second Series Debentures, the optional early redemption of all Second Series Debentures (Partial Optional Early Redemption being prohibited, with the consequent cancellation of such Debentures ("Discretionary Optional Early Redemption"). The amount to be paid in relation to each of the Debentures subject to the Discretionary Optional Early Redemption will be the Nominal Unit Value or the balance of the Nominal Unit Value, plus the Remuneration calculated <i>pro rata temporis</i> from the First Payment Date or the Payment Date of Immediately previous remuneration, as applicable, until the date of effective payment, without prejudice to the payment of the respective Late Payment Charges and Expenses, when applicable, and any other amounts eventually owed by the Issuer under the terms of this Debenture Issuance Deed and/ or any of the other Transaction Documents, if applicable ("Discretionary Optional Early Redemption Value"), plus a premium, levied on the Discretionary Optional Early Redemption Value, according to the formula: ("Discretionary Optional Early Redemption Premium").
Debt securities characteristics	The Debentures will be simple, that is, not convertible into shares issued by the Issuer. The Debentures will be unsecured, in accordance with article 58, caput, of the Brazilian Corporate Laws, without guarantee and without preference. The Second Series will have a maturity period of 1,459 (one thousand, four hundred and fifty-nine) days from the Issuance Date, therefore expiring on September 13, 2027 ("Due Date of Second Series Debentures").
Conditions for changing the rights assured by such securities	Without prejudice to the specific quorums set forth in this Indenture and in the applicable law, the Debenture Holders may, at any time, hold a general meeting, as set forth in article 71 of the Brazilian Corporate Laws, and applying, where appropriate, the provisions of CVM Resolution No. 81, of March 29, 2022, as in force ("CVM Resolution 81"), in order to deliberate on matters of interest to the Debenture Holder ("General Meeting of Debenture Holders"). The General Meeting of Debenture Holders can be called by the Issuer or the Debenture Holder.
Other relevant characteristics	See item 12.9

Security	Debentures
Identification of the security	Debentures of the 8th Issue (Single Series) – CRI (3rd Series)
Issue date	09/15/2023
Due Date	09/12/2030
Number	200,000
Total amount (BRL)	200,000,000.00
Outstanding Debt Balance	198,820,482.87
Circulation restriction	No
Convertibility	No
Possibility of redemption	Yes

12.3 Other securities issued in Brazil

Event and calculation of the redemption value	The Issuer may, at its sole discretion, carry out, at any time from October 15, 2026 (including) for the Third Series Debentures, the optional early redemption of all Third Series Debentures (Partial Optional Early Redemption being prohibited, with the consequent cancellation of such Debentures ("Discretionary Optional Early Redemption"). The amount to be paid in relation to each of the Debentures subject to the Discretionary Optional Early Redemption will be the Nominal Unit Value or the balance of the Nominal Unit Value, plus the Remuneration calculated <i>pro rata temporis</i> from the First Payment Date or the Payment Date of Immediately previous remuneration, as applicable, until the date of effective payment, without prejudice to the payment of the respective Late Payment Charges and Expenses, when applicable, and any other amounts eventually owed by the Issuer under the terms of this Debenture Issuance Deed and/ or any of the other Transaction Documents, if applicable ("Discretionary Optional Early Redemption Value"), plus a premium, levied on the Discretionary Optional Early Redemption Value, according to the formula: ("Discretionary Optional Early Redemption Premium").
Debt securities characteristics	The Debentures will be simple, that is, not convertible into shares issued by the Issuer. The Debentures will be unsecured, in accordance with article 58, caput, of the Brazilian Corporate Laws, without guarantee and without preference. The Third Series will have a maturity period of 2,554 (two thousand, five hundred and fifty-four) days from the Issuance Date, therefore expiring on September 12, 2030 ("Due Date of the Third Series Debentures").
Conditions for changing the rights assured by such securities	Without prejudice to the specific quorums set forth in this Indenture and in the applicable law, the Debenture Holders may, at any time, hold a general meeting, as set forth in article 71 of the Brazilian Corporate Laws, and applying, where appropriate, the provisions of CVM Resolution No. 81, of March 29, 2022, as in force ("CVM Resolution 81"), in order to deliberate on matters of interest to the Debenture Holder ("General Meeting of Debenture Holders"). The General Meeting of Debenture Holders can be called by the Issuer or the Debenture Holder.
Other relevant characteristics	See item 12.9

Security	Debentures
Identification of the security	Debentures of the 9th Issue (Single Series)
Issue date	04/22/2024
Due Date	04/22/2031
Number	600,000
Total amount (BRL)	600,000,000.00
Outstanding Debt Balance	600,000,000.00
Circulation restriction	No
Convertibility	No
Possibility of redemption	Yes

12.3 Other securities issued in Brazil

Event and calculation of the redemption value	The Issuer may, at its sole discretion, carry out the optional early redemption of all Debentures ("Total Optional Early Redemption") at any time, after the 48th (forty-eighth) month counted from the Issuance Date, that is, on 22 April 2028 (exclusive). Upon Total Optional Early Redemption, the amount due by the Issuer will be equivalent to: (i) the Nominal Unit Value (or balance of the Nominal Unit Value, as applicable) of the Debentures, plus (ii) the Remuneration of the Debentures, calculated pro rata temporis from the Profitability Start Date or the immediately preceding Remuneration Payment Date (inclusive), as applicable, until the date of the effective Total Optional Early Redemption (exclusive); (iii) any Late Payment Charges (if any); and (iv) a premium equivalent to 0.35% (thirty-five hundredths of a percent) per year, calculated in accordance with the following formula ("Anticipated Redemption Value").
Debt securities characteristics	The Debentures will be simple, that is, not convertible into shares issued by the Issuer. The Debentures will be unsecured, in accordance with article 58, caput, of the Brazilian Corporate Laws, without guarantee and without preference. Subject to the provisions of this Deed of Issuance, the Debentures will have a maturity period of 7 (seven) years from the Issuance Date, therefore expiring on April 22, 2031 ("Maturity Date").
Conditions for changing the rights assured by such securities	Without prejudice to the specific quorums established in this Deed of Issuance and in the applicable legislation, the deliberations of the General Meetings of Debenture Holders will depend on the approval of, at least, (i) Debenture Holders representing 2/3 (two thirds) of the Debentures in Circulation, in first call; or (ii) 2/3 (two thirds) of the Debenture Holders present at the General Meeting of Debenture Holders, on second call, provided that they represent at least 50% (fifty percent) percent plus one of the Outstanding Debentures.
Other relevant characteristics	See item 12.9

12.4 Number of security holders

Securities	Individuals	Legal Entities	Institutional Investors
Debêntures	21	16	225

12.5 Trading markets in Brazil

12.5. State the Brazilian markets where the issuer's securities are admitted for trading

The Company's shares are traded on B3, Mercadorias e Futuros, in São Paulo, under ticker RADL3.

(a) Debentures 2nd issue in nine series.

The Debentures shall be deposited for:

(i) distribution in the primary market through MDA – Asset Distribution Module (“MDA”), managed and operated by B3 S.A. – Brasil, Bolsa, Balcão – Segmento CETIP UTVM (“B3”), with the distribution being financially settled through B3; and

(ii) trading in the secondary market through CETIP21 – Títulos e Valores Mobiliários (“CETIP21”), managed and operated by B3, with the trading being financially settled by means of B3, and the Debentures electronically held in custody at B3.

The Debentures may only be traded in the regulated securities markets after ninety (90) days counted from the date of each subscription or acquisition by Professional Investors, as provided in articles 13 and 15 of CVM Rule No. 476 and once compliance by the Company with its obligations set forth in article 17 of CVM Rule No. 476 is verified, and the trading of Debentures shall always observe the applicable legal and regulatory provisions.

(b) Debentures 3rd Issue Single Series.

The Debentures will not be registered or deposited for trading in any regulated securities market. The Debentures cannot, in any way, be assigned, sold, disposed of, or transferred, except for (i) the transfer between the Initial Debenture Holder and the Securitization Company referred to in Clause 6 of the Indenture of Private Issue of Simple Unsecured Debentures, Non-Convertible Into Shares, In A Single Series, Of The Third (3rd) Issue Of Raia Drogasil S.A; or (ii) in the event of liquidation of the separate equity, under the terms to be provided for in the Securitization Instrument. The transfer of ownership of the Debentures shall be carried out in accordance with the Bookkeeping Agent's procedures.

(c) Debentures 4th Issue Single Series.

The Debentures shall be deposited for:

(i) distribution in the primary market, through the Asset Distribution Module (“MDA”), managed and operated by B3 S.A. - Brasil, Bolsa, Balcão - Segmento CETIP UTVM (“B3”), with the distribution of the Debentures being financially settled by B3; and (ii) trading in the secondary market through CETIP21 – Bonds and Securities (“CETIP21”), managed and operated by B3, with the trading in the Debentures being financially settled by means of B3 and the Debentures electronically deposited with B3.

The Debentures may only be traded in the regulated securities markets after ninety (90) days counted from the date of each subscription or acquisition, as provided in article 13 of CVM Rule No. 476 and once compliance by the Issuer with its obligations set forth in article 17 of CVM Rule No. 476 is verified, and the trading of Debentures shall always observe the applicable legal and regulatory provisions.

(d) Debentures 5th Issue Single Series.

The Debentures shall be deposited for:

(i) public distribution in the primary market through the MDA - Asset Distribution Module (“MDA”), managed and operated by B3 S.A. – Brasil, Bolsa, Balcão – B3 Branch (“B3”), the distribution being

financially settled through B3; and (ii) trading in the secondary market through CETIP21 – Títulos e Valores Mobiliários (“CETIP21”), managed and operated by B3, with the trading in the Debentures being financially settled and the debentures electronically held in custody at B3

The Debentures may only be traded on the regulated securities markets after ninety (90) days have elapsed from each subscription or acquisition by a Professional Investor (as defined below), pursuant to the provisions of article 13 of CVM Instruction 476, and upon verification of fulfillment, by the Issuer, of its obligations set forth in article 17 of CVM Instruction 476, and the trading in Debentures shall always observe the applicable legal and regulatory provisions, except for the tranche of Debentures object of the firm guarantee exercised by the Underwriters (as defined below) , subject to the provisions of article 13, item II of CVM Instruction 476, and the sole paragraph of article 13 of CVM Instruction 476, and the trading in Debentures shall always observe the applicable legal and regulatory provisions.

(e) Debentures 6th Issue Single Series.

The Debentures shall be subject to private placement. The Debentures will not be registered or deposited for trading in any regulated securities market. The Debentures may not be in any way assigned, sold, disposed of, or transferred, except in the event of liquidation of the separate equity, under the terms to be provided for in the Securitization Instrument. The transfer of ownership of the Debentures shall be carried out in accordance with the Bookkeeping Agent's procedures.

(f) Debentures 7th Issue Single Series.

The Debentures shall be subject to private placement. The Debentures will not be registered or deposited for trading in any regulated securities market. The Debentures may not be in any way assigned, sold, disposed of, or transferred, except in the event of liquidation of the separate equity, under the terms to be provided for in the Securitization Instrument. The transfer of ownership of the Debentures shall be carried out in accordance with the Bookkeeping Agent's procedures.

(g) Debentures 8th Issue Single Series.

The Debentures shall be subject to private placement. The Debentures will not be registered or deposited for trading in any regulated securities market. The Debentures may not be in any way assigned, sold, disposed of, or transferred, except in the event of liquidation of the separate equity, under the terms to be provided for in the Securitization Instrument. The transfer of ownership of the Debentures shall be carried out in accordance with the Bookkeeping Agent's procedures.

(h) Debentures 9th Issue Single Series.

The Debentures will be deposited to:

(i) distribution in the primary market through the MDA – Asset Distribution Module (“MDA”), managed and operated by B3, with the distribution being financially settled through B3; and (ii) trading on the secondary market through CETIP21 – Securities (“CETIP 21”), managed and operated by B3, with the negotiations being financially settled and the Debentures held electronically at B3. Pursuant to article 86, item II, of CVM Resolution 160, Debentures may be traded on regulated markets and on the secondary securities market (i) between qualified investors (as defined in article 12 of CVM Resolution 30) after 6 (six) months from the date of publication of the Offer Closing Announcement; and (ii) to the investing public in general after 1 (one) year has passed from the date of publication of the Offer Closing Announcement. In any case, the obligations set out in CVM Resolution 160 and other applicable legal and regulatory provisions must be observed.

12.6 Trading foreign markets

Valor Mobiliário	Identificação do Valor Mobiliário	País	Mercado Valor Mobiliário
ADR nível 1		Estados Unidos	Balcão (OTC)
Entidade Administradora			
The Bank of New York			
Data de admissão	Data de Início listagem	Percentual	
21/03/2016	21/03/2016	0,23	
Segmento de Negociação	Descrição de Segmento de Negociação		
Sim:	ADR Nível 1		
Proporção de Certificados de Depósito no Exterior	Descrição de Proporção de Certificados de Depósito no Exterior		
Sim:	1 ação ordinária de emissão da Companhia para cada ADR		
Banco Depositário	Descrição do Banco Depositário		
Sim:	The Bank of New York Mellon		
Instituição Custodiante	Descrição da Instituição Custodiante		
Sim:	Itaú Unibanco		

12.7 Securities issued abroad

Reasons for not completing the table:

No securities were issued abroad.

12.8. If the issuer has made a public distribution of securities offer in the last 3 fiscal years, indicate:

There was no public offering of the Company's shares in the last three fiscal years.

The net proceeds obtained by the Issuer through the 2nd Issue of Debentures on April 02, 2018 will be used to reinforce working capital.

The net proceeds obtained by the Issuer through the 3rd Issue of Debentures on March 13, 2019 will be allocated by the Company, in its entirety, by the Due Date, directly for the construction, expansion, development, and renovation of certain properties.

The net proceeds obtained by the Issuer through the 4th Issue of Debentures on June 17, 2019 will be used to reinforce working capital.

The net proceeds obtained by the Issuer through the 5th Issue of Debentures on January 25, 2022 will be used to lengthen the debt profile and reinforce cash.

The net proceeds obtained by the Issuer through the 6th Issue of Debentures on March 07, 2022 will be allocated by the Company, in its entirety, by the Due Date of the CRI, directly to reimburse expenditures, costs, and expenses of a real estate nature and predetermined, incurred by the Company prior to the issuance of the Debentures, subject to the limit of twenty-four (24) months prior to the closing of the CRI Offering, directly related to the acquisition, construction, and/or renovation of business units located in the properties described in the Debenture Indenture.

The net proceeds obtained by the Issuer through the 7th Issue of Debentures on June 26, 2022 will be allocated by the Company, for (i) payment of expenditures, costs, and expenses not yet incurred by the Issuer, directly related to the acquisition, construction, expansion, development, maintenance, and/or renovation, as well as payment of rent, units of certain properties and/or real estate developments, and (ii) reimbursement of expenditures, costs, and expenses of a real estate nature and predetermined, already incurred by the Issuer prior to issue of the Debentures.

The net resources obtained by the Issuer through the 8th Issuance of Debentures on September 15, 2023 will be allocated by the Company, for (i) expenses, costs and expenses related to the payment of rents not yet incurred by the Issuer, of business units and (ii) reimbursement of expenses, costs and predetermined expenses, already incurred by the Issuer prior to the issuance of the Debentures.

The net resources obtained by the Issuer through the 9th Issuance of Debentures on April 22, 2024 will be used to reinforce cash.

12.9 Other relevant information

SECOND (2nd) ISSUE OF SIMPLE, NON-CONVERTIBLE, UNSECURED DEBENTURES IN NINE SERIES, OF OI S.A., FOR PUBLIC DISTRIBUTION WITH RESTRICTED EFFORTS

Authorization: This Debenture Indenture is signed based on the authorization of the Issuer's Board of Directors Meeting held on March 23, 2018 ("Issuer RCA"), in which (i) the terms and conditions for the issue of simple, non-convertible, unsecured debentures, in nine series, of the second (2nd) issue of the Issuer ("Debentures" and "Issue", respectively) and the Offer (as defined below) were approved, pursuant to article 59, paragraph 1 of Law No. 6,404 of December 15, 1976, as amended ("Brazilian Corporate Laws"); and (ii) the Company's executive office was authorized to carry out all acts necessary to implement the resolutions contained therein, including the execution of all documents necessary to carry out the Issue and the Offer (as defined below).

Issue Number: This Issue is the second (2nd) issue of debentures of the Issuer.

Number of Series: The Issue will be carried out in nine series ("1st Series", "2nd Series", "3rd Series", "4th Series", "5th Series", "6th Series", "7th Series", "8th Series", and "9th Series". Series", and when referred to jointly, "Series").

Convertibility: The Debentures shall be simple, that is, not convertible into shares issued by the Issuer.

Type: The Debentures shall be unsecured

Term and Due Date: Subject to the provisions of this Indenture, except for cases of early settlement resulting from an Event of Default, Optional Early Redemption, or Total Early Redemption Offer (as defined below), the Debentures of each Series shall have the term and date due date as below:

- (i) the 1st Series Debentures shall have a term of twelve (12) months, counted from the Issue Date, expiring, therefore, on April 02, 2019 ("Due Date of the 1st Series");
- (ii) the 2nd Series Debentures shall have a term of eighteen (18) months, counted from the Issue Date, expiring, therefore, on October 02, 2019 ("Due Date of the 2nd Series");
- (iii) the 3rd Series Debentures shall have a term of twenty-four (24) months, counted from the Issue Date, expiring, therefore, on April 02, 2020 ("Due Date of the 3rd Series");
- (iv) the 4th Series Debentures shall have a term of thirty (30) months, counted from the Issue Date, expiring, therefore, on October 02, 2020 ("Due Date of the 4th Series");
- (v) the 5th Series Debentures shall have a term of thirty-six (36) months, counted from the Issue Date, expiring, therefore, on April 02, 2021 ("Due Date of the 5th Series");
- (vi) the 6th Series Debentures shall have a term of forty-two (42) months, counted from the Issue Date, expiring, therefore, on October 02, 2021 ("Due Date of the 6th Series");
- (vii) the 8th Series Debentures have a term of forty-eight (48) months, counted from the Issue Date, expiring, therefore, on April 02, 2022 ("Due Date of the 7th Series");
- (viii) the 8th Series Debentures shall have a term of fifty-four (54) months, counted from the Issue Date, expiring, therefore, on October 02, 2022 ("Due Date of the 8th Series"); and
- (ix) the 9th Series Debentures shall have a term of validity of sixty (60) months, counted from the Issue Date, expiring, therefore, on April 02, 2023 ("Due Date of the 9th Series" and, jointly with the Due Date of the 1st Series, Due Date of the 2nd Series, Due Date of the 3rd Series, Due Date of the 4th Series, Due Date of the 5th Series, Due Date of the 6th Series, Due Date of the 7th Series, and Due Date of the 8th Series, "Due Dates").

Unit Par Value: The nominal par value of the Debentures shall be ten thousand reais (BRL 10,000.00), on the Issue Date ("Unit Par Value").

12.9 Other relevant information

Quantity of Debentures Issued: Forty thousand (40,000) Debentures shall be issued, it being understood that (i) four thousand, four hundred and forty-four (4,444) Debentures shall be allocated in the 1st Series; (ii) four thousand, four hundred and forty-four (4,444) Debentures in the 2nd Series; (iii) four thousand, four hundred and forty-four (4,444) Debentures in the 3rd Series; (iv) four thousand, four hundred and forty-four (4,444) Debentures in the 4th Series; (v) four thousand, four hundred and forty-four (4,444) Debentures in the 5th Series; (vi) four thousand, four hundred and forty-four (4,444) Debentures in the 6th Series; (vii) four thousand, four hundred and forty-four (4,444) Debentures in the 7th Series; (viii) four thousand, four hundred and forty-four (4,444) Debentures in the 8th Series; (ix) four thousand, four hundred and forty-eight (4,448) Debentures in the 9th Series.

Monetary Adjustment of the Debentures: The Unit Par Value will not be monetarily adjusted.

Total Issue Amount: The total value of the Issue shall be four hundred million reais (BRL 400,000,000.00), on the Issue Date (as defined below) ("Total Issue Value").

Compensation:

Compensation of the 1st series Debentures: The Unit Par Value of the 1st Series Debentures or the balance of the Unit Par Value, as the case may be, shall be subject to interest corresponding to one hundred and two point twenty-five percent (102.25%) of the accrued variation of the daily average rate of the DI – Interbank Deposits of one day, "over extra group", expressed as a percentage per year of on the basis of two hundred and fifty-two (252) Business Days, daily calculated and disclosed by B3 in the daily bulletin available on its website (<http://www.cetip.com.br>) ("DI Rate") ("1st Series Compensation").

Compensation of the 2nd series Debentures: The Unit Par Value or the balance of the Unit Par Value, as the case may be, of the 2nd Series Debentures shall be subject to interest corresponding to one hundred and two point twenty-five percent (102.25%) of the accumulated variation of the DI Rate ("2nd Series Compensation").

Compensation of the 3rd series Debentures: The Unit Par Value or the balance of the Unit Par Value, as the case may be, of the 3rd Series Debentures shall be subject to interest corresponding to one hundred and two point seventy-five percent (102.75%) of the accumulated variation of the DI Rate ("3rd Series Compensation").

Compensation of the 4th series Debentures: The Unit Par Value or the balance of the Unit Par Value, as the case may be, of the 4th Series Debentures shall be subject to interest corresponding to one hundred and three percent (103.00%) of the accumulated variation of the DI Rate ("4th Series Compensation").

Compensation of the 5th series Debentures: The Unit Par Value or the balance of the Unit Par Value, as the case may be, of the 5th Series Debentures shall be subject to interest corresponding to one hundred and three point seventy-five percent (103.75%) of the accumulated variation of the DI Rate ("5th Series Compensation").

Compensation of the 6th series Debentures: The Unit Par Value or the balance of the Unit Par Value, as the case may be, of the 6th Series Debentures shall be subject to interest corresponding to one hundred and four percent (104.00%) of the accumulated variation of the DI Rate ("6th Series Compensation").

Compensation of the 7th series Debentures: The Unit Par Value or the balance of the Unit Par Value, as the case may be, of the 7th Series Debentures shall be subject to interest corresponding to one hundred and five point twenty-five percent (105.25%) of the accumulated variation of the DI Rate ("7th Series Compensation").

Compensation of the 8th series Debentures: The Unit Par Value or the balance of the Unit Par Value, as the case may be, of the 8th Series Debentures shall be subject to interest corresponding to one hundred and six percent (106.00%) of the accumulated variation of the DI Rate ("8th Series Compensation").

Compensation of the 9th series Debentures: The Unit Par Value or the balance of the Unit Par Value, as the case may be, of the 9th Series Debentures shall be subject to interest corresponding to one hundred and six point twenty-five percent (106.25%) of the accumulated variation of the DI Rate ("9th Series Compensation" and, jointly with the 1st Series Compensation, 2nd Series Compensation, 3rd Series Compensation, 4th Series Compensation, 5th Series Compensation, 6th Series Compensation, 7th Series Compensation, and 8th Series Compensation, "Compensation").

12.9 Other relevant information

Payment of the Compensation: Without prejudice to payments resulting from any early maturity of obligations arising from the Debentures or early redemption, as applicable, under the terms set forth in this Indenture, the respective Compensation shall be paid semi-annually, as of the Issue Date, and the first payment shall be due on October 02, 2018, and the other payments due always on the 2nd day of April and October of each year, until the respective Due Date (each of these dates, a "Compensation Payment Date"), as per Exhibit I to this Indenture.

Those that are debenture holders at the end of the Business Day prior to each Compensation Payment Date provided for in this Indenture shall be entitled to the payments of the Debentures.

Total Optional Early Redemption: Subject to compliance with the conditions below, the Issuer may, at its sole discretion, carry out, only for the 4th Series, 5th Series, 6th Series, 7th Series, 8th Series, and 9th Series, as the case may be, at any time from (and including) April 02, 2020, the optional early redemption of all Debentures of the 4th Series, 5th Series, 6th Series, 7th Series, 8th Series, and/or 9th Series (with the partial optional early redemption of said Series being prohibited), with consequent cancellation of such Debentures ("Optional Early Redemption").

The Issuer shall notify the Debenture Holders of the 4th Series, 5th Series, 6th Series, 7th Series, 8th Series, and/or 9th Series, as the case may be, by publishing an announcement, pursuant to Clause 4.18 above, or upon written communication addressed to each of the Debenture Holders of the respective Series, with a copy to the Fiduciary Agent, at least five (5) Business Days in advance of the date of the event. Such communication to the respective Debenture Holders shall describe the terms and conditions of the Optional Early Redemption, including (a) the projection of the Optional Early Redemption Amount (as defined below); (b) the effective date for the Optional Early Redemption; and (d) other information that may be necessary to implement the Optional Early Redemption ("Optional Early Redemption Notice").

The amount to be paid in relation to each of the Debentures of the 4th Series, 5th Series, 6th Series, 7th Series, 8th Series and/or 9th Series, as the case may be, object of the Optional Early Redemption shall be the balance of the Unit Par Value, plus the respective Compensation, calculated on a *pro rata temporis* basis from the respective Payment Date or the respective immediately previous Compensation Payment Date, as the case may be, until the effective payment date, plus a premium, levied on the balance of the Unit Par Value of the Debentures ("Optional Early Redemption Amount"), set according to the formula below:

Premium = $p * \text{dup}/\text{dut} * \text{balance of the Unit Par Value}$

where:

p: sixty hundredths percent (0.60%);

dup: Number of Business Days counted from the date of the respective Optional Early Redemption until the respective Due Date; and

dut: Number of Business Days counted from April 02, 2020 until the respective Due Date.

The payment of the Early Redemption cannot occur on a date that coincides with any date of payment of the Unit Par Value or balance of the Unit Par Value, as the case may be, of the 4th Series, 5th Series, 6th Series, 7th Series, 8th Series, and 9th Series Debentures, as the case may be, and/or the respective Compensation.

The Issuer shall, at least three (3) Business Days before the respective date of the Optional Early Redemption, inform the Bookkeeping Agent, the Settlement Bank, and B3 of the respective date of the Optional Early Redemption.

Early Redemption Offer: At any time as from the Issuance Date, the Issuer may make, at its sole discretion, an offer to redeem all or part of the Debentures in advance, addressed to all Debenture Holders, and all Debenture Holders, without distinction, shall be ensured equal conditions to accept the redemption of the Debentures held by them, pursuant to this Indenture and the applicable law, including, but not limited to, the Brazilian Corporate Laws ("Early Redemption Offer").

12.9 Other relevant information

In the case of a partial Early Redemption Offer in which Debenture Holders holding a number of Debentures greater than that subject to the Early Redemption Offer, the Fiduciary Agent shall coordinate the draw, pursuant to article 55, paragraph 2, item I, of the Brazilian Corporate Laws, the result of which shall be communicated by the Issuer to the Debenture Holders that adhere to the Early Redemption Offer at least three (3) Business Days before effective completion of the early redemption of the Debentures by the same means set forth in Clause 5.2.3 below, and all validation, calculation, apportionment, and qualification steps shall be carried out outside the scope of B3.

The amount to be paid to the Debenture Holders that adhere to the Early Redemption Offer shall be equivalent to the Unit Par Value or balance of the Unit Par Value, as the case may be, plus (i) the respective Compensation due on the redemption date and not yet paid up to the date of the redemption, calculated on a *pro rata temporis* basis, and of the respective Late Payment Charges, if applicable, and (ii) of any redemption premium to be offered to the Debenture Holders, at the Issuer's sole discretion, which cannot be negative ("Redemption Offer Price").

Optional Extraordinary Amortization: Subject to compliance with the conditions below, the Issuer may, at its sole discretion, carry out at any time, from (and including) April 02, 2020, and with prior notice to the Debenture Holders, pursuant to Clause 4.18 above, or upon written notice addressed to each Debenture Holder, with a copy to the Fiduciary Agent, at least three (3) Business Days before the date of the event, extraordinary amortizations of the Debentures of all Series, jointly ("Optional Extraordinary Amortization"). The Optional Extraordinary Amortization shall be carried out on the balance of the Unit Par Value of the Debentures of each Series, upon payment of a portion of the balance of the Unit Par Value of the Debentures of each Series to be amortized, limited to ninety-eight percent (98%) of the balance of the Debentures' Unit Par Value, plus the respective Compensation, calculated on a *pro rata temporis* basis from the respective Payment Date or the respective payment date of the immediately preceding Compensation, as the case may be, until the effective payment date, plus premium, levied on the portion of the balance of the Unit Par Value of the Debentures to be amortized, fixed according to the formula below:

Premium = $p * \text{dup} / \text{dut} * \text{portion of the Unit Par Value that will be extraordinarily amortized where:}$

p: sixty hundredths percent (0.60%);

dup: Number of Business Days counted from the Optional Extraordinary Amortization date to the respective Due Date; and

dut: Number of Business Days counted from April 02, 2020 until the respective Due Date.

The payment of the Optional Extraordinary Amortization cannot occur on a date that coincides with any date of payment of the Compensation of each of the Series.

The Issuer shall, at least three (3) Business Days before the date of the event, inform the Fiduciary Agent, the Bookkeeping Agent, the Settlement Bank, and B3 of the date of the Optional Extraordinary Amortization.

Optional Acquisition: The Issuer may, at any time, acquire Debentures, subject to the provisions of article 55, paragraph 3 of the Brazilian Corporate Laws, provided that it observes any rules issued by the CVM, and such fact, if so required by the applicable legal and regulatory provisions, appear in the Issuer's management report and financial statements. The Debentures acquired by the Issuer under this Clause may, at the discretion of the Issuer, be canceled, be held in Issuer's treasury, or be replaced on the market, observing the restrictions imposed by CVM Ruling 476. Those Debentures acquired by the Issuer to be held in treasury pursuant to this Clause, when replaced on the market, shall be entitled to the same Compensation applicable to the other Debentures of the respective Series.

Early Maturity: The Fiduciary Agent shall declare the early maturity of all the obligations contained in this Indenture and demand immediate payment, by the Issuer, of the Unit Par Value or the respective balance of the Unit Par Value, as the case may be, plus the respective Compensation, calculated on a *pro rata temporis* basis from the respective Payment Date or the date of payment of the immediately preceding Compensation, as the case may be, until the date of

12.9 Other relevant information

actual payment, without prejudice to the payment of Late Payment Charges, when applicable, and any other amounts that may be due by the Issuer under the terms of this Indenture, regardless of notice or judicial or extrajudicial notification, upon becoming aware of the occurrence of the following events (each of them, an "Event of Default"):

- (i) (a) liquidation, dissolution, and/or any similar event that characterizes the Issuer's state of insolvency, by any subsidiary (according to the definition of control provided for in article 116 of the Brazilian Corporate Laws) the shareholders' equity of which is equivalent to at least 20% of the Issuer's shareholders' equity ("Relevant Subsidiary"), except if the liquidation and/or dissolution results from a corporate transaction that does not represent an Event of Default, under the terms permitted by item "vi" below; (b) adjudication of bankruptcy of the Issuer; (c) filing for voluntary bankruptcy by the Issuer; (d) filing for bankruptcy of the Issuer made by third parties not dismissed within the legal term; or (e) filing for judicial or extrajudicial reorganization of the Company, regardless of the granting of the respective claim;
- (ii) failure by the Issuer to pay the amortization of the Unit Par Value and/or Compensation, on the respective due dates provided for in this Indenture, not cured within one (1) Business Day as from the respective due dates;
- (iii) conversion of the corporate type of the Issuer, pursuant to articles 220 to 222 of the Brazilian Corporate Laws;
- (iv) declaration of early maturity of any debt and/or obligations assumed by the Issuer in the local or international financial or stock market, in an individual or global amount greater than thirty million reais (BRL 30,000,000.00) or its equivalent in other currencies, which amount shall be annually adjusted by the IPCA as from the Issue Date;
- (v) default, by the Issuer and/or by any Relevant Subsidiary (even if in the capacity as guarantor), (a) of any debt or obligation assumed in the financial or stock market, in an individual or aggregate amount equal to or greater than thirty million reais (BRL 30,000,000.00) or (b) other obligations and debts, in an individual or aggregate amount equal to or greater than seventy million reais (BRL 70,000,000.00), which amounts shall be annually adjusted by the Broad Consumer Price Index (IPCA) as from the Issue Date, or its equivalent in other currencies, in any event, as applicable, provided that it is not cured (x) within one (1) Business Day as from the date of the respective default in relation to the debt or obligation assumed in the financial or stock markets; (y) within five (5) Business Days as from the date of the respective default in relation to the other debts and obligations or (z) within the cure period established in each of the aforementioned agreements, if the same terms are different from those described in items (x) and (y) above;
- (vi) if the Issuer's controlling shareholders, signatories of the "Raia Drogasil S.A. Shareholders' Agreement." entered into on November 10, 2011, as amended ("Shareholders' Agreement"), sell shares issued by the Issuer in order to reduce their joint interest to less than twenty percent (20%) of the shares representing the Issuer's common stock, except if previously authorized by Debenture Holders representing at least two thirds (2/3) of the Outstanding Debentures;
- (vii) if any spin-off, consolidation, incorporation, incorporation of shares or other form of corporate restructuring takes place, with or without a change in control (according to the definition of control provided for in article 116 of the Brazilian Corporate Laws), involving the Issuer or any Relevant Subsidiary, except: (a) if previously authorized by the Debenture Holders representing, at least, two thirds (2/3) of the Outstanding Debentures; (b) exclusively in the case of spin-off, consolidation, or incorporation of the Issuer, if it has been secured to those Debenture holders that wish so, during a minimum period of six (6) months counted as of the date of publication of the minutes of the corporate acts related to the transaction, the redemption of the Debentures they hold, upon payment of the Unit Par Value or respective debt balance of the Unit Par Value, plus the respective Compensation, calculated *pro rata temporis* since the immediately preceding respective Payment Date or respective Compensation Payment Date, as the case may be, until the actual payment date; (c) by the incorporation, by the Issuer, of any Relevant Subsidiary or shares issued by any Relevant Subsidiary of the Issuer; or (d) if carried out exclusively between subsidiaries of the Issuer;

12.9 Other relevant information

(viii) non-compliance, by the Issuer, with any final and unappealable court order and/or any final adverse arbitral award, in any event, of a pecuniary nature, against the Issuer and/or any Relevant Subsidiary, the individual or global value of which is greater than ten million reais (BRL 10,000,000.00) or the equivalent amount in other currencies, which amount shall be annually adjusted by the IPCA as from the Issue Date;

(ix) change in the Issuer's corporate purpose, as provided for in Clause 3.1 above, which substantially changes the main activity carried out by the Issuer, except if previously authorized by Debenture Holders representing at least two thirds (2/3) of the Outstanding Debentures;

(x) judicial challenge, by the Issuer, by any Controlling Shareholder, and/or by any Relevant Subsidiary, and/or by any affiliate of the Issuer, of this Indenture;

(xi) invalidity, nullity, or unenforceability of this Indenture;

(xii) assignment, assignment commitment or any form of transfer or transfer commitment to third parties, in whole or in part, by the Issuer, of any of its obligations under this Indenture, without the prior written consent from Debenture Holders representing at least two-thirds (2/3) of the Outstanding Debentures;

(xiii) legitimate protest of instruments against the Issuer, the individual or aggregate amount of which is greater than seventy-five million reais (BRL 75,000,000.00) or its equivalent in other currencies, which amount shall be annually adjusted by the IPCA as from the Issue Date, as long as it is not duly suspended or canceled within five (5) Business Days as from the date of acknowledgment, by the Issuer (through its notification as provided by law), of the occurrence of the protest;

(xiv) voluntary cancellation of the Issuer's registration as a publicly-held company with the CVM without complying with the applicable regulations or cancellation, at the initiative of the authorities, of the Issuer's registration as a publicly-held company by the CVM, except, in the first case, prior approval by all the Outstanding Debentures;

(xv) failure by the Issuer to comply with any ancillary pecuniary obligation related to the Issue and not referred to in item "ii" above or non-pecuniary obligation provided for in this Indenture, in any case, provided that it is not cured within thirty (30) days as from the communication of said non-compliance: (a) by the Issuer to the Fiduciary Agent; or (b) by the Fiduciary Agent to the Issuer, whichever is earlier, and this term does not apply to obligations for which a specific term has been stipulated, which shall be observed to characterize or not the occurrence of the events provided for herein;

(xvi) distribution of dividends above the mandatory minimum whenever the Issuer is in breach of any pecuniary obligation provided for in this Indenture, as provided for in article 202 of the Brazilian Corporate Laws;

(xvii) proof of the untruthfulness of any statements made by the Issuer in this Indenture, as well if they prove to be incorrect, misleading, inconsistent, or inaccurate, on the date on which they were provided;

(xviii) reduction of the Issuer's common stock without observing the provisions of article 174, paragraph 3 of the Brazilian Corporate Laws, except if carried out in the context of the operations described in item (vi) above and/or to absorb accumulated losses;

(xix) final cancellation of the registration of the Debentures by B3; and

(xx) non-compliance by the Issuer, for two (2) consecutive quarters, with the following financial index ("Financial Index"), to be monitored quarterly by the Fiduciary Agent, to be calculated by the Issuer, and revised quarterly by the auditors retained by the Issuer, based on the consolidated quarterly information ("ITR") or consolidated financial statements ("DF"), as the case may be, of the Issuer, related to March 31, June 30, September 30, and December 31, the first calculation being as from the second quarter of 2018:

The Financial Ratio obtained by dividing Net Financial Debt by EBITDA (as defined below) cannot exceed three integers (3.0) times.

Where:

12.9 Other relevant information

"Financial Net Debt" means the Debt of the Issuer and its subsidiaries on a consolidated basis according to the most recent quarterly accounting result less cash and financial investments, calculated based on the line "Loans and Financing" and "Debentures", as applicable, from the DF/ITR.

"Debt" means the total financial debt of the Issuer.

"Adjusted EBITDA" means the net profit or loss of the Issuer, on a consolidated basis, for the last twelve (12) months, before: (a) net financial expenses (revenue), (b) income tax and social contribution, (c) depreciation and amortization expenses, (d) the cost of any share-based compensation plan, including stock option or restricted share plan, (e) non-recurring expenses and (f) impairment, as recorded in the DF/ITR in the applicable lines.

THIRD PRIVATE ISSUE OF SIMPLE UNSECURED NON-CONVERTIBLE DEBENTURES, IN A SINGLE SERIES.

Authorization: Meeting of the Company's Board of Directors held on February 1, 2019 ("RCA"), in which (i) the terms and conditions for the Issuance of Debentures were approved, pursuant to article 59, paragraph 1 of the Brazilian Corporate Law; and (ii) the Company's executive office was authorized to carry out all acts necessary for carrying out the resolutions contained therein, including the signing of all documents necessary for completion of the Issue of Debentures.

Issue Number: This Issue represent the third (3rd) issue of debentures of the Issuer.

Number of Series: The Issue shall be made in a single series.

Convertibility: The Debentures shall be simple, therefore not convertible into shares issued by the Company.

Type: The Debentures shall be unsecured.

Term and Due Date: The Debentures shall have a maturity term of two thousand five hundred and fifty-seven (2,557) days as from the Issue Date, therefore falling due on March 13, 2026 ("Due Date").

Unit Par Value: The Debentures shall have a unit par value of one thousand reais (BRL 1,000.00) on the Debentures Issue Date.

Quantity of Debentures Issued: Two hundred and fifty thousand (250,000) Debentures shall be issued.

Monetary Adjustment of the Debentures: The Unit Par Value will not be monetarily adjusted.

Total Issue Amount: The total amount of the Issue of Debentures shall be two hundred and fifty million reais (BRL 250,000,000.00), on the Debenture Issue Date

Compensation: Over the Unit Par Value of the Debentures or balance of the Unit Par Value of the Debentures, as the case may be, interest at the rate of ninety-eight integers and fifty-hundredths percent (98.50%) shall be levied on the accrued variation of the DI Rate ("Debenture Compensation"), calculated exponentially and cumulatively on a *pro rata temporis* basis per Business Days elapsed, from the first Payment Date or the immediately preceding Compensation Payment Date, as applicable, to the actual payment date. The Debenture Compensation shall be calculated in accordance with the following formula:

$$J = VNe \times (FatorDI - 1)$$

Payment of the Compensation: Without prejudice to the payments resulting from the early redemption and/or extraordinary amortization of the Debentures or early maturity of the obligations arising from the Debentures, under the terms set forth in this Debenture Indenture, the Compensation shall be paid, semi-annually, as from the Debenture Issue Date, in March and September of each year, it being understood that the first payment shall be due on September 13, 2019 and the last on the Due Date.

12.9 Other relevant information

Total Optional Early Redemption: The Company may, at its sole discretion, at any time from and including March 13, 2022, promote the early redemption of all Debentures (partial redemption being prohibited), with the consequent cancellation of such Debentures, by sending a notice at least four (4) Business Days in advance of the actual redemption date to the Debenture Holder and Bookkeeping Agent, with a copy to the Fiduciary Agent of the Debentures, upon payment of the balance of the Unit Par Value of the Debentures, plus (i) the Compensation, calculated on a *pro rata temporis* basis from the first Payment Date or the immediately preceding Compensation Payment Date, as the case may be, to the actual payment date; and (ii) the Premium set forth in Clause 8.1.2 of the debenture indenture.

Optional Extraordinary Amortization: 8.3.1 The Company may, at its sole discretion, at any time from and including March 13, 2022, promote the optional extraordinary amortization of the Unit Par Value or the balance of the Unit Par Value of the Debentures, limited to ninety-eight percent (98%) of said value, which shall cover, proportionally, all Debentures, by sending a notice at least four (4) Business Days in advance of the actual date of extraordinary amortization to the Debenture Holder, with a copy to the Fiduciary Agent of the Debentures and to the Bookkeeping Agent, upon payment of the portion of the Unit Par Value of the Debentures, plus (i) the Compensation, calculated on a *pro rata temporis* basis from the first Payment Date or the immediately preceding Compensation Payment Date, as the case may be, to the actual payment date; and (ii) the Premium set forth in Clause 8.1.2 of the debenture indenture.

Optional Acquisition: The Company may not acquire Outstanding Debentures.

Early Maturity: Subject to the provisions of Clauses 9.1.1 to 9.4 below, the Fiduciary Agent of the Debentures shall consider the obligations arising from the Debentures to be due in advance, and demand immediate payment, by the Company, of the Unit Par Value or balance of the Unit Par Value, as the case may be, of the Debentures, plus the Compensation, calculated *pro rata temporis* from the first Payment Date or the immediately preceding Compensation Payment Date, as the case may be, until the actual payment date, without prejudice, when applicable, to the Late Payment Charges, in the event of any of the events provided for in Clauses 9.1.1 and 9.1.2 below and subject, when expressly indicated below, to the respective cure periods.

9.1.1 The following represent maturity events that lead to the automatic maturity of the obligations arising from the Debentures (“Automatic Early Maturity Events”), regardless of notice or judicial or extrajudicial notification, subject to application of the provisions of Clause 9.2 below:

- (i) (a) liquidation, dissolution, and/or any similar event that characterizes a state of insolvency of the Company and/or by any Relevant Subsidiary, except if the liquidation and/or dissolution arises from a corporate transaction that does not constitute an Early Maturity Event, as permitted by item (vii) below; (b) adjudication of bankruptcy of the Company; (c) filing for voluntary bankruptcy by the Company; (d) filing for bankruptcy of the Company made by third parties not dismissed within the legal term; or (e) filing for judicial or extrajudicial reorganization of the Company, regardless of the granting of the respective claim;
- (ii) failure by the Company to pay the amortization of the Unit Par Value or balance of the Unit Par Value and/or the respective Compensation, on the respective due dates provided for in this Debenture Indenture, not cured within one (1) Business Day as from the respective due dates;
- (iii) conversion of the corporate type of the Company, pursuant to articles 220 to 222 of the Brazilian Corporate Laws;
- (iv) declaration of early maturity of any debt and/or obligation assumed by the Company and/or by any subsidiary in the local or international financial or stock market, in an individual or aggregate amount equal to or greater than thirty million reais (BRL 30,000,000.00) or its equivalent in other currencies, which amount shall be annually adjusted by the IPCA as from the Issue Date of the Debentures;
- (v) default, by the Company and/or by any Subsidiary (even if in the capacity as guarantor), (a) of any debt or obligation assumed in the financial or stock market, in an individual or aggregate amount equal to or greater than thirty million reais (BRL 30,000,000.00) or (b) other obligations and debts, in an individual or aggregate amount equal to or greater than seventy million reais (BRL 70,000,000.00), which amounts shall be annually adjusted by the Broad Consumer Price Index (IPCA) as from the Issue Date of the Debentures, or its equivalent in other currencies, in any event, as applicable, provided that it is not cured (1) within one (1) Business Day as from the date of the respective default in relation to the debt or obligation assumed in the financial or stock markets; (2) within five (5) Business Days as from the date of the respective default in relation to the other debts and obligations or (3) within the cure period established in each of the aforementioned agreements, if the same terms are different from those described in items (1) and (2) above;

12.9 Other relevant information

- (vi) if the Company's Controlling shareholders, signatories to the Shareholders' Agreement, during the term of the Shareholders' Agreement, sell shares issued by the Company in order to reduce their joint shareholding to a level lower than that allowed in the Shareholders' Agreement, except if previously authorized by CRI holders;
- (vii) if any transaction or group of transactions involving spin-off, consolidation, incorporation or incorporation of shares occurs, which results in a change of Control, involving the Company or any Subsidiary, except if previously authorized by CRI holders, subject to the provisions of the Securitization Instrument;
- (viii) non-compliance, by the Company, with any final and unappealable court order and/or any final adverse arbitral award, in any event, of a pecuniary nature, against the Company and/or any Relevant Subsidiary, the individual or aggregate value of which is greater than thirty million reais (BRL 30,000,000.00) or the equivalent amount in other currencies, which amount shall be annually adjusted by the IPCA as from the Issue Date of the Debentures;
- (ix) change in the Company's corporate purpose, as provided for in Clause 4.1 above, which changes the main activity carried out by the Company, except if previously authorized by CRI holders, subject to the provisions of the Securitization Instrument;
- (x) judicial challenge, by the Company, by any Controlling Shareholder, and/or by any Relevant Subsidiary, and/or by any affiliate of the Company, of this Debenture Indenture and/or of any of the other Transaction Documents;
- (xi) invalidity, nullity, or unenforceability of this Debenture Indenture and/or any of the other Transaction Documents;
- (xii) assignment, promise of assignment or any form of transfer or promise of transfer to third parties, in whole or in part, by the Company, of any of its obligations under this Debenture Indenture and other Transaction Documents, to which it is a party, without the prior consent of the CRI holders, subject to the provisions of the Securitization Instrument;
- (xiii) distribution of dividends above the mandatory minimum whenever the Company is in breach of any pecuniary obligation provided for in this Debenture Indenture or in any of the other Transaction Documents, as applicable, as provided for in article 202 of the Brazilian Corporate Laws;
- (xiv) voluntary cancellation of the Company's registration as a publicly-held company with the CVM without complying with the applicable regulations or cancellation, at the initiative of the authorities, of the Company's registration as a publicly-held company by the CVM, except, in the first case, prior approval by CRI holders representing all the Outstanding CRI, subject to the provisions of the Securitization Instrument; and
- (xv) use of net proceeds from the Issue of Debentures in noncompliance with the provisions of Clause 5.1 above.

9.1.2 Any of the events provided by law and/or any of the following events are non-automatic maturity events ("Non-Automatic Early Maturity Events" and, jointly with Automatic Early Maturity Events, "Early Maturity Events") that may lead to the maturity of obligations arising from the Debentures, subject to the provisions in Clause 9.3 below:

- (i) failure by the Company to comply with any ancillary pecuniary obligation related to the Issue of Debentures and the Issue of CRI and not referred to in Clause 9.1.1, item (ii) above, or non-pecuniary obligation provided for in this Debenture Indenture, including any of the obligations set forth in Clause 10 below, and in the other Transaction Documents, in any case, provided that it is not cured within a period of thirty (30) days as from the aforementioned non-compliance: (a) by the Company to the Fiduciary Agent of the Debentures; or (b) by the Fiduciary Agent of the Debentures to the Company, whichever is earlier, and this term does not apply to obligations for which a specific term has been stipulated, which shall be observed to characterize or not the occurrence of the events provided for herein;
- (ii) non-compliance by the Company and/or any subsidiary, as of the date hereof, with any provision of the Anti-Corruption Laws, Law 12,529 and the Money Laundering Law;

12.9 Other relevant information

- (iii) existence of a final and unappealable adverse judgment due to the practice of acts, by the Company and/or by any subsidiary, in the performance of its duties, (a) which result in child labor or forced labor; and/or (b) which imply a crime against the environment, except if a redress is imposed on the Company and/or any Subsidiary and it is compliant with the exact provisions, conditions, and terms stipulated in the judgment;
- (iv) non-renewal, cancellation, revocation, or suspension of authorizations, concessions, permits, or licenses, including environmental ones, required by the competent bodies, and which are not cured within sixty (60) days as from such non-renewal, cancellation, revocation, or suspension, and as long as it causes a Relevant Adverse Effect;
- (v) proof of the untruthfulness of any statements made by the Company in this Debenture Indenture or in any of the other Transaction Documents to which it is a party, as well if they prove to be incorrect, misleading, inconsistent, or inaccurate, on the date on which they were provided;
- (vi) if, upon completion of an investigation, inquiry, or administrative or judicial proceedings, a complaint is received against the Company, its direct Controlling Shareholder, any of its Subsidiaries or affiliates involving the violation of any provision of any law or regulation against the practice of corruption or acts harmful to the government, including, without limitation, Anti-Corruption Laws;
- (vii) legitimate protest of instruments against the Company and/or any Subsidiary, the individual or aggregate amount of which is equal to or greater than thirty million reais (BRL 30,000,000.00) or its equivalent in other currencies, which amount shall be annually adjusted by the IPCA as from the Issue Date of the Debentures, as long as it is not duly suspended or canceled within five (5) Business Days as from the date of acknowledgment, by the Company (through its notification as provided by law), of the occurrence of the protest;
- (viii) reduction of the Company's common stock without observing the provisions of article 174, paragraph 3 of the Brazilian Corporate Laws, except if carried out in the context of the operations described in Clause 9.1.1, item (vi) above and/or to absorb accumulated losses; and
- (ix) non-compliance by the Company, for two (2) consecutive quarters, with the following financial index ("Financial Index"), to be monitored quarterly by the Fiduciary Agent of the Debentures, to be calculated by the Company, and revised quarterly by the auditors retained by the Company, based on the ITR or DF, as the case may be, of the Company, related to March 31, June 30, September 30, and December 31 of each year, the first calculation being as from disclosure of the DF relating to the fiscal year of the Company ended December 31, 2018:

The Financial Ratio obtained by dividing Net Financial Debt by the Adjusted EBITDA cannot exceed three integers (3.0) times.

9.2 Upon occurrence of any of the Automatic Early Maturity Events provided for in Clause 9.1.1 above (subject to the respective cure periods, as applicable), the obligations arising from the Debentures shall automatically become due, regardless of notice or judicial or extrajudicial notification.

9.3 Upon occurrence of any of the Non-Automatic Early Maturity Events provided for in Clause 9.1.2 above (subject to the respective cure periods, as applicable), the Fiduciary Agent of the Debentures shall call, within a term of up to two (2) Business Days as from the date on which it becomes aware of occurrence thereof, a general meeting of Debenture Holder (subject to the provisions of Clause 12 below). If, at the aforementioned general meeting of Debenture Holders, the Debenture Holder decides not to consider the early maturity of the obligations arising from the Debentures, the Fiduciary Agent of the Debentures shall not declare the early maturity of the obligations arising from the Debentures; otherwise, or in case the meeting is not opened on second call, or in case it is opened on second call in which there is so sufficient quorum to pass resolutions, at said general meeting of the Debenture Holders, the Fiduciary Agent of the Debentures shall immediately declare the early maturity of the obligations arising from the Debentures.

12.9 Other relevant information

9.4 In the event of early maturity of the obligations arising from the Debentures, the Company agrees to redeem all the Debentures, with consequent cancellation thereof, upon payment of the Unit Par Value or balance of the Unit Par Value, as the case may be, of the Debentures, plus the Compensation, calculated on a *pro rata temporis* basis from the first Payment Date or the immediately preceding Compensation Payment Date, as the case may be, until the actual payment date, without prejudice to the payment of Late Charges, when applicable, and any other amounts that may be due by the Company under the terms of this Debenture Indenture and/or any of the other Transaction Documents, as applicable, within a term of up to two (2) Business Days as from the date on which the Company receives a written notice from the Fiduciary Agent of the Debentures in this regard, under penalty of, if it fails to do so, it being also required to pay the Late Payment Charges. The payments mentioned in this Clause 9.4 shall be due by the Company within the term provided above, and the Debenture Holder and/or Fiduciary Agent of the Debentures may adopt all necessary measures to satisfy their credit, regardless of any operational period necessary for redemption of the Debentures.

9.5 For purposes of item (i) of Clause 9.1.1 above, any similar procedure provided for by law that replaces or complements the current legislation applicable to bankruptcy, judicial and extrajudicial reorganization shall be deemed adjudication of bankruptcy or judicial or extrajudicial reorganization.

FOURTH (4th) ISSUE OF SIMPLE, NON-CONVERTIBLE, UNSECURED DEBENTURES, IN A SINGLE SERIES, FOR PUBLIC DISTRIBUTION WITH RESTRICTED EFFORTS, OF RAIA DROGASIL S.A.

Authorization: This Debenture Indenture is signed based on the authorization of the Issuer's Board of Directors Meeting held on June 11, 2019 ("Issuer RCA"), in which (i) the terms and conditions of the fourth (4th) issue of simple, non-convertible, unsecured debentures, in a single series, of the Issuer ("Debentures" and "Issue", respectively) and the Offer (as defined below) were approved, pursuant to article 59, paragraph 1 of Law No. 6,404 of December 15, 1976, as amended ("Brazilian Corporate Laws"); and (ii) the Issuer's executive office was authorized to carry out all acts necessary to implement the resolutions contained therein, including the execution of all documents necessary to carry out the Issue and the Offer (as defined below), including the amendment to the Indenture to reflect the outcome of the Bookbuilding Process (as defined below).

Issue Number: This Issue represent the fourth (4th) issue of debentures of the Issuer.

Number of Series: The Issue shall be made in a single series.

Convertibility: The Debentures shall be simple, that is, not convertible into shares issued by the Issuer.

Type: The Debentures shall be unsecured, under the terms of article 58, main section of the Brazilian Corporate Laws, without security interest and without preemptive right.

Term and Due Date: Subject to the provisions of this Indenture, the Debentures shall have a maturity term of eight (8) years as from the Issue Date, therefore falling due on June 17, 2027 ("Due Date").

Unit Par Value: The unit par value of the Debentures shall be one thousand reais (BRL 1,000.00), on the Issue Date ("Unit Par Value").

Quantity of Debentures Issued: Three hundred thousand (300,000) Debentures shall be issued.

Monetary Adjustment of the Debentures: The Unit Par Value will not be monetarily adjusted.

Total Issue Amount: The total value of the Issue shall be three hundred million reais (BRL 300,000,000.00) on the Issue Date (as defined below) ("Total Issue Amount").

12.9 Other relevant information

Compensation: The Unit Par Value of the 1st Series Debentures or the balance of the Unit Par Value, as the case may be, shall be subject to interest corresponding to the accrued variation of a given percentage, to be defined in accordance with the Bookbuilding Procedure and, in any case, limited to one hundred and six point ninety-nine percent (106.99%) of the accrued variation of the daily average rate of the DI – Interbank Deposits of one day, “over extra group”, expressed as a percentage per year of on the basis of two hundred and fifty-two (252) Business Days, daily calculated and disclosed by B3 in the daily bulletin available on its website (<http://www.cetip.com.br>) (“DI Rate” and “Compensation”, respectively). The percentage that will remunerate the Debentures, defined in the terms described above, shall be ratified by means of an amendment to this Indenture, and the Issuer and the Fiduciary Agent are hereby authorized and obliged to enter into such amendment without the need to call a General Meeting of Debenture Holders and /or any corporate approval by the Issuer.

Payment of the Compensation: Without prejudice to payments resulting from any early maturity of obligations arising from the Debentures or early redemption, under the terms set forth in this Indenture, the Compensation shall be paid semi-annually, as of the Issue Date, and the first payment shall be due on December 17, 2019, and the other payments due always on the 17th day of June and December of each year, until the Due Date (each of these dates, a “Compensation Payment Date”).

Total Optional Early Redemption: Subject to compliance with the conditions below, the Issuer may, at its sole discretion, carry out, at any time from (and including) June 17, 2024, the optional early redemption of all Debentures (partial optional early redemption being prohibited), with the consequent cancellation of such Debentures (“Optional Early Redemption”).

The Issuer shall notify the Debenture Holders of the Optional Early Redemption by publishing an announcement, pursuant to Clause 4.18 of the indenture, or upon written communication addressed to Debenture Holder, with a copy to the Fiduciary Agent, at least five (5) Business Days in advance of the date of the event. Such communication to the Debenture Holders shall describe the terms and conditions of the Optional Early Redemption, including (i) the projection of the Optional Early Redemption Amount (as defined below); (ii) the effective date for the Optional Early Redemption; and (iii) other information that may be necessary to implement the Optional Early Redemption (“Optional Early Redemption Notice”).

The amount to be paid in relation to each of the Debentures subject to the Optional Early Redemption will be the Unit Par Value or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated on a *pro rata temporis* basis from the Compensation Payment Date immediately prior to the date of actual payment (“Optional Early Redemption Amount”), plus a premium, which cannot be negative, levied on the Optional Early Redemption Amount, according to the formula below (“Optional Early Redemption Premium”):

$$V_{\text{premium}} = p \times \text{dup} / 252 \times (\text{Optional Early Redemption Amount})$$

where:

V_{premium} : value of the Optional Early Redemption Premium;

p : twenty hundredths percent (0.20%);

dup : Number of Business Days from the date of the Optional Total Early Redemption until the Due Date;

12.9 Other relevant information

The payment of the Optional Early Redemption cannot occur on a date that coincides with any date of payment of the Unit Par Value of the Debentures and/or the Compensation, under the terms of this Indenture, and it must be a Business Day.

The Issuer shall, at least three (3) Business Days before the respective date of the Optional Early Redemption, inform the Bookkeeping Agent, the Settlement Bank, and B3 of the respective date of the Optional Early Redemption. The payment of the Optional Early Redemption Amount plus the Optional Early Redemption Premium, which cannot be negative, levied on the Optional Early Redemption Amount shall be made (i) through the procedures adopted by B3 for the Debentures held in electronic custody at B3, or (ii) through procedures adopted by the Settlement Bank and Bookkeeping Agent, in the case of Debentures that are not electronically held in custody at B3.

Optional Extraordinary Amortization: Subject to compliance with the conditions below, the Issuer may, at its sole discretion, carry out at any time from (and including) June 17, 2024, and with prior notice to the Debenture Holders, pursuant to Clause 4.18 above, or upon written communication addressed to each Debenture Holder, with a copy to the Fiduciary Agent, at least four (4) Business Days in advance of the date of the event, extraordinary amortizations ("Optional Extraordinary Amortization") of the Unit Par Value or the outstanding balance of the Unit Par Value, as the case may be, upon payment of a portion of the Unit Par Value or the balance of the Unit Par Value, as the case may be, to be amortized, limited to ninety-eight percent (98%) of the Unit Par Value or the outstanding balance of the Unit Par Value, plus the Compensation, calculated on a *pro rata temporis* basis from the immediately preceding Compensation Payment Date until the effective payment date ("Optional Extraordinary Amortization Amount"), plus a premium, which cannot be negative, levied on the portion of the Optional Extraordinary Amortization Amount to be amortized, calculated according to the formula below ("Optional Extraordinary Amortization Premium"):

$$V_{\text{premium}} = p \times \text{dup} / 252 \times (\text{Optional Extraordinary Amortization Amount})$$

where:

V_{premium} : value of the Optional Extraordinary Amortization

Premium; p: twenty hundredths percent (0.20%)

dup: Number of Business Days from the Optional Extraordinary Amortization date to the Due Date;

The payment of the Optional Extraordinary Amortization cannot occur on a date that coincides with any date of payment of the amortization of the Unit Par Value of the Debentures and/or the Compensation, under the terms of this Indenture.

The Issuer shall, at least three (3) Business Days before the date of the event, inform the Fiduciary Agent, the Bookkeeping Agent, the Settlement Bank, and B3 of the date of the Optional Extraordinary Amortization.

Optional Acquisition: The Issuer may, at any time, acquire Debentures, subject to the provisions of article 55, paragraph 3 of the Brazilian Corporate Laws, articles 13 of CVM Instruction 476 and applicable CVM regulations, and such fact, if so required by the applicable legal and regulatory provisions, appear in the Issuer's management report and financial statements. The Debentures acquired by the Issuer under this Clause may, at the discretion of the Issuer, be canceled, be held in Issuer's treasury, or be replaced on the market, observing the restrictions imposed by CVM Ruling 476. Those Debentures acquired by the Issuer to be held in treasury pursuant to this **Clause**, when replaced on the market, shall be entitled to the same Compensation applicable to the other Debentures.

Early Maturity: The Fiduciary Agent shall in advance and automatically declare the maturity of all obligations contained in the Indenture and demand the immediate payment, by the Issuer, of the Unit Par Value or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated on a *pro rata temporis* basis from the first Payment Date or the immediately preceding payment date of the Compensation, as the case may be, until the date of actual payment, without prejudice to the payment of Late Payment Charges, when applicable, and any other amounts that may be due by the Issuer under the terms of the Indenture, regardless of notice or judicial or extrajudicial notification, upon becoming aware of the occurrence of the events mentioned in the Indenture.

12.9 Other relevant information

FIFTH (5th) ISSUE OF SIMPLE, NON-CONVERTIBLE, UNSECURED DEBENTURES, IN A SINGLE SERIES, FOR PUBLIC DISTRIBUTION WITH RESTRICTED EFFORTS, OF RAIA DROGASIL S.A.

Authorization: This Debenture Indenture is signed based on the authorization of the Issuer's Board of Directors meeting held on January 14, 2022 ("Issuer RCA"), in which (i) the terms and conditions of the fifth (5th) issue of simple, non-convertible, unsecured debentures, in a single series, of the Issuer ("Debentures" and "Issue", respectively) and the Offer (as defined below) were approved, pursuant to article 59, paragraph 1 of Law No. 6,404 of December 15, 1976, as amended ("Brazilian Corporate Laws"); and (ii) the Issuer's executive office was authorized to carry out all acts necessary to implement the resolutions contained therein, including the execution of all documents necessary to carry out the Issue and the Offer (as defined below), including the amendment to the Indenture to reflect the outcome of the Bookbuilding Process (as defined below).

Issue Number: This Issue represent the fifth (5th) issue of debentures of the Issuer.

Total Issue Amount: Up to five hundred million reais (BRL 500,000,000.00).

Number of Series: The Issue shall be made in a single series.

Convertibility: The Debentures shall be simple, that is, not convertible into shares issued by the Issuer.

Type: The Debentures shall be unsecured, under the terms of article 58, main section of the Brazilian Corporate Laws, without security interest and without preemptive right.

Term and Due Date: Subject to the provisions of this Indenture, the Debentures shall have a maturity term of seven (7) years as from the Issue Date, therefore falling due on January 25, 2029 ("Due Date").

Unit Par Value: The unit par value of the Debentures shall be one thousand reais (BRL 1,000.00), on the Issue Date ("Unit Par Value").

Quantity of Debentures Issued: Five hundred thousand (500,000) Debentures shall be issued.

Monetary Adjustment of the Debentures: The Unit Par Value will not be monetarily adjusted.

Compensation: On the Unit Par Value or the balance of the Unit Par Value, as the case may be, interest corresponding to one hundred percent (100%) of the accrued variation of the average reference rates for interbank deposits in Brazil - Interbank Deposit Certificates - DI of one day over extra group calculated and disclosed by B3 S.A. - Brasil, Bolsa, Balcão, in the daily newsletter available on its website (http://www.b3.com.br/pt_br/) expressed as a percentage and calculated daily in the form of compound capitalization, based on a year of two hundred and fifty-two (252) Business Days ("DI Rate"), capitalized exponentially, plus a surcharge (spread) equivalent to one and forty-nine hundredths percent (1.49%) per year, based on a year of two hundred and fifty-two (252) Business Days ("Compensation").

Payment of the Compensation: Without prejudice to the payments due to any early maturity of the obligations arising from the Debentures, any Total Optional Early Redemption, any early redemption resulting from the Total Early Redemption Offer, any Optional Extraordinary Amortization or any Optional Acquisition, with cancellation of all of the Debentures, under the terms set forth in this Indenture, the Compensation shall be paid semi-annually, as of the Issue Date, with the first payment due on July 25, 2022, and the other payments always due on the 25th of January and July of each year.

12.9 Other relevant information

Total Optional Early Redemption: Subject to compliance with the conditions below, the Issuer may, at its sole discretion, carry out, at any time from (and including) January 25, 2026, the optional early redemption of the entirety of the Debentures (it being understood that partial optional early redemption shall be prohibited, pursuant to Clause 7.5 of the indenture), with the consequent cancellation of such Debentures ("Total Optional Early Redemption").

The Issuer shall notify the Debenture Holders of the Total Optional Early Redemption by publishing an announcement, pursuant to Clause 6.19 above, or upon written communication addressed to Debenture Holder, with a copy to the Fiduciary Agent, at least five (5) Business Days in advance of the date of the event. Such communication to the Debenture Holders shall describe the terms and conditions of the Total Optional Early Redemption, including (i) the estimate of the Total Optional Early Redemption Amount (as defined below); (ii) the effective date for the Total Optional Early Redemption, which must be a Business Day; and (iii) other information that may be necessary to implement the Total Optional Early Redemption ("Total Optional Early Redemption Notice").

The amount to be paid in relation to each of the Debentures subject to the amount to be paid in relation to each of the Debentures object of the Total Optional Early Redemption will be Unit Par Value or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated *pro rata temporis* from the First Payment Date or the First Payment Date or Compensation Payment Date immediately preceding, as the case may be, up to the date of actual payment and the respective Late Payment Charges, if applicable ("Total Optional Early Redemption Amount"), plus a premium, which cannot be negative, levied on the Total Optional Early Redemption Amount, as well as Late Charges, if any, according to the formula below ("Total Optional Early Redemption Premium"):

$$PU\text{premium} = \text{premium} \times \left(\frac{dup}{252} \right) \times (PU\text{debenture})$$

where:

PUpremium: unit amount to be paid to the Debenture Holders within the scope of the Total Optional Early Redemption;

PUdebenture: Unit Par Value of the Debentures or balance of the Unit Par Value of the Debentures, as the case may be, plus the Compensation, calculated *pro rata temporis*, from the First Payment Date or the immediately preceding Compensation Payment Date, as the case may be, until the date of actual Total Optional Early Redemption, as well as Late Charges, if any;

premium: zero point thirty-five percent (0.35%); and

dup: number of Business Days from the date of the Optional Total Early Redemption until the Due Date;

The payment of the Total Optional Early Redemption Amount plus the Optional Total Early Redemption Premium, which cannot be negative, levied on the Total Optional Early Redemption Amount shall be made (i) through the procedures adopted by B3 for the Debentures held in electronic custody at B3, or (ii) through procedures adopted by the Settlement Agent and Bookkeeping Agent, in the case of Debentures that are not electronically held in custody at B3.

Optional Extraordinary Amortization: Subject to compliance with the conditions below, the Issuer may, at its sole discretion, carry out at any time from (and including) January 25, 2026, and with prior notice to the Debenture Holders, pursuant to Clause 6.19 above, or upon written communication addressed to each Debenture Holder, with a copy to the Fiduciary Agent, at least four (4) Business Days in advance of the date of the event, extraordinary amortizations ("Optional Extraordinary Amortization") of the Unit Par Value or the balance of the Unit Par Value, as the case may be, upon payment of a portion of the Unit Par Value or the balance of the Unit Par Value, as the case may be, to be amortized, limited to ninety-eight percent (98%) of the Unit Par Value or the outstanding balance of the Unit Par Value, plus the Compensation, calculated on a *pro rata temporis* basis from the First Payment Date or immediately preceding Compensation Payment Date, as the case may be, until the effective payment date and respective Late Payment Charges, if applicable ("Optional Extraordinary Amortization Premium"), plus a premium, which may not be negative,

12.9 Other relevant information

levied on the Optional Extraordinary Amortization Amount to be amortized, as well as Late Payment Charges, if any, calculated according to the formula below ("Optional Extraordinary Amortization Premium"):

$$PU\text{premium} = \text{premium} \times \left(\frac{dup}{252} \right) \times (PU\text{debenture})$$

where:

PUpremium: unit amount to be paid to the Debenture Holders within the scope of the Optional Early Amortization;

PUdebenture: portion of the Unit Par Value of the Debentures and/or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated pro rata temporis, from the First Payment Date or the immediately preceding Compensation Payment Date, as the case may be, until the date of the actual Optional Extraordinary Amortization, as well as Late Charges, if any;

premium: zero point thirty-five percent (0.35%); and;

dup: number of Business Days from the Optional Extraordinary Amortization date to the Due Date

The payment of the Optional Early Amortization cannot occur on a date that coincides with any date of payment of the amortization of the balance of the Unit Par Value of the Debentures and/or payment of the Compensation, under the terms of this Indenture, and it must be a Business Day.

The Issuer shall, at least three (3) Business Days before the respective date of the Optional Extraordinary Amortization, inform the Bookkeeping Agent, the Settlement Bank, and B3 of the respective date of the Optional Extraordinary Amortization.

Optional Acquisition: The Debentures may, at any time as from the Issue Date, be acquired by the Issuer, in the secondary market, conditional upon acceptance of the respective selling Debenture Holder and subject to the provisions of article 55, paragraph 3 of the Brazilian Corporate Laws and in article 13 of CVM Instruction No. 620 of March 17, 2020, as in effect ("CVM Instruction 620"): (i) for an amount equal to or less than the Unit Par Value or balance of the Unit Par Value of the Debentures, as the case may be, which fact shall be stated in the Issuer's management report and financial statements; or (ii) for an amount greater than the Unit Par Value or balance of the Unit Par Value of the Debentures, as the case may be, and the Issuer shall, prior to the acquisition, communicate its intention to the Fiduciary Agent and to all Debenture Holders, pursuant to Clause 6.19 above, subject to the provisions of article 9 *et seq.* of CVM Instruction 620. The Debentures acquired by the Issuer may (i) be cancelled, subject to the provisions of the applicable regulations; (ii) remain in treasury; or (iii) be put back in the market. Those Debentures acquired by the Issuer to be held in treasury pursuant to this Clause, when replaced on the market, shall be entitled to the same Compensation applicable to the other Debentures of the respective Series ("Optional Acquisition").

Early Maturity: The Fiduciary Agent shall consider the early and automatic maturity of all obligations contained in this Indenture and demand the immediate payment, by the Issuer, of the Unit Par Value or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated on a *pro rata temporis* basis from the First Payment Date or the immediately preceding Compensation Payment Date, as the case may be, until the date of actual payment, without prejudice to the payment of Late Payment Charges, when applicable, and any other amounts that may be due by the Issuer under the terms of this Indenture, regardless of notice or judicial or extrajudicial notification, upon becoming aware of the occurrence of the events of maturity set forth in the indenture.

12.9 Other relevant information

SIXTH (6th) PRIVATE ISSUE OF SIMPLE, NON-CONVERTIBLE, UNSECURED DEBENTURES, IN A SINGLE SERIES, OF THE SIXTH (6th) ISSUE OF RAIA DROGASIL S.A.

Authorization: (A) at a meeting of the Issuer's Board of Directors held on February 8, 2022, the minutes of which were filed with the JUCESP under No. 88.841/22-4 on February 14, 2022 and published in the Official State Press of São Paulo and in the newspaper "O Estado de São Paulo" on February 16, 2022 ("RCA issuer"), it was resolved, among other matters, on the carrying out of the sixth (6th) issue of simple, non-convertible, unsecured debentures, in a single series, for private placement, pursuant to the Debenture Indenture (as defined below), as well as its respective terms and conditions ("Issue" and "Debentures", respectively);

Issue Number: This Issue represent the sixth (6th) issue of debentures of the Issuer.

Total Issue Amount: Up to two hundred and fifty million reais (BRL 250,000,000.00).

Number of Series: The Issue shall be made in a single series.

Convertibility: The Debentures shall be simple, that is, not convertible into shares issued by the Issuer.

Type: The Debentures shall be unsecured, under the terms of article 58, main section of the Brazilian Corporate Laws, without security interest and without preemptive right.

Term and Due Date: Subject to the provisions of this Debenture Indenture, the Debentures shall have a maturity term of one thousand eight hundred and twenty-four (1,824) days as from the Issue Date, therefore falling due on March 05, 2027 ("Due Date").

Unit Par Value: The unit par value of the Debentures shall be one thousand reais (BRL 1,000.00), on the Issue Date ("Unit Par Value").

Quantity of Debentures Issued: Two hundred and fifty thousand (250,000) Debentures shall be issued.

Monetary Adjustment of the Debentures: The Unit Par Value will not be monetarily adjusted.

Compensation: On the Unit Par Value or the balance of the Unit Par Value, as the case may be, interest corresponding to one hundred percent (100%) of the accrued variation of the average reference rates for interbank deposits in Brazil - Interbank Deposit Certificates - DI of one day over extra group calculated and disclosed by B3 S.A. - Brasil, Bolsa, Balcão, in the daily newsletter available on its website (http://www.b3.com.br/pt_br/) expressed as a percentage and calculated daily in the form of compound capitalization, based on a year of two hundred and fifty-two (252) Business Days ("DI Rate"), capitalized exponentially, plus a surcharge (spread) equivalent to one and seven hundredths percent (0.70%) per year, based on a year of two hundred and fifty-two (252) Business Days ("Compensation").

Payment of the Compensation: Without prejudice to the payments due to any early maturity of the obligations arising from the Debentures, any Total Optional Early Redemption, any early redemption resulting from the Total Early Redemption Offer, any Optional Extraordinary Amortization or any Optional Acquisition, with cancellation of all of the Debentures, under the terms set forth in this Indenture, the Compensation shall be paid semi-annually, as of the Issue Date, with the first payment due on September 06, 2022, and the other payments always due on the 6th of March and September of each year.

Total Optional Early Redemption: Subject to compliance with the conditions below, the Issuer may, at its sole discretion, carry out, at any time from (and including) April 07, 2025, the optional early redemption of all Debentures (Partial Optional Early Redemption being prohibited pursuant to Clause 9.6 below), with the consequent cancellation of such Debentures ("Discretionary Total Optional Early Redemption").

12.9 Other relevant information

The Issuer shall notify the Debenture Holder of the Discretionary Total Optional Early Redemption upon written communication addressed to the Debenture Holder, with a copy to the Fiduciary Agent of the CRI, at least five (5) Business Days in advance of the date of the event. Such communication to the Debenture Holder shall describe the terms and conditions of the Discretionary Total Optional Early Redemption, including (i) the estimate of the Discretionary Total Optional Early Redemption Amount (as defined below); (ii) the effective date for the Discretionary Total Optional Early Redemption, which must be a Business Day; and (c) other information that may be necessary to implement the Discretionary Total Optional Early Redemption.

The amount to be paid in relation to each of the Debentures subject to the amount to be paid in relation to each of the Debentures object of the Discretionary Total Optional Early Redemption will be Unit Par Value or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated *pro rata temporis* from the First Payment Date or the First Payment Date or Compensation Payment Date immediately preceding, as the case may be, up to the date of actual payment and the Late Payment Charges, if applicable, and of any other amounts due by the Issuer under this Indenture and/or any of the other Transaction Documents, if applicable (“Discretionary Total Optional Early Redemption Amount”), plus a premium, levied on the Discretionary Total Optional Early Redemption Amount, according to the formula below (“Discretionary Total Optional Early Redemption Premium”):

$$PU_{premium} = premium \times \left(\frac{dup}{252} \right) \times (PU_{debenture})$$

where:

PU_{premium}: unit amount to be paid to the Debenture Holders within the scope of the Total Optional Early Redemption;

PU_{debenture}: Unit Par Value of the Debentures or balance of the Unit Par Value of the Debentures, as the case may be, plus the Compensation, calculated *pro rata temporis*, from the First Payment Date or the immediately preceding Compensation Payment Date, as the case may be, until the date of actual Total Optional Early Redemption, as well as Late Charges, if any;

premium: zero point thirty-five percent (0.35%); and

dup: number of Business Days from the date of the Optional Total Early Redemption until the Due Date;

The payment of the Discretionary Total Optional Early Redemption cannot occur on a date that coincides with any date of payment of the Unit Par Value of the Debentures and/or the Compensation, under the terms of this Debenture Indenture, and it must be a Business Day.

The Issuer shall, at least three (3) Business Days before the respective date of the Discretionary Total Optional Early Redemption, inform the Bookkeeping Agent of the respective date of the Discretionary Total Optional Early Redemption.

The Issuer shall deposit in the Separate Equity Account, by twelve noon (12:00) of the Business Day prior to the Discretionary Total Optional Early Redemption, the Discretionary Total Optional Early Redemption Amount plus the Discretionary Total Optional Early Redemption Premium, levied on the Discretionary Total Optional Early Redemption Amount, observing the procedures adopted by the Bookkeeping Agent, as the case may be.

Optional Extraordinary Amortization: Subject to compliance with the conditions below, the Issuer may, at its sole discretion, carry out at any time from (and including) April 07, 2025, and with prior notice to the Debenture Holder, by means of a written communication addressed to the Debenture Holder, with a copy to the Fiduciary Agent of the CRI, at least four (4) Business Days in advance of the date of the event, extraordinary amortizations (“Optional Extraordinary Amortization”) of the Unit Par Value or the balance of the Unit Par Value, as the case may be, upon payment of a portion of the Unit Par Value or the balance of the Unit Par Value, as the case may be, to be amortized, limited to

12.9 Other relevant information

ninety-eight percent (98%) of the Unit Par Value or of the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated *pro rata temporis* from the First Payment Date or the First Payment Date or Compensation Payment Date immediately preceding, as the case may be, up to the date of actual payment and the Late Payment Charges, if applicable, and of any other amounts due by the Issuer under this Indenture and/or any of the other Transaction Documents, if applicable (“Optional Extraordinary Amortization Amount”), plus a premium, levied on the Optional Extraordinary Amortization to be amortized, calculated according to the formula below (“Optional Extraordinary Amortization Premium”):

$$PU\text{premium} = \text{premium} \times \left(\frac{dup}{252}\right) \times (PU\text{debenture})$$

where:

PUpremium: unit amount to be paid to the Debenture Holders within the scope of the Optional Early Amortization;

PUdebenture: portion of the Unit Par Value of the Debentures and/or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated *pro rata temporis*, from the First Payment Date or the immediately preceding Compensation Payment Date, as the case may be, until the date of the actual Optional Extraordinary Amortization, as well as Late Charges, if any;

premium: zero point thirty-five percent (0.35%); and;

dup: number of Business Days from the Optional Extraordinary Amortization date to the Due Date

Payment of the Optional Extraordinary Amortization cannot occur on a date that coincides with any payment date for the amortization of the balance of the Unit Par Value of the Debentures and/or payment of the Compensation, under the terms of this Debenture Indenture, and it must be a Business Day The Issuer shall, at least three (3) Business Days in advance of the respective Optional Extraordinary Amortization date, inform the Bookkeeping Agent, the Settlement Agent, and B3 of the respective Optional Extraordinary Amortization date.

The Issuer shall, at least three (3) Business Days before the respective date of the Optional Extraordinary Amortization, inform the Bookkeeping Agent of the respective date of the Optional Extraordinary Amortization.

The Issuer shall deposit in the Separate Equity Account, by twelve noon (12:00) of the Business Day prior to the Optional Extraordinary Amortization, the Optional Extraordinary Amortization Amount plus the Optional Extraordinary Amortization Premium, levied on the Optional Extraordinary Amortization Amount, observing the procedures adopted by the Bookkeeping Agent, as the case may be.

Early Maturity: The Debenture Holder shall consider the early and automatic maturity of all obligations contained in this Debenture Indenture and demand the immediate payment, by the Issuer, of the Unit Par Value or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated on a *pro rata temporis* basis from the First Payment Date or the immediately preceding Compensation Payment Date, as the case may be, until the date of actual payment, without prejudice to the payment of Late Payment Charges and Expenses, when applicable, and any other amounts that may be due by the Issuer under the terms of this Debenture Indenture and/or of any of the other Transaction Documents, regardless of notice or judicial or extrajudicial notification, upon becoming aware of the occurrence of the events of early maturity described in the indenture.

12.9 Other relevant information

SEVENTH (7th) PRIVATE ISSUE OF SIMPLE, NON-CONVERTIBLE, UNSECURED DEBENTURES, IN A SINGLE SERIES, OF RAIA DROGASIL S.A.

Authorization: This Debenture Indenture is signed based on the authorization of the Issuer's Board of Directors meeting held on May 31, 2022 ("RCA Issuer"), in which (i) the terms and conditions of the Debenture Issue were approved, pursuant to article 59, paragraph 1 of the Brazilian Corporate Laws; and (ii) the Issuer's executive office was authorized to carry out all acts necessary to implement the resolutions contained therein, including the execution of all documents necessary to carry out the Issue of the Debentures, including the amendment to the Debenture Indenture to reflect the outcome of the Bookbuilding Process (as defined below).

Issue Number: This Issue represent the seventh (7th) issue of debentures of the Issuer.

Total Issue Amount: Up to five hundred and fifty million reais (BRL 550,000,000.00).

Number of Series: The Issue shall be made in a single series.

Convertibility: The Debentures shall be simple, that is, not convertible into shares issued by the Issuer.

Type: The Debentures shall be unsecured, under the terms of article 58, main section of the Brazilian Corporate Laws, without security interest and without preemptive right.

Term and Due Date: Subject to the provisions of this Debenture Indenture, the Debentures shall have a maturity term of two thousand five hundred and fifty-six (2,556) days as from the Issue Date, therefore falling due on June 25, 2029 ("Due Date").

Unit Par Value: The unit par value of the Debentures shall be one thousand reais (BRL 1,000.00), on the Issue Date ("Unit Par Value").

Quantity of Debentures Issued: Five hundred and fifty thousand (550,000) Debentures shall be issued.

Monetary Adjustment of the Debentures: The Unit Par Value will not be monetarily adjusted.

Compensation: On the Unit Par Value or the balance of the Unit Par Value, as the case may be, interest corresponding to one hundred percent (100%) of the accrued variation of the average reference rates for interbank deposits in Brazil - Interbank Deposit Certificates - DI of one day over extra group calculated and disclosed by B3 S.A. - Brasil, Bolsa, Balcão, in the daily newsletter available on its website (http://www.b3.com.br/pt_br/) expressed as a percentage and calculated daily in the form of compound capitalization, based on a year of two hundred and fifty-two (252) Business Days ("DI Rate"), capitalized exponentially, plus a surcharge (spread) equivalent to one and forty-nine hundredths percent (0.75%) per year, based on a year of two hundred and fifty-two (252) Business Days ("Compensation").

Payment of the Compensation: Without prejudice to the payments due to any early maturity of the obligations arising from the Debentures, any Total Optional Early Redemption, any early redemption resulting from the Total Early Redemption Offer, any Optional Extraordinary Amortization or any Optional Acquisition, with cancellation of all of the Debentures, under the terms set forth in this Indenture, the Compensation shall be paid semi-annually, as of the Issue Date, with the first payment due on December 23, 2022, and the other payments always due on the 25th of July and December of each year.

Total Optional Early Redemption: Subject to compliance with the conditions below, the Issuer may, at its sole discretion, carry out, at any time from (and including) July 26, 2026, the optional early redemption of all Debentures (partial optional early redemption being prohibited pursuant to Clause 9.6 of the debenture indenture), with the consequent cancellation of such Debentures ("Total Optional Early Redemption").

12.9 Other relevant information

The Issuer shall notify the Debenture Holders of the Total Optional Early Redemption by publishing an announcement, pursuant to Clause 6.19 above, or upon written communication addressed to Debenture Holder, with a copy to the Fiduciary Agent, at least five (5) Business Days in advance of the date of the event. Such communication to the Debenture Holders shall describe the terms and conditions of the Total Optional Early Redemption, including (i) the estimate of the Total Optional Early Redemption Amount (as defined below); (ii) the effective date for the Total Optional Early Redemption, which must be a Business Day; and (iii) other information that may be necessary to implement the Total Optional Early Redemption ("Total Optional Early Redemption Notice").

The amount to be paid in relation to each of the Debentures subject to the amount to be paid in relation to each of the Debentures object of the Total Optional Early Redemption will be Unit Par Value or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated *pro rata temporis* from the First Payment Date or the First Payment Date or Compensation Payment Date immediately preceding, as the case may be, up to the date of actual payment and the respective Late Payment Charges, if applicable ("Total Optional Early Redemption Amount"), plus a premium, which cannot be negative, levied on the Total Optional Early Redemption Amount, as well as Late Charges, if any, according to the formula below ("Total Optional Early Redemption Premium")

$$PU_{premium} = premium \times \left(\frac{dup}{252} \right) \times (PU_{debenture})$$

where:

PU_{premium}: unit amount to be paid to the Debenture Holders within the scope of the Total Optional Early Redemption;

PU_{debenture}: Unit Par Value of the Debentures or balance of the Unit Par Value of the Debentures, as the case may be, plus the Compensation, calculated *pro rata temporis*, from the First Payment Date or the immediately preceding Compensation Payment Date, as the case may be, until the date of actual Total Optional Early Redemption, as well as Late Charges, if any;

premium: zero point thirty-five percent (0.35%); and

dup: number of Business Days from the date of the Optional Total Early Redemption until the Due Date;

The payment of the Total Optional Early Redemption Amount plus the Optional Total Early Redemption Premium, which cannot be negative, levied on the Total Optional Early Redemption Amount shall be made (i) through the procedures adopted by B3 for the Debentures held in electronic custody at B3, or (ii) through procedures adopted by the Settlement Agent and Bookkeeping Agent, in the case of Debentures that are not electronically held in custody at B3.

Optional Extraordinary Amortization: Subject to compliance with the conditions below, the Issuer may, at its sole discretion, carry out at any time from (and including) July 26, 2026, and with prior notice to the Debenture Holders, upon written communication addressed to each Debenture Holder, with a copy to the Fiduciary Agent of the CRI, at least four (4) Business Days in advance of the date of the event, extraordinary amortizations ("Optional Extraordinary Amortization") of the Unit Par Value or the balance of the Unit Par Value, as the case may be, upon payment of a portion of the Unit Par Value or the balance of the Unit Par Value, as the case may be, to be amortized, limited to ninety-eight percent (98%) of the Unit Par Value or the outstanding balance of the Unit Par Value, as the case may be, plus the Compensation, calculated on a *pro rata temporis* basis from the First Payment Date or immediately preceding Compensation Payment Date, as the case may be, until the effective payment date and respective Late Payment Charges and Expenses, as the case may be, and any other amounts due by the Issuer pursuant to this Debenture Indenture and/or any of the other Transaction Documents, if applicable ("Optional Extraordinary Amortization Amount"), plus a premium, levied on the

12.9 Other relevant information

Optional Extraordinary Amortization Amount to be amortized, calculated according to the formula below (“Optional Extraordinary Amortization Premium”):

$$PU_{premium} = premium \times (dup/252) \times (PU_{debenture})$$

where:

PU_{premium}: unit amount to be paid to the Debenture Holders within the scope of the Optional Early Amortization;

PU_{debenture}: portion of the Unit Par Value of the Debentures and/or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated *pro rata temporis*, from the First Payment Date or the immediately preceding Compensation Payment Date, as the case may be, until the date of the actual Optional Extraordinary Amortization, as well as Late Charges, if any;

premium: zero point thirty-five percent (0.35%); and;

dup: number of Business Days from the Optional Extraordinary Amortization date to the Due Date

The payment of the Optional Early Amortization cannot occur on a date that coincides with any date of payment of the amortization of the balance of the Unit Par Value of the Debentures and/or payment of the Compensation, under the terms of this Indenture, and it must be a Business Day.

The Issuer shall, at least three (3) Business Days before the respective date of the Optional Extraordinary Amortization, inform the Bookkeeping Agent, the Settlement Bank, and B3 of the respective date of the Optional Extraordinary Amortization.

Optional Acquisition: The Issuer may not carry out the optional acquisition of Debentures.

Early Maturity: The Fiduciary Agent shall consider the early and automatic maturity of all obligations contained in this Indenture and demand the immediate payment, by the Issuer, of the Unit Par Value or the balance of the Unit Par Value, as the case may be, plus the Compensation, calculated on a *pro rata temporis* basis from the First Payment Date or the immediately preceding Compensation Payment Date, as the case may be, until the date of actual payment, without prejudice to the payment of Late Payment Charges, when applicable, and any other amounts that may be due by the Issuer under the terms of this Indenture, regardless of notice or judicial or extrajudicial notification, upon becoming aware of the occurrence of the events of maturity set forth in the indenture.

EIGHTH (8th) PRIVATE ISSUE OF SIMPLE, NON-CONVERTIBLE, UNSECURED DEBENTURES, IN 3 (THREE) SERIES, FROM RAI DROGASIL S.A.

Authorization: This Debenture Issuance Deed is signed based on the authorization of the meeting of the Board of Directors of the Issuer held on August 16, 2023 (“RCA Issuer”), in which (i) the terms and conditions of the Debenture Issuance were approved, in accordance with article 59, §1, of the Brazilian Corporate Law; and (ii) the Issuer’s management was authorized to carry out all acts necessary to implement the deliberations embodied therein, including the execution of all documents necessary to carry out the Issuance of Debentures, including the addition to the Deed of Issuance of Debentures to reflect the result of the Bookbuilding Procedure.

Issue Number: This Issue represent the eighth (8th) issue of debentures of the Issuer.

Total Issue Amount: The total value of the Issuance will be R\$ 700,000,000.00 (seven hundred million reais), on the Issuance Date (as defined below) (“Total Issuance Value”), noting that (i) the total value of the Debentures of the First Series is R\$ 350,000,000.00 (three hundred and fifty million reais) on the Debentures Issuance Date; (ii) the total value of the Second Series Debentures is R\$ 150,000,000.00 (one hundred and fifty million reais) on the Debentures Issuance Date; and (iii) the total value of the Third Series Debentures is R\$ 200,000,000.00 (two hundred million reais) on the Debentures Issuance Date. The Issuance and Offer could not have their value and number of Debentures increased

12.9 Other relevant information

under any circumstances, and there was, therefore, no additional batch of Debentures, under the terms of article 50 of CVM Resolution 160.

Number of Series: The Issuance will be carried out in 3 (three) series, in the system of communicating vessels (“Communicating Vessel System”), with the volume and final quantity of Debentures allocated in each series being defined in accordance with the Bookbuilding Procedure.

Convertibility: The Debentures shall be simple, that is, not convertible into shares issued by the Issuer.

Type: The Debentures shall be unsecured, under the terms of article 58, main section of the Brazilian Corporate Laws, without security interest and without preemptive right.

Term and Due Date: Subject to the provisions of this Debenture Issuance Deed, (i) the First Series Debentures will have a maturity period of 727 (seven hundred and twenty-seven) days from the Issuance Date, therefore expiring on September 11, 2025 (“Due Date of First Series Debentures”); (ii) the Debentures of the Second Series will have a maturity period of 1,459 (one thousand, four hundred and fifty-nine) days from the Issuance Date, therefore expiring on September 13, 2027 (“Due Date of the Debentures of the Second Series”); and (iii) the Third Series Debentures will have a maturity period of 2,554 (two thousand, five hundred and fifty-four) days from the Issuance Date, therefore expiring on September 12, 2030 (“Due Date of Third Series Debentures” and, together with the Due Date of the First Series Debentures and the Due Date of the Second Series Debentures, the “Due Date”).

Unit Par Value: The unit par value of the Debentures shall be one thousand reais (BRL 1,000.00), on the Issue Date (“Unit Par Value”).

Quantity of Debentures Issued: 700,000 (seven hundred thousand) Debentures will be issued, of which (i) 350,000 (three hundred and fifty thousand) First Series Debentures; (ii) 150,000 (one hundred and fifty thousand) Second Series Debentures; and (iii) 200,000 (two hundred thousand) Third Series Debentures. The Issuance could not have its value or number of Debentures increased under any circumstances, and there was, therefore, no additional batch of Debentures. There were no maximum quantities set.

Monetary Adjustment of the Debentures: The Unit Par Value will not be monetarily adjusted.

Compensation: On the Unit Par Value or the balance of the Unit Par Value, as the case may be, interest corresponding to one hundred percent (100%) of the accrued variation of the average reference rates for interbank deposits in Brazil - Interbank Deposit Certificates - DI of one day over extra group calculated and disclosed by B3 S.A. – Brasil, Bolsa, Balcão, in the daily newsletter available on its website (http://www.b3.com.br/pt_br/) expressed as a percentage and calculated daily in the form of compound capitalization, based on a year of two hundred and fifty-two (252) Business Days (“DI Rate”), capitalized exponentially, plus the following surcharges (spread):

(i) 0.3000% (three thousand ten thousandths percent) per year, based on a year of 252 (two hundred and fifty-two) Business Days, for the First Series Debentures (“Remuneration of the First Series Debentures”); and

(ii) 0.6500% (six thousand and five hundred ten thousandths percent) per year, based on a year of 252 (two hundred and fifty-two) Business Days, for the Second Series Debentures (“Remuneration of the Debentures of the Second Series”); and

(iii) 1.1000% (one integer and one thousand ten thousandths of a percent) per year, based on a year of 252 (two hundred and fifty-two) Business Days, for the Third Series Debentures (“Remuneration of Third Series Debentures” and, together with the Remuneration of the First Series Debentures and the Remuneration of the Second Series Debentures, “Remuneration”).

Payment of the Compensation: Without prejudice to payments resulting from any early maturity of obligations arising from the Debentures and/or any early redemption, under the terms set out in this Debenture Issuance Deed, the Remuneration of the respective series will be paid semiannually, from the Issuance Date, being the first payment due on March 13, 2024, and the remaining payments due on the respective Remuneration Payment Dates, until the Maturity Date of the respective series.

Discretionary Optional Early Redemption: Subject to compliance with the conditions below, the Issuer may, at its sole discretion, carry out, at any time from October 15, 2024 (including) for the First Series Debentures, from October 15, 2025 (including) for Second Series Debentures and from October 15, 2026 (including) for Third Series Debentures, the optional early redemption of all First Series Debentures, Second Series Debentures and/or Third Series Debentures, as the case may be (Partial Optional Early Redemption being prohibited, under the terms of Clause 9.6 of the Deed of Issuance), with the consequent cancellation of such Debentures (“Discretionary Optional Early Redemption”).

12.9 Other relevant information

The Issuer must inform the Debenture Holder about the performance of the Discretionary Optional Early Redemption through written communication addressed to the Debenture Holder, with a copy to the Fiduciary Agent, at least 5 (five) Business Days in advance of the date of the event. Such communication to the Debenture Holder must describe the terms and conditions of the Discretionary Optional Early Redemption, including (i) the estimate of the Discretionary Optional Early Redemption Value (as defined in the Deed of Issuance); (ii) the effective date for the Discretionary Optional Early Redemption, which must be a Business Day; and (iii) other information necessary for the operationalization of the Discretionary Optional Early Redemption.

The amount to be paid in relation to each of the Debentures subject to the Discretionary Optional Early Redemption will be the Nominal Unit Value or the balance of the Nominal Unit Value of the respective series, as applicable, plus the Remuneration of the respective series, calculated *pro rata temporis* from the First Payment Date of the respective series or the Remuneration Payment Date of the respective immediately preceding series, as applicable, until the date of actual payment, without prejudice to the payment of the respective Late Payment Charges and Expenses, when applicable, and any other amounts eventually owed by the Issuer under the terms of this Debenture Issuance Deed and/or any of the other Transaction Documents, if applicable (“Discretionary Optional Early Redemption Value”), plus a premium, levied on the Early Redemption Value Optional Discretionary, according to the formula below (“Discretionary Optional Early Redemption Premium”):

$$PU_{premium} = premium \times \left(\frac{dup}{252} \right) \times (PU_{debenture})$$

where:

PU_{premium}: unit value of premium to be paid to the Debenture Holder within the scope of the Discretionary Optional Early Redemption of the respective series;

PU_{debenture}: Discretionary Optional Early Redemption Value, as defined above;

premium: zero point thirty-five percent (0.35%); and

dup: number of Business Days counted from the date of the Optional Extraordinary Amortization until the Maturity Date of the respective series;

The payment of the Optional Extraordinary Amortization cannot occur on a date that coincides with any date of payment of amortization of the balance of the Nominal Unit Value of the Debentures of the respective series and/or payment of the Remuneration of the respective series, under the terms of this Debenture Issuance Deed, and must be a Business Day.

Optional Extraordinary Amortization: Subject to compliance with the conditions below, the Issuer may, at its sole discretion, carry out at any time from October 15, 2024 (including) for the First Series Debentures, from October 15, 2025 (including) to the Second Series Debentures and from October 15, 2026 (including) for the Third Series Debentures, and with prior notice to the Debenture Holder, through written communication addressed to the Debenture Holder, with a copy to the Fiduciary Agent of the CRI, in advance of, at least 4 (four) Business Days counted from the date of the event, extraordinary amortizations of the Nominal Unit Value or the balance of the Nominal Unit Value, as applicable, of the First Series Debentures, the Second Series Debentures and/or the Debentures of the Third Series, as applicable (“Optional Extraordinary Amortization”), upon payment of a portion of the Nominal Unit Value or the balance of the Nominal Unit Value of the respective series, as applicable, to be amortized, limited to 98% (ninety-eight percent) of the Nominal Unit Value or the balance of the Nominal Unit Value of the respective series, as applicable, plus the Remuneration of the respective series, calculated *pro rata temporis* from the First Payment Date of the respective series or the Remuneration Payment Date of the respective immediately previous series, as applicable, until the date of effective payment, without prejudice to the payment of the respective Late Charges and Expenses, when applicable, and any other amounts eventually owed by the Issuer under the terms of this Debenture Issuance Deed and /or any of the other Operation Documents, if applicable (“Optional Extraordinary Amortization Amount”), plus a premium, levied on the Optional Extraordinary Amortization Amount to be amortized, calculated according to the formula below (“Optional Extraordinary Amortization Premium”):

12.9 Other relevant information

$$PU_{premium} = premium \times (dup/252) \times (PU_{debentureAmort})$$

where:

PU_{premium}: unit amount to be paid to the Debenture Holders within the scope of the Optional Early Amortization;

PU_{debentureAmort}: Value of the Optional Extraordinary Amortization, as defined above;

premium: zero point thirty-five percent (0.35%); and;

dup: number of Business Days counted from the date of the Optional Extraordinary Amortization until the Due Date of the respective series.

The payment of the Optional Early Amortization cannot occur on a date that coincides with any date of payment of the amortization of the balance of the Unit Par Value of the Debentures and/or payment of the Compensation, under the terms of this Indenture, and it must be a Business Day.

The Issuer shall, at least three (3) Business Days before the respective date of the Optional Extraordinary Amortization, inform the Bookkeeping Agent of the respective date of the Optional Extraordinary Amortization.

Optional Acquisition: The Issuer may not carry out the optional acquisition of Debentures.

Early Maturity: The Fiduciary Agent shall consider the early and automatic maturity of all obligations contained in this Indenture and demand the immediate payment, by the Issuer, of the Nominal Unit Value or the balance of the Nominal Unit Value, as the case may be, plus the respective Remuneration, calculated based on a *pro rata temporis* from the First Payment Date of the respective series or the immediately preceding Remuneration Payment Date, as the case may be, until the date of actual payment, without prejudice to the payment of Late Payment Charges and Expenses, when applicable, and any other amounts eventually owed by the Issuer under the terms of this Debenture Issuance Deed and/or any of the other Operation Documents, regardless of notice, interpellation or notification, judicial or extrajudicial, in the knowledge of the occurrence of the automatic early maturity hypotheses set out in the issuance deed.

NINTH (9th) PRIVATE ISSUE OF SIMPLE, NON-CONVERTIBLE, UNSECURED DEBENTURES, IN A SINGLE SERIES, FOR PUBLIC DISTRIBUTION WITH RESTRICTED EFFORTS, FROM RAI DROGASIL S.A.

Authorization: This Deed of Issuance is executed in accordance with the authorization of the Board of Directors Meeting of the Issuer, held on April 19, 2024 ("RCA Issuer"), in which the terms and conditions of the 9th (ninth) issuance of simple debentures, not convertible into shares, of the unsecured type, in a single series, from the Issuer ("Issuance" and "Debentures", respectively), in accordance with the provisions of article 59, caput and first paragraph of Law No. 6,404, of December 15, 1976, as amended ("Corporate Law"), which will be subject to public distribution, under the rite of automatic distribution registration, without prior analysis by the CVM, intended exclusively for Professional Investors (as defined below), pursuant to Law No. 6,385, of December 7, 1976, as amended ("Securities Market Law"), CVM Resolution No. 160, of July 13, 2022, as amended ("CVM Resolution 160"), and other applicable legal provisions ("Offer").

Issue Number: This Issue represent the ninth (9th) issue of debentures of the Issuer.

Total Issue Amount: Up to R\$600,000,000.00 (six hundred million reais).

Number of Series: The Issuance will be carried out in a single series.

Convertibility: The Debentures shall be simple, that is, not convertible into shares issued by the Issuer.

Type: The Debentures shall be unsecured, under the terms of article 58, main section of the Brazilian Corporate Laws, without security interest and without preemptive right.

Term and Due Date: Subject to the provisions of this Deed of Issuance, the Debentures will have a maturity period of 7 (seven) years from the Issuance Date, therefore expiring on April 22, 2031 ("Maturity Date").

Unit Par Value: The unit par value of the Debentures shall be one thousand reais (BRL 1,000.00), on the Issue Date (“Unit Par Value”).

Quantity of Debentures Issued: 600,000 (six hundred thousand) Debentures will be issued.

Monetary Adjustment of the Debentures: The Unit Par Value will not be monetarily adjusted.

Compensation: On the Unit Par Value or the balance of the Unit Par Value, as the case may be, interest corresponding to one hundred percent (100%) of the accrued variation of the average reference rates for interbank deposits in Brazil - Interbank Deposit Certificates - DI of one day over extra group calculated and disclosed by B3 S.A. – Brasil, Bolsa, Balcão, in the daily newsletter available on its website (http://www.b3.com.br/pt_br/) expressed as a percentage and calculated daily in the form of compound capitalization, based on a year of two hundred and fifty-two (252) Business Days (“DI Rate”), capitalized exponentially, plus a surcharge (spread) equivalent to 0.65% (six thousand and five hundred ten thousandths percent) per year, based on a year of 252 (two hundred and fifty-two) Business Days (“Remuneration”).

Payment of the Compensation: The effective payment of the Debenture Remuneration will be made in semi-annual and consecutive installments, always on the 22nd of April and October, with the first payment due on October 22nd, 2024 and the last payment, on the Maturity Date, except for payments on due to early maturity of the Debentures due to the occurrence of one of the Hypotheses of Early Maturity, Optional Acquisition, Optional Extraordinary Amortization, and/or early redemption of the Debentures as a result of the Total Optional Early Redemption or Offer of Early Redemption, as provided for in the Deed of Issuance.

Discretionary Optional Early Redemption: The Issuer may, at its sole discretion, carry out the optional early redemption of all Debentures (“Total Optional Early Redemption”), at any time, after the 48th (forty-eighth) month counted from the Issuance Date, that is, on April 22, 2028 (exclusive). Upon Total Optional Early Redemption, the amount due by the Issuer will be equivalent to: (i) the Nominal Unit Value (or balance of the Nominal Unit Value, as applicable) of the Debentures, plus (ii) the Remuneration of the Debentures, calculated pro rata temporis from the Profitability Start Date or the immediately preceding Remuneration Payment Date (inclusive), as applicable, until the date of the effective Total Optional Early Redemption (exclusive); (iii) any Late Payment Charges (if any); and (iv) a premium equivalent to 0.35% (thirty-five hundredths of a percent) per year, calculated in accordance with the following formula (“Anticipated Redemption Value”):

$$PU = [(1+i) \times \left(\frac{dup}{252}\right) - 1] \times VR$$

where:

PUpremium: Total Optional Early Redemption premium, calculated to 8 (eight) decimal places, without rounding;

i: 0.35% (thirty-five hundredths percent);

VR: Nominal Unit Value or balance of the Nominal Unit Value of the Debentures plus the Remuneration, calculated pro rata temporis, from the Profitability Start Date or the immediately previous Remuneration Payment Date, as applicable, until the date of effective payment, plus possible Late Payment Charges (if any); and

du: number of Business Days to elapse between the effective date of the Total Optional Early Redemption and the Expiration Date;

If the Total Optional Early Redemption date coincides with a Remuneration Payment Date, the premium provided for in item “(iv)” of Clause 6.1.1 above must be calculated on the Nominal Unit Value of the Debentures or on the balance of the Nominal Unit Value, as applicable, after said payment (i.e., without considering the remuneration to be paid on the respective Remuneration Payment Date).

The Total Optional Early Redemption will only be carried out by sending an individual communication to the Debenture Holders, or publishing an announcement, in accordance with Clause 5.23 above, in both cases with a copy to the Trustee, 5 (five) Business Days in advance of the date in which it is intended to carry out the effective Total Optional Early Redemption (“Redemption Communication”), and said communication must include: (i) the date of the Total Optional Early Redemption, which must be a Business Day; (ii) the mention that the value corresponding to the payment will be the Nominal Unit Value

of the Debentures or the balance of the Nominal Unit Value, as applicable, plus (a) Remuneration of the Debentures, calculated as provided for in Clause 5.15 above; (b) any Late Payment Charges (if any); and (c) redemption premium, calculated as provided in Clause 6.1.1 above; and (iii) any other information necessary for the operation of the Total Optional Early Redemption.

B3, the Bookkeeper and the Settlement Bank must be notified of the completion of the Total Optional Early Redemption at least 3 (three) Business Days in advance.

The Total Optional Early Redemption of Debentures held electronically at B3 will follow the event settlement procedures adopted by it. If the Debentures are not held electronically at B3, the Full Optional Early Redemption will be carried out through the Bookkeeper.

The Debentures redeemed by the Issuer, as provided for in this Clause, will be obligatorily cancelled.

Partial optional early redemption of Debentures will not be permitted.

Optional Extraordinary Amortization: The Issuer may, at its sole discretion, carry out, at any time, after the 48th (forty-eighth) month counted from the Issue Date, that is, on April 22, 2028 (exclusive), extraordinary amortizations of the Nominal Unit Value or of the balance of the Nominal Unit Value, as applicable, limited to 98% (ninety-eight percent) of the Nominal Unit Value or balance of the Nominal Unit Value of the Debentures ("Optional Extraordinary Amortization"), upon prior written communication with, at least, 10 (ten) Business Days in advance of the date of the intended Optional Extraordinary Amortization, under the terms of Clause 6.2.3 below.

The Optional Extraordinary Amortization will be carried out through the payment of (a) the portion of the Nominal Unit Value or the balance of the Nominal Unit Value of the Debentures, as the case may be, to be amortized, plus (b) the Remuneration, calculated pro rata temporis from the Date from the Start of Profitability, or the Remuneration Payment Date (inclusive), as the case may be, until the date of the effective Optional Extraordinary Amortization (exclusive), levied on the portion of the Nominal Unit Value or balance of the Nominal Unit Value of the Debentures and others charges due and unpaid up to the date of the Optional Extraordinary Amortization; (c) any Late Payment Charges (if any); and (d) a premium equivalent to 0.35% (thirty-five hundredths of a percent) per year, according to the following formula ("Amount of the Optional Extraordinary Amortization"):

$$PU = [(1+i) \times \left(\frac{dup}{252} - 1\right) \times VR$$

where:

PUpremium: Total Optional Early Redemption premium, calculated to 8 (eight) decimal places, without rounding;

i: 0.35% (thirty-five hundredths percent);

VR: Nominal Unit Value or balance of the Nominal Unit Value of the Debentures plus the Remuneration, calculated pro rata temporis, from the Profitability Start Date or the immediately previous Remuneration Payment Date, as applicable, until the date of effective payment, plus possible Late Payment Charges (if any); and

du: number of Business Days to elapse between the effective date of the Total Optional Early Redemption and the Expiration Date;

Communication of the Optional Extraordinary Amortization must be made through individual written communication to Debenture Holders, with a copy to the Trustee and/or publication of a notice to Debenture Holders to be widely disseminated in accordance with Clause 5.23 above, with a copy to the Trustee, in advance minimum of 5 (five) Business Days from the date of the event. The communication to Debenture Holders mentioned in Clause 6.2.3 above must include (i) the date of the Optional Extraordinary Amortization, which must be a Business Day; (ii) the estimated value of the payment due to Debenture Holders; and (iii) any other information necessary for the operationalization and implementation of the Optional Extraordinary Amortization of Debentures, observing the provisions of Clause 6.2.1 et seq.

B3, the Bookkeeper and the Settlement Bank must be notified of the completion of the Optional Extraordinary Amortization at least 3 (three) Business Days in advance.

6.2.5 Subject to the provisions above, the Optional Extraordinary Amortization must cover, proportionally, all Debentures, and must comply with the maximum amortization limit of 98% (ninety-eight percent) of the Nominal Unit Value or balance of the Nominal Value Unit of Debentures.

Optional Acquisition: The Issuer may, at any time, acquire Debentures, subject to the provisions of article 55, paragraph 3, of the Corporations Law, provided that it observes any rules issued by the CVM, and such fact, if so required by the provisions applicable legal and regulatory provisions, as set out in the Issuer's management report and financial statements ("Optional Acquisition"). The Debentures acquired by the Issuer in accordance with this Clause may, at the Issuer's discretion, be cancelled, remain in the Issuer's treasury or be placed on the market again, subject to the restrictions imposed by CVM Resolution No. 77, of March 29, 2022, as amended. The Debentures acquired by the Issuer to remain in treasury, under the terms of this Clause, if and when placed back on the market, will be entitled to the same Remuneration applicable to the other Debentures.

Early Maturity: Subject to the provisions of Clauses 8.1.1 and 8.1.2 below, the Trustee must consider all obligations arising from the Debentures due in advance and demand immediate payment, by the Issuer to the Debenture Holders, of the Nominal Unit Value or balance of the Nominal Unit Value of the Debentures, plus the Remuneration, calculated pro rata temporis from the Profitability Start Date, or the last Remuneration Payment Date, whichever occurs last, until the date of its effective payment, without prejudice to the payment of Late Payment Charges, when applicable, and any other amounts eventually owed by the Issuer under the terms of this Deed of Issuance and/or any of the other Transaction Documents, in the occurrence of the hypotheses indicated below (each, an "Early Maturity Hypothesis").

13.0 Identification

Name of person responsible for the form content

Flavio de Moraes Correia

Title of the responsible person

Investor Relations and Corporate Affairs Director

Name of person responsible for the form content

Marcilio D'Amico Pousada

Title of the responsible person

Chief Executive Officer

13.1 Statement by CEO



Raia Drogasil S.A.
Companhia Aberta de Capital Autorizado
CNPJ/MF nº 61.585.865/0001-51
Código CVM: 5258

Declaração

Declaro, nos termos da Resolução CVM nº 80 e posteriores alterações, que na qualidade de Diretor Presidente da Raia Drogasil S.A.:

1. Revisei o formulário de referência
2. Todas as informações contidas no formulário atendem ao disposto na Resolução CVM nº 80, em especial aos arts. 15 a 20; e
3. O conjunto de informações nele contido retratam de modo verdadeiro, preciso e completo as atividades da Raia Drogasil S.A. e dos riscos inerentes às suas atividades.

São Paulo, 30 de maio de 2023.

Marcilio D'Amico Pousada
Diretor Presidente

13.2 Statement by the investor relations officer

Raia Drogasil S.A.
Companhia Aberta de Capital Autorizado
CNPJ/MF nº 61.585.865/0001-51
Código CVM: 5258

Declaração

Declaro, nos termos da Resolução CVM nº 80 e posteriores alterações, que na qualidade de Diretor de Relações com Investidores e Assuntos Corporativos da Raia Drogasil S.A.:

1. Revisei as informações que foram atualizadas no formulário de referência após a data de minha posse;
2. Todas as informações que foram atualizadas no formulário na forma do item "a" acima atendem ao disposto na Resolução CVM nº 80, em especial aos arts. 15 e 20.

São Paulo, 10 de maio de 2024.

Flávio de Moraes Correia
Diretor de Relações com Investidores e Assuntos Corporativos

PAGE 274	
RD Gente, Saúde e Bem-estar	People, Health, and Well-Being
Companhia Aberta de Capital Autorizado	Publicly-Held Company with Authorized Capital
Código CVM: 5258	CVM Code: 5258
Declaração	Declaration
Declaro, nos termos da resolução CVM nº 80 e posteriores alterações, que na qualidade de Diretor Presidente da Raia Drogasil S.A.:	I declare, pursuant to CVM Resolution No. 80 and subsequent amendments, that in the capacity as Chief Executive Officer of Raia Drogasil S.A.:
1. Revisei o formulário de referência	1. I reviewed the reference form
2. Todas as informações contidas no formulário atendem ao disposto na Resolução CVM nº 80, em especial aos arts. 15 a 20; e	2. All information contained in the Form complies with CVM Resolution No. 80, notably its articles 15 to 20; and
3. O conjunto de informações nele contido retratam de modo verdadeiro, preciso e completo as atividades da Raia Drogasil S.A. e dos riscos inerentes às suas atividades.	3. The information contained therein truly, accurately and completely portrays the activities of Raia Drogasil S.A. and the risks inherent to its activities.
São Paulo, 30 de maio de 2023	São Paulo, May 30, 2023
Diretor Presidente	CEO

PAGE 275	
RD Gente, Saúde e Bem-Estar	People, Health, and Well-Being
Companhia Aberta de Capital Autorizado	Publicly-Held Company with Authorized Capital
Código CVM: 5258	CVM Code: 5258
Declaração	Declaration
Declaração, nos termos da Resolução CVM nº 80 e posteriores alterações, que na qualidade de Diretor de Relações com Investidores e Assuntos Corporativos da Raia Drogasil S.A.:	I declare, pursuant to CVM Resolution No. 80 and subsequent amendments, that in the capacity as Investor Relations and Corporate Affairs Director of Raia Drogasil S.A.:
1. Revisei as informações que foram atualizadas no formulário de referência após a data da minha posse;	1. I reviewed the information that was updated on the reference form after the date I started in the job position;
2. Todas as informações que foram atualizadas no formulário na forma do item "a" acima, atendem ao disposto na Resolução CVM nº 80, em especial aos arts. 15 a 20.	2. All information that was updated in the form of item "a" above, complies with the CVM Resolution No. 80, notably its articles 15 to 20.
10 de maio de 2024	São Paulo, May 10, 2024
Diretor de Relações com Investidores e Assuntos Corporativos	Investor Relations and Corporate Affairs Director

13.3 Statement by CEO/investor relations officer

13.3 - Statement by CEO/investor relations officer

Not applicable. The Declarations by the Chief Executive Officer and Investor Relations and Corporate Affairs Director can be found in items 13.1 and 13.2 of this form, respectively.